paclitaxel has been researched along with deoxycytidine in 1695 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 91 (5.37) | 18.2507 |
| 2000's | 636 (37.52) | 29.6817 |
| 2010's | 713 (42.06) | 24.3611 |
| 2020's | 255 (15.04) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, TD; Burris, HA; Havlin, KA; O'Rourke, TJ; Rodriguez, GI; Wall, JG; Weiss, GR | 1 |
| Roth, BJ | 1 |
| Ettinger, DS | 1 |
| Neijt, JP | 1 |
| Klastersky, J | 1 |
| Niitani, H | 1 |
| Grant, SC; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR | 1 |
| Fukuoka, M; Yoshikawa, A | 1 |
| Bajorin, DF; Roth, BJ | 1 |
| Eisenhauer, EA; Hansen, HH; Hansen, M; Neijt, JP; Piccart, MJ; Sessa, C; Thigpen, JT | 1 |
| Ariyoshi, Y; Sugiura, T | 1 |
| Edelman, MJ; Gandara, DR | 1 |
| Macdonald, JS; Schnall, SF | 1 |
| Fields, AL; Goldberg, GL; Runowicz, CD | 1 |
| Abi-Aad, AS | 1 |
| Drengler, R; Eckardt, J; Eckhardt, G; Villalona-Calero, M; Von Hoff, D | 1 |
| Pronk, LC; Schellens, JH; Verweij, J | 1 |
| Sakata, Y; Suzuki, H; Takemori, H | 1 |
| Francis, PA; Michael, M; Millward, MJ; Rischin, D; Shapiro, JD; Toner, GC; Walcher, V | 1 |
| Kennedy, MJ | 1 |
| Mani, S; Ratain, MJ | 1 |
| Christensen, IJ; Holm, B; Jensen, PB; Sehested, M; Sorensen, M | 1 |
| Natale, RB | 2 |
| Pedersen, AG | 1 |
| Sculier, JP | 1 |
| Boyer, MJ; Clarke, SJ | 1 |
| Devriendt, D; Klastersky, J | 1 |
| Murray, N | 1 |
| Androulakis, N; Dimopoulos, MA; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kotsakis, T; Kourousis, C; Merambeliotakis, N; Papadakis, E; Vardakis, N | 1 |
| Androulakis, N; Bouros, D; Dimopoulos, MA; Georgoulias, V; Hatzakis, K; Hatzidaki, D; Heras, P; Kakolyris, S; Kalbakis, K; Kotsakis, T; Kourousis, C; Meramveliotakis, N; Papadimitriou, C; Vardakis, N | 1 |
| Ozols, RF | 1 |
| Furuse, K | 1 |
| Masuda, N | 2 |
| Negoro, S | 1 |
| Athanassiades, A; Bacoyiannis, C; Briassoulis, E; Fountzilas, G; Kalogera-Fountzila, A; Kosmidis, P; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Boyer, MJ | 1 |
| Ghaemmaghami, M; Jett, JR | 1 |
| Cook, JA; Fisher, J; Liebmann, JE; Mitchell, JB; Russo, A; Teague, D; Theodossiou, C | 1 |
| Fukase, Y; Ishikawa, T; Ishitsuka, H; Nishida, M; Sawada, N; Yoshikubo, T | 1 |
| Bunn, PA; Kelly, K | 1 |
| Rigas, JR | 2 |
| Loddenkemper, R; Schönfeld, N; Serke, M | 1 |
| Dombernowsky, P; Giaccone, G; Sandler, A; Schwartsmann, G | 1 |
| Carney, DN | 1 |
| Fey, V; Gazitt, Y; Hilsenbeck, SG; Montegomrey, W; Rothenberg, ML; Thomas, C | 1 |
| Aylesworth, C; Burris, HA; Eckardt, JR; Eckhardt, SG; Forral, K; Kraynak, MA; Nicol, SJ; Rinaldi, DA; Rodriguez, GI; Rothenberg, ML; Sharma, A; Stephens, CD; Villalona-Calero, MA; Von Hoff, DD; Weiss, GR | 1 |
| Antoine, EC; Khayat, D | 1 |
| Budman, DR; Calabro, A; Kreis, W | 1 |
| Ajani, JA | 1 |
| Karlsson, G; Ragnarson Tennvall, G | 1 |
| Androulakis, N; Dimopoulou, I; Georgopoulou, T; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kakolyris, S; Kotsakis, A; Kouroussis, C; Papadakis, E; Papadimitriou, C; Souglakos, J; Tzannes, S; Vardakis, N | 1 |
| Jones, J; Laufman, LR; Nicol, S; Rhodes, VA; Spiridonidis, CH; Wallace, K | 1 |
| Amadori, D; Barzanti, F; Casadei Giunchi, D; Dal Susino, M; Frassineti, GL; Milandri, C; Ricotti, L; Zoli, W | 1 |
| Agelidou, A; Androulakis, N; Apostolopoulou, F; Bouros, D; Dimopoulos, MA; Georgoulias, V; Hatzakis, K; Kakolyris, S; Kalbakis, K; Kotsakis, A; Kouroussis, C; Papadakis, E; Papadimitriou, C; Vardakis, N; Vlachonicolis, J | 1 |
| Blum, JL; Brown, CS; Burger, HU; Buzdar, AU; Griffin, T; Jones, SE; Kuter, I; LoRusso, PM; Osterwalder, B; Vogel, C | 1 |
| Agelaki, S; Alexopoulos, A; Apostolaki, F; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kalbakis, K; Kosmas, C; Kourousis, C; Malamos, N; Mavroudis, D; Potamianou, A; Rigatos, G; Samonis, G; Sarra, E; Vlachonicolis, J | 1 |
| Cree, IA; Foss, AJ; Hungerford, JL; Kurbacher, CM; Myatt, N; Neale, MH; Plowman, PN | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hon, JK; Kalman, LA; Meluch, AA; Morrissey, LH; Scullin, DC; Smith, SW | 1 |
| Shepherd, FA | 1 |
| Giaccone, G | 2 |
| Bunn, PA | 2 |
| Brady, MF; McGuire, WP; Ozols, RF | 1 |
| Hansen, SW; Sessa, C; Tuxen, MK | 1 |
| Bacoyiannis, C; Daniilidis, J; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Kosmidis, P; Nicolaides, C; Nikolaou, A; Papadimitriou, C; Pavlidis, N; Samantas, E; Stathopoulos, G | 1 |
| Howell, SB; Lin, X | 1 |
| Blum, JL | 1 |
| van Oosterom, AT | 1 |
| Rizvi, NA | 1 |
| Manegold, C | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P | 1 |
| Khattab, J; Urba, SG | 1 |
| Bateman, AC; Cook, T; Dunsford, ML; Mead, GM; Tung, K | 1 |
| Bailey, RD; Blaskovich, MA; Hamilton, AD; Knowles, D; Ohkanda, J; Qian, Y; Sebti, SM; Sun, J | 1 |
| Chakravarthy, A; Choy, H; Johnson, D | 1 |
| Comella, G; Frasci, G; Pacilio, G; Panza, N | 1 |
| Burger, HU; Burris, HA; Drengler, RL; Eckhardt, SG; Griffin, T; Kraynak, M; Moczygemba, J; Reigner, B; Rodrigues, G; Rowinsky, EK; Villalona-Calero, MA; Von Hoff, DD; Weiss, GR | 1 |
| Beijnen, JH; Giaccone, G; Kroep, JR; Peters, GJ; Pinedo, HM; Postmus, PE; Rosing, H; Smit, EF; van Groeningen, CJ; van Moorsel, CJ; Voorn, DA | 1 |
| Belli, M; Bilancia, D; Carpagnano, F; Cioffi, R; Comella, G; Comella, P; Contu, A; De Cataldis, G; De Lena, M; Frasci, G; Lorusso, V; Maiorino, L; Manzione, L; Mascia, V; Massidda, B; Micillo, E; Natale, M; Nicolella, GP; Panza, N; Pusceddu, G | 1 |
| Dombernowsky, P; Hansen, HH; Stenbygaard, LE; Sørensen, JB | 1 |
| Amadori, D; Bacci, F; Barzanti, F; Dal Susino, M; Folli, S; Frassineti, GL; Ricotti, L; Tesei, A; Zoli, W | 1 |
| Antoniou, F; Aspropotamitis, A; Athanassiou, A; Batzios, S; Halikia, A; Kalantaridou, A; Karvounis, N; Pectasides, D; Visvikis, A | 1 |
| Balaña, C; Martin, C; Rosell, R | 1 |
| Nervi, AM; Ornstein, DL; Rigas, JR | 1 |
| Bengtson, EM; Rigas, JR | 1 |
| Bhargava, P; Dahut, W; Davis, TH; Figuera, M; Hawkins, MJ; Marshall, JL; Rizvi, NA; Spiridonidis, CH | 1 |
| Langer, CJ; Socinski, MA | 1 |
| Baccala, P; Berg, D; Clark, JW; Finkelstein, D; Fuchs, CS; Grenon, N; Grossbard, ML; Lynch, TJ; Mayer, RJ; Ryan, DP; Seiden, MV | 1 |
| Cascinu, S; Catalano, G; Catalano, V; Gasparini, G; Gattuso, D; Giordani, P; Morabito, A; Pancera, G; Silva, RR | 1 |
| Adenis, A; Conroy, T; Paillot, B | 1 |
| Ferreira, CG; Giaccone, G; Kummer, AJ; Peters, GJ; Pinedo, HM; Span, SW; Tolis, C; van Lopik, T | 1 |
| Atassi, G; Guilbaud, N; Jan, M; Kraus-Berthier, L; Naze, M; Pierré, A | 1 |
| Bajorin, DF; Boyle, MG; Dodd, PM; Herr, H; Hilton, S; Icasiano, E; Kelly, WK; Mazumdar, M; McCaffrey, JA | 1 |
| Abbruzzese, JL; Crane, CH; Evans, DB; Hudec, WA; Janjan, NA; Lahoti, S; Lee, JE; Lenzi, R; Pisters, PW; Raijman, I; Rich, TA; Wolff, RA | 1 |
| Giaccone, G; Golding, RP; Laan, D; Pinedo, HM; Postmus, PE; Smit, EF; Splinter, T; van Meerbeeck, JP; van Tinteren, H | 1 |
| Dimitriadis, K; Dimopoulos, A; Fountzilas, G; Kalophonos, C; Kosmidis, P; Mylonakis, N; Pavlidis, N; Samantas, E; Skarlos, D; Tsavdaridis, D | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hon, JK; Kalman, LA; Morrissey, LH; Scullin, DC; Smith, SW | 1 |
| Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A; Orlandini, C | 1 |
| Alonso, S; Barnadas, A; Carañana, V; Colomer, R; De Paz, L; Fernández, Y; Guillem, V; Llombart, A; Lluch, A; Ojeda, B | 1 |
| Akaza, H; Hattori, K | 1 |
| Ardiet, CJ; Bernard, E; Droz, JP; Guillot, A; Peguy, M; Rebattu, P; Tranchand, B; Zanetta, S | 1 |
| Kelly, K | 2 |
| Jekunen, A; Knuuttila, A; Linnainmaa, K; Mattson, K; Ollikainen, T; Suhonen, S; Taavitsainen, M | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; De Rosa, V; Elmo, M; Frasci, G; Lapenta, L; Petrillo, A; Thomas, R; Vallone, P | 1 |
| Fukuoka, M | 1 |
| Bishop, J; Boyer, M; Davison, J; Emmett, E; McClure, B; Michael, M; Millward, M; Rischin, D; Smith, J; Zalcberg, J | 1 |
| Barret, JM; Etiévant, C; Hill, BT | 1 |
| Gordon, RJ; Osterwalder, B; Planting, AS; Pronk, LC; Reigner, B; Sparreboom, A; Twelves, C; Vasey, P; Verweij, J | 1 |
| Albanell, J; Baselga, J; Bellmunt, J; Carles, J; Cortés-Funes, H; González-Larriba, JL; Guillem, V; Paz-Ares, L; Tabernero, JM | 1 |
| Bajorin, DF | 1 |
| Burris, HS; Greco, FA; Hainsworth, JD; Meluch, AA | 1 |
| Aravantinos, G; Bafaloukos, D; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Nicolaides, C; Pavlidis, N; Samelis, G | 1 |
| Fiebiger, WC; Greul, R; Hejna, M; Kornek, GV; Marosi, L; Raderer, M; Scheithauer, W; Schneeweiss, B; Ulrich-Pur, H | 1 |
| Glisson, BS; Hong, WK; Khuri, FR; Lippman, SM; Shin, DM | 1 |
| Bhupalam, L; Fleming, DR; Glisson, SD; Goldsmith, GH; LaRocca, RV; Michelson, GD | 1 |
| Cappuzzo, F; Green, MR; Rocha Lima, CM; Sherman, CA | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD | 2 |
| Comella, P | 2 |
| Kosmidis, P | 1 |
| Altavista, P; Ceciarelli, F; Cividalli, A; Cruciani, G; Livdi, E; Mauro, F; Tirindelli Danesi, D | 1 |
| Buccheri, G; Ferrigno, D | 1 |
| Dalbot, DC; Gordon, RJ; Griffin, T; Moiseenko, VM; O'Reilly, SM; Osterwalder, B; Van Belle, S | 1 |
| Sandler, A | 2 |
| Albanell, J; Banús, JM; Baselga, J; Bastús, R; Batiste-Alentorn, E; Bellmunt, J; Carles, J; Climent, MA; Cortés-Funes, H; de la Cruz, JJ; Diaz-Rubio, E; Font, A; Gallardo, E; González-Larriba, JL; Guillem, V; López-Brea, M; Nogué, M; Paz-Ares, L; Sáenz, A | 1 |
| Giaccone, G; Groeningen, CJ; Kroep, JR; Loves, WJ; Peters, GJ; Pinedo, HM; Tolis, C; Voorn, DA | 1 |
| Catania, C; Cinieri, S; Curigliano, G; Danesi, R; de Braud, F; De Pas, T; del Tacca, M; Fogli, S; Goldhirsch, A; Marrocco, E; Milani, A; Rocca, A; Sbanotto, A; Sessa, C; Zampino, G | 1 |
| Bunn, PA; Kelly, K; Mikhaeel-Kamel, N; Murphy, J; Pan, Z; Prindiville, S | 1 |
| Barbarisi, A; Benassai, G; Carbone, I; Ciccarelli, PD; Crovella, F; De Rosa, P; Frattolillo, A; Iaffaioli, RV; Libutti, M; Santangelo, M; Tortoriello, A; Turitto, G | 1 |
| Awada, A; Piccart, MJ | 1 |
| Arita, K; Daido, K; Nakamura, K; Ohashi, N | 1 |
| Cox, G; Jeyapalan, K; Muller, S; O'Byrne, KJ; Sharma, RA; Shields, F; Steward, WP; Thomas, AL | 1 |
| Briasoulis, E; Constantopoulos, S; Froudarakis, M; Milionis, HJ; Pavlidis, N; Peponis, I | 1 |
| Azinovic, I; Brugarolas, A; Calvo, E; Cortes, J; de Irala, J; Fernandez-Hildago, O; Garzon, C; Martinez-Aguillo, M; Martinez-Monge, R; Ramon Y Cajal, T; Rodriguez, J | 1 |
| Abu-Rustum, N; Barakat, RR; Brown, CL; Chi, DS; Curtin, JP; Hoskins, WJ; Husain, A; Poynor, EA; Prasad, M | 1 |
| Barbarisi, A; De Marino, V; Elia, S; Facchini, G; Fraioli, G; Frattolillo, A; Gentile, M; Gravina, A; Griffo, S; Iaffaioli, RV; Illiano, A; Libutti, M; Muto, P; Tortoriello, A; Turitto, G | 1 |
| Gérinière, L; Souquet, PJ | 2 |
| Barbieri, F; Bearz, A; Ceresoli, GL; Favaretto, A; Frustaci, S; Ghiotto, C; Oniga, F; Paccagnella, A; Schiavon, S; Villa, E | 1 |
| Heinemann, V | 5 |
| D'Agostino, G; Ferrandina, G; Greggi, S; Lorusso, D; Mancuso, S; Manzione, L; Salerno, MG; Scambia, G | 1 |
| Carroll, J; Gurnani, M; Hajian, G; Johnson, RC; Mathis, JM; Nielsen, LL; Shi, B; Terracina, G | 1 |
| Alberola, V; Artal, A; Azagra, P; Camps, C; Carrato, A; Felip, E; González-Larriba, JL; Isla, D; Martin, C; Massutí, B; Rosell, R; Sánchez, JJ | 1 |
| Vokes, EE | 1 |
| Endo, M; Kadou, T; Kotani, Y; Ohbayashi, K; Satouchi, M; Takada, Y | 1 |
| Brescia, FJ; Green, MR; Rocha Lima, CM; Sherman, CA; Urbanic, JJ | 1 |
| Bonomi, P; Shirazi, W | 1 |
| Belani, CP; Calvo, AR | 1 |
| Agelaki, S; Aravantinos, G; Georgoulias, V; Kakolyris, S; Karabekios, S; Kouroussis, C; Mavroudis, D; Rigatos, SK; Stathopoulos, GP; Tsavaris, N | 1 |
| Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Greco, F; Guarneri, V; Innocenti, F; Menconi, MC; Orlandini, C; Pazzagli, I | 1 |
| Blair, S; Carman, L; Colborn, D; George, C; Jones, J; Kuebler, JP; Laufman, LR; Moore, T; Patel, T; Roach, R; Rupert, R; Spiridonidis, CH; Zangmeister, J | 1 |
| Georgoulias, VA | 1 |
| Aragão, BC; Garcia, R; Guimarães, RC; Murad, AM; Rodrigues, VH; Scalabrini'Neto, AO | 1 |
| Ansari, R; Gize, G; Miller, KD; Monaco, F; Nattam, S; Pennington, K; Sisk, J; Sledge, GW | 1 |
| Cetto, GL; Conte, P; Crino, L; Donati, S; Galligioni, E; Gennari, A; Mansutti, M; Mazzoni, F; Molino, A; Salvadori, B | 1 |
| Carrasco, E; Dueñas, R; Fernández, M; González, E; Jaén, A; Lozano, A; Martos, M; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Abbruzzese, JL; Breslin, TM; Cleary, KR; Crane, CH; Dackiw, AP; Evans, DB; Harbison, DB; Hess, KR; Janjan, NA; Jean, ME; Lee, JE; Pisters, PW; Vauthey, JN; Wolff, RA | 1 |
| Douillard, JY; Eckardt, J; Georgoulias, V; Manegold, C; Miller, V; Scagliotti, G | 1 |
| Blesch, K; Reigner, B; Weidekamm, E | 1 |
| Malkowicz, SB; Vaughn, DJ | 2 |
| Fujimoto-Ouchi, K; Tanaka, Y; Tominaga, T | 1 |
| Agelaki, S; Androulakis, N; Bania, E; Chainis, K; Georgoulias, V; Kakolyris, S; Kalofonos, C; Kouroussis, C; Papadakis, E; Rapti, A; Sarra, E; Toubis, M; Tsiafaki, X; Vardakis, N | 1 |
| Du, W; Hussain, M; Redman, B; Smith, DC; Vaishampayan, U | 1 |
| Antonopoulos, M; Kalofonos, HP; Kosmas, C; Kourelis, T; Malamos, N; Panopoulos, C; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Assouline, D; Bennouna, J; Douillard, JY; Grau, B; Haller, AM; Lerouge, D; Monnier, A; Rivière, A; Sun, XS | 1 |
| Brátová, M; Kohout, P; Králícková, P; Melichar, B; Solichová, D; Zadák, Z | 1 |
| Conte, P; Donati, S; Gennari, A; Landucci, E; Salvadori, B | 1 |
| Alexopoulos, A; Georgoulias, V; Palamidas, P; Papadakis, E; Rapti, A; Tsiafaki, X; Veslemes, M; Vlachonikolis, I | 1 |
| Bengala, C; Conte, P; Donati, S; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Salvadori, B | 1 |
| Aragão, BC; Garcia, R; Guimarães, RC; Murad, AM; Rodrigues, VH; Scalabrini-Neto, AO | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Johnson, V; Meluch, AA; Morrissey, LH; O'Rourke, T; Ortega, G; Steis, RG | 1 |
| Fine, RL; Sherman, WH | 1 |
| Blum, JL; Diab, S; Elledge, R; Griffin, T; Jones, SE; Khoury, P; Kraynak, M; Kromelis, P; Moczygemba, J; Rowinsky, EK; Villalona-Calero, MA; Von Hoff, D | 1 |
| Botwood, N | 1 |
| Mattson, K | 1 |
| Edelman, MJ; Gandara, DR; Lara, P; Lau, DH; Lauder, IJ; Tracy, D | 1 |
| Kielb, SJ; Rubin, MA; Sanda, MG; Shah, NL | 1 |
| Soloway, MS | 1 |
| Carpini, RD; Fedier, A; Fink, D; Haller, U; Schwarz, VA; Walt, H | 1 |
| Bookman, MA | 4 |
| Murren, JR | 1 |
| Bunnell, CA; Burstein, HJ; Winer, EP | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; De Rosa, V; Frasci, G; Thomas, R | 1 |
| Chalas, E; Hindenburg, A; Jeyakumar, A | 1 |
| Rixe, O | 1 |
| Beryt, M; Felber, M; Hepp, H; Kahlert, S; Konecny, G; Langer, E; Lude, S; Pegram, M; Slamon, D; Untch, M | 1 |
| Edelman, MJ; Mullins, B; Quam, H | 1 |
| Bhargava, P; Dahut, W; Figuera, M; Fried, K; Gehan, E; Hanfelt, J; Hawkins, MJ; Lefebvre, P; Marshall, JL; Rizvi, NA; Williams, M | 1 |
| Gatzemeier, U | 1 |
| Baron, A; Bunn, PA; Chan, DC; Franklin, WA; Helfrich, B; Hirsch, FR; Soriano, AF; Varella-Garcia, M; Zeng, C | 1 |
| Satoh, H; Sekizawa, K | 1 |
| Baldini, E; Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A; Orlandini, C; Pazzagli, I; Salvadori, B | 1 |
| Schwetz, BA | 1 |
| Leyland-Jones, B | 1 |
| Burstein, HJ; Winer, EP | 1 |
| Carman, L; Colborn, D; Gutterman, L; Jones, J; Kuebler, JP; Larrimer, N; Laufman, LR; Moore, T; Patel, T; Pritchard, J; Roach, R; Segal, M; Spiridonidis, CH; Zangmeister, J | 1 |
| Bontenbal, M; Smorenburg, CH; Sparreboom, A; Verweij, J | 1 |
| du Bois, A | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Alexopoulos, A; Georgoulias, V; Giannakakis, T; Grigoratou, T; Kakolyris, S; Kouroussis, C; Mavroudis, D; Palamidas, P; Papadakis, E; Rapti, A; Samonis, G; Tsiafaki, X; Veslemes, M; Vlachonikolis, J | 1 |
| Caffo, O | 1 |
| Belani, CP; Harrington, D; Johnson, DH; Krook, J; Langer, C; Sandler, AB; Schiller, J; Sweeney, CJ; Zhu, J | 1 |
| Blum, JL; Buzdar, A; Dieras, V; Horton, J; Lo Russo, PM; Osterwalder, B; Rutman, O | 1 |
| Baker, M; Billings, FT; Bradof, JE; Burris, HA; Greco, FA; Hainsworth, JD | 1 |
| Kalofonos, HP; Kosmas, C; Koutras, A; Malamos, N; Onyenadum, A; Polyzos, A; Rokana, S; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
| Calabrò, F; Marini, L; Pizzocaro, G; Schnetzer, S; Sella, A; Sternberg, CN | 1 |
| Chacón, JI; de Castro, J; Dorta, J; Espinosa, E; Feliu, J; González Barón, M; Lizón, J; Martin, G; Rodríguez, A; Sánchez Heras, B; Torrego, JC | 1 |
| de Wit, R | 1 |
| Belani, CP; Harrington, D; Johnson, DH; Krook, J; Langer, C; Sandler, A; Schiller, JH; Zhu, J | 1 |
| Favaudon, V; Hennequin, C | 1 |
| Clegg, A; Hewitson, P; Scott, DA; Sidhu, M; Waugh, N | 2 |
| Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; Di Bonito, M; Frasci, G; Rubulotta, R; Thomas, R; Vallone, P | 1 |
| Brugnatelli, S; Danova, M; De Bella, MT; Manuguerra, G; Palmeri, S; Riccardi, A; Vaglica, M | 1 |
| Clark, JW; Earle, CC; Fuchs, CS; Grossbard, ML; Grossman, SR; Kim, H; Kulke, MH; Mayer, RJ; Morgan, JA; Ryan, DP; Shivdasani, R | 1 |
| Milowsky, MI; Nanus, DM; Papanicolaou, N; Rosmarin, A; Tickoo, SK | 1 |
| Curigliano, G; Danesi, R; De Braud, F; De Pas, T; Del Tacca, M; Fogli, S; Giovannetti, G | 1 |
| Thigpen, T | 3 |
| Hansen, SW | 1 |
| O'Shaughnessy, J | 3 |
| Wilke, H | 1 |
| Chen, YM; Lee, CS; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 1 |
| Athanassiou, A; Bountouroglou, N; Glotsos, J; Karvounis, N; Kouloubinis, A; Mitakidis, N; Pectasides, D; Ziras, N | 1 |
| von der Maase, H | 1 |
| Stadler, WM | 1 |
| Hussain, M; Smith, DC; Vaishampayan, U | 1 |
| Misset, JL | 1 |
| Cowan, DS; Egorin, MJ; Lee, CM; Tannock, IF; Tunggal, JK | 1 |
| Barton, JH; Bradof, JE; Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Litchy, S; Morrissey, LH; Richards, P; Scullin, DC | 1 |
| Maher, JF; Villalona-Calero, MA | 1 |
| Dueñas, MR; Fernández, M; González, E; Jaén, A; Lozano, A; Martos, M; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Conte, PF; Dani, D; Donati, S; Gennari, A; Giorgetti, A; Landucci, E; Mariani, G; Pisani, P; Poli, M; Puccini, G; Salvadori, B; Salvadori, PA; Sorace, O | 1 |
| Kato, Y; Saijo, N | 1 |
| Catalano, P; Einhorn, LH; Hinton, S; Kuzel, T; Loehrer, PJ; Vaughn, D; Wilding, G | 1 |
| Riviere, A | 1 |
| Morere, JF | 2 |
| Mavroudis, D | 1 |
| Hisada, T; Ito, T; Masuda, S; Mochida, A; Morinari, H; Nakahara, K; Nishi, K; Saito, K; Sasaki, S; Tahara, M; Yakumaru, K | 1 |
| Brandl, M; Burger, AM; Fiebig, HH; Massing, U; Moog, R; Schubert, R; Schüler, J; Unger, C | 1 |
| Ackland, S; Alba Conejo, E; Burger, HU; Eisenberg, P; Laws, S; Melnychuk, D; Moiseyenko, V; O'Reilly, SM; Osterwalder, B; Pienkowski, T; Talbot, DC; Van Belle, S | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kovats, E; Kwasny, W; Lang, F; Payrits, T; Raderer, M; Scheithauer, W; Schüll, B | 1 |
| Fujikawa, K; Fukuzawa, S; Iwamura, H; Matsui, Y; Oka, H; Takeuchi, H | 1 |
| Algarra, I; Gaforio, JJ; Jaén, A; Lozano, A; Sánchez-Rovira, P; Serrano, MJ | 1 |
| Clinton, S; Erdal, S; Hauger, M; Kraut, E; Monk, P; Nadella, P; Otterson, GA; Shah, M; Shapiro, C; Stanek, M; Villalona-Calero, MA | 1 |
| Angiolini, C; Baldini, A; Bergaglio, M; Canavese, G; Del Mastro, L; Garrone, O; Lambiase, A; Merlano, M; Rosso, R; Tolino, G; Venturini, M | 1 |
| Zielinski, CC | 1 |
| Dueñas, R; Fernández, M; Jaén, A; Lozano, A; Martínez, E; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Hensley, ML | 1 |
| Bruckner, HW; Kozuch, P; Petryk, M | 1 |
| Ryan, DP; Willett, CG | 1 |
| Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S | 1 |
| Aghajanian, C; Barakat, R; Geller, G; Hensley, ML; Lovegren, M; Maki, R; Sabbatini, P; Spriggs, DR; Tong, W; Venkatraman, E | 1 |
| Kalofonos, HP; Kosmas, C; Tsavaris, N | 1 |
| Cortés-Funes, H | 1 |
| Gray, JR; Greco, FA; Hainsworth, JD; Hon, JK; Kalman, LA; Morrissey, LH | 1 |
| Culine, S | 1 |
| Takigawa, N | 1 |
| Takeda, K | 1 |
| Watanabe, H | 1 |
| Okamoto, H; Watanabe, K | 1 |
| Arbea, L; Calvo, E; Cambeiro, M; Cortes, J; Diaz-Gonzalez, JA; Garcia-Foncillas, J; Garzon, C; Gil-Bazo, I; Gurpide, A; Martin-Algarra, S; Navarro, V; Nicolas, AI; Rodriguez, J | 1 |
| Logothetis, C; Millikan, R | 1 |
| Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A | 1 |
| Chiu, HC; Chu, CY; Yang, CH | 1 |
| Fife, K; Ganjoo, KN; Gordon, MS; Loehrer, PJ; Poirier, S; Sandler, AB; Seshadri, R; Warner, RE | 1 |
| Perez, EA; Qu, G | 1 |
| Allott, CP; Boxall, FE; Kelland, LR; Rogers, P; Stephens, TC | 1 |
| Green, MR | 1 |
| de Boeck, G; de Bruijn, E; de Jonge, MJ; Dumez, H; Guetens, G; Highley, M; Louwerens, M; Mantel, M; Pawinsky, A; Planting, AS; Van Oosterom, AT; Verweij, J | 1 |
| Casado, E; De Castro, J; Feliu, J; González Barón, M; Ordoñez, A | 1 |
| Alvarez Castelo, L; Blanco Díez, A; Fernández Rosado, E; González Martín, M; Rodríguez Gómez, I; Sánchez Rodríguez Losada, J; Suárez Pascual, G | 1 |
| Akerman, P; Cioffi, W; Cruff, D; Dipetrillo, T; Iannitti, D; Quirk, D; Ramdin, N; Rich, T; Safran, H; Shah, S | 1 |
| Castro Kreder, N; Franken, NA; Haveman, J; Loves, WJ; Peters, GJ; van Bree, C | 1 |
| O'Brien, ME; Waters, JS | 1 |
| Eichelmann, K; Fahlke, J; Hribaschek, A; Kuhn, R; Ridwelski, K; Rudolph, S | 1 |
| Bacoyiannis, C; Boukovinas, J; Dimopoulos, M; Economopoulos, T; Fountzilas, G; Kalophonos, C; Kosmidis, P; Mylonakis, N; Nicolaides, C; Papakostas, P; Samantas, E; Skarlos, D; Tsavdaridis, D | 1 |
| Jacobs, AD | 1 |
| Albanell, J; Baselga, J; Bellmunt, J; Carles, J; Climent, MA; Cortés-Funes, H; de la Cruz, JJ; Díaz-Rubio, E; González-Larriba, JL; Guillem, V; Paz-Ares, L | 1 |
| Baker, CH; Bucana, CD; Fidler, IJ; Kedar, D; McCarty, MF; Tsan, R; Weber, KL | 1 |
| Barton, JH; Burris, HA; Butts, JA; Erland, JB; Gray, JR; Greco, FA; Hainsworth, JD; Houston, GA; Litchy, S; Scott, C; Thompson, DS; Webb, C | 1 |
| Adachi, S; Fung, MC; Ishiguro, H; Sakata, T | 1 |
| Cox, K; Faul, MM; Keyes, K; Mann, L; Shih, C; Teicher, BA; Treadway, P | 1 |
| Popa, IE; Rizvi, NA; Smith, FP; Stewart, K | 1 |
| Ansari, R; Bhatia, S; Einhorn, L; Hanna, N; Ng, E; Pletcher, W; Sandler, A | 1 |
| Borsellino, N; Cazzato, C; Colucci, G; Durini, E; Galetta, D; Gebbia, V; Giotta, F; Pezzella, G; Romito, S | 1 |
| Twelves, CJ; Wright, TL | 1 |
| Crawford, J; Green, MR; Herndon, JE; Leopold, KA; Miller, AA; Perry, MC; Vokes, EE | 1 |
| Chen, YM; Lin, WC; Perng, RP; Tsai, CM; Whang-Peng, J; Wu, HW | 1 |
| Brierre, JE; Buller, EJ; Cole, JL; Fontenot, MF; Lormand, NA; Rainey, JM; Rinaldi, DA; Stagg, MP | 1 |
| Barsoum, J; Brickelmaier, M; Carmillo, A; Goelz, S; Qin, XQ | 1 |
| Adamo, V; Altavilla, G; Boni, C; Ceribelli, A; Clerici, M; Crinò, L; De Marinis, F; Di Costanzo, F; Failla, G; Frontini, L; Gridelli, C; Marangolo, M; Matano, E; Ricci, S; Rinaldi, M; Scagliotti, GV; Tonato, M | 1 |
| Hahn, PF; Halpern, EF; Jhaveri, KS; Prasad, SR; Saini, S; Sumner, JE | 1 |
| Harper, P; Marx, G | 1 |
| Bankhead, C | 1 |
| Adjei, AA; Dy, GK | 1 |
| Budman, DR | 1 |
| Depierre, A; Jacoulet, P; Westeel, V | 1 |
| Choma, D; Jacot, W; Pujol, JL; Quantin, X | 1 |
| André, T; Artru, P; Louvet, C | 1 |
| Besse, B; Spano, JP | 1 |
| Gutierrez, M; Lhomme, C; Pautier, P | 1 |
| André, T; Culine, S; Epaud, C; Gligorov, J | 1 |
| Ash-Bernal, R; Browner, I; Erlich, R | 1 |
| Carpagnano, F; Crucitta, E; De Lena, M; Guida, M; Lorusso, V; Mancarella, S; Panza, N; Sambiasi, D; Silvestris, N | 1 |
| Aapro, M; O'Shaughnessy, J; Twelves, C | 1 |
| Miles, D; Seidman, AD; von Minckwitz, G | 1 |
| Aramendia, JM; Aristu, JJ; Bosch, A; Brugarolas, A; Calvo, E; Claver, A; Cortes, J; Garcia-Foncillas, J; Gurpide, A; Lopez-Picazo, JM; Martin-Algarra, S; Rodriguez, J; Salgado, E | 1 |
| Terao, I | 1 |
| Crinò, L | 1 |
| Douillard, JY; Eckardt, J; Scagliotti, GV | 1 |
| Gridelli, C; Hainsworth, J | 1 |
| Friberg, LE; Henningsson, A; Karlsson, MO; Maas, H; Nguyen, L | 1 |
| Budd, GT; Bukowski, RM; Elson, P; Hutson, TE; Mekhail, T; Olencki, T; Peereboom, D; Pelley, R; Srkalovic, G | 1 |
| Bonavida, B; Emmanouilides, C; Jazirehi, AR | 1 |
| Fournel, P | 1 |
| Adachi, S; Iijima, T; Ito, K; Kimura, T; Nakatsuji, Y; Nobunaga, T | 1 |
| Fukushima, M; Furuse, K; Harada, H; Hosoe, S; Iwamoto, Y; Kawahara, M; Komuta, K; Morioka, T; Ohsaki, Y; Origasa, H; Shibata, K | 1 |
| Amadori, D; De Paola, F; Frassineti, GL; Milandri, C; Ricotti, L; Tesei, A; Ulivi, P; Zoli, W | 1 |
| Abbruzzese, JL | 1 |
| Senzer, N | 1 |
| Castro, M | 1 |
| Bighin, C; Colozza, MA; Contu, A; Del Mastro, L; Durando, A; Garrone, O; Genta, F; Lambiase, A; Stevani, I; Venturini, M | 1 |
| Colowick, AB; Fleishman, A; Glaspy, JA; Jadeja, JS; Justice, G; Rossi, G | 1 |
| Butzbach, D; Cairdella, M; Capanna, T; DiPaola, RS; Dvorzhinski, D; Eid, J; Goodin, S; Rubin, E; Shih, JW; Todd, MB; Toppmeyer, D | 1 |
| Bunn, PA; Lilenbaum, R | 1 |
| Bengala, C; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Fogli, S; Guarneri, V; Innocenti, F; Mariani, M; Pazzagli, I | 1 |
| Inciūra, A; Juozaityte, E | 1 |
| Chávez-Blanco, A; Dueñas-González, A; García-López, P; González-Fierro, A; Lizano-Soberon, M; Mariscal, I; Pérez-Cárdenas, E; Segura-Pacheco, B; Taja-Chayeb, L; Trejo-Becerril, C; Treviño-Cuevas, H; Wegman-Ostrosky, T | 1 |
| al-Jazayrly, G; Edelman, MJ; Gandara, DR; Houston, J; Lara, PN; Lau, DH; Lauder, I; Lim, N; Tanaka, M | 1 |
| Bunn, PA; Simon, GR | 1 |
| Amant, F; Berteloot, P; D'Agostino, G; Scambia, G; Vergote, I | 1 |
| Colangelo, D; Mahboobi, H; Osella, D; Viarengo, A | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Matsumoto, T; Niho, S; Nishiwaki, Y; Ohmatsu, H | 1 |
| Ayoub, J; Charpentier, D; Desjardins, P; Hirsh, V; Langleben, A; Ofiara, L; Pintos, J; Small, D; Whittom, R | 1 |
| Arai, Y; Endo, M; Hagisawa, S; Hiramatu, M; Hoshi, S; Ohyama, C; Satoh, M; Watanabe, R | 1 |
| Faucette, SR; Gillenwater, HH; Hawke, RL; Lindley, C; Pescatore, SL; Shord, SS; Socinski, MA | 1 |
| Fumoleau, P | 1 |
| Sledge, GW | 2 |
| Marchettini, P; Mohamed, F; Stuart, OA; Sugarbaker, PH; Urano, M | 1 |
| O'Shaughnessy, JA | 1 |
| Dreicer, R; George, CS; Manola, J; Roth, BJ; Schneider, DJ; Schwerkoske, JF; Wilding, G | 1 |
| Ilersich, AL; Verma, S | 1 |
| Mayor, S | 1 |
| Chang, TW; Chen, GY; Chen, WC | 1 |
| Bepler, G; Boni, C; Cooc, J; Crinò, L; Danenberg, KD; De Marinis, F; Di Costanzo, F; Gozzelino, F; Lord, RV; Marangolo, M; Novello, S; Rinaldi, M; Rosell, R; Salonga, D; Sánchez, JJ; Scagliotti, G; Stephens, C; Taron, M; Tonato, M | 1 |
| Alberti, D; Arzoomanian, RZ; Bailey, HH; Binger, K; Feierabend, C; Liu, G; Marnocha, R; Thomas, JP; Volkman, J; Wilding, G | 1 |
| Berghe, KV; Berkenblit, A; Cannistra, SA; Feyler, H; Kim, Y; Niloff, J; Tung, N | 1 |
| Flaherty, KT; Hahn, SM; O'Dwyer, PJ; Redlinger, M; Stevenson, JP | 1 |
| Heimans, JJ; Hoekman, K; Postma, TJ; Verstappen, CC | 1 |
| Abrams, RA; Regine, WF; Rich, TA; Safran, H; Willett, CG | 1 |
| Blohmer, J; Kaubitzsch, S; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D | 2 |
| Sternberg, CN; Vogelzang, NJ | 1 |
| Duan, Y; Duan, Z; Lamendola, DE; Naeem, R; Penson, RT; Seiden, MV; Yusuf, RZ | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Loprevite, M; Pirani, P; Semino, C | 1 |
| Behrns, K; Bernard, SA; Calvo, B; Cance, W; Churchel, MA; Detterbeck, FC; Koruda, M; Ollila, D; Poole, ME; Weissler, MC | 1 |
| Hussain, SA; James, ND | 1 |
| Bookman, M; Copeland, LJ; Trimble, E | 1 |
| Mutch, DG | 1 |
| Belinson, J; Kulp, B; Markman, M; Peterson, G; Webster, K; Zanotti, K | 1 |
| Haller, DG | 1 |
| Hanibuchi, M; Hirano, H; Ito, M; Maeda, H; Nakagawa, M; Okumura, Y; Sawabata, Y; Takeda, S; Uematsu, K | 1 |
| Dundr, P; Dvorácek, J; Pesl, M; Povýsil, C; Vítková, I | 1 |
| Brancaccio, L; Cortesi, E; Crispino, C; De Marinis, F; Gridelli, C; Martelli, O; Migliorino, MR; Nelli, F; Portalone, L; Treggiari, S | 1 |
| Dowlati, A; Levitan, N | 1 |
| Biesma, B; Debruyne, C; Gaafar, R; Giaccone, G; Legrand, C; Lianes, P; Manegold, C; Neymark, N; Schramel, F; Smit, EF; Smit, H; van Meerbeeck, JP | 1 |
| Allen, HJ; Baker, C; Bosserman, LD; Chapman, Y; Figlin, RA; Gitlitz, BJ; Patel, R; Sanchez, JD; Shapiro, RM | 1 |
| Chun, JH; Han, JY; Hong, EK; Kim, HY; Lee, DH; Lee, HG; Lee, JS; Lee, SY; Shin, EH; Yoon, SM | 1 |
| Badalamenti, G; Fulfaro, F; Gebbia, N; Russo, A; Valerio, MR | 1 |
| Boni, C; Zanelli, F | 1 |
| Coker, A; Kamer, E; Ozer, E; Ozkara, E; Ozzeybek, T; Sevinç, AI | 1 |
| Amadori, D; Fabbri, M; Frassineti, GL; Ibrahim, T; Monti, M; Ricotti, L; Zoli, W | 1 |
| Gschwend, JE; Hautmann, RE; Simon, J; Volkmer, B | 1 |
| Andruccetti, M; Bartolini, S; Benedetti, G; Calandri, C; Cappuzzo, F; Cortesi, E; Crinò, L; De Marinis, F; Maestri, A; Martelli, O; Migliorino, MR; Nelli, F; Rastelli, F | 1 |
| Furukawa, K; Kataba, H; Kato, H; Miura, T; Saito, M | 1 |
| Dawson, NA; Edelman, MJ; Houston, J; Lara, PN; Lauder, I; Law, LY; Meyers, FJ | 1 |
| Comella, G; Comella, P; De Cataldis, G; De Rosa, V; Fiore, F; Frasci, G; Lapenta, L; Licenziato, M; Maiorino, L | 1 |
| Bookman, MA; Herzog, TJ; Look, KY; Rocereto, T; Schol, J; Vinters, J | 1 |
| Aravantinos, G; Briassoulis, E; Dimopoulos, MA; Fountzilas, G; Gika, D; Kalofonos, C; Moulopoulos, LA; Papadimitriou, CA | 1 |
| Alonso, S; Barnadas, A; Carañana, V; Colomer, R; Fernández, Y; García-Conde, J; Guillem, V; Hornedo, J; Llombart-Cussac, A; Lluch, A; Montero, S; Ojeda, B | 1 |
| Balbiani, L; Brosio, C; Caccia, G; Delfino, C; Flores Morales, D; Mickiewicz, E; Riva Gonzáles, L; Rodger, J; Zori Comba, A | 1 |
| Murad, AM | 1 |
| Pfisterer, J | 1 |
| Beraldi, E; English, JC; Evans, K; Fazli, L; Gleave, ME; July, LV; So, A | 1 |
| Balbiani, L; Brosio, C; Caccia, G; Comba, AZ; Delfino, C; Gonzáles, LR; Mickiewicz, E; Morales, DF; Rodger, J | 1 |
| Aghajanian, C; Ben-Porat, L; Chi, DS; Hensley, ML; Hoppe, B; Prasad, M; Sabbatini, P | 1 |
| Bold, RJ; Fahy, BN; Schlieman, MG; Virudachalam, S | 1 |
| Barlow, C; Fennell, D; Gallagher, C; Ismay, J; Nystrom, M; Oesterling, C | 1 |
| MacLeod, P; Maziak, DE; Shamji, FM; Stewart, DJ; Tomiak, E | 1 |
| Bahador, A; Facio, G; Garcia, AA; Jeffers, S; Kim, DY; O'Meara, A; Roman, L | 1 |
| Beryt, M; Konecny, GE; O'Callaghan, C; Pegram, MD; Pietras, R; Slamon, DJ | 1 |
| Ahlgren, J; Batista, N; Carabantes, F; Casinello, J; Castellanos, J; Constenla, M; Gonzalez Barón, M; Murias, A; Perez-Manga, G; Regueiro, P; Ruiz, A; Söderberg, M; Villman, K | 1 |
| Aguiar Bujanda, D; Aguiar Morales, J; Bohn Sarmiento, U | 1 |
| Rugo, HS | 1 |
| Amin, B; Chen, YM; Gradishar, WJ; Hill, T; Lower, EE; Marcom, PK; Meza, LA; Samid, D | 1 |
| Ardavanis, A; Baziotis, N; Gerasimidis, G; Rigatos, G; Tryfonopoulos, D; Yiotis, I | 1 |
| Kim, CH; Kim, HT; Lee, JC; Park, YH; Ryoo, BY | 1 |
| A'Hern, R; Cole, C; Everard, M; Gibbens, I; Gore, M; Hall, G; Harries, M; Jenkins, A; Kaye, S; Moss, C; Perren, T; Pizzada, O; Shah, R | 1 |
| Argiris, A; Kies, MS; LaCombe, M; Liptay, M; Marymont, M; Masters, G; Sundaresan, S | 1 |
| Buzzi, F; Carnicelli, P; Cioffi, R; Comella, P; Filippelli, G; Frasci, G; Guida, M; Maiorino, L; Mancarella, S; Massidda, B; Panza, N | 1 |
| Bengala, C; Campani, D; Collecchi, P; Conte, PF; Donati, S; Gennari, A; Guarneri, V; Maur, M; Orlandini, C | 1 |
| Ho, ES; Hung, MJ; Hwang, SF; Ke, YM; Liu, FS; Lu, CH | 1 |
| Argiris, A; Eng, C; Haraf, DJ; Kozloff, MF; Milano, MT; Mittal, BB; Pelzer, H; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Albain, K; Bhoopalam, N; Chansky, K; Clark, JI; Crowley, J; Edelman, MJ; Gandara, DR; Giguere, JK; Kelly, K; Weiss, GR | 1 |
| Hatayama, O; Hayasaka, M; Inou, H; Koizumi, T; Kubo, K; Sasabayashi, M; Tsushima, K; Yamamoto, H; Yoshiike, F | 1 |
| Birk, CL; Brown, JV; Goldstein, BH; Graham, C; Mattison, J; Micha, JP; Rettenmaier, MA | 1 |
| Barbone, F; Belvedere, O; Ceschia, T; Fasola, G; Follador, A; Grossi, F; Guglielmi, A; Morelli, A; Puglisi, F; Recchia, L; Rizzato, S; Sibau, A; Sobrero, AF; Talmassons, G; Vigevani, E | 1 |
| Chen, YR; Li, H; Lu, YP; Sun, M; Wang, ZP; Wei, Q; Yang, YR; Yue, ZJ | 1 |
| Chen, Y; Li, H; Lu, Y; Sun, M; Wang, Z; Wei, Q; Yang, Y; Yue, Z | 1 |
| Bastert, G; Beldermann, F; Hamerla, R; Huober, J; Krauss, K; Rudlowski, C; Schneeweiss, A; Sinn, HP; Solomayer, E; von Fournier, D; Wallwiener, D | 1 |
| Lilenbaum, RC | 1 |
| Breton, JL; Gervais, R; Jacot, W; Pujol, JL; Quantin, X; Rebattu, P | 1 |
| Aebi, S; Ballabeni, P; Brauchli, P; Mingrone, W; Pestalozzi, BC; Rauch, D; Rijken, N; Rochlitz, C; Uhlmann, C | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hermann, R; Litchy, S; Morrissey, LH; Rodriguez, GI; Shaffer, DW; Yardley, DA | 1 |
| Herzog, TJ | 1 |
| Aravantinos, G; Christodoulou, C; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Karina, M; Papakostas, P; Razis, E; Skarlos, D; Tsavdaridis, D | 1 |
| Bader, K; Brown, JV; Goldstein, BH; Graham, C; Markman, M; Mattison, JA; Micha, JP; Rettenmaier, MA | 1 |
| Bang, SM; Chung, HW; Chung, JB; Kang, JK; Kim, JW; Lee, WJ; Park, SW; Seong, JS; Song, SY | 1 |
| Aguiar, D; Aguiar, J; Bohn, U | 1 |
| Aieta, M; De Giorgi, U; Fochessati, F; Marangolo, M; Paoluzzi, L; Papiani, G; Rosti, G; Valduga, F | 1 |
| Chen, CS; Chidiac, T; Lane, SR; Lilenbaum, RC; Schwarzenberger, PO; Thant, M; Versola, M | 1 |
| Arceci, RJ; Loeb, DM; Mack, AK; Small, D; Spevak, M; Strouse, JJ | 1 |
| Palmieri, FM; Perez, EA; Tack, DK | 1 |
| Foo, KF; Leong, SS; Lim, WT; Tan, EH; Tan, SB; Tan, T; Tay, MH; Thng, CH; Toh, CK; Wee, J | 1 |
| Addeo, A; Barone, C; Berruti, A; Bertetto, O; Buffoni, L; Dongiovanni, D; Dongiovanni, V; Fissore, C; Ottaviani, D; Polimeni, MA | 1 |
| Comella, P; Crucitta, E; De Lena, M; Gebbia, V; Lorusso, V; Mancarella, S; Mangiameli, A; Manzione, L; Muci, D; Palmeri, S; Pezzella, G; Rosati, G; Silvestris, N; Sobrero, A | 1 |
| Choi, M; Fogoros, S; Griffith, KA; Hu, YY; Liu, JR; Lucas, PC; Williams, J | 1 |
| Belau, A; Burges, A; du Bois, A; Elser, G; Jackisch, C; Lueck, HJ; Olbricht, S; Pfisterer, J; Richter, B; Schmalfeldt, B; Schroeder, W; Staehle, A; Wagner, U | 1 |
| Mikami, K; Miki, T; Mizutani, Y | 1 |
| Colomer, R | 2 |
| Poole, C | 1 |
| Belani, CP; Eckardt, J | 1 |
| Gillenwater, HH; Hensing, TA; Qaqish, BF; Socinski, MA; Stinchcombe, TE; Tyann, M | 1 |
| Ansari, R; Einhorn, LH; Fisch, MJ; Fox, E; Juliar, B; Li, J; Sweeney, CJ; Yiannoutsos, C | 1 |
| Dumontet, C; Sève, P | 1 |
| Alsina, M; Beam, C; Beaupre, DM; Dalton, W; Gerbino, E; Hamilton, AD; Kerr, WG; Lichtenheld, MG; Mackley, PA; Muro-Cacho, C; Sebti, SM; Zhu, K | 1 |
| Beslija, S; Brodowicz, T; Cervek, J; Chernozemsky, I; Ghilezan, N; Grgic, M; Inbar, M; Kahan, Z; Khamtsov, D; Mrsic-Krmpotic, Z; Pawlega, J; Soldatenkova, V; Spanik, S; Szanto, J; Tzekova, V; Vrbanec, D; Wagnerova, M; Welnicka-Jaskiewicz, M; Wiltschke, C; Zielinski, C | 1 |
| Argiris, A; Haraf, DJ; Kao, J; Milano, MT; Mittal, BB; Salama, JK; Stenson, KM; Vokes, EE; Weichselbaum, RR; Witt, ME | 1 |
| Guardino, AE; Srinivas, S | 1 |
| Bearden, JD; Greco, FA; Hainsworth, JD; Litchy, S; Meluch, AA; Schnell, FM; Yost, K | 1 |
| Hlavatá, Z; Koza, I; Mardiak, J; Mego, M; Obertová, J; Recková, M; Sálek, T; Sycová-Milá, Z | 1 |
| Crinò, L; De Marinis, F; Foggi, P; Kielhorn, A; Maestri, A; Migliorino, AM; Novello, S; Rinaldi, M; Scagliotti, GV; Selvaggi, G; Stynes, G; Tilden, D; Tonato, M | 1 |
| Arora, R; Awasthy, BS; Fuloria, J; Ganesh, N; Gupta, SK; John, S; Naik, R; Selvamani, B | 1 |
| Barlési, F; Pujol, JL | 1 |
| De Marinis, F; De Petris, L; Gebbia, V | 1 |
| Adams, DJ; Colvin, OM; Flowers, JL; Rizzieri, DA; Shanks, RH | 1 |
| Athanasiadis, A; Athanasiadou, DC; Papakostoulis, T; Roussos, G; Stathopoulos, GP | 1 |
| Bannowsky, A; Hamann, M; Hautmann, S; Jünemann, KP; Naumann, M; Wefer, B | 1 |
| Coleman, RE; El-Helw, L | 1 |
| Bang, YJ; Heo, DS; Kim, DW; Kim, DY; Kim, NK; Kim, TY; Lee, KW; Yun, T | 1 |
| Broggini, M; Kei Lee, M; Sabapathy, K; Siddique, MM; Vikhanskaya, F | 1 |
| Farmakis, D; Pectasides, D; Pectasides, M | 1 |
| Ueoka, H | 1 |
| Achiwa, H; Bessho, Y; Maeda, H; Muramatsu, H; Niimi, T; Oguri, T; Sato, S; Ueda, R | 1 |
| Chen, YM; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 2 |
| Kegel, T; Mueller, T; Schmoll, HJ; Simon, H; Voigt, W; Weiss, M | 1 |
| Furukawa, T; Hata, K; Hirai, I; Kawago, M; Kokawa, Y; Okamura, Y; Oura, S; Tanino, H; Yoshimasu, T | 1 |
| Chen, T; Chu, ZH; Liu, JP; Ou, QJ; Wang, J; Zhao, HY | 1 |
| Bartolini, S; Cappuzzo, F; Crinò, L; Finocchiaro, G; Metro, G; Toschi, L; Trisolini, R | 1 |
| Yardley, DA | 1 |
| Gradishar, WJ | 2 |
| Busby, EM; Carey, D; Divers, SG; Hyatt, MD; Robert, F; Spencer, SA | 1 |
| Duska, L; He, X; Klein, A; Mallett, A; Roche, M; Seiden, MV; Supko, JG | 1 |
| Arslan, M; Demiray, M; Ercan, I; Evrensel, T; Gokgoz, S; Gonullu, G; Kanat, O; Kurt, E; Manavoglu, O; Saraydaroglu, O; Tasdelen, I; Tolunay, S; Topal, U | 1 |
| Biroccio, A; D'Angelo, C; Leonetti, C; Lopez, M; Paoletti, G; Scarsella, M; Zupi, G | 1 |
| Chmura, SJ; Haraf, DJ; Kao, J; Milano, MT; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Montie, JE | 1 |
| Brown, ER; Shepherd, FA | 1 |
| Forkert, R; Fronhoffs, S; Ko, Y; Koll, C; Neuhaus, T; Stier, S; Tuohimaa, A; Vetter, H | 1 |
| Aida, Y; Honma, K; Okura, M; Tanaka, N; Tanimura, S; Tsutsumi, K; Yamamoto, H | 1 |
| Brody, JR; Cunningham, SC; DeMarzo, AM; Dezentje, DA; Gallmeier, E; Hruban, RH; Isacoff, WH; Kern, SE; Offerhaus, GJ; Swartz, MJ; van der Heijden, MS | 1 |
| De Petris, L; Friesland, S; Lax, I; Sirzén, F | 1 |
| Grénman, SE; Jalkanen, JT; Kuoppala, TA; Leminen, AO; Mäenpää, JU; Puistola, US; Vuolo-Merilä, PM; Yliskoski, MH | 1 |
| Lianes, P; Neymark, N; Smit, EF; van Meerbeeck, JP | 1 |
| Moreno-Aspitia, A; Perez, EA | 1 |
| Bordonaro, R; Castorina, S; Giannitto, GC; Giuffrida, D; La Venia, G; Marletta, F; Pappalardo, A; Potenza, E; Russo, A; Saita, S; Vincenzi, B | 1 |
| Horio, Y; Mitsudomi, T; Shimizu, J | 1 |
| Bilancia, D; Cognetti, F; Di Costanzo, F; Gasperoni, S; Landucci, E; Manzione, L; Mazzoni, F; Papaldo, P | 1 |
| Bavieri, M; Bigiani, N; Brambilla, E; Casali, C; Cavazza, A; Fabbri, LM; Facciolongo, N; Longo, L; Maiorana, A; Marchioni, A; Migaldi, M; Morandi, U; Rossi, G; Sartori, G; Schirosi, L | 1 |
| Allouache, D; Bozec, L; Gawande, SR; Genot, JY; Mefti, F; Piperno-Neumann, S; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Akerman, P; Barnett, JM; Cioffi, W; Cruff, D; Dipetrillo, T; Iannitti, D; Kennedy, T; Maia-Acuna, C; Martel, D; Miner, T; Remis, M; Safran, H | 1 |
| Addeo, A; Barone, C; Berruti, A; Bertetto, O; Buffoni, L; Dongiovanni, D; Dongiovanni, V; Fissore, C; Grillo, R | 1 |
| Marutaka, M; Miyake, M; Suguri, T; Yoshimura, K | 1 |
| Alvero, AB; Brown, D; Chen, W; Garg, M; Kelly, G; Mor, G; O'Malley, D; Rutherford, T | 1 |
| Corti, A; Curnis, F; Gallo-Stampino, C; Gasparri, A; Sacchi, A; Toma, S | 1 |
| Albers, P; Fechner, G; Kobalz, L; Reimann, M; Siener, R | 1 |
| Habuchi, T; Higashi, S; Itoh, N; Kamoto, T; Kinoshita, H; Nakamura, E; Nishiyama, H; Ogawa, O; Segawa, T; Takahashi, T; Yamamoto, S | 1 |
| Barbieri, F; Bearz, A; Belloni, P; Biason, R; Ceresoli, G; Chella, A; Clerici, M; Favaretto, A; Ghi, MG; Nicoletto, MO; Oniga, F; Paccagnella, A; Riccardi, A; Ridolfi, R; Tirelli, U; Tumolo, S; Veglia, F | 1 |
| Perez, E; Wirk, B | 1 |
| Barlesi, F; Daurès, JP; Pujol, JL | 1 |
| Kawauchi, A; Miki, T; Mizutani, Y; Nakamura, T; Nomoto, T | 1 |
| Aghajanian, C; Chi, DS; Correa, DD; Dupont, J; Hensley, ML; Sabbatini, P; Spriggs, D; Thaler, H; Venkatraman, E; Wilton, A | 1 |
| Muss, HB; Perez, E | 1 |
| Bell, MD | 1 |
| Beijnen, JH; Giaccone, G; Kroep, JR; Peters, GJ; Pinedo, HM; Postmus, PE; Smit, EF; Van der Born, K; Van der Vijgh, WJ; Van Groeningen, CJ | 1 |
| Carvalho, FM; Carvalho, JP; Feher, O; Maluf, FC; Schütz, FA | 1 |
| Amadori, D; Frassineti, GL; Gianni, L; Maltoni, R; Massa, I; Milandri, C; Nanni, O; Passardi, A; Zoli, W; Zumaglini, F | 1 |
| Du, W; Posner, M; Schmidt, H; Shafaee, Z; Weichselbaum, R | 1 |
| Belani, CP | 1 |
| Chellappan, S; Dasgupta, P; Decook, C; Haura, E; Joshi, B; Kinkade, R | 1 |
| Angelos, P; Sturgeon, C | 1 |
| Cheong, KA; Chrystal, K; Galani, E; Gallagher, C; Harper, PG; Lofts, F; Marx, GM; Steer, CB; Strickland, AH; Thomas, H; Yip, D | 1 |
| Bhalla, S; Guerreiro, M; Laranjeira, L; Pimentel, FL | 1 |
| Ledermann, JA; Pfisterer, J | 1 |
| Odicino, F; Pasinetti, B; Pecorelli, S; Tisi, G | 1 |
| Krazkowski, M | 1 |
| Caprio, G; Di Seri, M; Frati, L; Romiti, A; Spinelli, GP; Terzoli, E; Tomao, F; Tomao, S | 1 |
| Capomolla, E; Carpano, S; Cauchi, C; Conti, F; Foggi, P; Giacinti, L; Giannarelli, D; Leonetti, C; Lopez, M; Paoletti, G; Vici, P | 1 |
| Blum, JL; O'Shaughnessy, JA | 1 |
| Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M | 1 |
| Doi, M; Fukuhara, K; Kuwabara, M; Maeda, H; Miyamoto, S; Sumiyoshi, H; Yamasaki, M | 1 |
| Fan, Z; Glazer, RI; Li, X; Liang, K; Lu, Y; Mills, GB; Zeng, X | 1 |
| Aisner, J; Guensch, L; Joyce, M; Lutzker, S; Schwartz, S; Sovak, MA; Wu, Y; Zheng, L | 1 |
| Angouridakis, N; Aravantinos, G; Bafaloukos, D; Bamias, A; Christodoulou, C; Dafni, U; Daniilidis, J; Economopoulos, T; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Karina, M; Makatsoris, T; Maniadakis, N; Nikolaou, A; Papakostas, P; Pavlidis, N; Stathopoulos, G; Syrigos, K | 1 |
| Smith, IE | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Ho, C; Lara, PN; Mack, P | 1 |
| Campos, S; Duska, LR; Falke, R; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT; Roche, M; Seiden, MV; Smith, LM | 1 |
| Amadori, D; Cecconetto, L | 1 |
| Favaretto, AG | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Kim, DW; Kim, TY; Lee, KH; Oh, DY | 1 |
| Götz, C; Harlozinska, A; Kartarius, S; Montenarh, M; Touma, R | 1 |
| Bustam, A; Khoo, KS; Lehnert, M; Manzoor Zaidi, SH; Nair, R; Ngelangel, CA; Reece, WH; Song, S; Srimuninnimit, V | 1 |
| Fan, W; Kraft, AS; Sui, M; Xiong, X | 1 |
| Hirakawa, K; Ren, J; Yashiro, M; Zhang, X | 1 |
| Akerley, W; Kennedy, T; Mega, T; Ready, N; Safran, H; Zaner, K | 1 |
| Akel, A; Bachmann, C; Dreischer, P; Eisele, K; Gulbins, E; Huober, J; Kempe, DS; Klarl, BA; Lang, F; Lang, PA; Niemoeller, OM; Sobiesiak, M; Wieder, T | 1 |
| Asmar, L; Blum, JL; Boehm, KA; Chacko, A; Dees, EC; Doane, L; Ethirajan, S; Hopkins, J; Ilegbodu, D; McMahon, R; Merten, S; Negron, A; Neubauer, M; O'Shaughnessy, JA | 1 |
| Mountzios, G; Soria, JC | 1 |
| Li, L; Liu, L; Wang, XW; Yu, XJ; Zhang, WD; Zhang, X | 1 |
| Huang, HB; Lin, PL; Lin, ZC; Liu, T; Zhong, JT | 1 |
| Gazitt, Y; Rothenberg, ML; Shaughnessy, P | 1 |
| Fangusaro, J; Finlay, J; Rook, J; Rosser, T | 1 |
| Delorme, S; Hauschild, A; Kaatz, M; Neuber, K; Pföhler, C; Reinhold, U; Rittgen, W; Schadendorf, D; Spieth, K; Thoelke, A; Tilgen, W; Ugurel, S; Ulrich, J | 1 |
| Bonassi, S; Cellini, F; Cesario, A; Ciresa, M; Corbo, GM; Cortesi, E; D'Angelillo, RM; De Marinis, F; Granone, P; Margaritora, S; Migliorino, MR; Nelli, F; Porziella, V; Ramella, S; Russo, P; Trodella, L; Valente, S | 1 |
| Bodo, J; Duraj, J; Rauko, P; Sedlak, J; Sulikova, M | 1 |
| Boselli, S; Catania, C; Curigliano, G; de Braud, F; De Pas, T; Milani, A; Noberasco, C; Orlando, L; Putzu, C; Sabrina, B; Spaggiari, L | 1 |
| Calabrò, F; Sternberg, CN | 1 |
| Furukawa, K; Ito, T; Kitsukawa, S; Noda, K; Saito, M; Samejimai, T | 1 |
| Belani, CP; Clark, RH; Dakhil, S; Desch, CE; Monberg, MJ; Obasaju, CK; Rooney, DK; Waterhouse, DM; Ye, Z | 1 |
| Bamias, A; Bozas, G; Dimopoulos, MA; Efstathiou, E; Gika, D; Koutsoukou, V; Papadimitriou, CA | 1 |
| Bosch, RJ; Herrera, E; López, N; Tejera, A | 1 |
| Bianco, M; Buzzi, F; Cioffi, R; Comella, P; De Cataldis, G; Filippelli, G; Frasci, G; Gambardella, A; Ghiani, M; Maiorino, L; Mancarella, S; Massidda, B; Masullo, P; Milia, V; Natale, D; Palmeri, S; Putzu, C; Roselli, M | 1 |
| Ariyoshi, Y; Fukuoka, M; Kubota, K; Nakagawa, K; Negoro, S; Nishiwaki, Y; Ohashi, Y; Ohe, Y; Saijo, N; Tamura, T | 1 |
| Bartel, P; Ecke, TH; Koch, S; Ruttloff, J; Theissig, F | 1 |
| Kamiyama, Y; Kano, Y; Kodama, T; Kondo, T; Mori, K | 1 |
| Bentzen, JD; Hansen, HS | 1 |
| Comella, G; Danova, M; Ferraú, F; Lorusso, V; Massidda, B; Nortilli, R; Palmeri, L; Palmeri, S; Porta, C; Vaglica, M | 1 |
| Burstein, HJ; Rugo, HS; Sledge, GW | 1 |
| Ahmad, SA; Firdaus, I; Howington, JA; James, L; Jazieh, AR; Lowy, AM; Redmond, K; Reed, MF; Rose, P; Roychowdhury, D; Safa, M; Sussman, JJ | 1 |
| Bendell, JC; Blobe, GC; Czito, BG; D'Amico, TA; Fernando, NH; Harpole, DH; Honeycutt, W; Hurwitz, HI; Kelsey, CR; Morse, MA; Willett, CG; Yu, D | 1 |
| Bajorin, DF; Boyle, MG; Galsky, MD; Iasonos, A; Mironov, S; Scattergood, J | 1 |
| Albiol, S; Baselga, J; Bellmunt, J; Carles, J; Cecere, FL; Cuello, M; de la Cruz, JJ; Gallardo, E; Guillem, V; Mendez, P; Paz-Ares, L; Rosell, R; Taron, M | 1 |
| Furukawa, T; Hata, K; Hirai, I; Kawago, M; Kokawa, Y; Nakamura, R; Ohta, F; Okamura, Y; Oura, S; Tamaki, T; Tanino, H; Yoshimasu, T | 1 |
| Johnson, DH; Langer, C; Li, S; Rapoport, BL; Schiller, J; Tester, W | 1 |
| Banerjee, S; Chiritescu, G; Dahrouge, S; Stewart, DJ; Tomiak, EM | 1 |
| Brames, MJ; Einhorn, LH; Juliar, B; Williams, SD | 1 |
| Avallone, A; Barbato, E; Comella, P; Condemi, G; De Cataldis, G; Franco, L; Gambardella, A; Massidda, B; Putzu, C | 1 |
| Cho, H; Conaway, M; Hampton, G; Havaleshko, DM; Lee, JK; Owens, CR; Theodorescu, D | 1 |
| De Grève, J; De Mey, J; Fontaine, C; Meysman, M; Neyns, B; Schallier, D; Steene, JV | 1 |
| Aebi, S; Ballabeni, P; Gick, U; Hess, V; Lanz, D; Mingrone, W; Pestalozzi, B; Rauch, D; Rochlitz, C | 1 |
| Aggarwal, BB; Kamat, AM; Sethi, G | 1 |
| Brown, JV; Goldstein, BH; Graham, C; Hu, JC; Markman, M; Micha, JP; Rettenmaier, MA | 1 |
| Amare, M; Asmar, L; Blum, JL; Dees, EC; Gill, DP; Ilegbodu, D; McMahon, RT; O'Shaughnessy, JA; Vukelja, SJ | 1 |
| Alexopoulos, CG; Berchier, MC; Berghmans, T; Collon, T; Efremidis, A; Giner, V; Lafitte, JJ; Lecomte, J; Meert, AP; Ninane, V; Paesmans, M; Scherpereel, A; Sculier, JP; Van Cutsem, O | 1 |
| Abratt, RP; Boyer, M; Brnabic, AJ; Han, JY; Kim, SW; Lee, JS; Lehnert, M; Mok, T; Reece, WH; Tsai, CM | 1 |
| Hosomi, Y; Shibuya, M | 1 |
| Yoneda, S | 1 |
| Clegg, AJ; Jones, J; Loveman, E; Takeda, AL; Tan, SC | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Crino, L; Finocchiaro, G; Hirsch, FR; Ligorio, C; Magrini, E; Paioli, D; Rossi, E; Toschi, L; Trisolini, R; Varella-Garcia, M | 1 |
| Alexopoulos, CG; Berchier, MC; Berghmans, T; Collon, T; Efremidis, A; Giner, V; Lafitte, JJ; Leclercq, N; Lecomte, J; Meert, AP; Ninane, V; Paesmans, M; Scherpereel, A; Sculier, JP; Van Cutsem, O | 1 |
| Ito, N; Kamoto, T; Ogawa, O; Shang, D | 1 |
| Kim, R; Saif, MW | 1 |
| Dent, S; Messersmith, H; Trudeau, M | 1 |
| Vaughn, DJ | 1 |
| Chatta, GS; Chen, H; Dunn, RL; Glode, LM; Hussain, MH; Lara, PN; MacVicar, GR; Nanus, DM; Petrylak, DP; Smith, DC; Trump, DL; Vaishampayan, U | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Giassas, S; Kalykaki, A; Kentepozidis, N; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P; Vamvakas, L | 1 |
| Belzer, K; Gadgeel, S; Heilbrun, LK; Kalemkerian, GP; Kraut, MJ; Kucuk, O; Venkatramanamoorthy, R; Wozniak, AJ | 1 |
| Fujino, M; Maruhashi, K; Mitsudou, Y; Nakamura, T; Shimomatsuya, T; Shiraishi, S; Yonezawa, K | 1 |
| Bianco, A; Campbell, S; Caputo, F; D'Agostino, D; Gilli, M; Marsico, SA; Mazzarella, G; Piantedosi, FV; Pontillo, A | 1 |
| Kurebayashi, J; Masuda, N; Nakayama, T; Noguchi, S; Sakamoto, J; Shiba, E; Taguchi, T; Takatsuka, Y; Watatani, M | 1 |
| Géczi, L | 1 |
| Inui, K; Ito, N; Jiko, M; Kamoto, T; Masuda, S; Motohashi, H; Nakamura, E; Ogawa, O; Okuda, M; Sato, E; Segawa, T; Takahashi, K; Yano, I | 1 |
| Avallone, A; Comella, P; Costanzo, R; Frasci, G; Gambardella, A | 1 |
| Bréchot, JM; Morère, JF; Pailler, M | 1 |
| Baggstrom, MQ; Fried, DB; Hensing, TA; Poole, C; Socinski, MA; Stinchcombe, TE | 1 |
| Abbas, F; Gligorov, J; Khalil, A; Lotz, JP; Namer, M; Selle, F | 1 |
| Girard, N; Mornex, F | 1 |
| Seto, T | 1 |
| Havrilesky, LJ; Kulasingam, S; Myers, E; Secord, AA | 1 |
| Bendell, JC; Chino, JP; Clough, RW; Czito, BG; D'Amico, TA; Hurwitz, HI; Kelsey, CR; Morse, MA; Willett, CG | 1 |
| Dong, P; Jiang, AC; Li, L; Wan, Y; Yu, ZW | 1 |
| Faerber, GJ; Weizer, AZ; Wolf, JS | 1 |
| Ayoub, JP; Charpentier, D; Del Vecchio, P; Duclos, M; Faria, S; Gruber, J; Hirsh, V; Ofiara, L; Portelance, L; Souhami, L; Soulieres, D | 1 |
| Gluck, S; Lobo, C; Lopes, G; Silva, O | 1 |
| Aravantinos, G; Economopoulos, T; Gaglia, A; Gouveris, P; Koumarianou, A; Papaxoinis, G; Pectasides, D; Pectasides, E; Psyrri, A; Sykiotis, C; Xiros, N | 1 |
| Miletzki, A | 1 |
| Burris, HA; Gandhi, JG; Gray, JR; Greco, FA; Hainsworth, JD; Kuzur, ME; Pati, A; Shipley, D; Spigel, DR; Thompson, DS; Webb, CD; Yardley, DA | 1 |
| Akbunar, T; Evrensel, T; Kanat, O; Kurt, E; Manavoglu, O; Yalcinkaya, U | 1 |
| Bafaloukos, D; Bakogiannis, C; Bamias, A; Boukovinas, I; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Kalofonos, HP; Kosmidis, PA; Makatsoris, T; Nicolaides, C; Samantas, E; Skarlos, D; Syrigos, K; Xiros, N | 1 |
| Baba, S; Irie, A; Iwamura, M; Matsumoto, K; Okazaki, M; Satoh, T | 1 |
| Cordes, T; Fischer, D; Friedrich, M; Lüdders, D; Maass, N; Schroer, A; Villena-Heinsen, C | 1 |
| Bozionelou, V; Georgoulias, V; Gioulbasanis, I; Kalykaki, A; Karabeazis, A; Karampeazis, A; Kentepozidis, N; Kotsakis, A; Mavroudis, D; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Böhlke, I; Bokemeyer, C; Hartmann, JT; Honecker, F; Kollmannsberger, C; Mayer, F; Oechsle, K; Waller, CF | 1 |
| Chang, YC; Cheng, AL; Hsu, C; Hsu, CH; Lin, CC; Lin, ZZ; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Ceribelli, A; Cognetti, F; Fariello, AM; Gamucci, T; Giampaolo, MA; Mansueto, G; Narducci, F; Pino, MS; Sperduti, I; Trapasso, T | 1 |
| Alami, N; Belanger, S; Grieshaber, CK; Juste, S; Leyland-Jones, B; Paterson, J | 1 |
| Fujiwara, S; Ino, K; Kajiyama, H; Kato, S; Kikkawa, F; Nakamura, S; Nawa, A; Shibata, K; Suzuki, K | 1 |
| Brunet, J; Colomer, R; De Llorens, R; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A | 1 |
| Detterbeck, FC; Edelman, MJ; Govindan, R; Gralla, RJ; Jahan, TM; Limentani, SA; Loesch, DM; Monberg, MJ; Obasaju, CK; Socinski, MA; Ye, Z; Zaman, MB | 1 |
| Rödel, C; Sauer, R; Weiss, C | 1 |
| Benson, AB; Small, W; Wahl, AO; Wisinski, KB | 1 |
| Davies, AM; Gandara, DR; Sangha, R | 1 |
| Bedor, M; Brahmer, J; Bridges, BB; Doyle, LA; Edelman, MJ; Hausner, PF; Smith, R; Thomas, L | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JS; Oh, ST; Ryu, MH; Sohn, HJ; Yook, JH | 1 |
| Klein, F | 1 |
| De Grève, J; De Mey, J; Decoster, L; Everaert, H; Meysman, M; Neyns, B; Nieboer, K; Schallier, D | 1 |
| Burris, HA | 1 |
| Choi, SH; Han, SS; Kang, SB; Kim, JW; Lee, HP; Lee, YK; Park, NH; Song, YS | 1 |
| Dees, EC; Goldberg, RM; Hayes, DN; Lee, CB; Moore, DT; Socinski, MA; Stinchcombe, TE | 1 |
| Aydiner, A; Derin, D; Guney, N; Tas, F; Topuz, E | 1 |
| Dhabhar, B; Hazarika, N; Saikia, TK | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Karina, M; Kosmidis, P; Koutras, A; Maniadakis, N; Matsiakou, F; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Skarlos, D | 1 |
| Blackstock, AW; Bogart, JA; Green, M; Gu, L; Masters, GA; Miller, AA; Munley, M; Rosenman, J; Sleeper, A; Socinski, MA; Ungaro, P; Vokes, EE; Wang, X | 1 |
| Hino, N; Ikushima, Y; Miyake, H; Ogasawara, T; Ohura, R; Sohnaka, Y; Tsuyuguchi, M; Wada, D; Yamamoto, Y; Yamasaki, S | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Dikilitas, M; Kaya, AO; Ozkan, S; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R | 1 |
| Erovic, BM; Heiduschka, G; Kloimstein, P; Martinek, H; Selzer, E; Skoda, C; Thurnher, D; Vormittag, L; Wachek, V; Wrba, F | 1 |
| Han, HS; Kang, HS; Kim, SW; Lee, DH; Lee, ES; Lee, H; Lee, KS; Nam, BH; Ro, J; Seo, JA | 1 |
| Bandstra, B; Bilynsky, BT; Bondarenko, IN; Eisenfeld, AJ; Ganul, VL; Hotko, YS; Kostinsky, IY; O'Brien, ME; Oldham, FB; Popovich, AY; Sandalic, L; Sandler, AB; Singer, JW; Socinski, MA; Tomova, A | 1 |
| Cameron, DA; Stein, S | 1 |
| Blackwell, KL; Byrne, JA; Di Leo, A; Gomez, HL; Koch, KM; Koehler, M; Laabs, SM; Lacouture, ME; Preston, AJ; Salazar, VM; Sweetman, RW | 1 |
| Hee, SW; Leong, SS; Lim, WT; Poon, D; Rajan, S; Tan, EH; Tay, MH; Toh, CK; Wee, J | 1 |
| Eisenkop, SM; McAlpine, JN; Spirtos, NM | 1 |
| Furuiye, M; Inase, N; Ishiwata, N; Jin, Y; Miyake, S; Miyashita, Y; Takano, S; Yoshizawa, M; Yoshizawa, Y | 1 |
| Ansari, R; Geyer, CE; Hamm, JT; Kardinal, CG; Kim, W; Lembersky, BC; Paik, S; Rastogi, P; Raymond, JM; Robidoux, A; Shalaby, IA; Song, YK; Tseng, GC; Wilson, JW; Wolmark, N | 1 |
| Bowman, A; Coleman, RE; Dunn, JA; Earl, HM; Fernando, IN; Hiller, L; Howard, HC; Poole, CJ; Ritchie, DM; Wardley, AM | 1 |
| Cheng, T | 1 |
| Abe, K; Fujiwara, J; Hayashi, I; Ishida, H; Kawauchi, A; Miki, T; Mizuno, M; Mizutani, Y; Nakanishi, H; Okada, K; Toiyama, D; Yamamoto, K; Yoshida, J | 1 |
| Albain, KS; Calderillo-Ruiz, G; Jordaan, JP; Llombart, AC; Melemed, AS; Nag, SM; O'Shaughnessy, J; Pluzanska, A; Reyes-Vidal, JM; Rolski, J; Sekhon, JS; Simms, L | 1 |
| Aggarwal, AN; Singh, N | 1 |
| Bang, S; Chung, JB; Kim, YJ; Park, JY; Park, SW; Song, SY | 1 |
| Benezra, R; Bertolini, F; Colleoni, M; Daenen, LG; Emmenegger, U; Henke, E; Kerbel, RS; Langenberg, MH; Man, S; Mancuso, P; Roodhart, JM; Shaked, Y; Strieter, RM; Tang, T; Voest, EE; Witte, L; Xu, P; Zhu, Z | 1 |
| Bosnjak, SM; Radulovic, S; Susnjar, S | 1 |
| Eggemann, H; Elling, D; Harbeck, N; Janni, W; Kaufmann, M; Kiechle, M; Kümmel, S; Loibl, S; Nekljudova, V; Sommer, H; von Minckwitz, G | 1 |
| Amorós, A; Casinello, J; Heredia, M; Lázaro, A; López-Alfonso, A | 1 |
| Azim, H; Azim, HA; Elattar, I; Ganti, AK; Loberiza, FR; Mok, T | 1 |
| Akita, H; Hokari, M; Iwasaki, Y; Kamoshima, Y; Sawamura, Y | 1 |
| Harris, P; Hartwell, D; Loveman, E; Takeda, A; Welch, K | 1 |
| Dafni, U; Fountzilas, G; Fragkoulidi, A; Fragoulakis, V; Galani, E; Grimani, I; Maniadakis, N | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Beekman, K; Dunn, RL; Hussain, M; Lee, CT; Mackler, NJ; Montie, JE; Petrylak, DP; Quinn, DI; Sanda, M; Smith, DC; Vaishampayan, U; Wood, D | 1 |
| Kamiyama, Y; Kano, Y; Kobayashi, H; Kodama, T; Mori, K | 1 |
| Horiguchi, J; Iino, Y; Ishikawa, Y; Kikuchi, M; Koibuchi, Y; Nagaoka, R; Odawara, H; Rokutanda, N; Sato, A; Takeyoshi, I; Tokiniwa, H | 1 |
| Fujita, Y; Fukushima, M; Furuse, K; Kawahara, M; Komuta, K; Kubota, K; Minato, K; Nishiwaki, Y; Ogawara, M; Teramukai, S | 1 |
| Arnold, A; Crabb, SJ; Ellis, PM; Goss, G; Laurie, SA; Leighl, NB; Patsios, D; Powers, J; Sauerbrei, E; Seymour, L; Shepherd, FA | 1 |
| Al-Batran, SE; Aldaoud, A; Bernhard, H; Burkart, C; Folprecht, G; Hoffmann, M; Huebner, G; Jahn, A; Kaiser, U; Kohne, CH; Kretzschmar, A; Kullmann, F; Link, H; Menges, M; Otremba, B; Schoffski, P; Stahl, M; Steinbach, S | 1 |
| Bane, CL; Gross, GG; LaPlant, BR; Palmieri, FM; Roy, V | 1 |
| Kanai, K; Kikuchi, E; Miyajima, A; Nakagawa, K; Nakashima, J; Ohigashi, T; Oya, M | 1 |
| Choy, H; Curran, W; Demas, WF; Ettinger, DS; Jain, AK; Moughan, J; Whipple, G | 1 |
| Abakar-Mahamat, A; Baize, N; Berthier, F; Caroli-Bosc, FX; Mounier, N | 1 |
| Cobb, P; Houts, AC; Schwartzberg, LS; Stepanski, EJ; Walker, MS | 1 |
| Barlési, F; Berard, H; Chouaïd, C; Corre, R; Fournel, P; Le Caer, H; Marin, B; Tillon, J; Vergnenègre, A; Vernejoux, JM | 1 |
| Gennatas, K; Gennatas, S; Michalaki, V | 1 |
| Ansari, RH; Detterbeck, FC; Edelman, MJ; Gralla, RJ; Jahan, TM; Luketich, JD; Monberg, M; Moore, DT; Obasaju, CK; Peng, G; Rivera, MP; Socinski, MA | 1 |
| Egoshi, K; Fukasawa, S; Hamano, M; Ichikawa, T; Imamura, Y; Maruoka, M; Miyasaka, K; Nakamura, K; Nihei, N; Sazuka, T; Suyama, T; Ueda, T | 1 |
| Hoskins, PJ | 1 |
| Accario-Winslow, C; Alberts, DS; Argenta, PA; Bookman, MA; Brady, MF; Burger, RA; Colombo, N; De Geest, K; Fowler, JM; Friedlander, M; Harper, PG; McGuire, WP; Mutch, DG; Roth, LM; Swart, AM; Trimble, EL | 1 |
| Kang, HS; Kim, EA; Kim, SW; Kwon, Y; Lee, ES; Lee, KS; Nam, BH; Ro, J; Shin, KH | 1 |
| Apte, S; Boren, T; Chan, G; Chen, DT; Dressman, H; Hakam, A; Kamath, SG; Lancaster, JM; Wenham, R; Xiong, Y | 1 |
| Biasoni, D; Gianni, L; Milani, A; Necchi, A; Nicolai, N; Piva, L; Pizzocaro, G; Salvioni, R; Stagni, S; Torelli, T | 1 |
| Fujimoto, T; Koshiji, M; Nambu, Y; Yamamoto, N | 1 |
| Bao, QL; Chen, P; Dai, CH; Li, J; Li, XQ | 1 |
| Chang, K; Goedegebuure, PS; Hawkins, WG; Hotchkiss, RS; Kashiwagi, H; Mach, RH; McDunn, JE; Simon, PO; Vangveravong, S | 1 |
| Asanuma, F; Atsuda, K; Hiraku, O; Inoue, G; Morimoto, Y; Sasaki, K; Suzuki, Y; Takeuchi, O; Takizawa, A; Yamada, Y; Yoshizawa, J | 1 |
| Crawford, ED; deVere White, RW; Goldman, B; Hussain, MH; Lara, PN; Smith, DC; Tangen, CM; Wood, DP | 1 |
| Jaén, P; Muñoz-Zato, E; Pérez, B; Truchuelo, M; Vano-Galvan, S | 1 |
| Brown, JV; Goldstein, BH; John, CR; Markman, M; Micha, JP; Rettenmaier, MA | 1 |
| Alonso, S; Calabrò, F; Di Paula, ED; Frassineti, L; Lorusso, V; Manzione, L; Rosati, G; Sava, T; Sternberg, CN | 1 |
| Bral, S; De Grève, J; De Mey, J; Decoster, L; Fontaine, C; Ilsen, B; Meysman, M; Neyns, B; Schallier, D | 1 |
| Georgoulias, V; Kotsakis, A; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P; Saridaki, Z; Souglakos, J; Vardakis, N | 1 |
| Bartel, P; Ecke, TH; Gerullis, H; Koch, S; Ruttloff, J | 1 |
| Cao, Y; Chen, B; Cheng, H; Cheng, L; Feng, J; Ji, J; Li, F; Lu, Z; Ma, J; Qin, S; Sun, N; Sun, X; Zhou, Y | 1 |
| de la Peña, FA; Garcia-Martinez, E; Vicente, E; Zafra, M | 1 |
| Bonomi, P; Langer, C; Lilenbaum, R; O'Brien, M; O'Byrne, K; Oldham, FB; Ross, HJ; Sandilac, L; Singer, JW; Socinski, M; Villaflor, VM | 1 |
| Patel, SR; Shord, SS | 1 |
| Avallone, A; Chiuri, VE; Cioffi, R; Comella, P; Costanzo, R; De Cataldis, G; Filippelli, G; Franco, L; Greco, E; Maiorino, L; Mancarella, S; Palmeri, L; Putzu, C; Vessia, G | 1 |
| Adema, AD; Honeywell, RJ; Peters, GJ; van der Born, K | 1 |
| Alvarado-Miranda, A; Arrieta, O; Bargallo-Rocha, E; Gamboa-Vignolle, C; Lara-Medina, F; Morales-Barrera, R; Perez-Sanchez, V; Ramirez-Ugalde, T; Saavedra-Perez, D; Zinser-Sierra, J | 1 |
| Coffey, MC; Mussio, JK; Nagashima, K; Parchment, RE; Sei, S; Shoemaker, RH; Tomaszewski, JE; Yang, QE | 1 |
| Felekouras, E; Giannakopoulos, K; Giannopoulos, A; Gogas, H; Karatzas, T; Lagadas, A; Papadopoulos, O; Polyzos, A; Polyzos, K; Tsavaris, N; Tsigris, C | 1 |
| Li, J; Li, Y; Lu, M; Shen, L; Xiao, Y; Zhang, J; Zhang, XD | 1 |
| Fushida, S; Kimura, H; Mukawa, A | 1 |
| Bajorin, DF; Iasonos, A; Maluf, FC; Milowsky, MI; Mironov, S; Nanus, DM; Regazzi, A; Riches, J; Shi, W | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sun, JM | 1 |
| Bohnenkamp, H; Bruns, CJ; Dellian, M; Eichhorn, ME; Guenzi, E; Ischenko, I; Jauch, KW; Luedemann, S; Michaelis, U; Papyan, A; Preissler, G; Strieth, S; Werner, A | 1 |
| Benda, J; Boardman, CH; Cella, D; Cohn, DE; McMeekin, DS; Monk, BJ; Ramondetta, LM; Sill, MW | 1 |
| Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Makatsoris, T; Papadimitriou, CA; Papakostas, P; Zagouri, F | 1 |
| Bockisch, A; Dralle, H; Kegel, T; Mann, K; Matuszczyk, A; Petersenn, S; Schmoll, HJ; Voigt, W | 1 |
| Alamara, C; Chatzidarellis, E; Georgiadis, E; Giza, L; Makrilia, N; Syrigos, KN | 1 |
| Bartel, P; Ecke, TD; Gerullis, H; Koch, S; Ruttloff, J | 1 |
| Che, G; Gong, Y; Hou, M; Huang, M; Li, L; Li, T; Li, W; Liu, L; Liu, Y; Lu, Y; Ren, L; Tang, B; Wang, J; Xu, Y; Zhou, L; Zhu, J; Zou, B | 1 |
| Teng, KY; Xu, RH | 1 |
| Ansari, R; Belani, CP; Catalano, RB; Comis, RL; Edelman, MJ; Gillenwater, HH; Gonin, R; Marinucci, DM; Obasaju, CK; Rowland, KM; Socinski, MA; Treat, JA | 1 |
| Kawauchi, A; Mikami, K; Miki, T; Nakamura, T; Shiraishi, T; Takaha, N | 1 |
| Bender, GP; Masellis, AM; Sielaff, TD | 1 |
| Amour, E; Beckendorf, V; Bossard, N; Douillard, JY; Girard, N; Grunenwald, D; Milleron, B; Mornex, F; Quoix, E | 1 |
| Beal, K; Damast, S; Elkin, E; Fornier, MN; Ho, AY; Ishill, N; McCormick, B; Montgomery, L | 1 |
| Cormier, JN; Du, XL; Hardy, D; Liu, CC; Xia, R; Xing, Y | 1 |
| Kennedy, AM; Nam, KH; Rapoport, N; Scaife, CL; Shea, JE | 1 |
| García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L | 1 |
| Auner, V; Horvat, R; Oskay-Oezcelik, G; Sehouli, J; Speiser, P; Zeillinger, R | 1 |
| Carrasco, E; Chacón, I; de la Torre-Cabrera, C; Dueñas, B; Dueñas-García, R; Fernández-Navarro, M; García-Tapiador, AM; Jaén-Morago, A; Martín-Salvago, MD; Martínez, J; Martínez-Ortega, E; Ortega-Granados, AL; Ribelles, N; Rueda, AI; Sánchez-Muñoz, A; Sánchez-Rovira, P; Tortosa, CR | 1 |
| Groe, R; Grothey, A; Kantelhardt, EJ; Kegel, T; Koelbl, H; Mueller, LP; Schmoll, HJ; Seliger, G; Strauss, HG; Thomssen, C | 1 |
| Crinò, L; De Marinis, F; Gridelli, C; Liepa, AM; Peterson, P; Ricci, S; Rinaldi, M; Scagliotti, GV; Tonato, M; Zhao, YD | 1 |
| Baker, MK; Branch, KD; Gluck, S; Goldsberry, GT; Montero, AJ; Talebi, TN; Zhu, Y | 1 |
| Ansari, RH; Belani, CP; Chen, R; Edelman, MJ; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Favaretto, AG; Magro, C; Pasello, G | 1 |
| Hirai, T; Ichikawa, Y; Kishikawa, H; Kobayashi, Y; Nishimura, K; Soda, T; Yamanaka, K | 1 |
| Santoni-Rugiu, E; Sørensen, JB; Vilmar, AC | 1 |
| Komori, E; Nogami, H; Ogino, A; Sawada, S; Segawa, Y; Shinkai, T; Suehiro, H; Yamashita, M | 1 |
| Garber, K | 1 |
| Belani, CP; Chen, R; Edelman, MJ; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Edina, M; László, L; Tamás, N | 1 |
| Dumontet, C; Hage-Sleiman, R; Herveau, S; Laurier, JF; Matera, EL | 1 |
| Hirakawa, K; Matsuzaki, T; Nishii, T; Qiu, H; Yashiro, M; Zhang, X | 1 |
| Agarwal, R; Carty, K; Gabra, H; Gore, ME; Gourley, C; Kaye, SB; Parkin, DE; Paul, J; Perren, TJ; Reed, N; Rustin, GJ | 1 |
| Santoni-Rugiu, E; Sørensen, JB; Vilmar, A | 1 |
| Daugaard, G; Gothelf, A; Møller, AK; Pedersen, KD | 1 |
| Ansari, RH; Belani, CP; Catalano, RB; Chen, R; Comis, RL; Edelman, MJ; Gonin, R; Marinucci, DM; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Pineda de la Losa, F; Prieto García, A | 1 |
| Lv, M; Ren, S; Xu, J; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Bepler, G; Cognetti, F; Conti, F; Di Lauro, L; Fabi, A; Giannarelli, D; Lopez, M; Metro, G; Sergi, D; Tomao, F; Vici, P | 1 |
| Aryal, S; Hu, CM; Zhang, L | 1 |
| Baez, O; Castrellon, A; Ferrell, A; Glück, S; Higgins, C; Hurley, E; Hurley, J; Lobo, C; Lopes, G; Reis, I; Richman, S; Seo, P; Silva, O; Slingerland, J; Tukia, K; Welsh, C | 1 |
| Ansari, RH; Catalano, RB; Chen, R; Comis, RL; Liles, DK; Marinucci, DM; Monberg, MJ; Obasaju, CK; Ribeiro, MJ; Socinski, MA; Treat, J | 1 |
| Ahmad, A; Azmi, AS; Banerjee, S; Kong, D; Li, Y; Sarkar, FH; Wang, Z | 1 |
| Aogi, K; Fujimoto, T; Funai, J; Kamigaki, S; Okazaki, M; Saeki, T; Sagara, Y; Takashima, S; Toi, M; Yoshida, M | 1 |
| Boku, N; Fukutomi, A; Kojima, T; Machida, N; Onozawa, Y; Shukuya, T; Taku, K; Yamazaki, K; Yasui, H | 1 |
| Leaw, SJ; Luo, J; Xu, Y; Zheng, D | 1 |
| Burris, HA; Daniel, B; Hainsworth, JD; Inhorn, R; Lane, CM; Naot, Y; Vazquez, ER; Yardley, DA; Zubkus, J | 1 |
| Chen, CW; Cheng, AL; Chiang, CT; Feng, WC; Gao, M; Hsu, CH; Kuo, SH; Lu, YS; Yeh, LC; Yeh, PY | 1 |
| Brandberg, Y; Einbeigi, Z; Hatschek, T; Johansson, H; Svensson, H | 2 |
| Albers, P; Fechner, G; Fimmers, R; Heidenreich, A; Heimbach, D; Lehmann, J; Niegisch, G; Park, SI; Siener, R; Steiner, U | 1 |
| Chen, H; Li, C; Pan, Y; Sun, Y; Wang, Q; Yang, S | 1 |
| Borowicz, H; Glados, M; Heilmann, V; Hinke, A; Jackisch, C; Lehnert, A; Möbus, V; Müller, V; Schmidt, M; Thomssen, C | 1 |
| Ito, T; Kawashima, H; Nakatani, T; Omachi, T; Tamada, S | 1 |
| Fukami, T; Funakoshi, A; Kuroki, M; Miyamoto, S; Yagi, H; Yoshizato, T; Yotsumoto, F | 1 |
| Bischoff, HG; Chouaid, C; de Castro Carpeño, J; Heigener, DF; Mueller, E; Schmidt, E; Stanisic, S; Vergnenègre, A; Walzer, S | 1 |
| Matouskova, E; Mladkova, J; Sanda, M; Selicharova, I | 1 |
| Bergin, P; Damianovich, D; Findlay, M; Hanning, F; Hill, A; McKeage, MJ; Thompson, P | 1 |
| Avall-Lundqvist, E; Burges, A; du Bois, A; Gropp, M; Hardy-Bessard, AC; Harter, P; Herrstedt, J; Huober, J; Jackisch, C; Jelic, S; Joly, F; Kristensen, G; Kurzeder, C; Müller, HH; Pfisterer, J; Pujade-Lauraine, E; Sehouli, J; Staehle, A; Weber, B; Wimberger, P | 1 |
| Brigulová, K; Cervinka, M; Sedláková, I; Tošner, J | 1 |
| Benda, J; Boardman, CH; Cella, D; Cohn, D; Huang, HQ; McMeekin, DS; Monk, BJ; Ramondetta, L; Wenzel, L | 1 |
| Berthillot, C; Gaertner, S; Miréa, C; Stephan, D; Welsch, M | 1 |
| Billaud, EM; Bobin-Dubigeon, C; Boisdron-Celle, M; Boyer, JC; Chatelut, E; Concordet, D; Durdux, C; Etienne-Grimaldi, MC; Evrard, A; Floquet, A; Gladieff, L; Laffont, CM; Lafont, T; Lansiaux, A; Le Guellec, C; Mazières, J; Mousseau, M; Ollivier, F; Pinguet, F; Schmitt, A | 1 |
| Aklilu, M; Blackstock, AW; Clark, P; Geisinger, KR; Isom, S; Levine, EA; Mishra, G; Monjazeb, AM; Riedlinger, G | 1 |
| Bafaloukos, D; Bakogiannis, C; Boukovinas, J; Dimopoulos, MA; Eleftheraki, AG; Fountzilas, G; Kalofonos, HP; Katirtzoglou, N; Kosmidis, PA; Lambaki, S; Pectasides, D; Pentheroudakis, G; Samantas, E; Skarlos, D; Syrigos, KN | 1 |
| Aneiros-Fernandez, J; Arias-Santiago, S; Husein-ElAhmed, H; Naranjo-Sintes, R | 1 |
| Brandt, R; Lane, HA; Lassota, P; McSheehy, PM; O'Reilly, T; Wartmann, M | 1 |
| Der, CJ; Roberts, PJ; Socinski, MA; Stinchcombe, TE | 1 |
| Friedman, GK; Hilliard, LM; Kelly, DR; Vaid, YN; Walsh, A | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Alvarez, PJ; Aranega, A; Burgos, M; Hita, F; Melguizo, C; Ortiz, R; Prados, J; Rama, AR; Ramos, JL; Rodríguez-Serrano, F | 1 |
| Chen, L; Jiao, SC; Li, J; Lv, YL; Shi, Y; Sun, Q; Wang, LX | 1 |
| Guan, Z; Jiang, Z; Shen, Z; Xu, B; Zhang, X | 1 |
| Fujita, S; Fukuhara, A; Hata, A; Hatachi, Y; Kaji, R; Katakami, N; Kim, YH; Masago, K; Mio, T; Mishima, M | 1 |
| Baumunk, D; Fotopoulou, C; Schmidt, SC; Schumacher, G | 1 |
| Inoue, M; Nagashima, A; Nakanishi, K; Nakanishi, R; Osaki, T; Sakata, H; Uchiyama, A; Uramoto, H; Yasumoto, K; Yoshimatsu, T | 1 |
| Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW | 1 |
| Arenas, DR; Arvelo, F; Kouznetsov, VV; Muñoz, A; Sojo, F | 1 |
| Airoldi, M; Amoroso, D; Ardizzoia, A; Aurilio, G; Bajetta, E; Ballardini, P; Balzelloni, ML; Banna, GL; Barbieri, F; Barletta, E; Basso, U; Bernardini, I; Boni, C; Bordin, V; Bretti, S; Bria, E; Bronte, G; Brunetti, C; Buti, S; Capanna, L; Collovà, E; Colombo, A; Condemi, G; Cortinovis, D; Dambrosio, M; Di Fonzo, C; Di Lucca, G; Di Maio, M; Dima, G; Falzetta, A; Favaretto, A; Ferraù, F; Follador, A; Garetto, L; Gebbia, V; Genestreti, G; Gentile, AL; Giovanardi, F; Labianca, R; Lorusso, V; Mantovani, G; Martelli, O; Massari, F; Mazzoli, M; Menis, J; Michetti, G; Mordenti, P; Mucciarini, C; Munao, S; Nacci, A; Novello, S; Pogliani, C; Procopio, G; Riccardi, F; Rizzato, S; Rossi, A; Rosti, G; Russo, P; Saladino, T; Salesi, N; Santangelo, D; Sava, T; Savarino, A; Spinnato, F; Tiseo, M; Tomassi, O; Tondulli, L; Tonini, G; Turano, S; Valerio, MR; Verderame, F; Zanelli, F; Zanon, E | 1 |
| Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L | 1 |
| Fukuda, M; Kasai, T; Kinoshita, A; Kohno, S; Masuda, N; Nagashima, S; Nakamura, Y; Nakatomi, K; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsukamoto, K | 1 |
| Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK | 1 |
| Chen, SM; Chen, YY; Huang, CH; Li, SH; Rau, KM; Tang, Y; Wu, SC | 1 |
| Asmar, L; Kobina, S; Neubauer, MA; Pritchard, S; Reynolds, CH; Weissman, CH | 1 |
| Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D | 1 |
| Wang, XY; Zhao, YL | 1 |
| Biesma, B; Dalesio, O; Groen, HJM; Slaets, JPJ; Smit, EF; Smit, HJM; Stigt, JA; van Felius, CL; van Putten, JWG; Vincent, A; Wymenga, ANM | 1 |
| Abo-Elyazeed, A; El-Hadaad, HA; Halim, AA; Wahba, HA | 1 |
| Bepler, G; Chen, DT; Chiappori, A; Dilling, TJ; Greenberg, H; Haura, E; Hazelton, T; Simon, G; Stevens, C; Tanvetyanon, T; Wagner, H; Walsh, F; Williams, C | 1 |
| Ando, M; Fukuoka, M; Iwamoto, Y; Katakami, N; Kurata, T; Maeda, M; Nakagawa, K; Nakano, T; Saito, H; Takeda, K | 1 |
| Blomfield, P; Bohmer, R; Chan, WS; McIntosh, R | 1 |
| Nam, KH; Rapoport, N; Scaife, CL; Shea, JE | 1 |
| Ducoloné, A; Fraisse, P; Mennecier, B; Quoix, E | 1 |
| Akino, H; Aoki, Y; Ito, H; Miwa, Y; Oyama, N; Yokoyama, O | 1 |
| Biganzoli, L; Bogdanova, N; Chen, Z; Cheng, Y; Chmielowska, E; Crivellari, D; Dalenc, F; Delva, R; Di Vincenzo, E; Espié, M; Hamm, C; Jiang, Z; Just, M; Lichinitser, M; Semiglazov, V; Shen, Z; Smith, I; Vinholes, J; Vivanco, GL | 1 |
| Egawa, S; Katayose, Y; Maeda, S; Morikawa, T; Motoi, F; Naitoh, T; Onogawa, T; Rikiyama, T; Sakata, N; Shigeru, O; Takadate, T; Unno, M | 1 |
| Al-Barrak, J; Gilks, CB; Hoskins, P; Lau, H; Santos, JL; Swenerton, KD; Tinker, A | 1 |
| Chung, HC; Del Giglio, A; Feng, J; Jiang, Z; Kim, SB; Malzyner, A; Pen, DL; Shen, LJ; Xu, B; Yu, S | 1 |
| Blackstock, AW; Bogart, JA; Crawford, JC; Gu, L; Morano, K; Salama, JK; Socinski, MA; Stinchcombe, TE; Vokes, EE; Wang, X | 1 |
| Hirakawa, K; Miwa, A; Qiu, H; Yashiro, M; Zhang, X | 1 |
| Brodowicz, T; Loibl, S; Lück, HJ; Nekljudova, V; Schwenkglenks, M; Skacel, T; von Minckwitz, G; Zielinski, C | 1 |
| Bento, S; Dávila, C; Ferreira, A; Pereira, D; Rodrigues, A; Rodrigues, H; Vieira, C | 1 |
| Cleves, A; Mason, M; Shelley, M; Wilt, TJ | 1 |
| Ambrosone, CB; Bookman, M; Darcy, KM; Deloia, JA; Gallion, H; Krivak, TC; Tian, C | 1 |
| Adenis, A; Conroy, T; Gavoille, C | 1 |
| Eller, J; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Molnár, J; Pálföldi, R; Szántó, E; Thurzó, L; Tiszlavicz, L | 1 |
| Agelaki, S; Ardavanis, A; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Giassas, S; Karachaliou, N; Kotsakis, A; Pallis, AG; Polyzos, A; Samonis, G; Saridaki, Z; Syrigos, K; Vamvakas, L; Vardakis, N; Varthalitis, I | 1 |
| Jenks, S | 1 |
| Liu, T; Zhang, JQ; Zhang, L | 1 |
| Gao, J; Li, YY; Lu, M; Shen, L; Yu, JW | 1 |
| Cunningham, D; Hawkes, EA; Okines, AF; Plummer, C | 1 |
| Eastwood, A; Epstein, D; Fox, D; Rodgers, M; Soares, M; Yang, H | 1 |
| Huang, XE; Jin, GF; Li, Y; Shen, HB; Xu, L | 1 |
| Blasco, A; Cabrera, A; Camps, C; Carrato, A; Gil, M; Gómez-Aldaraví, L; González-Larriba, JL; Guijarro, R; Iranzo, V; Jantus, E; Massuti, B; Provencio, M; Rossell, R; Sanmartín, E; Sirera, R; Velasco, A | 1 |
| Boehlke, I; Bokemeyer, C; Hartmann, JT; Honecker, F; Kollmannsberger, C; Mayer, F; Oechsle, K; Waller, CF | 1 |
| Hoshino, K; Ide, H; Masuda, T; Satou, A; Tasaka, Y; Uchida, Y; Yasumizu, Y | 1 |
| Beck, T; Bromund, J; Brufsky, A; Frontiera, M; Hainsworth, J; Hoelzer, K; Keaton, M; Krill-Jackson, E; Kroener, J; Marciniak, MD; Middleman, E; Nadella, P; Obasaju, C; Orlando, M; Panella, T; Paul, D; Tai, F; Whorf, R; Zhao, L | 1 |
| Deng, AM; Liang, AB; Qu, YQ; Wang, H; Xiu, B; Zeng, HZ; Zhang, WJ | 1 |
| Bari, M; Ciruelos, E; De Benedictis, E; Dittrich, C; Gaion, F; Gomez, P; Lluch, A; Luca, G; Mansutti, M; Morandi, P; Pavesi, L; Semiglazov, V; Valagussa, P; Zamagni, C; Zambetti, M | 1 |
| Filatova, LV; Gershanovich, ML; Latipova, DKh; Semiglazova, TIu | 1 |
| Baudrin, L; Bennouna, J; Bigay-Game, L; Dansin, E; Dauba, J; Debieuvre, D; Ducoloné, A; Herman, D; Laporte, S; Lavolé, A; Lebitasy, MP; Milleron, B; Molinier, O; Moro-Sibilot, D; Oster, JP; Pichon, E; Poudenx, M; Quoix, E; Souquet, PJ; Tredaniel, J; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Reckamp, KL | 1 |
| Albers, P; Fimmers, R; Niegisch, G; Park, SI; Siener, R | 1 |
| Ando, M; Hasegawa, Y; Isa, S; Kawaguchi, T; Kubo, A; Nakagawa, K; Ou, SH; Shiraishi, J; Takada, M; Tsuji, T; Tsujino, K | 1 |
| Jiang, PY; Kantorowitz, D; Yanke, R | 1 |
| Fukushima, M; Furuse, K; Kawahara, M; Kubota, K; Origasa, H; Shinkai, T; Tada, H; Teramukai, S; Tokoro, A | 1 |
| Choi, HL; Han, JY; Kim, HT; Kim, HY; Lee, JS; Nam, BH; Yun, T | 1 |
| Bechstein, WO; Bodoky, G; Cwiertka, K; Fischbach, W; Fölsch, UR; Haas, SL; Jäger, D; Löhr, JM; Lutz, MP; Osinsky, D; Prausova, J; Schmidt, WE | 1 |
| Baba, S; Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Minamida, S; Satoh, T; Tabata, K | 1 |
| Albain, KS; Donaldson, GW; Liepa, AM; Melemed, AS; Moinpour, CM; O'Shaughnessy, J | 1 |
| Culine, S; Demery, ME; Pouessel, D; Thézenas, S | 1 |
| Alexandre, J; Bachelot, T; Bourgeois, H; de Rauglaudre, G; Hardy-Bessard, AC; Jaubert, D; Largillier, R; Lortholary, A; Paraiso, D | 1 |
| Cetina, L; Coronel, J; Dueñas-Gonzalez, A | 1 |
| Chen, CP; Jablons, DM; Jahan, TM; Weinberg, VK; Yom, SS | 1 |
| Borad, MJ; Desai, N; Hidalgo, M; Iglesias, JL; Korn, RL; Laheru, DA; Maitra, A; Rajeshkumar, NV; Ramanathan, RK; Shi, T; Smith, LS; Soon-Shiong, P; Trieu, V; Von Hoff, DD; Wood, TE; Zhang, H | 1 |
| Burkholder, TL; Chen, MD; Gill, JF; Gordon, AN; Hines, J; Homesley, HD; Janicek, MF; Lim, PC; McMeekin, S; Obasaju, CK; Orlando, M; Tai, DF; Teneriello, M; Vaccarello, L; Wang, Y; Zhao, L | 1 |
| Jung, SY; Kang, HS; Kim, SW; Ko, K; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J; Shin, KH | 1 |
| Ahn, H; Ahn, JH; Ahn, S; Hong, JH; Kim, CS; Kwon, JH; Lee, JL; Lim, HY; Park, SH; Song, C | 1 |
| Movva, S; Verschraegen, C | 1 |
| Croom, KF; Dhillon, S | 1 |
| Brekken, RA; Gazdar, AF; Girard, L; Greer, RM; Harran, P; Larsen, JE; Minna, JD; Peyton, M; Wang, L; Wang, X; Xie, Y | 1 |
| Bahleda, R; Bosq, J; Hartl, DM; Hollebecque, A; Massard, C; Soria, JC | 1 |
| Ahn, JH; Ahn, JS; Ha, SW; Im, SA; Im, YH; Kang, HS; Kim, JH; Kim, SB; Kwon, Y; Lee, ES; Lee, KS; Noh, DY; Park, IA; Ro, J; Shin, KH | 1 |
| Aström, G; Bergh, J; Brandberg, Y; Carlsson, L; Carstensen, J; Einbeigi, Z; Fernö, M; Hatschek, T; Hellström, M; Lidbrink, E; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundquist, M; Svensson, H; Walz, TM | 1 |
| Ambrosone, CB; Armstrong, DK; Bookman, MA; Darcy, KM; Davis, W; DeLoia, JA; Gallion, H; Krivak, TC; Moysich, K; Tian, C; Zhao, H | 1 |
| Chen, F; Liu, Y; Sun, Y; Wu, X | 1 |
| Aggarwal, BB; Gupta, SC; Kim, JH; Park, B; Yadav, VR | 1 |
| Arena, FP; Epperson, AL; Mintzer, DM; Schwartzberg, LS; Walker, MS | 1 |
| Baker, JH; Kyle, AH; Minchinton, AI | 1 |
| Bauknecht, T; Benhadji, KA; Davidson, N; Gümüş, M; Soldatenkova, V | 1 |
| Jiang, G; Li, J; Li, X; Li, Y; Liu, J; Wang, J; Yang, F; Zhao, H | 1 |
| Bellot, GL; Koh, D; Tan, WH; Tay, LL; Wang, X | 1 |
| Orlova, RV; Protasova, AE | 1 |
| Matsuo, T; Miyata, Y; Ohba, K; Sagara, Y; Sakai, H; Takahashi, H; Watanabe, S | 1 |
| Altevogt, P; Dieckmann, C; Kiefel, H; Korniienko, O; Krüger, A; Moldenhauer, G; Salnikov, A; Schäfer, H; Sebens, S | 1 |
| Bordeleau, L; Kim, S; Seki, J; Sridhar, S; Tannock, I | 1 |
| Furuya, T; Hirowatari, H; Ito, K; Izawa, H; Karasawa, K; Mitsuhashi, N; Ozawa, S; Saito, M; Suzuki, T | 1 |
| Brons, S; Combs, SE; Debus, J; Haberer, T; Habermehl, D; Rieken, S; Weber, KJ; Winter, M; Zipp, L | 1 |
| Dorigo, O; Eng, C; Fekete, M; Santiskulvong, C | 1 |
| Belmont, LD; Fairbrother, WJ; Peale, FV; Tan, N; Wong, M; Yue, P; Zha, J | 1 |
| Booser, DJ; Brewster, AM; Broglio, K; Buzdar, AU; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Hunt, KK; Ibrahim, NK; Kelly, CM; Thomas, ES; Valero, V; Walters, RS | 1 |
| Imai, A; Mizuta, N; Nakatsukasa, K; Sakaguchi, K; Taguchi, T | 1 |
| Gao, Q; Wang, FY; Yu, H | 1 |
| Colantonio, I; Comino, A; Crook, T; Denaro, N; Gasco, M; Lattanzio, L; Lo Nigro, C; Merlano, M; Monteverde, M; Natoli, G; Russi, E; Syed, N; Vivenza, D | 1 |
| Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Somwangprasert, A; Srisukho, S; Sukthomya, V; Tharavichitkul, E; Trakultivakorn, H; Watcharachan, K | 1 |
| Bellmunt, J; Boehle, A; Chevreau, C; Collette, S; Daugaard, G; De Santis, M; de Wit, R; Laufman, LR; Marreaud, S; Mead, GM; Paz-Ares, L; Raghavan, D; Skoneczna, I; Sylvester, R; von der Maase, H; Winquist, E | 1 |
| Aiba, T; Furukawa, K; Hayashi, M; Igarashi, K; Sato, M; Shibuya, H; Sugimura, K; Waguri, N; Yoneyama, O | 1 |
| Inoue, T; Kamba, T; Matsui, Y; Nishiyama, H; Ogawa, O; Saito, R; Sumiyoshi, T; Xing, ND; Yoshimura, K | 1 |
| Hiraki, Y; Iino, S; Kurahara, H; Maemura, K; Mataki, Y; Natsugoe, S; Sakoda, M; Shinchi, H; Takao, S; Ueno, S | 1 |
| Antoine, M; Beau-Faller, M; Bergot, E; Brambilla, E; Braun, D; Creveuil, C; de Fraipont, F; Debieuvre, D; Favrot, MC; Hainaut, P; Levallet, G; Milleron, B; Morin, F; Moro-Sibilot, D; Mounawar, M; Quoix, E; Richard, N; Rouquette, I; Westeel, V; Zalcman, G | 1 |
| Anderson, R; Balkrishnan, R; Camacho, F; Kamal, AH; Kimmick, G; Wei, W | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Behrens, C; Correa, AM; Erasmus, JJ; Kalhor, N; Kim, ES; Lee, JJ; Pataer, A; Raso, MG; Roth, JA; Stewart, DJ; Swisher, SG; Vaporciyan, AA; Wistuba, II | 1 |
| Aracil, M; Arguelaguet, E; Hernández-Losa, J; Jimeno, J; Marés, R; Pons, B; Ramón Y Cajal, S; Somoza, R; Teixidó, C | 1 |
| Bouchardy, C; Dehler, S; Ess, S; Frick, H; Joerger, M; Konzelmann, I; Savidan, A; Thürlimann, B | 1 |
| Cariello, A; Casanova, C; Cruciani, G; Dazzi, C; Freier, E; Gamboni, A; Leoni, M; Mazza, V; Milandri, C; Montanari, M; Papi, M; Papiani, G; Verlicchi, A; Vertogen, B | 1 |
| Clark, JW | 1 |
| Bapiro, TE; Cook, N; Frese, KK; Jodrell, DI; Lolkema, MP; Neesse, A; Tuveson, DA | 1 |
| Antón, A; Barnadas, A; Carrasco, E; Castellá, E; García-Andrade, C; Lomas, M; Palacios, JL; Ramírez, C; Ramírez, JL; Ríos, MJ; Rodríguez-Pinilla, M; San Antonio, B; Sánchez-Rovira, P; Velasco, A | 1 |
| Beslija, S; Brodowicz, T; Greil, R; Inbar, MJ; Kahán, Z; Kaufman, B; Lang, I; Messinger, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z | 1 |
| Cai, XY; Cai, YC; Cao, Y; Hu, WH; Jiang, WQ; Jin, Y; Shi, YX; Xia, XY; Zhang, WD | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Sugawara, M; Takahashi, N; Takekuma, Y | 1 |
| Hoshina, A; Onishi, T; Sasaki, T | 1 |
| Chen, J; He, J; Jiang, L; Li, B; Sun, G; Wang, L; Xiu, Q; Yu, H; Zhao, L | 1 |
| Gao, J; Li, Y; Lu, Z; Shen, L; Yu, J | 1 |
| Baudrin, L; Cadranel, J; Coëtmeur, D; Duruisseaux, M; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Mourlanette, P; Quoix, E; Soria, JC; Westeel, V; Wislez, M | 1 |
| Kaklamani, V; Raffin, M; Reddy, S | 1 |
| Chu, Z; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 2 |
| Kanetake, H; Matsuo, T; Miyata, Y; Nomata, K; Ohba, K; Sagara, Y; Sakai, H | 1 |
| Lim, E; Lin, NU | 1 |
| Abotouk, N; Halim, A | 1 |
| Inal, A; Isikdogan, A; Kaplan, MA; Karakus, A; Kucukoner, M; Urakci, Z | 1 |
| Chen, LK; Liang, Y; Liu, GZ; Wei, WD; Xu, F; Xu, GC; Yang, QY; Zhou, NN | 1 |
| Hu, LM; Hu, ZB; Huang, MD; Shen, HB; Shu, YQ; Wang, ZW; Xu, JL; Yin, ZQ | 1 |
| Cao, N; Li, Z; Ma, B; Mi, D; Tian, J; Yang, K | 1 |
| Arcand, SL; Caceres, KY; Cyr, L; de Ladurantaye, M; Delvoye, N; Létourneau, IJ; Mes-Masson, AM; Meunier, L; Portelance, L; Provencher, DM; Quinn, MC; Shen, Z; Tonin, PN; Wang, LL | 1 |
| Ding, Y; Liao, Y; Peng, RQ; Zhang, X; Zhang, XS; Zheng, LM | 1 |
| Belli, C; Cereda, S; Reni, M | 1 |
| Chen, Y; Cohen, RB; Herbst, RS; Kim, S; Kozloff, MF; Martin, LP; Olszanski, AJ; Rado, T; Rosbrook, B; Samuel, TA; Starr, A; Tarazi, J; Tortorici, M | 1 |
| Bussink, J; Soetekouw, PM; Timmer-Bonte, JN; Tjan-Heijnen, VC; van der Drift, MA; van Die, L; van Leeuwen, F; Wagenaar, M | 1 |
| Alici, S; Berk, V; Camcı, C; Coskun, U; Degerli, H; Gumus, M; Kaya, AO; Kefeli, U; Oner, MK; Ozdemir, NY; Ozkan, M; Ozturk, C; Sevinc, A; Unal, OU; Yilmaz, AU | 1 |
| Santoni-Rugiu, E; Sorensen, JB; Vilmar, AC | 1 |
| Dito, E; Jones, KA; Kantoff, E; Ko, AH; Ong, A; Tempero, MA; Truong, TG | 1 |
| Caffo, O; Fellin, G; Galligioni, E; Mussari, S; Russo, L; Veccia, A | 1 |
| Date, M; Fujiwara-Honjo, N; Haba, R; Hashimoto, S; Houchi, H; Kontani, K; Kuroda, N; Kushida, Y; Murazawa, C; Norimura, S; Ohtani, M; Tanaka, H; Yamauchi, A; Yokomise, H | 1 |
| Avancha, K; Glück, S; Lopes, G; Montero, AJ | 1 |
| Antoine, M; Belmont, L; Cadranel, J; Duruisseaux, M; Giroux Leprieur, E; Gounant, V; Lacave, R; Lavolé, A; Milleron, B; Poulot, V; Rabbe, N; Vieira, T; Wislez, M | 1 |
| Dong, HX; Ke, HG; Li, J; Liu, JH; Shen, Y; Shen, ZY; Yan, Y; You, QS | 1 |
| Allred, JB; Fitch, TR; Hobday, TJ; Liu, H; Lyss, AP; Northfelt, DW; Perez, EA; Rodacker, MW | 1 |
| Gao, J; He, Q; Hua, D; Li, Y; Mao, Y; Shen, L | 1 |
| Cronin, EB; DeFusco, PA; Hart, J; Hegde, PU; Kane, M; Ricci, A; Tannenbaum, SH; Tavakoli, B; Xu, Y; Zhu, Q | 1 |
| Bhattacharyya, J; Chilkoti, A; Hammer, DA; Hassouneh, W; McDaniel, JR; Vargo, KB | 1 |
| Hirashima, T; Imamura, F; Kawase, I; Kijima, T; Komuta, K; Minami, S; Nakatani, T; Namba, Y; Ogata, Y; Okafuji, K; Osaki, T; Otsuka, T; Shiroyama, T; Tachibana, I; Uchida, J; Yamamoto, S | 1 |
| Ishigatsubo, Y; Kaneko, T; Klinman, DM; Sato, T; Shimosato, T; Takahashi, R | 1 |
| Beslija, S; Brodowicz, T; Greil, R; Kahan, Z; Kaufman, B; Lang, I; Melichar, B; Messinger, D; Pienkowski, T; Ryvo, L; Sirbu, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z | 1 |
| Alba-Conejo, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Llácer, C; Lomas-Garrido, M; Navarro-Perez, V; Plata-Fernández, YM; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P | 1 |
| Aström, G; Blomqvist, L; Carlsson, L; Einbeigi, Z; Fujii, H; Glimelius, B; Hatschek, T; Jacobsson, H; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundqvist, M; Suzuki, C; Walz, TM | 1 |
| Furuya, Y; Ishida, T; Masuda, N; Matsunami, N; Miyashita, M; Nagata, T; Nakayama, T; Noguchi, S; Nomura, M; Oba, K; Sakamoto, J; Taguchi, T; Wakita, K; Yamamoto, D; Yoshidome, K; Yoshino, H | 1 |
| Miles, DW | 1 |
| Hess, KR; Hong, D; Naing, A; Nwosu, U; Tsimberidou, AM; Wheler, J; Wolff, RA; Ye, Y | 1 |
| Barlow, LJ; Benson, MC | 1 |
| Almasan, A; Dreicer, R; Ecsedy, JA; Hansel, DE; Lindner, D; Mir, MC; Parker, Y; Singh, K; Teh, BT; Zhang, Z; Zhou, N | 1 |
| Apolo, AB; Bajorin, DF; Halabi, S; Iasonos, A; Milowsky, MI; Ostrovnaya, I; Philips, GK; Riches, J; Rosenberg, JE; Small, EJ | 1 |
| Bingjing, Z; Hu, L; Liang, G; Rufu, X; Xiangdong, Z; Yuliang, W | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, HJ; Kim, HP; Kim, MS; Kim, TY; Lee, GS; Oh, DY; Yoon, YK | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R | 1 |
| Kim, R; Kothari, N; Saif, MW | 1 |
| Li, YH; Luo, HY; Qiu, MZ; Wang, DS; Wang, F; Wang, FH; Wang, ZQ; Xu, RH; Zhang, DS | 1 |
| Einsele, H; Germer, CT; Hartlapp, I; Isbert, C; Kenn, W; Kunzmann, V; Müller, J; Scheurlen, M; Steger, U | 1 |
| Banna, GL; Basile, A; Fraggetta, F; Ippolito, M; Lipari, H; Marletta, F; Nicolosi, M; Saita, S; Terminella, A; Urso, OE; Vaglica, M | 1 |
| Fang, J; Li, S; Lv, C; Ma, Y; Sun, Y; Wu, N; Yan, S; Yang, Y; Zheng, Q | 1 |
| Cheng, J; Gao, J; Liu, X; Wang, J; Wang, L; Xiong, L | 1 |
| Han, JC; Li, HB; Li, XD; Wu, XY; Zhang, YJ | 1 |
| Boy, D; Bruzzi, P; Ceccarelli, M; Cognetti, F; De Laurentiis, M; De Placido, S; Del Mastro, L; Durando, A; Fabi, A; Kazeem, G; La Torre, I; Mansutti, M; Marchi, P; Merlo, DF; Venturini, M | 1 |
| Angelini, C; Arosio, P; Bertuzzi, A; Colombo, P; Cucchiari, D; De Sanctis, R; Faucher, E; Fusco, N; Pellegrinelli, A | 1 |
| Chen, AB; Johnson, BE; Schrag, D; Sharma, DB; Weeks, JC; Zhu, J | 1 |
| Borzási, E; Együd, Z; Fodor, E; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Pálföldi, R; Tiszlavicz, L; Varga, Z | 1 |
| Ahn, JH; Ahn, JS; Han, SW; Im, SA; Im, YH; Jung, KH; Kang, SY; Kim, JH; Kim, SB; Lee, KS; Lee, MH; Lee, S; Nam, BH; Oh, DY; Park, HS; Park, IH; Park, YH; Ro, J; Sohn, JH | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Anile, M; Ciccone, AM; D'Andrilli, A; Ibrahim, M; Maurizi, G; Rendina, EA; Venuta, F | 1 |
| patel, J | 1 |
| Dahlberg, SE; Hoang, T; Johnson, DH; Schiller, JH | 1 |
| Chen, B; Cheng, H; Cheng, L; Li, F; Lu, Z; Qin, Q; Sun, N; Sun, X | 1 |
| Cho, YJ; Hwang, YS; Jeong, YY; Kim, HC; Kim, IS; Kim, MJ; Kim, SH; Lee, GW; Lee, JD; Lee, S; Ling, H; Oh, SY | 1 |
| Abu-Rustum, NR; Andikyan, V; Barakat, RR; Chi, DS; Khoury-Collado, F; Konner, JA; O'Cearbhaill, RE; Sandadi, S; Sonoda, Y; Tew, WP | 1 |
| Alva, A; Daignault-Newton, S; Grivas, PD; Hafez, K; Hollenbeck, B; Hussain, M; Lee, CT; Montgomery, JS; Montie, JE; Smith, DC; Weizer, A; Wood, D | 1 |
| Khunnarong, J; Manusirivithaya, S; Pataradool, K; Pitakkarnkul, S; Prutthiphongsit, W; Srijaipracharoen, S; Tangjitgamol, S; Thavaramara, T | 1 |
| Bigay-Game, L; Braun, D; David, P; Debieuvre, D; Depierre, A; Douillard, JY; Laporte, S; Lavolé, A; Lebeau, B; Lemarié, E; Milleron, B; Molinier, O; Morin, F; Ozenne, G; Poudenx, M; Pujol, JL; Puyraveau, M; Quoix, E; Rivière, A; Westeel, V; Zalcman, G | 1 |
| An, G; Chen, W; Wei, P; Yan, D | 1 |
| Darwiche, K; Freitag, L; Goldberg, EP; Huang, H; Li, Q; Petridis, D; Ritzoulis, C; Spyratos, D; Yarmus, L; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Beckmann, M; Du Bois, A; Eidtmann, H; Heilmann, V; Hubalek, M; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Richter, B; Schrader, I; Schuster, T; Stähler, A; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Wollschläger, K | 1 |
| Akagi, Y; Ishikawa, H; Kinugasa, T; Mizobe, T; Ohshima, K; Oka, Y; Setojima, K; Shiratsuchi, I; Shirouzu, K | 1 |
| Awasthi, N; Hinz, S; Schwarz, AM; Schwarz, MA; Schwarz, RE; Wang, C; Williams, NS; Zhang, C | 1 |
| Cheney, DL; Ghandehari, H; Kopeček, J; Larson, N; Ray, A; Yang, J | 1 |
| Jarboe, J; Saif, MW | 1 |
| Saif, MW; Skoura, E; Syrigos, KN | 1 |
| Ducreux, M; Heinemann, V; Macarulla, T; Reni, M; Richel, DJ; Ychou, M | 1 |
| Boeck, S; Haas, M; Heinemann, V | 1 |
| Fujita, S; Katagata, N; Matsuzaki, M; Nomizu, T; Saito, M; Sakuma, T; Takenoshita, S; Watanabe, F | 1 |
| Alvarez, R; Barbacid, M; Cubillo, A; de Vicente, E; Garcia-Garcia, E; Guerra, C; Hidalgo, M; Lopez-Casas, PP; Lopez-Rios, F; Megias, D; Muñoz, M; Musteanu, M; Plaza, C; Prados, S; Quijano, Y; Rodriguez-Pascual, J; Tabernero, S | 1 |
| Castiglioni, V; Cesca, M; Decio, A; Giavazzi, R; Rovida, A; Scanziani, E; Scarlato, V | 1 |
| Atkins, JN; Azar, CA; Biggs, DD; Brufsky, AM; Costantino, JP; Donnellan, PP; Fehrenbacher, L; Geyer, CE; Levine, EA; Mamounas, EP; Northfelt, DW; Paik, S; Polikoff, JA; Provencher, L; Rastogi, P; Robidoux, A; Swain, SM; Tang, G; Wolmark, N; Zapas, JL | 1 |
| da Silva, EM; de Castria, TB; Gois, AF; Riera, R | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Kolek, V | 1 |
| Lopes, Gde L | 1 |
| Barinoff, J; Bauerfeind, I; Belau, A; Clemens, M; Conrad, B; Diel, IJ; Elling, D; Forstbauer, H; Harbeck, N; Huober, J; Jackisch, C; Kreienberg, R; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Noeding, S; Schmidt, M; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Stinchcombe, TE | 1 |
| Balasubramanian, SU; Harfouche, R; Luchette, M; Papa, AL; Sarangi, S; Sengupta, S; Sidiqui, A | 1 |
| Jamil, K; Naidu Madireddy, UR; Natukula, K; Pingali, UR; Suresh Attili, VS | 1 |
| Alba, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Pascual, J; Plata-Fernández, Y; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P | 1 |
| Alcazar-González, GA; Barrera-Saldaña, HA; Calderón-Garcidueñas, AL; Castruita-Avila, AL; Cerda-Flores, RM; Escorza-Treviño, S; Garza-Rodríguez, ML; González-Guerrero, JF; le Brun, S; Olano-Martin, E; Rubio-Hernández, G; Simon-Buela, L | 1 |
| Ahn, SJ; Ban, HJ; Chung, WK; Kim, KS; Kim, YC; Kim, YI; Kwon, YS; Lim, SC; Nam, TK; Oh, IJ; Song, JY; Yoon, MS | 1 |
| Inagaki, A; Iwao, H; Izumi, Y; Miura, K; Nagayama, K; Shiota, M; Takahashi, K; Tanaka, M; Wanibuchi, H | 1 |
| Arena, FP; Bahary, N; Chiorean, EG; Dowden, S; Ervin, T; Goldstein, D; Harris, M; Hidalgo, M; Iglesias, J; Infante, J; Laheru, D; Ma, WW; Moore, M; Ramanathan, RK; Reni, M; Renschler, MF; Saleh, MN; Seay, T; Tabernero, J; Tjulandin, SA; Van Cutsem, E; Von Hoff, DD; Wei, X | 1 |
| Feng, J; Gao, J; Han, Y; Huang, H; Qu, L; Shen, L; Shou, C; Zhu, L | 1 |
| Chen, JH; Ma, GY; Meng, L; Wang, L; Wang, XW | 1 |
| Biasoni, D; Catanzaro, M; Farè, E; Giannatempo, P; Gianni, AM; Lo Vullo, S; Mariani, L; Milani, A; Necchi, A; Nicolai, N; Piva, L; Raggi, D; Salvioni, R; Stagni, S; Torelli, T | 1 |
| Clark, JI; Kucuk, O; Malhotra, B; Moon, J; Urba, SG; Wolf, GT; Worden, FP | 1 |
| Chi, HD; Liu, Z; Orlando, M; Quinlivan, M; Xu, B; Zhang, XQ | 1 |
| Villanueva, MT | 1 |
| Brons, S; Combs, SE; Debus, J; Haberer, T; Schlaich, F; Weber, KJ | 1 |
| Elsing, C; Hannig, CV; Herrmann, C; Herrmann, T; Jäger, D; Stremmel, W | 1 |
| Chen, MY; Guo, L; Hong, MH; Huang, HQ; Jiang, R; Liu, Q; Mai, HQ; Qian, CN; Qiu, F; Sun, R; Xia, ZJ; Zhang, L; Zou, X | 1 |
| Amadori, D; Aquilina, M; Burgio, MA; Carloni, S; Casadei Gardini, A; Frassineti, GL; Lucchesi, A; Oboldi, D; Tenti, E | 1 |
| Saif, MW | 1 |
| Kautio, AL; Kellokumpu-Lehtinen, PL; Lehtinen, I; Tanner, M; Tuunanen, T | 1 |
| Michl, P | 1 |
| Aljumaily, R; Gay, HA; Parent, T; Russo, S; Walker, PR; Zhang, J | 1 |
| Fujisawa, M; Inoue, T; Miyake, H; Miyazaki, A; Tanaka, H; Terakawa, T; Yokoyama, N | 1 |
| Carafa, M; Celia, C; Cilurzo, F; Di Marzio, L; Gentile, E; Paolino, D; Ventura, CA; Wolfram, J | 1 |
| Furuse, J | 1 |
| Alva, A; Daignault, S; Hussain, M; Smith, DC | 1 |
| Berger, AK; Jäger, D; Springfeld, C; Weber, TF | 1 |
| Abraham, J; Caldas, C; Chan, S; Dean, S; Dunn, J; Earl, HM; Fenwick, N; Gallagher, C; Gounaris, I; Harries, M; Hickish, T; Hiller, L; Houston, S; Hughes-Davies, L; Iddawela, M; Laing, R; McAdam, K; Provenzano, E; Ritchie, D; Skene, A; Vallier, AL; Wishart, G; Young, J | 1 |
| Ahn, JS; Chang, W; Choi, MK; Im, SA; Im, YH; Kim, S; Lee, SY; Park, YH; Woo, SY | 1 |
| Atxner, J; Buchwald, D; Happe, A; Kröz, M; Matthes, H; Popp, S; Schad, F | 1 |
| Jiang, Y; Yang, L; Yuan, Z; Zhang, Y; Zhao, Q | 1 |
| Antoine, M; Bonnette, P; Cadranel, J; Cazes, A; Duruisseaux, M; Girard, N; Mazieres, J; Monnet, I; Ung, M; Vieira, T; Wislez, M | 1 |
| Bai, C; Bai, Y; Cheng, Y; Fan, Q; Gong, J; Hu, B; Hu, G; Jiao, S; Liang, J; Liu, Y; Shen, L; Shi, Y; Wang, J; Xu, N; Xu, R; Zhang, F; Zhang, J; Zhang, X; Zheng, L | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY | 1 |
| Chan, EH; Chan, SL; Chan, ST; He, ZX | 1 |
| Goldstein, D; Renschler, MF; Von Hoff, DD | 1 |
| Bach, PB; Saltz, LB | 1 |
| Kumar, L; Sahoo, RK | 1 |
| Bai, Y; Chu, YP; Gong, JF; Li, J; Li, Y; Shen, L; Zhang, XT | 1 |
| Gong, JF; Li, J; Li, Y; Lu, M; Lu, ZH; Shen, L; Wang, XC; Zhang, XT; Zhou, J | 1 |
| Chen, X; Gao, G; He, Y; Li, W; Li, X; Ren, S; Zhang, L; Zhou, C; Zhou, F | 1 |
| Colussi, O; Landi, B; Lepère, C; Pernot, S; Portal, A; Rougier, P; Siauve, N; Taieb, J; Verrière, B; Zaanan, A | 1 |
| Cai, L; Li, CH; Li, DD; Liu, MY; Liu, W | 1 |
| Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y | 1 |
| Jia, Y; Marks, E; Saif, MW | 1 |
| Choi, M; Kim, R; Saif, MW | 1 |
| Deng, D; Shen, L; Wang, M | 1 |
| Railey, E; Sledge, GW; Smith, ML; White, CB | 1 |
| Botteman, M; Ji, X; Reni, M; Solem, C; Wan, Y; Whiting, S | 1 |
| Arce-Lara, C; Kelley, MJ; Santana-Davila, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H | 1 |
| Berlin, JD; Pauff, JM; Thota, R | 1 |
| Cheng, Y; Cun, Y; Li, M; Li, Z; Peng, Y; Qian, C; Ren, T; Wang, D; Xia, L; Xiong, Y; Zhang, S | 1 |
| Bottomley, A; Coens, C; Ediebah, DE; Flechtner, H; Gotay, C; Greimel, E; King, MT; Quinten, C; Reeve, BB; Ringash, J; Schmucker von Koch, J; Smit, EF; Taphoorn, MJ; Weis, J; Zikos, E | 1 |
| Chen, L; Huang, MJ; Lu, Y; Song, LL; Wang, YS; Xiong, WJ; Xue, JX; Zhang, XX | 1 |
| Chi, Y; Song, Y; Wang, J; Yang, L; Zhou, A | 1 |
| Ah Lee, S; Gwe Ahn, S; Jeong, J; Min Lee, H; Woo Lee, H | 1 |
| Archer, V; Burdaeva, O; Delmar, P; Gorbunova, V; Hilton, M; Juhasz, E; Mok, T; Orlov, S; Pallaud, C; Reck, M; Szima, B; Yu, CJ | 1 |
| Chen, L; Cress, WD; Kurtyka, CA | 1 |
| Higaki, K; Kuroi, K; Masuda, N; Matsunami, N; Miyamoto, T; Mizutani, M; Morimoto, T; Morita, S; Ohno, S; Ohtani, S; Takano, T; Toi, M | 1 |
| Borazanci, E; Von Hoff, DD | 1 |
| Ahn, HK; Cho, EK; Jeong, SH; Jung, M; Kang, SM; Kyung, SY; Park, JW; Shin, DB; Sym, SJ | 1 |
| Cheung, SS; Hasman, D; Tai, J | 1 |
| Conte, M; Ellingrod, VL; King, AN; O'Malley, M; Ramnath, N | 1 |
| Brana, I; Calles, A; Calvo, E; de Boer, CJ; LoRusso, PM; Puchalski, TA; Seetharam, S; Tabernero, J; Yee, LK; Zhong, B | 1 |
| Elity, MM; Sad, LM; Younis, SG | 1 |
| Du, QG; Guo, XY; Han, S; Hao, ZM; Liu, GS; Lv, YF; Wang, P; Zhu, SM | 1 |
| Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q | 1 |
| Eskander, RN; Tewari, KS | 1 |
| Abbruzzese, JL; Hess, KR | 1 |
| Bydder, G; Bydder, M; Carmona, R; Gulaya, S; Mell, LK; Pritz, J; Vaida, F; Welch, CS; Williamson, CW; Zhu, H | 1 |
| Dong, B; Gao, J; Gong, J; Li, Y; Li, Z; Lu, Z; Shen, L; Yu, J; Zhang, X | 1 |
| Alhamed, A; Chatterjee, A; Foster, DA; Hosny, C; Mukhopadhyay, S; Saqcena, M | 1 |
| Kaddis, N; Saif, MW | 1 |
| Daoud, V; Goodman, M; Saif, MW | 1 |
| Li, J; Saif, MW | 1 |
| Gao, XD; Ge, LH; Jin, ZY; Liang, JG; Te, MR; Wang, CL | 1 |
| Oettle, H | 1 |
| Kopeček, J; Sima, M; Yang, J; Zhang, R; Zhou, Y | 1 |
| Bai, C; Chen, H; Gao, Z; Han, B; Jin, L; Li, Q; Li, X; Lu, D; Qian, J; Shao, M; Song, X; Wang, J; Wang, S; Wu, J; Zhao, X | 1 |
| Baena, JM; Bayo, J; Blancas, I; Casal, J; Ciruelos, E; de la Haba, J; de Villena, MC; Galan, A; Gil, M; Jaen, A; Jara, C; Manso, L; Mel, JR; Murias, A; Salvador, J; Sanchez Rvira, P | 1 |
| Chen, X; Li, W; Li, X; Liu, L; Ren, S; Zhou, C; Zhou, F | 1 |
| Chen, GY; Cheng, Y; Huang, C; Song, Y; Wu, YL; Yan, HH; Yang, JJ; Zhou, Q | 1 |
| Garrido-Laguna, I; Patel, S; Reese, Z; Stenehjem, DD | 1 |
| Chen, F; Chen, Y; Cheng, B; Fang, Y; Qu, X; Wang, Z; Xiong, B | 1 |
| Lee, JL; Park, JH | 1 |
| Ai, Z; Lu, B; Sun, L; Xu, J; Yan, X | 1 |
| Chaturvedi, P; Gilkes, DM; Samanta, D; Semenza, GL; Xiang, L | 1 |
| Bos, MM; Boven, E; Braun, JJ; de Groot, SM; Honkoop, AH; Jager, A; Kroep, JR; Lam, SW; Linn, SC; ten Tije, AJ; van den Bosch, J; van Tinteren, H | 1 |
| Eustermann, H; Harich, HD; Hinke, A; Jackisch, C; Reichert, D; Schoenegg, W; Selbach, J; Tesch, H; Welslau, M; Wohlfarth, T | 1 |
| Butler, H; John, P; Saif, MW | 1 |
| Maneechawakajorn, J; Suksuperm, J | 1 |
| Aquino, JB; Malvicini, M; Mazzolini, G | 1 |
| Chiorean, EG; Ferrara, S; Ganju, V; Goldstein, D; Hingorani, SR; Infante, JR; Penenberg, DN; Ramanathan, RK; Romano, A; Scheithauer, W; Tabernero, J; Von Hoff, DD; Weekes, C | 1 |
| Barton, S; Edwards, SJ; Thurgar, E; Trevor, N | 1 |
| El-Maraghi, RH; Goldstein, D; Hammel, P; Heinemann, V; Kunzmann, V; Lu, B; Penenberg, DN; Romano, A; Sastre, J; Scheithauer, W; Siena, S; Tabernero, J; Teixeira, L; Tortora, G; Van Laethem, JL; Von Hoff, DD; Young, R | 1 |
| Ichimaru, N; Kojima, Y; Nonomura, N; Okumi, M; Takahara, S; Takahi, Y | 1 |
| Deng, W; Gao, J; Li, Y; Shen, L; Yuan, J; Zhou, J | 1 |
| Uwagawa, T; Yanaga, K | 1 |
| Ahluwalia, D; Bhupathi, D; Hart, CP; Li, W; Liu, Q; Meng, F; Ruprell, AS; Sun, JD; Wang, Y | 1 |
| Babacan, NA; Deveci, K; Kacan, T; Sancakdar, E; Seker, A; Seker, MM; Turesin, AK; Yilmaz, A | 1 |
| Cong, C; Dou, Y; Duan, L; Gao, A; Lai, Q; Sun, Y; Zheng, Y | 1 |
| Mahdi, H; Rizzo, A; Rose, PG | 1 |
| Alba, E; Moreno, I; Navarro-Perez, V; Plata-Fernández, Y; Ribelles, N; Sánchez-Muñoz, A; Santonja, A | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Chang, CH; Ji, Z; Liu, H; Liu, X; Meng, H; Nel, AE; Situ, A; Wang, M; Wu, B | 1 |
| Basso, SM; Bidoli, E; Foltran, L; Lo Re, G; Lumachi, F; Santeufemia, DA | 1 |
| Abraham, I; Bootman, JL; Gharaibeh, M; McBride, A | 1 |
| Carey, L | 1 |
| Cai, L; Feng, JF; Gu, YJ; Hu, XC; Jiang, ZF; Liu, DG; Lou, GY; Luo, JF; Pan, YY; Ragaz, J; Shao, ZM; Sun, K; Teng, YE; Tong, ZS; Wang, BY; Wang, XJ; Wang, ZH; Wu, CP; Wu, J; Xu, BH; Yin, YM; Zhang, J | 1 |
| Ding, T; Liu, XH; Lv, QY; Song, J; Wang, SH; Wang, Y; Wei, MH; Wu, MD; Yang, QH; Zhou, J; Zhou, YF | 1 |
| Li, Y; Shang, YM; Yang, Y; Zheng, H | 1 |
| Bai, C; Cao, S; Chen, H; Chen, J; Dai, J; Han, B; Hu, Z; Jin, G; Li, Q; Lu, D; Ma, H; Shen, H; Shu, Y; Song, X; Sun, C; Tang, S; Wang, C; Wang, S; Wu, J; Xu, L; Yin, R | 1 |
| Ettrich, TJ; Perkhofer, L; Seufferlein, T | 1 |
| Ang, MK; Cheah, SL; Fong, KW; Lim, WT; Ng, QS; Ong, WS; Quah, D; Soo, KC; Soong, YL; Tan, D; Tan, SH; Tan, T; Wee, J; Yip, C | 1 |
| Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
| Cheung, WY; Gill, S; Ho, M; Lim, HJ; Peixoto, RD; Renouf, DJ; Ruan, JY | 1 |
| Shimizu, S | 1 |
| Faure, R; Forestier, J; Hubault, M; Lombard-Bohas, C; Pivot, C; Walter, T | 1 |
| Abeni, C; Aroldi, F; Bertocchi, P; Di Biasi, B; Meriggi, F; Ogliosi, C; Rizzi, A; Rosso, E; Rota, L; Savelli, G; Zaniboni, A | 1 |
| Bouvet, M; Hoffman, RM | 1 |
| Choi, J; Choi, Y; Haam, S; Huh, YM; Kim, HO; Lee, DK; Noh, I | 1 |
| Dai, X; Jiang, Y; Tan, C | 1 |
| Jamil, K; Jayaraman, A; Subhani, S | 1 |
| Ali-El-Dein, B; Babjuk, M; Burger, M; Chang, SS; Clayman, RH; Daneshmand, S; Efstathiou, JA; Fritsche, HM; Gakis, G; Galland, S; Hrbacek, J; Keegan, KA; Mischinger, J; Morgan, TM; Olugbade, K; Rink, M; Schubert, T; Stenzl, A; Thalmann, GN; Todenhöfer, T; Zaid, HB | 1 |
| Hayashi, K; Homma, S; Ishidao, T; Ito, M; Kamata, Y; Kan, S; Koido, S; Komita, H; Nagasaki, E; Okamoto, M | 1 |
| Hisada, T; Imai, H; Ishihara, S; Kaira, K; Kuwako, T; Masuda, T; Minato, K; Miura, Y; Mogi, A; Saito, R; Shimizu, K; Sunaga, N; Takise, A; Tomizawa, Y; Yamada, M; Yoshino, R | 1 |
| Benedit, P; Carrato, A; García, P; Gostkorzewicz, J; López, R; Macarulla, T; Pérez-Alcántara, F; Rivera, F; Sastre, J | 1 |
| Abesada-Terk, G; Alemany, C; Brown, RH; Cartwright, TH; Faig, D; Fulp, WJ; Jacobsen, PB; Kim, GP; Lee, JH; Levine, RM; Malafa, M; Markham, MJ; Schreiber, F; Sharp, PV; Tanvetyanon, T | 1 |
| Tempero, MA | 1 |
| Boonmars, T; Hahnvajanawong, C; Jearanaikoon, P; Kanchanawat, S; Leelayuwat, C; Namwat, N; Seubwai, W; Techasen, A; Wattanawongdon, W | 1 |
| Chen, J; He, LJ; Li, Y; Li, YY; Lou, Y; Wang, LR; Wang, Y; Zhang, GB | 1 |
| Cerezuela Fuentes, P; Ferris Villanueva, E; García Márquez, A; Guerrero Bautista, R; Martínez Penella, M; Mira Sirvent, Mdel C | 1 |
| Bai, C; Gao, Z; Han, B; Li, H; Li, Q; Li, X; Liu, W; Lu, D; Ma, K; Qian, J; Wang, H; Wang, J; Wang, S; Wang, X; Wu, J; Wu, W; Zhao, X | 1 |
| Bartolotti, M; Brandes, AA; Cavallo, G; Di Battista, M; Genestreti, G | 1 |
| Huang, CB; Huang, LL; Lin, SJ; Pan, JJ; Qiu, SF; Xu, YJ; Zheng, W; Zong, JF | 1 |
| Deng, J; Deng, JH; Niu, PG; Ouyang, XN; Shi, DH | 1 |
| Ahn, JH; Ahn, JS; Han, SW; Im, SA; Im, YH; Jung, KH; Jung, SH; Kang, SY; Kim, JH; Kim, SB; Lee, KS; Lee, MH; Lee, S; Nam, BH; Oh, DY; Park, HS; Park, IH; Park, YH; Ro, J; Sohn, JH; Woo, SY | 1 |
| Baba, J; Ichikawa, K; Igarashi, N; Ishikawa, D; Kagamu, H; Kondo, R; Koshio, J; Koya, T; Miura, S; Nakata, K; Narita, I; Nozaki, K; Okajima, M; Saida, Y; Sato, K; Shoji, S; Tanaka, J; Tanaka, T; Watanabe, S; Yoshizawa, H | 1 |
| Al-Massarani, G; Alammar, M; Banat, I; Najjar, F | 1 |
| Bendaoud, S; de Mestier, L; Hammel, P; Hentic, O; Lekhal, C; Neuzillet, C | 1 |
| de Prado-Otero, DS; Poves-Alvarez, R; Trueba-Arguiñarena, FJ | 1 |
| Che, J; Cheng, R; Giroux-Leprieur, E; Hao, X; He, B; Jablons, DM; Jin, JQ; Li, H; Luh, TW; Mo, M; Tolani, B; Tseng, HH; Wang, C; Woodard, GA; Yang, C; Yang, Y; Yue, D; Zhang, H; Zhang, Y; Zheng, Q | 1 |
| Han, BH; Jin, B; Lou, YQ; Ren, ZH; Xu, JL; Yang, QZ; Zhou, ZR | 1 |
| Brachmann, CB; Heise, C; Hidalgo, M; Illei, P; Lopez-Casas, PP; Lopez-Rios, F; Menendez, C; Musteanu, M; Pierce, D; Plaza, C; Romano, A; Tabernero, J; Von Hoff, DD; Wei, X | 1 |
| Brames, MJ; Einhorn, LH; Mulherin, BP | 1 |
| Cheung, SS; Hasman, D; Ou, D; Tai, J; Warnock, GL | 1 |
| Skoropad, VY | 1 |
| Asai, A; Matsuo, T; Mitsunari, K; Miyata, Y; Ohba, K; Sakai, H | 1 |
| Dai, Y; Ishibashi, O; Kondo, T; Maeda, M; Ohkohchi, N; Watanabe, M | 1 |
| Fallon, JK; Lin, Z; Liu, D; Liu, F; Ma, Y; Wang, Y; Zhao, Q | 1 |
| Baranova, K; Carcangiu, ML; Dorman, SN; Knoll, JH; Mariani, G; Rogan, PK; Urquhart, BL | 1 |
| Arbaud, C; Bachet, JB; Bidault, AT; Bonnetain, F; Coriat, R; Dahan, L; de la Fouchardière, C; Dréanic, J; Dubreuil, O; Hammel, P; Lecomte, T; Lepère, C; Locher, C; Marthey, L; Pernot, S; Portal, A; Taieb, J; Tchoundjeu, B; Tougeron, D | 1 |
| Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB | 1 |
| Bokemeyer, C; Oechsle, K; Oing, C; Rink, M; Seidel, C; von Amsberg, G | 1 |
| André, T; Bachet, JB; Bonnetain, F; Chibaudel, B; Hammel, P; Louvet, C; Validire, P | 1 |
| Alessandri, G; Bondiolotti, G; Bonomi, A; Cavicchini, L; Ceserani, V; Ciusani, E; Coccè, V; Dossena, M; Dugnani, E; Parati, E; Pascucci, L; Pessina, A; Piemonti, L; Piovani, G; Sisto, F; Sordi, V | 1 |
| Guo, J; Tang, N; Wang, Y; Wang, Z; Zhang, Q | 1 |
| Lariño Noia, J | 1 |
| Ishitoya, S; Onishi, H; Takeuchi, E; Terashima, T; Uemura, Y; Ushida, H | 1 |
| Kitaoka, H; Kubo, T; Nakashima, Y; Syuin, T; Tanioka, K; Yamasaki, I; Yamasaki, N | 1 |
| Alexandrov, VA; Belyaev, AM; Belyaeva, OA; Bespalov, VG; Kireeva, GS; Kopteva, OS; Krasilnikova, LA; Maidin, MA; Semenov, AL; Stukov, AN; Vasilieva, IN; Vyshinskaya, EA | 1 |
| Ahn, SJ; Ban, HJ; Chung, WK; Jeong, JU; Kim, KS; Kim, YC; Kim, YH; Nam, TK; Oh, IJ; Song, JY; Yoon, MS | 1 |
| Clément, B; Coulouarn, C; Crouzet, L; Edeline, J; Garin, E; Lepareur, N; Pracht, M | 1 |
| Al-Batran, SE; Kullmann, F; Kunzmann, V; Oettle, H; Plentz, R; Riess, H; Siveke, J; Springfeld, C; Vogel, A | 1 |
| An, G; Ma, Y; Wang, J; Wang, Q; Xu, F; Yang, L | 1 |
| Ferrara, S; Goldstein, D; Greeno, E; Liu, H; Lu, B; Macarulla, T; Moore, M; Pilot, R; Ramanathan, RK; Tortora, G; Von Hoff, DD | 1 |
| Billadeau, DD; Chini, CC; Chini, EN; Escande, C; Espindola-Netto, JM; Guerrico, AM; Mondal, G; Nin, V; Sola-Penna, M; Zhang, JS | 1 |
| Barton, D; Beck, RM; Brufsky, A; Coleman, RE; Conte, PF; Cortes, J; Glück, S; Harbeck, N; Ko, A; Nabholtz, JM; O'Shaughnessy, J; Renschler, MF; Yardley, DA | 1 |
| Bokemeyer, C; Cathomas, R; de Wit, M; Dieing, A; Grünwald, V; Hentrich, M; Hornig, M; Lorch, A; Meiler, J; Oechsle, K; Seidel, C | 1 |
| Dobelbower, MC; Dreicer, R; George, A; Heney, NM; Kaufman, DS; Mitin, T; Sandler, HM; Shipley, WU; Souhami, L; Uzzo, RG; Wallace, HJ; Zietman, AL | 1 |
| Iwata, T; Nakajima, T; Suzuki, H; Tagawa, T; Yoshida, S; Yoshino, I | 1 |
| Campbell, MT; Carolla, RL; Harris, DR; Munsell, MF; Pagliaro, LC; Siefker-Radtke, AO | 1 |
| Adam, J; Bastien, B; Beck, JT; Chouaid, C; Debieuvre, D; Felip, E; Forget, F; Gervais, R; Halluard, C; Kazarnowicz, A; Lacoste, G; Lena, H; Limacher, JM; Losonczy, G; Madroszyk, A; Ottensmeier, C; Palanché, T; Papai, Z; Quoix, E; Szczesna, A; Tavernaro, A; Westeel, V | 1 |
| Ahmadloo, N; Askarian, M; Hatam, N; Javan-Noghabi, J; Mohammadianpanah, M | 1 |
| Chekerov, R; Ismaeel, F; Richter, R; Roots, I; Sehouli, J; Siepmann, T; Woopen, H | 1 |
| Arena, F; Goldstein, D; Korn, RL; Liu, H; Lu, B; McGovern, D; Moore, M; Ramanathan, RK; Siena, S; Tabernero, J; Teixeira, L; Van Laethem, JL; Von Hoff, DD | 1 |
| Arena, FP; Bathini, VG; Chiorean, EG; Clingan, PR; Goldstein, D; Infante, JR; Ko, A; Kunzmann, V; Lu, B; Mainwaring, PN; McGovern, D; Muldoon, RT; Ramanathan, RK; Reni, M; Tabernero, J; Von Hoff, DD; Wood, TE | 1 |
| Egawa, C; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Matsushita, K; Morimoto, Y; Motoyama, Y; Murakami, K; Naito, A; Ohmura, Y; Okishiro, M; Takeda, Y; Takeno, A; Tamura, S | 1 |
| du Bois, A; Grabowski, JP; Harter, P; Heitz, F; Heitz, J; Kristensen, G; Pfisterer, J; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Traut, A | 1 |
| Fujiwara, K; Hanaoka, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T | 1 |
| Itoi, T; Kamisawa, T; Takaori, K; Wood, LD | 1 |
| Buchsbaum, D; Grizzle, W; Hidalgo, M; Kim, H; Kovar, J; Lopez-Casas, P; Oelschlager, D; Samuel, S; Warram, J; Zinn, K | 1 |
| Furuse, J; Ikeda, M; Ioka, T; Mizuno, N; Nakajima, TE; Omuro, Y; Ueno, H; Ueno, M | 1 |
| Benepal, T; Cadranel, J; Christoph, DC; Das, M; Fennell, DA; Ferry, D; Lal, R; Maxwell, F; Summers, Y; Visseren-Grul, C | 1 |
| Audigier-Valette, C; Auliac, JB; Baize, N; Bérard, H; Bota, S; Chouaïd, C; Corre, R; Dansin, E; Daurès, JP; Decroisette, C; Descourt, R; Dujon, C; Falchero, L; Greillier, L; Lamy, R; Le Caër, H; Léna, H; Marcq, M; Massuti, B; Monnet, I; Pérol, M; Plassot, C; Vergnenègre, A | 1 |
| Ames, P; Berlin, J; Catalano, PM; Cohen, SJ; Davies, A; Horan, J; Leichman, L; McKinley, M; O'Neil, BH; Weekes, CD | 1 |
| Alvarez, R; Caruso, R; Diaz, E; Duran, H; Fabra, I; Ferri, V; Hidalgo, M; Ielpo, B; Malavé, L; Plaza, C; Quijano, Y; Vicente, E | 1 |
| Hou, W; Lin, HS; Liu, J; Wang, XQ | 1 |
| Costantini, M; Di Leone, A; Ferrucci, M; Franceschini, G; Masetti, R; Mulè, A; Sanchez, AM; Scaldaferri, A | 1 |
| Bowman, L; John, W; Liepa, AM; Melemed, A; Peterson, P; Shen, W; Smyth, EN | 1 |
| Chen, Y; Cheng, K; Li, ZK; Li, ZP; Liu, JY; Yang, Y | 1 |
| Chen, H; Li, Q; Tang, R; Wen, F; Wu, Y; Zhang, J; Zhang, P; Zhao, R; Zhou, J | 1 |
| Frank, H; Kitzwögerer, M; Moser, M; Wiedemann, D | 1 |
| Bekaii-Saab, T; El-Rayes, BF; Flowers, CR; Goldstein, DA; Krishna, K; Noonan, AM | 1 |
| Couture, F; Dowden, S; El-Maraghi, R; Kennecke, H; Lesperance, B; Letourneau, R; Liu, H; Romano, A; Tehfe, M | 1 |
| Caparello, C; Falcone, A; Fornaro, L; Vasile, E; Vivaldi, C | 1 |
| Bachet, JB; Pernot, S; Portal, A; Taieb, J | 1 |
| Bastiere-Truchot, L; Berton-Rigaud, D; Colombo, N; Del Campo, JM; du Bois, A; Gadducci, A; García, Y; González-Martín, A; Kiermaier, A; Kurzeder, C; Mahner, S; Marmé, F; Martin, N; Ortega, E; Ottevanger, P; Pautier, P; Rau, J; Selle, F | 1 |
| Byrne, KT; Vonderheide, RH | 1 |
| Doihara, H; Iwamoto, T; Matsuoka, J; Mitsuhashi, T; Mizoo, T; Motoki, T; Nogami, T; Ogasawara, Y; Shien, T; Taira, N; Tsuji, H; Yoshitomi, S | 1 |
| Anota, A; Bigay-Game, L; Bonnetain, F; Dansin, E; Dauba, J; Debieuvre, D; Fiteni, F; Milleron, B; Molinier, O; Morin, F; Oster, JP; Pichon, E; Poudenx, M; Quoix, E; Souquet, PJ; Westeel, V; Wislez, M; Zalcman, G | 1 |
| Isayama, H; Ishigami, H; Kitayama, J; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Satoi, S; Tada, M; Takahara, N; Watanabe, T; Yamaguchi, H; Yamamoto, N | 1 |
| Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME | 1 |
| Chiorean, EG; El-Maraghi, R; Goldstein, D; Harris, M; Li, JS; Liu, H; Lu, B; Ma, WW; Manax, V; Reni, M; Romano, A; Tabernero, J; Von Hoff, DD; Whorf, R | 1 |
| Arcidiacono, PG; Balzano, G; Ceraulo, D; Doglioni, C; Falconi, M; Fugazza, C; Gianni, L; Nicoletti, R; Passoni, P; Pepe, G; Reni, M; Zanon, S | 1 |
| Ding, ZY; Liu, ZL; Ren, YN; Zeng, TT; Zhang, L; Zhang, XX; Zhou, XJ | 1 |
| Ellenrieder, V; König, A; Seufferlein, T | 1 |
| Bateman, S; Heise, C; Hidalgo, M; Hou, S; Maitra, A; Pai, SG; Pierce, DW; Rajeshkumar, NV; Tong, Z; Von Hoff, DD; Yabuuchi, S | 1 |
| Alsdorf, WH; Bokemeyer, C; Oechsle, K; Oing, C; von Amsberg, G | 1 |
| Chllamma, MK; Cook, N; Dhani, NC; Dodd, A; Giby, K; Hedley, DW; Knox, JJ; Moore, MJ; Wang, L | 1 |
| Arya, N; Christensen, J; Kohler, E; Lamichhane, SP; Shastri, VP; Xiang, S | 1 |
| Andre, V; Enas, N; Gueorguieva, I; Ribba, B; Tate, SC | 1 |
| Ciardiello, F; Conzo, G; De Vita, F; Diana, A; Fabozzi, A; Febbraro, A; Galizia, G; Giordano, G; Laterza, MM; Orditura, M; Petrillo, A; Savastano, B; Troiani, T; Ventriglia, J | 1 |
| Hanai, K; Higure, T; Hoshi, A; Kawamura, Y; Nakajima, N; Nitta, M; Shimizu, Y; Terachi, T | 1 |
| Arpino, G; De Placido, S; Giuliano, M; Schettini, F | 1 |
| Msaouel, P; Tu, SM; Zhang, M | 1 |
| Kataoka, K; Maeda, M; Matsubara, H; Okamura, S; Urano, F | 1 |
| Altundag, K; Barnadas, A; Botha, M; Chan, A; Cinieri, S; Coskun, U; Dodyk, P; Lazzarelli, S; Rauch, D; Tubiana-Mathieu, N; Vandebroek, A; Villanova, G | 1 |
| Fujiwara, Y; Goto, K; Horinouchi, H; Hozumi, H; Kanda, S; Kitazono, S; Kubo, E; Mizugaki, H; Nokihara, H; Shiraishi, H; Sunami, K; Tamura, T; Tanaka, A; Utsumi, H; Yamamoto, N | 1 |
| Li, JS; McGovern, D; Romano, A; Römmler-Zehrer, J; Stahl, M; Vogel, A | 1 |
| Belau, AK; Bover-Barcelo, I; Canzler, U; Chekerov, R; Gonzalez-Martin, A; Hanker, LC; Harter, P; Hilpert, F; Keil, E; Klare, P; Kurzeder, C; Mahner, S; Meier, W; Petru, E; Reinthaller, A; Richter, R; Sehouli, J; Wimberger, P; Woopen, H; Zeimet, A | 1 |
| Chen, H; Fan, W; He, Y; Hu, H; Tang, S; Wang, P; Xu, P; Xu, Z; Yang, G; Yu, M; Zhang, Z; Zhao, X | 1 |
| Juszczak, M; Paschke, L; Slupski, M | 1 |
| Bahary, N; Bednar, F; Hogg, ME; Ocuin, LM; Steve, J; Winters, S; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Haruki, K; Horiuchi, T; Iwase, R; Ohashi, T; Saito, N; Shiba, H; Shirai, Y; Uwagawa, T; Yanaga, K | 1 |
| Abraham, I; Bootman, JL; Gharaibeh, M; McBride, A; Patel, H | 1 |
| Chan, DY; Chee, CE; Nga, ME; Phua, JN; Shabbir, A; So, JB; Soh, TI; Syn, NL; Yap, R; Yong, WP | 1 |
| Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS | 1 |
| Gajra, A | 1 |
| Biankin, A; Goldstein, D; Johns, A; Mawson, A; McCarroll, J; Nunez, A; Phillips, P; Sharbeen, G; Youkhana, J | 1 |
| Du, X; Li, X; Liu, N; Sheng, X; Wang, F; Yu, H | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Ibrahim, T; Kattan, J; Kourie, HR | 1 |
| Beyer, G; Javed, MA; Kohlmann, T; Krug, S; Le, N; Neesse, A; Schober, M; Sund, M; Vinci, A | 1 |
| Chisaki, Y; Nakamura, N; Yano, Y | 1 |
| Alazraki, A; Carden, MA; Meany, H; Rapkin, LB; Smith, S; Yin, H | 1 |
| Diao, T; Feng, F; Hou, R; Huhe, M; Liu, S; Nan, G; Sun, X; Tang, H; Wang, B; Wang, L; Wu, B; Zhang, Y; Zhang, Z; Zhu, Y | 1 |
| Arenare, L; Bergamini, A; Cecere, SC; Della Pepa, C; Di Napoli, M; Facchini, G; Gargiulo, P; Mangili, G; Pignata, S; Pisano, C; Rossetti, S; Tambaro, R | 1 |
| Fang, Y; Kopeček, J; Li, Y; Pan, H; Yang, J; Zhang, L; Zhang, R | 1 |
| Abbott, DE; Ahmad, SA; Al Humaidi, AH; Choe, KA; Dhar, VK; Fu, B; Habib, DA; Hanseman, DJ; Kharofa, J; Kim, Y; Levinsky, NC; Olowokure, OO; Smith, M; Wang, J; Wilson, GC; Xia, BT | 1 |
| Han, X; Lu, N; Pan, Y; Xu, J | 1 |
| Kaura, S; Khan, ZM; MacEwan, JP; Yin, W | 1 |
| Hagino, S; Nakayama, A; Sakamoto, K | 1 |
| Akiyama, Y; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Kuwahara, R; Morimoto, Y; Murakami, K; Naito, A; Ohmura, Y; Oneda, Y; Sakamoto, T; Takeda, Y; Takeno, A; Tamura, S | 1 |
| Fukabori, M; Itoh, Y; Morita, A; Nakayama, M; Saito, H; Suematsu, Y; Takahashi, M; Wakabayashi, K; Yamagishi, S | 1 |
| Fujimoto, T; Hazama, S; Iida, M; Kanekiyo, S; Matsui, H; Matsukuma, S; Nagano, H; Sakamoto, K; Shindo, Y; Suzuki, N; Takeda, S; Tokuhisa, Y; Tokumitsu, Y; Ueno, T; Yoshino, S | 1 |
| Hoshino, H; Hosoda, Y; Kakita, N; Kawada, J; Kim, Y; Nishino, M; Okano, M; Okuyama, M; Tsujinaka, T; Yamasaki, M | 1 |
| Bhosale, P; Dalton, HJ; Fleming, ND; Gershenson, DM; Schmeler, KM; Sun, CC | 1 |
| Darko, KO; He, C; Huang, Y; Liu, Z; Peng, M; Su, Q; Tao, T; Yang, X; Yin, T | 1 |
| Nanjappa, S; Pabbathi, S; Singh, V; Uttamchandani, S | 1 |
| Hayami, S; Hirono, S; Kawai, M; Kitahata, Y; Miyazawa, M; Okada, KI; Shimizu, A; Ueno, M; Yamaue, H | 1 |
| Alemany, R; Fillat, C; Maliandi, MV; Mato-Berciano, A; Montoliu, L; Raimondi, G | 1 |
| Assi, T; El Karak, F; El Rassy, E; Ghosn, M; Kattan, J | 1 |
| Hara, A; Ichinoe, M; Imaizumi, H; Iwai, T; Kaizu, T; Kaneda, T; Kawamata, H; Kida, M; Kumamoto, Y; Nakamoto, S; Nishiyama, R; Okuwaki, K; Suzuki, E; Tajima, H; Watanabe, M; Yamauchi, H; Yokota, M | 1 |
| Kusuhara, M; Sasaki, K; Serizawa, M; Todaka, A; Umehara, R; Urakami, K; Yamaguchi, K; Yasui, H | 1 |
| Anoopkumar-Dukie, S; Arora, D; Desbrow, B; Grant, GD; Hall, S; Hong, Y; Lai, R | 1 |
| Han, J; Li, K; Liang, Y; Tian, B; Wang, L; Wu, Z; Zhang, J | 1 |
| Belk, KW; Kim, GP; Parisi, MF; Patel, MB; Pelletier, CL | 1 |
| Janssen, S; Manig, L; Rades, D; Schild, SE | 1 |
| Beg, MS; Bolluyt, J; Boothman, DA; Deberardinis, RJ; Fattah, F; Gerber, DE; Huang, X; Laheru, D; Leff, R; Merritt, ME; Sarode, V; Silvers, MA; Xie, XJ | 1 |
| Huang, J; Li, Z; Shen, X; Wang, Y; Zhi, Q; Zhou, J | 1 |
| Alessandri, G; Balducci, L; Brini, AT; Cabeza, L; Ciusani, E; Cocce, V; Falchetti, ML; Parati, E; Pascucci, L; Pessina, A; Piovani, G; Sisto, F | 1 |
| Ahn, JS; Awada, A; Cortés, J; Diéras, V; Gómez-Pardo, P; Hannah, AL; Hoch, U; Im, SA; Mailliez, A; Moreno-Aspitia, A; O'Shaughnessy, J; Perez, EA; Potter, DA; Rugo, HS; Schwartzberg, LS; Tagliaferri, M; Twelves, C; Yardley, DA; Zhao, C | 1 |
| Avallone, A; Capozzi, M; Cavalcanti, E; DE Divitiis, C; DI Girolamo, E; Nasti, G; Ottaiano, A; Romano, G; Tafuto, S; Tatangelo, F; VON Arx, C | 1 |
| Akita, T; Kiuchi, Y; Kogo, M; Kurihara, T; Nakajima, H; Nakamura, S; Shikama, Y; Sunaga, T; Tobe, T; Yoneyama, K | 1 |
| Abrams, TA; Fuchs, CS; Meyer, G; Meyerhardt, JA; Schrag, D; Wolpin, BM | 1 |
| Abou-Khalil, J; Rocha, FG | 1 |
| Mahdi, H; Maurer, K; Michener, C; Rose, PG | 1 |
| Damhuis, RA; den Bakker, MA; Derks, JL; Dingemans, AC; Groen, HJ; Smit, EF; Speel, EM; Thunnissen, E; van den Broek, EC; van Suylen, RJ | 1 |
| Fong, KW; Hussain, A; Ong, WS; Sommat, K; Soong, YL; Tan, T; Wee, J | 1 |
| Abu-Suboh, M; Allende, E; Arribas, J; Balsells, J; Bernadó Morales, C; Bilal, F; Carreras, MJ; Macarulla, T; Massó-Vallés, D; Mohan, V; Pedersen, K; Sagi, I; Salcedo, MT; Serres, X; Soucek, L; Tabernero, J; Vivancos, A | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Bonnetain, F; de la Motte Rouge, T; Kalbacher, E; Lesoin, A; Pautier, P | 1 |
| Maloney, A; Relias, V; Saif, MW; Smith, MH | 1 |
| Achiwa, K; Fujita, M; Kataoka, K; Matsubara, H; Minami, Y; Naitoh, T; Urano, F; Yamada, M; Yamamoto, H | 1 |
| Arena, J; Bergamin, S; Chua, TC; Clarke, S; Diakos, C; Gibbs, E; Gill, AJ; Hruby, G; Itchins, M; Kim, S; Kneebone, A; Maher, R; Mittal, A; Nahm, CB; Pavlakis, N; Rabindran, J; Samra, J; Wong, M | 1 |
| Doi, M; Eguchi, H; Hirono, S; Kawai, M; Matsumoto, I; Murakami, Y; Okada, KI; Satoi, S; Shimokawa, T; Sho, M; Yamada, S; Yamaue, H | 1 |
| Fernandes Junior, HJ; Graziani, SR; Kalil Filho, R; Maranhão, RC; Morikawa, AT; Van Eyll, BM; Vital, CG | 1 |
| Bonafede, M; Cai, Q; McBride, A; Parisi, M; Patel, M; Pelletier, C; Princic, N; Tran, O | 1 |
| Ancrile, BB; Birkholz, JH; Blandford, JT; Dye, CE; Gusani, NJ; Headlee, BD; Heisey, HD; Levenick, JM; Maranki, JL; Mathew, A; McGarrity, TJ; Moyer, MT; Sharzehi, S | 1 |
| Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U | 1 |
| Coppola, L; D'Andrea, MR; Di Raimo, T; Giordano, G; Olivieri, N; Pancione, M; Parcesepe, P; Toffoli, G; Velocci, M | 1 |
| Al-Hazzouri, A; Bendell, JC; DeBusk, LM; Earwood, C; Guo, S; Ko, AH; Lane, CM; Murphy, PB; Peyton, JD; Rodriguez, FA; Shipley, DL; Tempero, MA; Waterhouse, DM; Womack, MS; Xiong, HQ | 1 |
| Liu, Y; Tamam, H; Yeo, Y | 1 |
| Bonetti, A; Giuliani, J | 1 |
| Ji, S; Liang, C; Liang, D; Meng, Q; Ni, Q; Qin, Y; Shi, S; Xu, J; Yu, X; Zhang, B | 1 |
| Goto, A; Horita, N; Ito, K; Kaneko, T; Nagashima, A; Nakashima, K; Shibata, Y; Yamanaka, T | 1 |
| Fujii, Y; Hamada, T; Hiyoshi, M; Imamura, N; Nanashima, A; Tsuchimochi, Y; Wada, T; Yano, K | 1 |
| Ahn, JH; Chae, YS; Han, HS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Lee, SJ; Park, IH; Park, YH; Sohn, JH | 1 |
| Alvarez, R; Caruso, R; Cubillo, A; Diaz, E; Duran, H; Fabra, I; Ferri, V; Ielpo, B; Kalivaci, D; Lazzaro, S; Malavé, L; Plaza, C; Quijano, Y; Vicente, E | 1 |
| Beck, J; Blaydorn, L; Bornemann-Kolatzki, K; Khemka, V; Schütz, E; Urnovitz, H; Weiss, GJ | 1 |
| Camateros, P; Cheung, WY; Wang, Y | 1 |
| Li, SY; Lin, XQ; Liu, YQ; Ouyang, M; Qin, YY; Xie, ZH; Zhang, DH; Zhang, JX; Zhou, CZ | 1 |
| Aktas, B; Bangemann, N; Braun, M; Christgen, M; Clemens, M; Forstbauer, H; Gluz, O; Grischke, EM; Hackmann, J; Harbeck, N; Kates, R; Kohls, A; Kreipe, HH; Kuemmel, S; Liedtke, C; Lindner, C; Nitz, U; Potenberg, J; Schumacher, C; Schumacher, J; Staib, P; Uleer, C; von Schumann, R; Warm, M; Wuerstlein, R | 1 |
| Aldrich, C; Bahary, N; Braiteh, F; Bullock, AJ; Chondros, D; Harris, WP; Hendifar, AE; Hingorani, SR; Jiang, P; Khelifa, S; Oberstein, PE; Pu, J; Ritch, PS; Seery, TE; Sigal, DS; Wang-Gillam, A; Wu, W; Zalupski, MM; Zheng, L | 1 |
| Corrie, PG; Doherty, GJ; Tempero, M | 1 |
| Gourd, E | 1 |
| Fushida, S; Harmon, JW; Hayashi, H; Kishimoto, K; Makino, I; Miyashita, T; Nakanuma, S; Ninomiya, I; Ohbatake, Y; Ohta, T; Okazaki, M; Tajima, H; Takamura, H; Yamaguchi, T | 1 |
| Bartscht, T; Hakim, SG; Idel, C; Rades, D | 1 |
| Hayashi, K; Inoue, T; Joh, T; Kato, A; Kondo, H; Naiki-Ito, A; Naitoh, I; Nakazawa, T; Nishi, Y; Okumura, F; Shimizu, S; Takada, H; Takahashi, S; Yoshida, M | 1 |
| Eshima, K; Fukushima, M; Iizuka, K; Jin, C; Zhang, C | 1 |
| Danter, WR; Koropatnick, J; Maleki Vareki, S; Salim, KY | 1 |
| Capurso, G; Delle Fave, G; Panzeri, V; Passacantilli, I; Sette, C; Terracciano, F | 1 |
| Ariake, K; Fukase, K; Hayashi, H; Ishida, M; Maeda, S; Masuda, K; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Sakata, N; Takadate, T; Unno, M | 1 |
| Deguchi, M; Ishida, M; Kaizaki, Y; Kitajima, T; Ohnishi, K; Ohno, N; Sawai, K; Tabata, S | 1 |
| Fujiyama, J; Hiramoto, H; Kawamura, Y; Masuyama, M; Nakashima, S; Nishida, M; Ochi, F; Shibamoto, J; Takashima, Y; Tsujiura, M | 1 |
| Hosoda, Y; Katayama, H; Katsushima, U; Kawai, J; Kiyochi, H; Komoto, I; Nishiyama, K; Ogura, N; Okabe, A; Oshima, Y; Sasaki, Y; Sugimoto, T; Taki, Y; Tsunekawa, S; Yanagihara, K | 1 |
| Hata, T; Hayashi, H; Iseki, M; Kanno, A; Kyakumoto, Y; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Sakata, N; Shimosegawa, T; Takadate, T; Unno, M | 1 |
| Hori, T; Kaizaki, R; Kanazawa, A; Kodai, S; Komatsu, R; Takahama, M; Takatsuka, S; Tsukamoto, T | 1 |
| Hirai, M; Kume, M; Makimoto, H; Minami, H; Mizuta, N; Nakagawa, T; Nishioka, T; Yamamoto, K; Yano, I | 1 |
| Biankin, AV; Chantrill, L; Chin, V; Nagrial, A; O'Connor, CA; Scholten, RJ; Sjoquist, K; Yip, D | 1 |
| Abe, K; Gocho, T; Haruki, K; Onda, S; Sakamoto, T; Takano, Y; Uwagawa, T; Yanaga, K | 1 |
| Bagust, A; Banks, L; Beale, S; Boland, A; Duarte, R; Greenhalgh, J; Kotas, E; Palmer, D; Richardson, M; Stainthorpe, A | 1 |
| Chen, H; Cohen, HJ; Edelman, MJ; Feliciano, JL; Gajra, A; Hurria, A; Jatoi, A; Lafky, J; Le-Rademacher, JG; Lilenbaum, R; Maggiore, R; McMurray, RP; Muss, HB; Wong, ML; Zemla, TJ | 1 |
| Chang, HM; Hong, SM; Hwang, DW; Hwang, I; Jeong, JH; Kang, J; Kim, KP; Kim, MH; Kim, SC; Lee, JH; Lee, SK; Lee, SS; Park, DH; Ryoo, BY; Seo, DW; Shin, SH; Song, KB; Song, TJ; Yoo, C | 1 |
| Kellett, C; Kim, CA; Lambert, P; Zhang, H | 1 |
| Endo, T; Hasegawa, K; Isogai, J; Kamiya, A; Kaneko, J; Kobayashi, K; Kondoh, I; Maejima, K; Maejima, S; Takatsuno, Y | 1 |
| Ebara, S; Edamura, K; Hanamoto, M; Hayashi, N; Hirata, T; Ogura, K; Saika, T; Takamura, K | 1 |
| Agócs, L; Döme, B; Fábián, K; Fillinger, J; Kajdácsi, Z; Moldvay, J; Pipek, O; Reiniger, L; Rojkó, L; Szállási, Z; Téglási, V; Tímár, J; Vágvölgyi, A | 1 |
| Kim, DU | 1 |
| Fan, Y; Feng, Y; Guo, X; Liu, T; Lou, W; Wang, D; Wang, Y; Wu, L; Wu, W; Xu, B; Xu, Y; Zhou, Y | 1 |
| Hu, Q; Liu, H; Xu, Y; Yang, W; Zhong, L | 1 |
| Bahary, N; Dhir, M; Hamad, A; Hogg, ME; Singhi, AD; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Alazraki, AL; Amankwah, EK; Cash, T; Clark, D; George, BA; Metts, JL; Olson, TA; Wasilewski-Masker, KJ | 1 |
| Iguchi, T; Kato, M; Kuratsukuri, K; Nakatani, T; Nishihara, C; Takeyama, Y; Tamada, S; Yamasaki, T | 1 |
| Duran, H; Ielpo, B; Quijano, Y; Vicente, E | 1 |
| Dong, S; Duan, Y; Guo, Y; Li, Z; Ma, M; Niu, L; Shi, Y; Wang, C; Wang, N; Zhang, M | 1 |
| Akao, J; Otsuka, N; Shimizu, K; Tahara, J; Takayama, Y; Tokushige, K | 1 |
| Chen, H; Cohen, HJ; Edelman, MJ; Feliciano, JL; Gajra, A; Hurria, A; Jatoi, A; Le-Rademacher, JG; Lilenbaum, R; McMurray, R; Muss, H; Zemla, T | 1 |
| Chouaib, S; Foucher, ED; Galon, J; Ghigo, C; Iovanna, J; Olive, D | 1 |
| Ali, H; Barton, D; Bengala, C; Brufsky, A; Coleman, R; Conte, P; Cortes, J; de la Cruz-Merino, L; Eakel, J; Glück, S; Harbeck, N; Li, H; Miller, J; O'Shaughnessy, J; Schneeweiss, A; Shtivelband, M; Wilks, S; Yardley, DA; Young, R | 1 |
| Bianchi, G; Capri, G; Cona, MS; de Braud, F; Ferrari, B; Huber, V; Maggi, C; Manoukian, S; Mariani, G; Mennitto, A; Milano, M; Prisciandaro, M; Rinaldi, L; Rivoltini, L; Vernieri, C | 1 |
| Cao, J; Hu, XC; Lin, Y; Luo, JF; Shao, ZM; Sun, XJ; Tao, ZH; Wang, BY; Wang, LP; Wang, ZH; Wu, J; Yang, WT; Zhang, J; Zhang, S | 1 |
| Qi, Y; Qian, S; Wu, X; Xing, K; Zhang, L; Zhang, P | 1 |
| Wang, Y; Xu, F; Xu, H; Ying, J; Zhu, W | 1 |
| Aly, A; Asghari, G; Beale, P; Botteman, M; Clingan, P; Ferrara, S; Harris, M; Mainwaring, P; Margunato-Debay, S; Parnis, FX; Romano, A; Young, R | 1 |
| An, C; Bang, S; Cho, IR; Chung, JB; Chung, MJ; Jo, JH; Jung, SY; Kang, H; Lee, HS; Park, JY; Park, MS; Park, SW; Song, SY | 1 |
| De Haes, P; Morren, MA; Noë, E; Van Cutsem, E; Van den Oord, JJ; Verhulst, L; Verslype, C | 1 |
| Jusko, WJ; Molins, EAG | 1 |
| Chen, GP; Chen, YQ; Hu, JL; Liu, NF; Sun, HY; Yang, Y; Yu, H; Zhu, JQ; Zhu, T | 1 |
| Gwynne, SH; Quinton, AE; Yim, KL | 1 |
| Anthony, L; Desimone, P; Dineen, S; Goel, G; Hosein, PJ; Husnain, M; Kudrimoti, M; Loaiza-Bonilla, A; Peterson, SL; Pimentel, A; Pollack, T; Ratermann, K; Tzeng, CD; Westendorf-Overley, C | 1 |
| Canale, TD; Cheung, WY; Cho, H | 1 |
| Abrams, SL; Candido, S; Cervello, M; Cocco, L; Falasca, M; Lertpiriyapong, K; Libra, M; Lombardi, P; Martelli, AM; McCubrey, JA; Montalto, G; Murata, RM; Ratti, S; Rosalen, PL; Steelman, LS; Yang, LV | 1 |
| Abraham, I; Alberts, DS; Alsaid, N; Bootman, JL; Erstad, B; Gharaibeh, M; McBride, A; Slack, M | 1 |
| Robson, M | 1 |
| Abe, M; Chiba, T; Iino, Y; Kato, N; Mikata, R; Ogawa, Y; Ohyama, H; Suzuki, E; Tsuyuguchi, T; Yasui, S | 1 |
| Álvarez, R; Carrato, A; Díaz, R; García, A; Hidalgo, M; Laquente, B; Macarulla, T; Muñoz, A; Sastre, J | 1 |
| Chan, MW; Chang, CC; Chen, HJ; Chen, LY; Huang, RL; Lai, HC; Liew, PL; Su, PH; Wang, YC; Weng, YC | 1 |
| Bahra, M; Denecke, T; Jühling, A; Klein, F; Pelzer, U; Riess, H; Roemmler-Zehrer, J; Sinn, M; Striefler, J; Wislocka, L | 1 |
| Chen, W; He, M; Liu, Q; Long, MM; Wang, H; Wang, J; Xu, SW; Yang, LH; Yang, RM; Zhan, M | 1 |
| Belle, S; Betge, J; Burgermeister, E; Chi-Kern, J; Ebert, MP; Gutting, T; Haertel, N; Jesenofsky, R; Maenz, M; Schulte, N; Wedding, U | 1 |
| Saito, K; Sato, A; Takahata, T; Yu, C | 1 |
| Chevalier, H; Neuzillet, C; Turpin, A | 1 |
| Fukuda, H; Fukutomi, A; Furuse, J; Ikeda, M; Ioka, T; Ishii, H; Katayama, H; Mizuno, N; Mizusawa, J; Okusaka, T; Ozaka, M; Ueno, H; Ueno, M | 1 |
| Barbie, D; Chaves, J; Fuchs, CS; Hahn, WC; Hendifar, A; Koh, B; Ng, K; Starodub, A; Yang, Y | 1 |
| Berlin, J; Cardin, D; Das, S | 1 |
| Akita, H; Asukai, K; Ioka, T; Ishikawa, O; Ohue, M; Takahashi, H; Tomokoni, A; Wada, H; Yano, M | 1 |
| Arcidiacono, PG; Balzano, G; Castoldi, R; Ceraulo, D; Chiaravalli, M; Doglioni, C; Falconi, M; Fugazza, C; Gianni, L; Macchini, M; Nicoletti, R; Partelli, S; Passoni, P; Peretti, U; Pircher, C; Reni, M; Zanon, S | 1 |
| Benson, AB; Catalano, PJ; Lubner, SJ; Menge, MR; Munshi, HG; Nimeiri, HS; O'Dwyer, PJ; Sahai, V; Zalupski, MM | 1 |
| Kim, S; Marshall, JL; Parisi, M; Patterson-Lomba, O; Signorovitch, JE; Ung, B; Xiang, CQ; Yang, H | 1 |
| Borbath, I; Conroy, T; Malka, D | 1 |
| Apolo, AB; Chowdhury, S; Galsky, MD; Hahn, NM; Merseburger, AS; Milowsky, MI; Petrylak, D; Powles, T; Quinn, DI; Rosenberg, JE; Siefker-Radtke, A; Sonpavde, G; Sternberg, CN | 1 |
| Bahra, M; Neumann, CCM; Pratschke, J; Reutzel-Selke, A; Sauer, IM; Schmuck, RB; Seidel, E; von Hörschelmann, E | 1 |
| Arroyo-Conde, C; Casanova-Martinez, C; González-Costas, S; Piñeiro-Corrales, G; Romero-Ventosa, EY | 1 |
| Chen, C; Meng, X; Qin, Z; Song, N; Wang, Y; Xia, J; Xu, L; Zhang, Q; Zhou, X | 1 |
| Copolla, D; Goyal, G; Kim, J; Kim, R; Kommalapati, A; Mahipal, A; Neuger, A; Soares, H; Tella, SH | 1 |
| Dhir, M; Zureikat, AH | 1 |
| Chang, HM; Hwang, I; Ip, HNN; Jeong, JH; Kang, J; Kim, KP; Ryoo, BY; Yoo, C | 1 |
| Bhosale, P; Fogelman, D; Gulhati, P; Javle, M; Katz, MHG; Koay, EJ; Lee, JE; Lee, JH; Maitra, A; Prakash, L; Shroff, R; Tamm, E; Tzeng, CD; Varadhachary, GR; Wang, H; Wang, X; Weston, B; Wolff, RA | 1 |
| Bi, H; Bold, RJ; Gonzalez, FJ; Ho, PY; Jian, C; Kim, EJ; Qiu, JX; Tu, MJ; Yu, AM; Zhang, QY | 1 |
| Choi, JH; Choi, YH; Huh, G; Kim, YT; Lee, SH; Paik, WH; Ryu, JK; You, MS | 1 |
| Fu, J; Jin, Y; Li, X; Liang, X; Luo, Y; Zhang, J; Zhang, P; Zou, Q | 1 |
| Li, B; Liao, W; Wen, H; Xu, P; Zhang, S; Zheng, L | 1 |
| Kumar, L; Tiwari, A | 1 |
| Gupta, S; Nayak, L; Ostwal, V; Ramaswamy, A; Sahu, A; Shetty, N; Shrikhande, SV; Zanwar, S | 1 |
| Lv, C; Wang, J; Wu, N; Yan, S; Yang, Y | 1 |
| Adeva, J; Alés-Díaz, I; Buxò, E; Cañabate, M; Carmona-Bayonas, A; De la Cámara, J; Fernández, A; Gallardo, E; Gallego, J; García, A; González, P; Guillén, C; Jiménez-Fonseca, P; Llorca, C; López, C; López, LJ; Muñoz, A; Navarro-Pérez, V; Pazo-Cid, RA; Quintero, G; Ramírez, P; Reboredo, M; Ruiz-Miravet, N; Salgado, M; Sanchez-Cánovas, M; Vera, R | 1 |
| Cao, S; Han, B; Teng, J; Xu, J; Zhong, H | 1 |
| Algül, H; Atzpodien, J; Berger, AW; Daum, S; Dickhut, A; Ettrich, TJ; Gallmeier, E; Geissler, M; König, A; Kornmann, M; Muche, R; Perkhofer, L; Prasnikar, N; Reinacher-Schick, A; Seufferlein, T; Tannapfel, A; Uhl, W; Wille, K; Wittel, U | 1 |
| Aldrich, JD; Overman, MJ; Raghav, KPS; Varadhachary, GR; Wolff, RA | 1 |
| Shi, S; Yu, X | 1 |
| Chawla, SP; Dry, SM; Eilber, FC; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kimura, H; Li, Y; Miwa, S; Miyake, K; Nelson, SD; Oshiro, H; Razmjooei, S; Singh, SR; Tsuchiya, H; Wangsiricharoen, S; Yamamoto, N; Zhang, Z | 1 |
| Blomstrand, H; Bratthäll, C; Elander, NO; Green, H; Scheibling, U | 1 |
| Andalibi, H; Heinrich, B; Kafka, A; Klaus, A; Öhler, L; Schima, W; Vogl, UM; Vormittag, L; Winkler, T | 1 |
| Buyse, M; Giai, J; Maucort-Boulch, D; Péron, J | 1 |
| Bates, SE; Chabot, JA; Manji, GA; Raufi, AG | 1 |
| Du, S; Lu, Y; Xiong, H; Xu, C; Yao, J | 1 |
| Fushida, S; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohbatake, Y; Ohta, T; Okamoto, K; Okazaki, M; Sakai, S; Tajima, H; Takamura, H; Terai, S | 1 |
| Amagasa, H; Ami, K; Andou, M; Fukuda, A; Ganno, H; Iida, S; Imai, K; Kajiyama, D; Kakuta, R; Kawaguchi, M; Maeda, S; Motoyama, K; Shibuya, G; Yamada, A | 1 |
| Bastiancich, C; Bastiat, G; Bozzato, E; Danhier, F; Luyten, U; Préat, V | 1 |
| Chang, YJ; Chen, HA; Huang, CY; Huang, MT; Makondi, PT; Wang, JW; Wei, PL | 1 |
| Ben, XS; Chen, GY; Chen, HJ; Cheng, Y; Huang, C; Jiang, BY; Song, Y; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Zhou, Q | 1 |
| Ahn, DH; Bekaii-Saab, T; Goldstein, D; Li, CP; Macarulla, T; O'Neil, B; Okusaka, T; Reni, M; Sonbol, MB; Tabernero, J; Van Cutsem, E | 1 |
| Hu, W; Li, M; Lu, H; Lu, S; Yang, D; Ye, J; Zhang, L | 1 |
| Bekaii-Saab, T | 1 |
| Le Tourneau, C; Ricci, F | 1 |
| Lin, J; Ma, L; Su, GH; Wei, J | 1 |
| Fujimori, N; Kakihara, D; Kimura, R; Matsuda, R; Miyasaka, Y; Mori, Y; Nakamura, M; Nakata, K; Oda, Y; Ohno, T; Ohtsuka, T | 1 |
| Bian, Y; Cao, K; Gao, S; Guo, S; Jiang, H; Jin, G; Shi, X; Wang, K; Zhang, H; Zhu, X | 1 |
| Hu, Y; Li, C; Xie, Y; Zeng, Q | 1 |
| Burges, A; Colomban, O; Du Bois, A; Freyer, G; Hardy-Bessard, AC; Kurzeder, C; Leary, A; Lortholary, A; Péron, J; Pfisterer, J; Ray-Coquard, I; Tod, M; You, B | 1 |
| Arteta, B; Benedicto, A; Hernandez-Unzueta, I; Herrero, A; Márquez, J; Olaso, E; Romayor, I; Sanz, E | 1 |
| Clay, T; Das, A; Dean, A | 1 |
| Fukushima, T; Kaneko, T; Maeda, S; Oka, H; Okada, K; Okazaki, H; Sugimori, K; Tozuka, Y | 1 |
| Ahn, DH; Bekaii-Saab, TS; Borad, MJ; Iwasaki, M; Javle, MM; Kaseb, AO; Masci, P; Raghav, KPS; Ramanathan, RK; Shroff, RT; Varadhachary, GR; Wolff, RA; Xiao, L | 1 |
| Goff, LW; Roth, MT | 1 |
| Asakuma, M; Gonen, M; Haeno, H; Hur, C; Inoue, Y; Kartoun, U; Kong, CY; Liu, LL; Michor, F; Nakamura, A; Shimizu, T; Stein, S; Tramontano, AC; Uchiyama, K; Yamamoto, KN | 1 |
| Chi, KN; Eigl, BJ; Forbes, C; Parimi, S; Tsang, ES | 1 |
| Chen, Q; Chen, X; Guo, Q; Jiang, C; Li, C; Liang, C; Lu, Y; Shi, S; Sun, T; Yu, X; Zhang, Y; Zhou, W | 1 |
| Bynon, JS; Cen, P; Dinh, BC; Gonzalez, A; Mohlere, V; Thosani, NC; Wray, CJ; Zhang, S | 1 |
| Amaravadi, RK; Borazanci, E; Burrell, JA; De Jesus-Acosta, A; Drebin, JA; Karasic, TB; Laheru, DA; Loaiza-Bonilla, A; O'Dwyer, PJ; O'Hara, MH; Redlinger, C; Reiss, KA; Teitelbaum, UR; Von Hoff, DD | 1 |
| Ahn, JH; Chae, YS; Han, HS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Lee, SJ; Park, IH; Park, S; Park, YH; Sohn, J | 1 |
| Awasthi, N; Hassan, MS; Kronenberger, D; Schwarz, MA; Schwarz, RE; Stefaniak, A; von Holzen, U | 1 |
| Ishigaki, A; Kainuma, O; Kato, M; Kuwayama, N; Maruyama, T; Matsumoto, Y; Miyazaki, A; Mizumoto, H; Natsume, T; Note, H; Oshima, S; Sato, Y; Shimizu, S; Suzuki, K; Tanaka, H; Yoshioka, T | 1 |
| Branstrom, A; Cao, L; Decker, AR; Eberle-Singh, JA; Hu, J; Kim, MJ; Maurer, HC; Mollin, A; Olive, KP; Palermo, CF; Sagalovskiy, I; Sastra, SA; Sheedy, J; Weetall, M | 1 |
| Ahmed, S; Chalchal, H; Haider, K; Moser, M; Olson, C; Papneja, N; Shaw, J; Tan, K; Zaidi, A | 1 |
| Aloia, TA; Fogelman, DR; Ho, L; Javadi, S; Katz, MHG; Kim, MP; Lee, JE; McAllister, F; Prakash, LR; Tzeng, CD; Varadhachary, G; Vauthey, JN; Vreeland, TJ | 1 |
| Hirose, Y; Ishii, A; Ishimoto, U; Iwaku, A; Kinoshita, A; Koike, K; Mizuno, Y; Saruta, M; Shibata, K; Shoji, R; Yokota, T | 1 |
| Kocher, HM; North, B; Sasieni, P | 1 |
| Furuse, J; Ikeda, M; Ioka, T; Mizuno, N; Nagashima, F; Nakajima, TE; Ohkawa, S; Omuro, Y; Ueno, H; Ueno, M | 1 |
| Ahmad, M; Akhlaq, M; Danish, Z; Saeed, H; Saleem, Z; Sattar, S | 1 |
| Abbott, DE; Ahmad, SA; Dudeja, V; Fields, RC; Franceschi, D; Hawkins, WG; Kim, HJ; Kooby, DA; Lee, RM; Livingstone, AS; Macedo, FI; Maduekwe, U; Maithel, SK; Martin, RCG; Merchant, NB; Patel, SH; Ryon, E; Schwartz, P; Scoggins, CR; Weber, SM; Williams, G | 1 |
| Levy, BP; Parisi, M; Patterson-Lomba, O; Signorovitch, JE; Xiang, CQ; Yang, H | 1 |
| Bang, K; Chang, HM; Hwang, I; Jeong, JH; Kim, KP; Kim, MH; Lee, K; Lee, SK; Lee, SS; Oh, D; Park, DH; Park, JH; Ryoo, BY; Song, TJ; Yoo, C | 1 |
| Hasegawa, R; Imaizumi, H; Iwai, T; Kaneko, T; Kawaguchi, Y; Kida, M; Koizumi, W; Kurosu, T; Matsumoto, T; Miyata, E; Ohno, T; Okuwaki, K; Uehara, K; Watanabe, M; Yamauchi, H | 1 |
| Anota, A; Aparicio, T; Bachet, JB; Bonnetain, F; Charton, E; Chibaudel, B; Cohen, R; Dauba, J; Debourdeau, P; Desramé, J; Guerin-Meyer, V; Hammel, P; Lecomte, T; Louvet, C; Seitz, JF; Taieb, J; Tournigand, C; Volet, J | 1 |
| Alfaro-Olea, A; Casajús-Navasal, A; Marín-Gorricho, R; Nebot-Villacampa, MJ; Uriarte-Pinto, M; Zafra-Morales, R | 1 |
| Berlin, J; Cardin, DB; Cohen, SJ; Davis, SL; Dotan, E; Kapoun, AM; Lenz, HJ; Messersmith, WA; O'Neil, BH; Shahda, S; Stagg, RJ | 1 |
| Auriemma, A; Bassi, C; Binco, A; Bonamini, D; Casciani, F; Casetti, L; Ciprani, D; D'Onofrio, M; Esposito, A; Landoni, L; Maggino, L; Malleo, G; Marchegiani, G; Melisi, D; Merz, V; Nessi, C; Paiella, S; Salvia, R; Secchettin, E; Sereni, E; Simionato, F; Tuveri, M; Viviani, E; Zecchetto, C | 1 |
| Bendell, JC; Bullock, A; Dupont, J; Firdaus, I; Hatoum, H; Holmgren, E; Hool, H; Hu, ZI; Kapoun, AM; Leach, JW; LoConte, NK; O'Reilly, EM; Patel, R; Picozzi, V; Ritch, P; Sahai, V; Sanchez, J; Sohal, DPS; Strickler, J; Wang-Gillam, A; Yu, KH; Zhou, L | 1 |
| Dvorak, P; Ehrlichova, M; Flasarova, D; Hlavac, V; Kocik, M; Mohelnikova-Duchonova, B; Ojima, I; Oliverius, M; Soucek, P; Strouhal, O | 1 |
| Chae, YS; Im, SA; Jung, KH; Kim, JH; Kim, JY; Kim, TY; Lee, E; Lee, KS; Park, K; Park, YH; Sohn, J | 1 |
| Bastière-Truchot, L; Berger, R; Berton-Rigaud, D; Cardona, A; Colombo, N; du Bois, A; González Martin, A; Greimel, E; Grischke, EM; Hilpert, F; Kroep, JR; Kurzeder, C; Lorusso, D; Lück, HJ; Martinez-Garcia, J; Mirza, MR; Ottevanger, P; Pardo, B; Rau, J; Redondo, A; Selle, F; Vergote, I | 1 |
| Biglietto, M; Calabrese, F; Caterino, M; Ciardiello, F; Conzo, G; De Vita, F; Laterza, MM; Molino, C; Orditura, M; Pappalardo, A; Petrillo, A; Pompella, L; Tirino, G; Ventriglia, A | 1 |
| Alimoghaddam, K; Alishahi, Z; Esmaeili, F; Eyvani, H; Ghaffari, P; Ghaffari, SH; Ghavamzadeh, A; Momeny, M; Tavakkoly-Bazzaz, J; Zaghal, A | 1 |
| Acramel, A; Chouquet, T; Goldwirt, L; Jouenne, F; Mourah, S; Plé, A; Sauvageon, H | 1 |
| Ando, K; Iwata, T; Mishima, H | 1 |
| Miyasaka, Y; Nakamura, M | 1 |
| Fushida, S; Gabata, R; Harmon, JW; Hayashi, H; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohbatake, Y; Ohta, T; Okamoto, K; Okazaki, M; Sakai, S; Shimbashi, H; Tajima, H; Takamura, H | 1 |
| An, T; Chen, H; Dong, Z; Jia, B; Li, J; Shi, A; Wang, Y; Wang, Z; Wu, M; Yang, S; Yang, X; Zhao, J; Zhong, J; Zhuo, M | 1 |
| Babu, T; Gandin, V; Gibson, D; Ishan, M; Karmakar, S; Nemirovski, A; Yempala, T | 1 |
| Arcieri, M; Ergasti, R; Fagotti, A; Marchetti, C; Palluzzi, E; Pietragalla, A; Rosati, A; Scaletta, G; Scambia, G | 1 |
| Guan, H; Liu, G; Sheng, Y; Shi, L; Xie, F | 1 |
| Artru, P; Béchade, D; Desrame, J; Hautefeuille, V; Le Roy, B; Locher, C; Lourenco, N; Pernot, S; Pointet, AL; Pozet, A; Soularue, E; Taieb, J; Tougeron, D; Trouilloud, I; Williet, N | 1 |
| Hashimoto, M; Hikichi, T; Irie, H; Konno, N; Nakamura, J; Ohira, H; Sato, Y; Sugimoto, M; Suzuki, R; Takagi, T | 1 |
| Cheung, WY; Gill, S; Kim, CA; Kong, S; Spratlin, J; Tsang, ES; Xu, Y | 1 |
| Hara, R; Ishii, H; Kita, E; Nakamura, K; Sudo, K; Takayama, W; Tsujimoto, A; Yamaguchi, T | 1 |
| Arias, J; Beca, JM; Berry, SR; Biagi, JJ; Chan, KKW; Cheng, S; Coburn, N; Dai, WF; Earle, C; Gavura, S; Guo, H; Isaranuwatchai, W; Kennedy, ED; McLeod, R; Meyers, BM; Mittmann, N; Qiao, L; Redmond-Misner, R; Schwartz, D; Welch, S | 1 |
| Lassaletta, A; Madero, L; Moreno-Tejero, ML; Pelaez, I; Perez-Somarriba, M; Rozas, MI | 1 |
| Ariake, K; Mitachi, K; Motoi, F; Unno, M | 1 |
| Abe, R; Izumi, H; Makuuchi, H; Mukai, M; Nomura, E; Tajiri, T; Yoshii, H | 1 |
| Asch, D; Beatty, GL; Domchek, SM; Nathanson, KL; O'Dwyer, PJ; Reiss, KA; Rosen, MA; Siegelman, ES; Wattenberg, MM; Yu, S | 1 |
| Alvarez Secord, A; Armstrong, DK; Azab, M; Banerjee, S; Basu, B; Birrer, MJ; Blagden, SP; Braly, P; Fleming, GF; Ghamande, S; Hall, GD; Hao, Y; Hirte, HW; Jueliger, S; Keer, H; Kristeleit, R; Markham, MJ; Matei, D; Matulonis, UA; McGuire, WP; Naim, S; Nemunaitis, J; Nephew, KP; Oganesian, A; Oza, AM; Provencher, DM; Roman, LD; Schwartz, B | 1 |
| Biasoni, D; Bisogno, G; Boldrini, R; Conte, M; Crocoli, A; D'Angelo, P; Dall'Igna, P; De Pasquale, MD; Inserra, A; Miele, E; Siracusa, F; Spreafico, F; Terenziani, M | 1 |
| Frank, RC; Lee, R; Levy, G; Lo, T; Lobo, S; Martino, C; Pandya, D | 1 |
| Anders, R; Batukbhai, B; Begum, A; De Jesus-Acosta, A; de Wilde, RF; Laheru, DA; Maitra, A; McAllister, F; O'Dwyer, PJ; Rajeshkumar, NV; Ramanathan, RK; Rasheed, Z; Sahin, I; Sugar, EA; Von Hoff, DD; Yabuuchi, S; Zheng, L | 1 |
| de Santibañes, E; de Santibañes, M; Mazza, O; Pekolj, J; Sanchez Clariá, R | 1 |
| Blanco, A; Li, J; Norgard, RJ; Stanger, BZ; Yamazoe, T; Yan, F; Yuan, S | 1 |
| Ahn, ER; Algül, H; Askoxylakis, V; Bendell, J; Charu, V; Gracian, AC; Ko, AH; Kuesters, G; Kundranda, M; Meiri, E; Pelzer, U; Pipas, JM; Rivera, F; Santillana, S; Watkins, D; Zafar, SF; Zalutskaya, A | 1 |
| Segar, J; Shroff, RT | 1 |
| Beumer, JH; Chen, Y; Diao, D; Li, S; Lu, B; Luo, Z; Parise, RA; Ren, P; Sun, J; Wan, Z; Xu, J | 1 |
| Fukushima, T; Hashimoto, Y; Hirotani, A; Ikeda, M; Imaoka, H; Kobayashi, S; Mitsunaga, S; Morimoto, M; Moriya, S; Ohno, I; Ozaka, M; Sano, Y; Sasahira, N; Sasaki, M; Sasaki, T; Tezuka, S; Tozuka, Y; Ueno, M; Umemoto, K; Watanabe, K; Yamada, I | 1 |
| Bi, J; Chen, S; Diao, C; Dong, Y; Fan, H; Fan, W; Feng, Q; Geng, D; Han, X; Huang, G; Li, F; Li, G; Li, P; Li, Q; Li, T; Li, W; Li, Y; Liu, B; Meng, M; Meng, Q; Ni, Y; Ren, H; Sheng, L; Sun, D; Sun, L; Sun, W; Sun, Y; Tian, H; Wang, C; Wang, J; Wei, Z; Xu, X; Xu, Y; Xue, G; Yang, X; Ye, X; Yu, G; Zhang, B; Zhang, K; Zhang, L; Zheng, A; Zou, Z | 1 |
| Besselink, MG; Creemers, GJ; de Groot, JWB; de Vos-Geelen, J; Haj Mohammad, N; Homs, MYV; Latenstein, AEJ; Mackay, TM; Molenaar, IQ; Ten Tije, BJ; van der Geest, LGM; van Eijck, CHJ; van Laarhoven, HWM; Wilmink, JW | 1 |
| Comlek, S | 1 |
| Han, J; Liang, Y; Svirskis, D; Tian, B; Wu, Z; Zhang, J | 1 |
| Fukui, I; Inoue, T; Masuda, H; Numao, N; Ogawa, M; Yamamoto, S; Yonese, J; Yuasa, T | 1 |
| Griffin, JI; Ho, RJY; McConnachie, LA; Mu, Q; Wu, Y; Yu, J; Zhu, L | 1 |
| Chen, H; Li, J; Liang, X; Pu, X; Shen, T; Song, Z; Wang, L; Wang, W; Xu, C; Yu, Z; Zhang, Y | 1 |
| Bun, S; Kato, MK; Kato, T; Miyasaka, N; Shimoi, T; Tamura, K; Yonemori, K; Yunokawa, M | 1 |
| Amaravadi, RK; Bahary, N; Bartlett, DL; Boone, BA; Espina, V; Hogg, ME; Lee, KK; Liotta, L; Lotze, MT; Marsh, JW; Miller-Ocuin, JL; Murthy, P; Normolle, DP; Seiser, N; Singhi, AD; Tang, D; Tsung, A; Zeh, HJ; Zureikat, AH | 1 |
| Kubo, S; Tomita, N; Yamano, T | 1 |
| Li, J; Li, W; Liang, L; Liu, Z; Wang, Y; Xu, F; Xu, H; Yang, G; Yang, L; Ying, J; Zhang, Q; Zhang, S | 1 |
| Abdelrahman, L; Banerjee, S; Kesh, K; Mendez, R | 1 |
| Antico, G; Blauer-Petersen, C; Doleh, Y; Lal, LS; Pishvaian, M | 1 |
| Akbulut, H; Aykan, F; Coskun, HS; Dane, F; Demirag, GG; Evrensel, T; Hayran, M; Isikdogan, A; Karabulut, B; Kilickap, S; Oksuzoglu, B; Ozdemir, F; Ozdemir, NY; Ozkan, M; Sevinc, A; Turna, H; Ustaoglu, MA; Yalcin, S; Yavuzsen, T; Yuce, D | 1 |
| Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Nokihara, H; Ohe, Y; Tamura, T; Yamamoto, N; Yamamoto, T | 1 |
| Kimura, S; Kurioka, Y; Matsumoto, T; Matsuo, Y; Miura, K; Morishita, H; Okazaki, U; Takagi, S; Takatani, M; Tsuduki, T | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Endo, I; Kumamoto, T; Matsuyama, R; Murakami, T; Sawada, Y; Tsuchiya, N; Yabushita, Y | 1 |
| Blasi, M; Bozorgmehr, F; Hommertgen, A; Kieser, M; Krisam, J; Kuon, J; Lasitschka, F; Maenz, M; Schneider, M; Stenzinger, A; Thomas, M | 1 |
| Bottinor, W; Das, S; Nunnery, S | 1 |
| Anthoney, A; Arif, S; Basu, B; Bax, L; Brais, R; Bridgewater, J; Bundi, P; Chhabra, A; Corrie, PG; Cummins, S; Dalchau, K; Dayim, A; Ellis, R; Evans, J; Falk, S; Gillmore, R; Gopinathan, A; Isherwood, C; Jodrell, DI; Lwuji, C; Ma, YT; Machin, A; McAdam, K; Neesse, A; Palmer, D; Propper, D; Qian, W; Scott-Brown, M; Skells, R; Tuveson, D; Valle, JW; Wadsley, J; Wall, L; Wasan, H | 1 |
| Barone, D; Bekaii-Saab, T; Flaherty, KT; Krause, S; Mahalingam, D; O'Reilly, EM; Richards, DA; Roach, JM; Rosano, M; Ryan, DP; Shao, SH; Wolf, J; Yu, KH | 1 |
| Jin, Y; Li, S; Li, Y; Ma, Z; Sun, R; Yan, H; Zhao, K; Zhao, W | 1 |
| Dwarkasing, RS; Eskens, FALM; Groot Koerkamp, B; Homs, MYV; Nuyttens, JJ; Suker, M; van Eijck, CHJ | 1 |
| Abushahin, L; Alexandra Diaz, D; Chen, W; Cloyd, JM; Dillhoff, M; Frankel, WL; Miller, ED; Noonan, A; Prabhakar, D; Williams, TM; Wolfe, AR; Yildiz, VO | 1 |
| Andrade, CF; Figueiró, F; Filippi-Chiela, E; Gonzalez, EA; Klamt, F; Nunes, V; Pilar, ES; Solari, JIG | 1 |
| Abdul-Rahim, O; Khushman, M; Phung, T; Surinach, A | 1 |
| Babu, S; Biankin, AV; Chang, DK; Escobar-Hoyos, LF; K Bai, JD; Kawalerski, RR; Leiton, CV; Otsuka, Y; Pan, CH; Scampavia, L; Shroyer, KR; Spicer, T; Sridharan, B; Torrente Gonçalves, M; Woo, M | 1 |
| Aly, A; Botteman, M; Chiorean, EG; Goldstein, D; Lee, CK; Louis, CU; Lu, B; Margunato-Debay, S; McGovern, D; Ramanathan, RK; Reni, M; Tabernero, J; Von Hoff, DD | 1 |
| Ibusuki, M; Inoue, T; Ito, K; Kimoto, S; Kitano, R; Kobayashi, Y; Nakade, Y; Ohashi, T; Sakamoto, K; Sumida, Y; Yoneda, M | 2 |
| Cai, R; Chen, S; Chen, X; Chen, Y; Fan, Y; Guan, Y; Lan, B; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Zhang, P; Zhao, W | 1 |
| Akagi, N; Burns, ST; Damon, L; Ko, AH; Laszik, Z | 1 |
| Bachet, JB; Bouhier Leporrier, K; Coriat, R; Gouttebel, MC; Gratet, A; Khemissa Akouz, F; Laharie, H; Le Malicot, K; Lepage, C; Louafi, S; Malka, D; Miglianico, L; Pointet, AL; Rinaldi, Y; Taieb, J; Terrebonne, E; Texereau, P; Thirot Bidault, A; Wahiba, B | 1 |
| Eguchi, H; Goda, K; Hashimoto, Y; Ikeda, M; Imaoka, H; Kan, M; Kimura, G; Mitsunaga, S; Ohno, I; Otsuru, T; Sasaki, M; Suzuki, Y; Takahashi, H; Umemoto, K; Watanabe, K | 1 |
| Fujiwara, M; Fukui, I; Hayashi, T; Komai, Y; Kouno, T; Numao, N; Takeda, H; Yamamoto, S; Yonese, J; Yuasa, T | 1 |
| Cao, D; Cheng, K; Guo, F; Li, J; Li, S; Li, X; Peng, Y; Shui, L; Shui, P; Yi, C | 1 |
| Li, H; Meng, R; Rui, M; Shang, Y; Shi, F | 1 |
| Berjon, A; Brenes, J; Casado, G; Castelo, B; Espinosa, E; Feliu, J; Gallego, A; Hardisson, D; Hernandez, A; Mendiola, M; Ramon-Patino, J; Redondo, A | 1 |
| Evans, DB | 1 |
| Ahmad, S; Barrord, M; Choe, K; Esslinger, H; Kharofa, J; Latif, T; Olowokure, O; Patel, S; Poreddy, S; Smith, M; Sussman, J | 1 |
| Hines, OJ; Ye, L | 1 |
| Fogelman, D; Herman, J; Ikoma, N; Javle, M; Katz, MHG; Kim, M; Koay, EJ; Lee, JE; Overman, M; Pant, S; Perri, G; Prakash, L; Qiao, W; Tzeng, CW; Varadhachary, GR; Wolff, R | 1 |
| Iede, K; Ikenaga, M; Kato, R; Matsuyama, J; Nakashima, S; Ohta, K; Tominaga, S; Tsuda, Y; Ueda, M; Yamada, T | 3 |
| Astsaturov, I; Brachmann, RK; Cardin, DB; Cohen, SJ; Denlinger, CS; Dotan, E; Kapoun, AM; Lenz, HJ; Messersmith, W; O'Neil, B; Shahda, S; Stagg, RJ; Uttamsingh, S; Weekes, C | 1 |
| Li, P; Tian, Z; Wang, J; Wang, X; Yang, J; Yao, W; Zhang, F; Zhang, P | 1 |
| Ahmad, SA; Beg, MS; Chiorean, EG; Duong, M; Gandhi, NS; Guthrie, KA; Hochster, HS; Lowy, AM; Philip, PA; Sohal, DPS; Wade, JL; Wang-Gillam, A | 1 |
| Andrikou, K; Bernardini, L; Casadei-Gardini, A; Catanese, S; Falcone, A; Formica, V; Fornaro, L; Lencioni, M; Massa, V; Pecora, I; Rapposelli, GI; Riggi, L; Rovesti, G; Salani, F; Vasile, E; Vivaldi, C | 1 |
| Lam, LL; Levingston, R; O'Neill, RS; Solanki, P; Thomas, D | 1 |
| Bendell, J; Berlin, J; Bhargava, P; Brachmann, CB; Chaves, J; Gordon, M; Khan, SA; Liu, J; Patel, MR; Shah, MA; Sharma, S; Starodub, A; Thai, D; Wainberg, ZA; Windsor, KS; Zavodovskaya, M | 1 |
| Alseidi, A; Carney, M; Carrier, E; Glaspy, J; Kouchakji, E; Larson, T; Matrana, M; Mody, K; Picozzi, V; Pishvaian, M; Porter, S; Rocha, F; Winter, J | 1 |
| Hatano, H; Imura, S; Johira, H; Kagajo, Y; Kashu, N; Kawata, N; Kimura, M; Tamura, S; Tomomatsu, M; Umeoka, T; Watanabe, R; Yunoki, S | 1 |
| Camara, JC; Franco, F; Gutiérrez-Abad, D; Juez, I; León, A; López-Alfonso, A; Marrupe, D; Martín-Valadés, JI; Martínez-Amores, B; Pérez, M; Royuela, A; Ruiz-Casado, A | 1 |
| Cha, HS; Hwang, JH; Kim, J; Kim, JW; Kim, MJ; Lee, JC; Lee, WJ; Park, P; Shin, DW; Woo, SM; Yang, SY | 1 |
| Aoe, K; Atagi, S; Ebiana, V; Fukuhara, T; Han, SR; Hida, T; Horiike, A; Horinouchi, H; Hotta, K; Katakami, N; Kishi, K; Kurata, T; Nakagawa, K; Noguchi, K; Nosaki, K; Ohira, T; Okamoto, H; Okamoto, I; Saka, H; Sakai, H; Satouchi, M; Sekine, A; Sugawara, S; Takahashi, T; Umemura, S; Yamamoto, N | 1 |
| Beumer, JH; Christner, S; Chu, E; Guo, J; Holleran, JL; Ivy, SP; Joshi, A; Kiesel, B; Miller, BM; Parise, RA; Taylor, S; Venkataramanan, R | 1 |
| Ceyhan, GO; Damm, M; Kordes, M; Maggino, L; Moir, J; Rosendahl, J; Schorn, S; Weniger, M | 1 |
| Baltatzis, M; De Liguori Carino, N; Rodriquenz, MG; Siriwardena, AK | 1 |
| Catalano, M; Conca, R; D'Angelo, A; Ianza, A; Mini, E; Nobili, S; Palmieri, VE; Panella, B; Petrioli, R; Ramello, M; Roviello, G | 1 |
| Hidaka, S; Ichita, C; Kako, M; Kimura, K; Koizumi, K; Kudo, M; Masuda, S; Moriya, H; Nishino, T; Sasaki, A; Tasaki, J; Tazawa, T; Uojima, H | 1 |
| Griffin, JI; Ho, RJ; McConnachie, LA; Mu, Q; Perazzolo, S; Shen, DD; Yu, J; Zhu, L | 1 |
| Cui, J; Qu, S; Wang, L; Zhang, X | 1 |
| Ito, K; Kawamoto, Y; Komatsu, Y; Nakano, S; Nakatsumi, H; Saito, R; Sakamoto, N; Yuki, S | 1 |
| Aghmesheh, M; Foroughi, J; Moulton, SE; Piper, AK; Sahin, Z; Talebian, S; Vine, KL; Wade, SJ; Wallace, GG | 1 |
| Abe, Y; Ashida, R; Fukutake, N; Ikezawa, K; Imai, T; Katayama, K; Kato, K; Kiyota, R; Kukita, Y; Nawa, T; Ohkawa, K; Takada, R; Yamai, T | 1 |
| Furuse, J; Ikeda, M; Imaoka, H; Inoue, H; Kawamoto, Y; Kobayashi, S; Maehara, K; Morizane, C; Nagano, H; Okamura, K; Ozaka, M; Sakaguchi, C; Shioji, K; Shirakawa, H; Suzuki, R; Terashima, T; Tsuji, K; Ueno, M; Umemoto, K | 1 |
| Björnsson, B; Blomstrand, H; Elander, NO; Fredrikson, M; Gränsmark, E; Green, H | 1 |
| Al-Batran, SE; Aldaoud, A; Behringer, DM; Bildat, S; Blau, W; Büchner-Steudel, P; Däßler, KU; Dörfel, S; Eschenburg, H; Ettrich, TJ; Feustel, HP; Fietz, T; Forstbauer, H; Gallmeier, E; Götze, TO; Groschek, M; Hahn, L; Harich, HD; Hausen, GZ; Höffkes, HG; Hofheinz, RD; Homann, N; Jacobasch, L; Koenigsmann, M; Kretzschmar, A; Kunzmann, V; Mahlmann, S; Messmann, H; Papke, J; Pauligk, C; Peters, U; Pink, D; Reichart, A; Schaaf, M; Schlag, R; Schönherr, C; Schubert, J; Schuch, G; Schulz, H; Schwindel, U; Siegler, G; Springfeld, C; Stauch, M; Trojan, J; Uhlig, J; Vehling-Kaiser, U; Vogel, A; von Weikersthal, LF; Waibel, K; Waidmann, O; Wehmeyer, J; Weniger, J; Wierecky, J; Wolf, M; Wörns, MA; Zahn, MO | 1 |
| Cha, J; Hsu, S; Huang, S; Jennings, E; Lee, JB | 1 |
| Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS | 1 |
| Inoue, Y; Ito, H; Mise, Y; Oba, A; Ono, Y; Ozaka, M; Saiura, A; Sasahira, N; Sasaki, T; Takahashi, Y | 1 |
| Abushahin, L; Chakravarti, A; Cruz-Monserrate, Z; Hegazi, A; Jacob, JR; Palanichamy, K; Robb, R; Shyu, DL; Trevino, JG; Williams, TM; Wolfe, AR; Yang, L | 1 |
| Cui, H; Dai, G; Deng, G; Guan, J; Lou, C; Yuan, J; Zhang, W; Zhang, Y; Zhou, A; Zhou, J | 1 |
| Kobayashi, M; Komatsu, Y; Saito, Y; Sugawara, M; Takekuma, Y | 1 |
| Canonge, JM; Claraz, P; Cretu, Y; Grand, A; Hennebelle, I; Perriat, S; Puisset, F; Riff, I; Vert, C; Wolff, E | 1 |
| Kawai, S; Kikuchi, S; Lin, Y; Suzuki, T; Ueno, M | 1 |
| Boras, B; Chen, W; D'Argenio, DZ; Hu, W; Spilker, ME; Sung, T | 1 |
| Aieta, M; Catalano, M; Conca, R; D'Angelo, A; Dreoni, L; Gasperoni, S; Ianza, A; Mini, E; Nobili, S; Petrioli, R; Ramello, M; Roviello, G | 1 |
| Fukuda, K; Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 2 |
| Lu, M; Peng, Z; Shen, L; Wang, X; Yuan, J; Zhou, J; Zong, Y | 1 |
| Ammori, JB; Bingmer, K; Hardacre, JM; Hue, JJ; Sugumar, K; Winter, JM | 1 |
| Hsia, RC; Kambhampati, SP; Kannan, RM; Kokkoli, E; Shabana, AM | 1 |
| Besselink, MG; Blomjous, JG; Bollen, TL; Bosscha, K; Brada, LJ; Bruijnen, RC; Busch, OR; Creemers, GJ; Daams, F; de Hingh, IH; de Meijer, VE; de Vos-Geelen, J; de Vries, JJJ; Festen, S; Hermans, JJ; Jan de Groot, D; Kerver, ED; Liem, MS; Los, M; Meijerink, MR; Mekenkamp, LJ; Mohammad, NH; Molenaar, IQ; Nederend, J; Nio, CY; Patijn, GA; Patuleia, SIS; Polée, MB; Pruijt, JF; Renken, NS; Rombouts, SJ; Schouten, TJ; Stommel, MWJ; van Dam, R; van der Leij, C; van Leeuwen, MS; van Lienden, KP; van Santvoort, HC; Verweij, ME; Vulink, A; Walma, MS; Wessels, FJ; Willem de Groot, J; Wilmink, JW | 1 |
| Andel, J; Arnold-Schrauf, C; Djanani, A; Eisterer, W; Gerger, A; Gruenberger, B; Heibl, S; Hubmann, E; Korger, M; Laengle, F; Mlineritsch, B; Neumann, HJ; Oehler, L; Pecherstorfer, M; Petzer, A; Philipp-Abbrederis, K; Pichler, P; Prager, GW; Sliwa, T; Trondl, R; Wilthoner, K; Winder, T; Wöll, E | 1 |
| Cao, D; Hu, Q; Wang, X; Xu, H; Zhou, S | 1 |
| Fukutomi, A; Furuse, J; Hashimoto, Y; Honda, G; Ioka, T; Miyamoto, A; Mizuno, N; Morinaga, S; Nakamori, S; Okusaka, T; Saiura, A; Sasahira, N; Seyama, Y; Shimizu, S; Shimizu, Y; Sugiyama, M; Takadate, T; Takahashi, H; Ueno, H; Ueno, M; Umemoto, K; Unno, M | 1 |
| Chen, G; Chen, K; Cui, J; Dong, X; Fan, Y; Fang, L; Gu, K; Guo, Q; He, J; Hu, C; Hu, X; Jiang, D; Jiang, L; Jiang, T; Li, J; Li, Y; Liang, D; Liu, J; Pan, Y; Peng, M; Ren, S; Shi, Q; Song, Y; Tan, W; Wang, G; Wang, H; Wang, Z; Wu, L; Wu, X; Xie, W; Xiong, J; Yang, N; Yao, W; Yi, T; Yu, G; Yue, L; Zang, A; Zhang, G; Zhang, H; Zhang, X; Zhao, G; Zhao, W; Zhao, Y; Zhou, C | 1 |
| Slater, H | 1 |
| Almuradova, E; Bulut, G; Ekinci, F; Erdoğan, AP; Karateke, M; Özveren, A; Yıldırım, S; Yılmaz, C | 1 |
| Aoki, Y; Hirose, Y; Ishimoto, U; Kinoshita, A; Koike, K; Mizuno, Y; Ohsawa, A; Saruta, M; Satou, N; Satou, Y | 1 |
| Arrigoni, E; Catanese, S; Crucitta, S; Cucchiara, F; Danesi, R; Del Re, M; Fornaro, L; Massa, V; Morganti, R; Pecora, I; Rofi, E; Salani, F; Vasile, E; Vivaldi, C | 1 |
| Akaike, H; Amemiya, H; Furuya, S; Higuchi, Y; Hosomura, N; Ichikawa, D; Kawaguchi, Y; Kawaida, H; Kono, H; Nakata, Y; Nakayama, T; Saito, R; Shoda, K; Sudo, M; Tsukahara, I | 1 |
| Bentsion, D; Bondarenko, I; Chen, CI; Cicin, I; Clingan, P; Gao, B; Gladkov, O; Gogishvili, M; Gullo, G; Gümüş, M; Kilickap, S; Lee, S; Li, S; Lowy, I; Makharadze, T; McGuire, K; Nechaeva, M; Özgüroğlu, M; Paydas, S; Rietschel, P; Rizvi, N; Seebach, F; Sezer, A; Sriuranpong, V; Turk, HM; Weinreich, DM; Yancopoulos, GD | 1 |
| Philip, PA | 1 |
| Al-Rajabi, R; Balducci, L; Banks, J; Brenner, W; Coveler, AL; Elquza, E; George, TJ; Hatoum, H; Hewitt, DB; Kennedy, E; Lavu, H; Leiby, B; Link, C; LoConte, N; Musher, B; Nissen, N; Rossi, G; Seng, J; Vaccaro, G; Vahanian, N; Yeo, CJ | 1 |
| Chen, X; Guo, G; He, W; Quan, Q; Wang, F; Wang, Y; Zhang, B; Zhang, D | 1 |
| Bates, SE; Conroy, T; Fojo, T; Juzyna, B; Mutetwa, T; Nadkarni, G; Park, YA; Polak, P; Sigel, C; Sigel, K; Wisnivesky, JP; Ychou, M; Yeh, C; Zhou, M | 1 |
| Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 1 |
| Araki, M; Edamura, K; Iwata, T; Katayama, S; Kobayashi, Y; Nasu, Y; Nishimura, S; Sadahira, T; Sako, T; Takamoto, A; Wada, K; Watanabe, M; Watanabe, T | 1 |
| Astaras, C; Borner, M; De Dosso, S; Fritsch, R; Meisel, A; Siebenhüner, AR; Szturz, P; Winder, T | 1 |
| Amini, A; Attiyeh, MA; Chung, V; Melstrom, LG | 1 |
| Brown, ZJ; Cloyd, JM | 1 |
| Burdio-Pinilla, F; Casasola-Sánchez, LE; Pereira-Rodríguez, JA; Radosevic, A; Sánchez-Velázquez, P; Visa, L | 1 |
| Alig, S; Bararia, D; Boeck, S; Haas, M; Haebe, S; Heinemann, V; Kobold, S; Kruger, S; Metzger, P; Ormanns, S; Rataj, F; Sams, L; von Bergwelt-Baildon, M; Weigert, O; Werner, J; Westphalen, CB; Zhang, D | 1 |
| Barrios-Anderson, A; Radhakrishnan, R; Shimanovsky, A; Yu, E | 1 |
| Barth, DA; Djanani, A; Gantschnigg, A; Gerger, A; Greil, R; Horvath, L; Moik, F; Pichler, M; Posch, F; Renneberg, F; Riedl, JM; Rossmann, CH; Schaberl-Moser, R; Schlick, K; Schwarzenbacher, E; Stöger, H; Stotz, M | 1 |
| Cho, IR; Chun, JW; Huh, G; Kim, JS; Kim, YT; Lee, SH; Paik, WH; Park, N; Ryu, JK | 1 |
| Fukahori, M; Kakuma, T; Miwa, K; Murotani, K; Nagasu, S; Naito, Y; Okabe, Y; Sakaue, T; Suga, H; Tanaka, T; Torimura, T; Ushijima, T | 1 |
| Chung, V; Fakih, M; Franko, J; Le, VH; Paz, BI; Singh, G | 1 |
| Callan, B; Callan, JF; Gao, J; Logan, KA; Love, M; McHale, AP; McKaig, T; Nesbitt, H; Taylor, M | 1 |
| Bartolini, G; Bernardini, L; Casadei-Gardini, A; Cucchetti, A; Frassineti, GL; Massa, V; Passardi, A; Rapposelli, IG; Vivaldi, C | 1 |
| Cheng, C; Lovell, JF; Sun, H; Wu, Y; Yan, L; Zhang, R | 1 |
| Gotoda, T; Hemmi, A; Iwatsuka, K; Kikuta, D; Moriyama, M; Nakagawara, H; Ogawa, M; Shibuya, H; Yamao, K | 1 |
| Bokas, A; Felekouras, E; Karamouzis, MV; Koustas, E; Papadimitropoulou, A; Papakotoulas, P; Papalampros, A; Papavassiliou, AG; Sarantis, P; Schizas, D; Theocharis, S | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Kawaguchi, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Murayama, K; Nakashita, S; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Oza, N; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Takahashi, H; Ueda, Y; Ureshino, N | 1 |
| Arima, S; Fukahori, M; Hashimoto, S; Honda, T; Ide, Y; Ido, A; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Fujii, H; Iihara, H; Iwashita, T; Kato-Hayashi, H; Kobayashi, R; Ohata, K; Sadaka, S; Shimizu, M; Suzuki, A; Uemura, S | 1 |
| Fujimoto, N; Harada, M; Inatomi, H; Minato, A; Onishi, R; Terado, M; Tomisaki, I | 1 |
| Yuasa, T | 1 |
| Ay, C; Barth, DA; Djanani, A; Fandler-Höfler, S; Gantschnigg, A; Gary, T; Gerger, A; Greil, R; Gressenberger, P; Hatzl, S; Horvath, L; Jost, PJ; Moik, F; Pichler, M; Posch, F; Renneberg, F; Riedl, JM; Schlick, K; Schwarzenbacher, E; Stotz, M | 1 |
| Aoyama, T; Hama, T; Hashiguchi, M; Hori, S; Ito, G; Kawakami, K; Kizaki, H; Nakamura, M; Ozaka, M; Sasahira, N; Yokokawa, T | 1 |
| Hayuka, K; Murakami, A; Nishiuchi, T; Okano, K; Okita, Y; Okuyama, H; Suzuki, Y; Tsuji, A | 1 |
| Chen, J; Hua, Q; Lin, Z; Pi, G; Wang, H; Yu, D; Zhang, D; Zhang, T; Zhao, L | 1 |
| Arscott, WT; Bear, A; Ben-Josef, E; Drebin, J; Lee, MK; Loaiza-Bonilla, A; Lukens, JN; Metz, J; Nead, KT; O'Hara, M; Plastaras, JP; Reiss, KA; Shabason, J; Shroff, SG; Teitelbaum, U; Venigalla, S; Wojcieszynski, A | 1 |
| Baron, MK; Garrido-Laguna, I; Haaland, B; Moser, JC; Nevala-Plagemann, C; Wang, X | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Ido, A; Kawahira, M; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Chambers, C; Chen, A; Eurich, DT; Ha, V; McCall, M; Sawyer, MB; Youn, S | 1 |
| Ahn, JH; Chae, YS; Cho, EH; Im, SA; Jang, JH; Jung, KH; Kim, JH; Kim, JY; Lee, KH; Lee, KS; Lee, SY; Park, MS; Park, YH; Sohn, J | 1 |
| Carvalho, T; Castillo Martin, M; Costa, B; Couto, N; Fior, R; Rebelo de Almeida, C; Tavares Barroso, M | 1 |
| Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Hama, N; Hashimoto, K; Kim, Y; Kobayashi, S; Morimoto, O; Murakami, M; Nakahira, S; Shimizu, J; Sugimoto, K; Takahashi, H; Takeda, Y; Tanemura, M; Tomokuni, A; Tsujie, M; Yamada, D; Yamada, T; Yokoyama, S | 1 |
| Fan, G; Hu, Q; Ji, S; Liu, M; Liu, W; Qin, Y; Xu, W; Xu, X; Ye, Z; Yu, X; Zhang, Z; Zhuo, Q | 1 |
| Dai, G; Jiang, N; Lau, WY; Liu, Q; Liu, R; Wang, Y; Xu, S; Zhang, X; Zhao, G; Zhao, Z; Zhu, L | 1 |
| Dotan, E; Handorf, E; Winer, A | 1 |
| Au, T; Biskupiak, J; Kharat, AA; Nelson, R | 1 |
| Chambers, CR; Chen, A; Ghosh, S; Ha, VH; Sawyer, MB | 1 |
| Chassagnon, G; Ginestet, C; Sabat, C | 1 |
| Hwang, JH; Kim, J; Kim, JH; Lee, JC; Lee, YS | 1 |
| Gao, P; Ha-Duong, T; Nicolas, J | 1 |
| Jensen, E; Nalluri, H; Staley, C | 1 |
| Bai, J; Chen, G; Chen, K; Cui, J; Dong, X; Fan, Y; Gu, K; Guo, Q; He, J; Hu, C; Hu, X; Jiang, D; Jiang, L; Li, J; Li, Y; Liu, J; Pan, Y; Peng, M; Shi, Q; Song, Y; Tan, W; Wang, G; Wang, H; Wang, Z; Wu, L; Wu, X; Xie, W; Xiong, J; Yang, N; Yao, W; Yi, T; Yu, G; Yue, L; Zang, A; Zhang, G; Zhang, J; Zhang, X; Zhao, G; Zhao, W; Zhou, C | 1 |
| Fujii, T; Gyoten, K; Hayasaki, A; Iizawa, Y; Isaji, S; Kishiwada, M; Komatsubara, H; Kuriyama, N; Maeda, K; Mizuno, S; Murata, Y; Nakagawa, Y; Noguchi, D; Sakurai, H; Shinkai, T; Tanemura, A | 1 |
| Hong, TH; Kim, H; Lee, MA; Park, SJ; Shin, K; Suh, JH | 1 |
| Hikita, K; Honda, M; Iwamoto, H; Kawamoto, B; Morizane, S; Shimizu, R; Takenaka, A; Teraoka, S; Yamaguchi, N; Yumioka, T | 1 |
| Holmes, B; Hossain, MA; Mukherjee, P; Tarannum, M; Vivero-Escoto, JL; Yan, S | 1 |
| Dai, GH; Deng, GC; Han, QL; Lv, Y; Pan, YT; Qu, TT; Sun, DC; Yan, H | 1 |
| Kaneyasu, T; Morimoto, K; Moriwaki, K; Nakayama, H; Shimozuma, K | 1 |
| Furukawa, M; Hisano, T; Lee, L; Miki, M; Sugimoto, R | 1 |
| Assenat, E; de la Fouchardière, C; Debourdeau, A; Desseigne, F; Fiess, C; Iltache, S; Mazard, T; Mollevi, C; Portales, F; Ychou, M | 1 |
| Albisinni, S; Awada, A; Barthelemy, P; Caparica, R; Carnot, A; Casert, V; Culine, S; Fantoni, JC; Gil, T; Gizzi, M; Martinez Chanza, N; Paesmans, M; Roumeguere, T; Sautois, B; Seront, E; Soukane, L; Staudacher, L; Tricard, T; Van den Brande, J; Vanhaudenarde, V | 1 |
| Barrera, LN; Brumskill, S; Calcraft, P; Costello, E; Phillips, C | 1 |
| Elango, S; Finkelmeier, F; Koch, C; Pession, U; Queck, A; Schmidt, J; Trebicka, J; Trojan, J; Waidmann, O; Walter, D | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Fang, J; Ge, C; Jin, N; Li, X; Li, Y; Liu, Z; Shang, C; Song, G; Sun, L; Xiu, Z; Yang, X; Zhu, Y | 1 |
| Kiyozuka, K; Kohei, N; Suzuki, R | 1 |
| Hwang, JH; Jung, JH; Jung, K; Kim, J; Lee, JC; Park, J | 1 |
| Ashida, R; Emori, T; Hatamaru, K; Itonaga, M; Kawai, M; Kawaji, Y; Kitano, M; Koike, M; Shimokawa, T; Sonomura, T; Tamura, T; Yamashita, Y | 1 |
| Dawe, DE; Kim, CA; Lambert, P; McAndrew, EN; Rittberg, R; Zhang, H | 1 |
| Artru, P; Auclin, E; Bechade, D; Ducoulombier, A; Edeline, J; Gilabert, M; Hautefeuille, V; Lièvre, A; Morin, C; Pernot, S; Sarabi, M; Taieb, J; Tougeron, D; Wasselin, J; Zaibet, S | 1 |
| Akazawa, M; Narimatsu, H; Sasahara, Y; Takumoto, Y | 1 |
| Ohata, C; Shimizu, Y | 1 |
| Cella, CA; Fazio, N; Gandini, S; Gervaso, L; Meneses-Medina, MI; Pellicori, S; Sousa, MJ | 1 |
| Bates, SE; Hur, C; Ingram, MA; Kastrinos, F; Kong, CY; Lauren, BN; Lim, F; Manji, GA; Park, J; Pumpalova, Y | 1 |
| Fujii, T; Hashimoto, D; Hirano, S; Honda, G; Kitayama, J; Kodera, Y; Miura, F; Motoi, F; Satoi, S; Sekimoto, M; Shimokawa, T; Uemura, K; Ueno, H; Unno, M; Yamaki, S; Yamamoto, T; Yamaue, H; Yoshitomi, H | 1 |
| Alemany, R; Álvarez, R; Bazan-Peregrino, M; Blasco, C; Blasi, E; Capella, G; Cascallo, M; Garcia-Carbonero, R; Gimenez-Alejandre, M; Ginestà, MM; Gornals, JB; Hidalgo, M; Laquente, B; Maliandi, MV; Mato-Berciano, A; Moreno, R; Morgado, S; Perea, S; Perez-Carreras, M; Prados, S; Riesco, MC; Rodríguez-García, A; Salazar, R | 1 |
| Abi Jaoude, J; Delahoussaye, AM; Feng, N; Fowlkes, N; Fujimoto, TN; Garcia Garcia, CJ; Gay, JP; Green, M; Marszalek, J; Molkentine, J; Taniguchi, CM | 1 |
| Iede, K; Ikenaga, M; Koh, M; Matsuyama, J; Nakashima, S; Ohta, K; Tanida, T; Tominaga, S; Tsuda, Y; Ueda, M; Yamada, T | 2 |
| Enomoto, A; Fujishiro, M; Iida, T; Imai, M; Ishikawa, T; Kawashima, H; Kinoshita, F; Kuwatsuka, Y; Mizutani, Y; Ohno, E; Shimizu, S; Tsuruta, T | 1 |
| Abe, Y; Daiku, K; Fujita, M; Fukutake, N; Higashi, S; Hiraga, E; Hirao, T; Ikezawa, K; Kai, Y; Kawamoto, Y; Maeda, S; Nakabori, T; Ohkawa, K; Takada, R; Uehara, H; Urabe, M; Yamai, T | 1 |
| Ebata, T; Fujii, T; Ishikawa, T; Kawashima, H; Kodera, Y; Maeda, O; Nagino, M; Ogawa, H; Ohno, E; Takami, H; Yamada, S; Yamaguchi, J; Yokoyama, Y | 1 |
| Inoue, Y; Ito, H; Mie, T; Oba, A; Ono, Y; Ozaka, M; Saiura, A; Sasahira, N; Sasaki, T; Sato, T; Takahashi, Y; Ushida, Y | 2 |
| Asama, H; Fukushima, T; Kawano, K; Kobayashi, S; Maeda, S; Morimoto, M; Nagashima, S; Ohira, H; Sano, Y; Tanaka, S; Ueno, M | 1 |
| Ashida, R; Emori, T; Hatamaru, K; Higashino, N; Ikoma, A; Itonaga, M; Kawai, M; Kawaji, Y; Kitano, M; Shimokawa, T; Sonomura, T; Tamura, T; Yamashita, Y | 1 |
| Abe, Y; Daiku, K; Higashi, S; Hirao, T; Ikezawa, K; Kai, Y; Kawamoto, Y; Maeda, S; Nakabori, T; Ohkawa, K; Takada, R; Uehara, H; Urabe, M; Yamai, T | 1 |
| Allard, J; Bonnet, M; Bouattour, M; Gagaille, MP; Laurent, L; Leclerc, V | 1 |
| Aprile, G; Catalano, M; Conca, R; Petrioli, R; Ramello, M; Roviello, G | 2 |
| Abou-Alfa, GK; Bartlett, A; Capanu, M; Chou, JF; Cooper, B; El Dika, I; Epstein, AS; Ilson, DH; Kelsen, DP; Ku, GY; Li, J; McCarthy, B; McCarthy, D; Mittal, A; O'Reilly, EM; Park, J; Park, W; Sangar, V; Varghese, AM; Yu, KH | 1 |
| Amar-Farkash, S; Aran, D; Collisson, EA; Klein-Brill, A; Lawrence, G | 1 |
| Fujita, Y; Hayashi, K; Hirano, A; Hori, Y; Inoue, T; Kataoka, H; Kato, A; Kato, H; Miyabe, K; Naiki-Ito, A; Naitoh, I; Natsume, M; Nishi, Y; Okumura, F; Sano, H; Takada, H; Takahashi, S; Yoshida, M | 1 |
| Huang, B; Li, C; Yan, Y; Yang, X | 1 |
| Arciero, V; Arias, J; Beca, JM; Biagi, JJ; Chan, KKW; Dai, WF; Earle, CC; Gavura, S; Habbous, S; Isaranuwatchai, W; Luo, J; Mittmann, N; Parmar, A; Raphael, MJ; Tadrous, M | 1 |
| Acar, R; Akcan, E; Aykan, MB; Erturk, I; Karadurmus, N; Yildiran, GS | 1 |
| Cai, L; Guo, X; Hu, X; Jiang, Z; Luo, J; Pan, Y; Shao, Z; Sun, T; Teng, YE; Wang, B; Wang, S; Wang, X; Wang, Z; Wu, J; Yan, M; Zhang, J; Zhao, Y | 1 |
| Aliru, M; Bagereka, P; Bhosale, P; Crane, CH; Das, P; Holliday, EB; Ikoma, N; Jacobson, G; Javle, M; Katz, MH; Kim, M; Koay, EJ; Koong, AC; Krishnan, S; Lee, JE; Ludmir, EB; Minsky, BD; Overman, M; Pant, S; Rodriguez, MJ; Smith, GL; Tamm, E; Taniguchi, CM; Tzeng, CW; Van Wieren, A; Varadhachary, G; Wang, H; Wang, X; Wolff, RA; Zaid, M | 1 |
| Esposito, F; Font, C; Garcia de Herreros, M; Sauri, T | 1 |
| Hattori, N; Hayashi, M; Inokawa, Y; Kanda, M; Kodera, Y; Kurimoto, K; Nakayama, G; Otsu, T; Shimizu, D; Takami, H; Tanaka, C; Tanaka, H; Tanaka, N | 1 |
| Hamauchi, S; Kawakami, T; Nakase, H; Ohwada, S; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Asagi, A; Hiasa, Y; Hino, K; Hyodo, I; Imamura, Y; Inoue, T; Kajiwara, T; Kanemitsu, K; Koizumi, M; Kokubu, M; Kumagi, T; Marui, K; Nadano, S; Nakasya, A; Nishide, N; Nishina, T; Numata, Y; Okujima, Y; Sakaguchi, C; Terao, T; Yoshimatsu, M | 1 |
| Arima, S; Doi, K; Furuse, J; Hayashi, H; Higuchi, H; Hisano, T; Imaoka, H; Ishii, H; Ishii, S; Kawabe, K; Kitano, Y; Kobayashi, S; Kojima, Y; Maruki, Y; Misumi, T; Miwa, H; Nagano, H; Naganuma, A; Nakashima, K; Okano, N; Ozaka, M; Shioji, K; Suzuki, M; Suzuki, R; Tanaka, K; Todaka, A; Tsuji, K; Tsumura, H; Ueno, M; Umemoto, K; Yamaguchi, H; Yamashita, T | 1 |
| Ananda, S; Burge, M; Clarke, K; Gibbs, P; Jennens, R; Lee, B; Lipton, L; Michael, M; Nikfarjam, M; Pattison, S; Santucci, J; Shapiro, J; Tacey, M; Thomson, B; Wong, R; Zielinski, R | 1 |
| Aucoin, N; Couture, F; Du, P; Gill, S; Harb, M; Jia, S; Jonker, D; Kavan, P; Kim, CA; Knox, JJ; Ko, YJ; Lemay, F; Loree, JM; Meyers, BM; O'Callaghan, CJ; Ramjeesingh, R; Renouf, DJ; Schaeffer, DF; Tang, PA; Tehfe, M; Topham, JT; Tu, D; Welch, S | 1 |
| Bertram, M; Binninger, A; Chiabudini, M; Hegewisch-Becker, S; Hollerbach, SH; Jänicke, M; Kaiser-Osterhues, A; Kreher, S; Marschner, N; Reiser, M; von der Heyde, E; Wolf, T | 1 |
| Brown, J; Correa Ordonez, I; Davis, M; Vanenkevort, E; Varun, S; Wojtowicz, M; Young, A | 1 |
| Dong, LP; Liu, YM; Lu, WJ; Tang, KZ | 1 |
| Goršić, I; Kekez, D; Librenjak, N; Pleština, S; Prejac, J; Tomek Hamzić, D | 1 |
| Furukawa, T; Ishitsuka, T; Kasuga, A; Matsuyama, M; Mie, T; Mori, C; Nakagawa, H; Nojima, M; Okamoto, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Udagawa, S; Yamada, M; Yamada, Y | 1 |
| Abdiannia, M; Acharya, A; Aranha, O; Belle, JI; Bogner, SJ; Boice, N; Breden, M; Brown, A; DeNardo, DG; Gao, F; Hawkins, WG; Herndon, J; Herzog, BH; Lim, KH; Lockhart, AC; McWilliams, R; Pedersen, K; Ratner, L; Suresh, R; Tan, B; Trikalinos, NA; Wang-Gillam, A; Yoon, HH; Zhu, M | 1 |
| Amin, MA; Der, CJ; Grierson, PM; Knoerzer, D; Kreider, B; Lim, KH; Liu, J; Park, H; Pedersen, KS; Reddy, A; Suresh, R; Tan, B; Trikalinos, NA; Wang-Gillam, A | 1 |
| Cheon, J; Choi, SH; Chon, HJ; Kang, B; Kang, I; Kim, DJ; Kim, G; Ko, KH; Kwon, CI; Lee, SH | 1 |
| Artru, P; Auvray Kuentz, M; Coutzac, C; de Mestier, L; Drouillard, A; Hammel, P; Hautefeuille, V; Lecomte, T; Lièvre, A; Malka, D; Nardon, V; Pernot, S; Taieb, J; Touchefeu, Y; Tran-Minh, ML; Trouilloud, I; Turpin, A; Williet, N; Zaanan, A | 1 |
| Bianchi, GV; Cantarelli, B; Capri, G; de Braud, F; Depretto, C; Fucà, G; Leporati, R; Ligorio, F; Lobefaro, R; Manoukian, S; Mariani, L; Peverelli, G; Presti, D; Pruneri, G; Rametta, A; Scaperrotta, G; Vernieri, C; Vingiani, A; Zattarin, E | 1 |
| Albers, D; Herold, T; Kasper, S; Linden, G; Markus, P; Prasnikar, N; Radunz, S; Schmidt, H; Schuler, M; Schumacher, B; Siveke, J; Ting, S; Treckmann, JW; Virchow, I; Wiesweg, M | 1 |
| Fujimori, N; Fukuda, H; Furukawa, M; Furuse, J; Ikeda, M; Imaoka, H; Ishii, H; Kamata, K; Katanuma, A; Kataoka, T; Katayama, H; Kobayashi, S; Komatsu, Y; Miwa, H; Mizukoshi, E; Mizuno, N; Mizusawa, J; Nakachi, K; Ohba, A; Okano, N; Okusaka, T; Ozaka, M; Sasahira, N; Takayama, Y; Terashima, T; Todaka, A; Tsumura, H; Ueno, M; Yamamoto, T | 1 |
| Su, J; Wang, W; Yang, L; Zhou, F | 1 |
| Albers, D; Kasper, S; Kostbade, K; Laue, K; Liffers, ST; Markus, M; Markus, P; Maßmann, M; Mende, B; Pogorzelski, M; Reissig, TM; Roehrle, J; Rosery, V; Schildhaus, HU; Schmid, K; Schuler, M; Schumacher, B; Siveke, JT; Ting, S; Treckmann, JW; Virchow, I; Wendling, J; Wiesweg, M; Zaun, G | 1 |
| Asaka, S; Kono, T; Kuhara, K; Nishiguchi, R; Ohigashi, S; Okayama, S; Shimakawa, T; Shimojima, Y; Shiozawa, S; Usui, T; Yokomizo, H | 1 |
| Doolin, JW; Paredes de la Fuente, R; Peters, ML | 1 |
| Aldakkak, M; Christians, KK; Clarke, CN; Erickson, BA; Evans, DB; George, B; Hall, WA; Kamgar, M; Smith, ZL; Thalji, SZ; Tolat, PP; Tsai, S | 1 |
| Hasegawa, R; Imaizumi, H; Ishizaki, A; Ishizaki, J; Iwai, T; Kaneko, T; Kida, M; Kurosu, T; Kusano, C; Okuwaki, K; Watanabe, M; Yamauchi, H | 1 |
| Balachandran, VP; Court, CM; Crane, CH; D'Angelica, MI; Drebin, JA; Ecker, BL; Gonen, M; Iacobuzio-Donahue, CA; Janssen, QP; Jarnagin, WR; Kingham, TP; O'Reilly, EM; Soares, KC; Tao, AJ; Vakiani, E; Varghese, AM; Walch, HS; Wei, AC | 1 |
| Azzouqa, AG; Colon-Otero, G; Kase, AM; Kochuveettil, S | 1 |
| Arias, J; Beca, JM; Biagi, JJ; Chan, KKW; Coburn, N; Dai, WF; Earle, CC; Gavura, S; Habbous, S; Raphael, M; Saluja, R | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shinohara, Y; Shirakawa, T; Taguchi, H; Ueda, Y; Ueno, S; Ureshino, N | 1 |
| Akdeniz, N; Beşiroğlu, M; Demirci, A; Ergün, Y; İnanç, M; Işikdoğan, A; Kaplan, MA; Kiliçkap, S; Küçüköner, M; Şendur, MAN; Topçu, A; Uncu, D; Urakçi, Z; Yerlikaya, H | 1 |
| Aquilini Mummolo, A; Bruno, G; Cincione, RI; Conteduca, V; Giordano, G; Landriscina, M; Lizzi, V; Losavio, F; Pacilli, M; Piscazzi, A; Senia, T | 1 |
| Cappetta, A; Catalano, M; Conca, R; D'Angelo, A; Petrioli, R; Ramello, M; Roviello, G; Siminonato, F | 1 |
| Akazawa, M; Asami, H; Shibahara, R; Takumoto, Y | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Okabe, Y; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Bajwa, A; Bisunke, B; Fang, J; Glazer, ES; Kansal, RG; Rana, M; Shibata, D; Yang, J | 1 |
| Chen, IM; Christensen, S; Detlefsen, S; Egendal, I; Johansen, JS; Ladekarl, M; Liposits, G; Pfeiffer, P; Rasmussen, LS; Shim, S; Ventzel, L; Weber, B; Winther, SB | 1 |
| Choi, JK; Han, JH; Lee, KJ; Park, BK; Seo, JH; Son, KJ | 1 |
| Bhardwaj, N; Chen, KT; Ebot, E; Fabrizio, D; Fleischmann, Z; Frampton, G; He, J; Hegde, P; Jin, D; Lofgren, KT; Madison, R; Moore, J; Newberg, J; Pishvaian, MJ; Schrock, A; Singhi, A; Sokol, E | 1 |
| Abbey, L; Abdelghany, TM; Abdellatif, MH; Abdelmohsen, UR; Abduljaleel Alzawar, NS; Abid, MF; Abu Kasim, AFB; Abu Saad, H; Adolpho, LF; Agostini, F; Agrizii, AP; Ahmed, S; Akce, M; Åkesson, D; Al-Awaadh, AM; Al-Mutar, DMK; Al-Odayni, AB; Al-Rajhi, AMH; Alaaeldin, R; Alam, M; Alam, MM; Alanazi, MA; Alattar, H; Alawlaqi, MM; Aldebis, HK; Algehainy, NA; Almeida, AA; Aloisi, F; Alrahlah, A; Alsenani, F; Alshabib, A; Altemani, FH; Althagafi, A; Amari, A; Andronesi, AG; Antonyuk, M; Arantes, TD; Araújo, R; Arrotti, S; Asakura, T; Asib, N; Atlaskin, AA; Aung, MS; Axiaq, A; Azekawa, S; Bacon, S; Bagalagel, A; Balbinot, GS; Barnet, LS; Baroyi, SAHM; Barreto, F; Barth, Y; Barysheva, AV; Bassa, E; Basu, R; Basu, S; Bates, C; Bautista, LS; Beitl, K; Beloti, MM; Benatti, G; Benavent-Celma, C; Bentaher, A; Bergsland, N; Bernardino, AF; Bernhardt, A; Bhandari, RK; Bhaskaran, K; Bhate, K; Bhattacharjee, A; Bian, X; Bien, EM; Birch, M; Bishara, K; Biswas, JP; Bleha, R; Bocale, R; Bona, S; Boriani, G; Bouyssi, A; Bradley, D; Bravo-Sánchez, MG; Bressan, GC; Brik, A; Brizuela, A; Brockbank, KGM; Buchner, F; Bunc, M; Buscombe, JR; Butler, AJ; Buzaleh, AM; Buzin, MI; Cabrera-Capetillo, CA; Calvo, AM; Camerota, A; Campagna, G; Campisi, M; Cano, K; Cao, HST; Cardellini, S; Carvalho, AP; Carvalho, BCR; Castillo-Baltazar, OS; Cataldo, P; Chai, P; Chakraborty, S; Chalo, DM; Chan, MY; Chander, S; Changbunjong, T; Chappuis, CJF; Chee, RCH; Chen, C; Chen, CJ; Chen, E; Chen, M; Chen, X; Chen, Y; Cheng, HT; Cheng, MC; Cheow, HK; Chi, Y; Chirikova, NK; Chiu, SH; Cho, G; Cho, HR; Cho, S; Cho, SJ; Choe, A; Choe, YH; Chun, BS; Chun, Z; Cinque, A; Ciopec, M; Cladas, Y; Cleary, SP; Clermont, O; Cléroux, M; Cockburn, J; Collares, FM; Colombini-Ishikiriama, BL; Conn, BN; Cortina, JL; Cox, DRA; Crini, G; Croker, R; Cursaru, DL; Curtis, HJ; da Silva, KJG; Dalla Costa, T; Davy, S; de Araújo, BV; de Cassia Ribeiro Gonçalves, R; de Gaetano, F; de Gregorio, C; de Oliveira, MG; De Vera, MAT; de Vos, M; de-la-Fuente, I; Dell'Oca, I; Delles, M; Déméautis, T; Dempster, M; Deng, YH; Denisenko, Y; Descombes, C; Desideri, G; Devarbhavi, H; Devouassoux, G; Di Bella, G; Di Marco, F; Diao, Y; Dias, BB; Dilgin, Y; Dimopoulou, I; Dionísio, TJ; Dobrovic, A; Dokin, ES; Dolby, T; Dong, X; Dong, Y; Dou, SX; Douglas, IJ; Dousset, S; Du, Z; Duan, M; Duan, SB; Duke-Williams, O; Duteanu, N; Dutertre, S; Dutta, S; Dwyer, MG; Ebenbauer, J; Eggo, RM; El-Mordy, FMA; Elbhnsawi, NA; Elrehany, MA; Elshewemi, SS; Elwakil, BH; Emadzadeh, D; Eraso, E; Ermolenko, E; Erten, K; Ettorre, E; Evans, D; Evans, SJ; Faheem, M; Fallanza, M; Faramarzi, M; Faria, FAC; Faro, DC; Fatma, YS; Fazil, S; Feng, Y; Ferguson, J; Fernandes, MH; Fernández-Domínguez, M; Ferrari, LAL; Ferraz, EP; Ferreira, LC; Ferri, C; Fikry, M; Floris, M; Forbes, H; Fotouh, B; Franke, K; Freitas, AC; Freitas, GP; Frieboes, HB; Fu, B; Fu, Y; Fukina, DG; Fukuda, DH; Fukunaga, K; Fulham, GJ; Furlan, L; Furtado Mesa, M; Furtunescu, FL; Gabbieri, D; Ganash, M; Gebers, JC; Gehman, V; Ghaedi, A; Ghazali, NSM; Ghebrekristos, Y; Gil, J; Gilbert, NM; Gimenes, R; Giordano, L; Glehen, O; Godeau, C; Goh, SK; Goldacre, B; Gomes, AM; Gomes, MPO; Gomes, PS; Gomes, RMODS; Gómez-Coma, L; Grenho, L; Gu, Q; Gu, T; Gu, YC; Guiducci, V; Guillemin, JP; Guo, W; Guo, YW; Gur, E; Guridi, A; Guzmán-López, A; Gvozdenko, T; H Elmaidomy, A; Hagar, M; Haider, S; Han, JM; Hanratty, J; Hans, R; Haque, N; Harharah, HN; Harharah, RH; Harper, S; Hasegawa, N; Hassanin, AH; Hastuti, YP; Hatem, AE; He, R; He, Y; Heinemann, C; Heinmaa, I; Heinzl, F; Helfer, VE; Hester, F; Hickman, G; Hill, MA; Hill, WG; Hintze, V; Ho, JSY; Ho, LY; Hoang, T; Holzer, I; Houbraken, J; Hsu, CN; Hu, J; Hu, X; Hu, Y; Hua, T; Huang, Z; Hulme, WJ; Hunter, A; Ianăşi, C; Ibañez, R; Iezzi, R; Iliuță, L; Im, YM; Imran, M; Inglesby, P; Inguimbert, N; Iqbal, A; Izawa, N; Jahaj, E; Jain, S; Jakimovski, D; Jalal, MM; Jaroszuk-Ściseł, J; Jasim, DJ; Jauregizar, N; Javle, MM; Jędryczka, M; Ji, H; Jiang, Y; Jin, J; Johnson, NT; Joshi, S; Jullok, N; Kachapulula, PW; Kaczmarek, J; Kaczmarek-Szczepańska, B; Kadota, K; Kaji, M; Kakeji, Y; Kakizoe, S; Kakudidi, E; Kalitukha, L; Kamata, H; Kang, YJ; Kapinos, AA; Karakaya, S; Kashchenko, NI; Kasyanov, S; Kataky, R; Katati, B; Kato, G; Katsina, AU; Kaya, A; Kaya, H; Kazarina, OV; Ke, Y; Keenan, C; Keilson, JM; Keshavan, A; Keskinidou, C; Khalifa, MA; Khan, R; Khan, S; Kim, D; Kim, K; Kim, MS; Kim, SM; Kim, WH; Kim, Y; Kim, YJ; Kishimura, H; Kitagawa, RR; Klemenkova, ZS; Kloss, F; Kobayashi, N; Kohlhoff, M; Kong, WKF; Konsek, H; Kornaros, M; Kotanidou, A; Kovacs, S; Kraska, J; Kruppke, B; Kumagai, Y; Kumar, S; Kumari, R; Kuruva, V; Kuster, RM; Kusumoto, T; Kutyła, M; Kwon, JH; Kwon, SH; Kwong, KY; Kyser, AJ; Lackner, M; Lass-Flörl, C; Lauri, C; Lavandera, JV; Lee, BH; Lee, ECY; Lee, HJ; Lee, J; Lee, PS; Lee, S; Lee, SE; Lee, SY; Lefort, F; Leite, JPV; Leo, G; Leonard, R; Leow, AST; Lepori, N; Leyden, K; Leys, L; Ležaić, L; Li, D; Li, H; Li, J; Li, S; Li, TYW; Li, X; Li, XH; Li, Y; Li, Z; Li, ZH; Liao, S; Liaqat, K; Lim, H; Lin, BS; Lin, MY; Lin, NH; Lin, X; Lin, Y; Liu, C; Liu, H; Liu, HK; Liu, HX; Liu, P; Liu, R; Liu, T; Liu, X; Liu, Y; Lock, GA; Lokaj, G; Lopes, HB; Losi, V; Lotsios, NS; Low, KE; Lu, Z; Luhana, S; Luo, X; Luo, XQ; Lutz, MB; Lysova, AA; Lyssenko, KA; Macit, M; MacIver, B; MacKenna, B; Magalhães, GAP; Magnavacchi, P; Mahadevan, J; Mahboubi, A; Maher, SA; Mahipal, A; Mahmoud, MY; Maithel, SK; Makhtar, MMZ; Makurat-Kasprolewicz, B; Malysheva, YB; Mansourizadeh, A; Marek, EJ; Maresca-Fichter, H; Martin, JT; Maslov, AA; Mastora, Z; Mastroiacovo, D; Mastropetros, SG; Matei, D; Mathur, R; Matos, AO; Matsuda, Y; Maurya, SK; Mayor, Á; Mayrhofer, D; Mazzuco, AC; McCaffrey, J; McClure, T; McDonald, HI; Mchunu, NP; McLaggan, D; Mehrkar, A; Meilik, B; Melito, VA; Mellem, J; Mengozzi, A; Menotti, J; Mesquita, V; Miao, Z; Mihai, S; Miller, S; Minassian, C; Mirabile, A; Mitra, S; Mladin, G; Mo, Z; Moawad, H; Mohamed, EM; Mohammed, TJ; Mohanlall, V; Mohyeldin, RH; Moldovan, H; Monneret, G; Monopoli, DE; Monte, IP; Monteiro, JRB; Morgante, V; Mori, M; Morin-Crini, N; Morita, A; Morton, CE; Mrak, M; Muhammed, AP; Mulick, A; Muralidharan, V; Murthy, P; Muselli, M; Mustafa, S; Mysore Visweswariah, A; Nagao, G; Naicker, S; Nakagawara, K; Namgoong, B; Namkoong, H; Namukobe, J; Nasir, AA; Nasreen, SA; Natarajan, P; Nchiozem-Ngnitedem, VA; Necozione, S; Negrea, A; Negrea, P; Ngubane, S; Nguyen, TT; Nicke, A; Nightingale, E; Nistor, CL; Nitsch, D; Njapau, H; Noman, M; Novgorodtseva, T; Nowak, A; O'Connor, SR; Ofoe, R; Oh, K; Oh, TH; Oki, E; Olama, ZA; Olennikov, DN; Oliveira, GM; Omar, D; Ong, SJ; Orfanos, SE; Origa-Oryem, H; Orita, H; Ortiz, I; Ota, M; Ott, J; Otvagina, KV; Pacheco, N; Pacheco, RR; Padmanabhan, D; Pagan, JD; Pagnotta, PA; Palangi, V; Palanisamy, G; Palanisamy, K; Palanisamy, S; Pan, SG; Panaitescu, E; Pang, X; Panoutsakopoulos, V; Parera, VE; Park, JI; Park, JS; Park, SW; Park, Y; Park, YS; Parkash, O; Parry, J; Parry, JP; Paul, SK; Pavšič, N; Pałubicka, A; Persat, F; Petriz-Prieto, MA; Petukhov, AN; Pham, T; Pillay, S; Poh, KK; Ponomarev, II; Pontons-Melo, JC; Posa, A; Powell, E; Priya, AK; Punekar, R; Puppin Rontani, RM; Purushottam, M; Pusphanathan, K; Qi, JY; Qin, J; Qin, Z; Qiu, B; Qiu, X; Quattrini, G; Quindós, G; Qureshi, F; Rabbany, MA; Rac-Albu, M; Rac-Albu, ME; Rădulescu, BC; Rafatullah, M; Rajab, TK; Rajna, S; Ramanathan, M; Rao, D; Raviglione, D; Razorenov, DY; Redd, MJ; Rehman, W; Reig, M; Rentsch, CT; Ribeiro, LMS; Robles, D; Rocchi, S; Rocha, FG; Rodrigues, C; Rodrigues, LA; Rodrigues, RP; Roh, GH; Ronowska, A; Root, A; Rosa, AL; Rossi, R; Roy, S; Roy, VC; Rupji, M; Saber, EA; Sadarat, F; Saed, Y; Saeed, WS; Saeki, H; Saha, B; Saiwichai, T; Sakowicz-Burkiewicz, M; Sampedro, T; Sands, K; Santos, CF; Sari, M; Sathi, FA; Sauro, S; Sazanova, TS; Scafa-Udriște, A; Schoustra, SE; Schultze, A; Seo, DJ; Sevillano, E; Sezmis, G; Sgura, FA; Shah, NNAK; Shani, N; Shankarappa, B; Sharkey, LM; Sharma, VK; Sharp, C; Shehata, N; Shelton, N; Shieh, PB; Shimokawa, M; Shin, J; Shin, SH; Shin, YN; Shin, YR; Shipilova, A; Shoparwe, NF; Shukor, H; Sia, CH; Siddiqui, MH; Siddiqui, MR; Siena, V; Signore, A; Silwane, B; Siqueira-Sandrin, VS; Siregar, A; Sirignano, P; Sit, NW; Skidmore, S; Skupov, KM; Smeeth, L; Smoczer, C; Smolyanskiy, E; Sohn, H; Solodeev, I; Solovyev, A; Şomoghi, R; Song, F; Song, H; Song, Z; Souf, YM; Sousa, SC; Souza, MT; Steinbach-Rankins, JM; Stockton, J; Stout, JR; Su, K; Su, MZ; Suarez-Lopez, YA; Sukkurd, R; Sultanov, R; Sun, Y; Sun, Z; Supernak, M; Supriyono, E; Suroshe, SS; Suvorov, SS; Svera M Ianăşi, P; Switchenko, JM; Syarif, NY; Synytsya, A; Taherzadeh, MJ; Tain, YL; Tamburino, C; Tammam, OY; Tan, BYQ; Tan, H; Tan, S; Tanaka, H; Tang, R; Tang, X; Tang, Z; Taurino, M; Tazare, J; Teresi, L; Testro, A; Thanasoponkul, W; Thangarasu, S; Thavaselvam, D; Theodoro, RC; Theron, G; Thomas, RH; Thomson, JJ; Tian, X; Tian, Y; Tomaszewski, CA; Tomlinson, LA; Torres, CMME; Tóth, M; Trecourt, A; Trevisani, F; Trimarchi, G; Tristán, C; Truong, VK; Tsigkou, K; Tsutsumi, S; Ubukata, Y; Uehara, H; Uwamino, Y; Vahedi-Shahandashti, R; Valberg, SJ; Valderrama, C; Valdovinos-García, EM; Valsecchi, D; van Diepeningen, AD; van West, P; Vargas-Osuna, E; Vassall, M; Vassilaki, N; Vassiliou, AG; Vecino, X; Velez-Irizarry, D; Venkatesh, YN; Vignali, L; Virdis, A; Viswanath, B; Voisin, AS; Volkova, YA; Vorotyntsev, AV; Vorotyntsev, IV; Vtyurina, ES; Vu, DH; Waldridge, B; Walker, AJ; Wallon, M; Wang, B; Wang, G; Wang, H; Wang, J; Wang, LJ; Wang, S; Wang, T; Wang, X; Wang, Z; Warren, RM; Warren-Gash, C; Wei, SH; Weinstock-Guttman, B; Wekwejt, M; Wessjohann, LA; Wiesmann, HP; Williams, ZJ; Williamson, EJ; Wilson, M; Wing, K; Wong, AY; Wong, BKL; Woodward, S; Wozniak, KL; Wu, C; Wu, K; Wu, S; Wu, Y; Xiang, D; Xie, H; Xiong, X; Xu, C; Xu, H; Xu, J; Xu, WH; Xu, Y; Xun, T; Yamaguchi, S; Yan, P; Yan, W; Yan, Z; Yang, B; Yang, F; Yang, L; Yao, XB; Yasui, H; Yenesew, A; Yeo, LLL; Yeo, TC; Yi, S; Yin, F; Yip, JWL; Yoon, SH; Yoon, SJ; Yoshida, M; Yoshizumi, T; Young, LA; Yu, C; Yu, DD; Yu, F; Yu, H; Yu, JD; Yu, NJ; Yu, X; Yuan, Y; Yurenko, A; Yusof, YA; Zahedipoor, A; Zahran, EM; Zainuddin, NI; Zanatta, AC; Zanotto, ED; Zanozin, ID; Zavascki, AP; Zenke, M; Zhang, F; Zhang, G; Zhang, H; Zhang, J; Zhang, L; Zhang, MX; Zhang, NY; Zhang, Q; Zhang, W; Zhang, X; Zhang, XM; Zhao, F; Zhao, Q; Zhao, R; Zhao, Y; Zheng, J; Zheng, S; Zhou, L; Zhou, X; Zhu, H; Zivadinov, R; Žižek, D; Zuccoli, JR; Zwaan, BJ | 1 |
| Bahary, N; Beatty, GL; Chang, RB; Delman, D; Garrido-Laguna, I; Kennedy, EP; Lee, JW; Li, JH; Liu, M; Rossi, GR; Wang-Gillam, A; Yu, J; Zhang, L | 1 |
| Gou, H; Huang, Q; Li, X; Tan, S; Yang, Y; Zhang, S; Zhou, N | 1 |
| Hosomi, T; Makino, Y; Otsuka, H; Shibasaki, N; Shichiri, Y; Uketa, S | 1 |
| Belfiore, A; de Braud, F; Depretto, C; Ferraris, C; Ficchì, A; Formisano, B; Franza, A; Fucà, G; Ligorio, F; Lobefaro, R; Martinetti, A; Nasca, V; Provenzano, L; Pruneri, G; Salvadori, G; Scaperrotta, G; Sottotetti, E; Sposetti, C; Vernieri, C; Vingiani, A; Zanenga, L | 1 |
| Bai, C; Cheng, Y; Tang, H; Wang, X; Wang, Y; Ying, J; Zhu, Z | 1 |
| Du, J; Hou, G; Li, M; Liang, J; Shao, Y; Silli, EK; Wang, Y; Zhang, Y | 1 |
| Geater, SL; Jirapongsak, J; Raungrut, P; Tanyapattrapong, S; Thongsuksai, P | 1 |
| Busch, OR; de Wilde, RF; Molenaar, IQ; Seelen, LWF; van Santvoort, HC; Wilmink, JW | 1 |
| Garajová, I; Gelsomino, F; Leonardi, F; Peroni, M | 1 |
303 review(s) available for paclitaxel and deoxycytidine
| Article | Year |
|---|---|
New anticancer agents.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Chrysenes; Deoxycytidine; Echinomycin; Epirubicin; Etanidazole; Flavonoids; Gemcitabine; Guanidines; Humans; Idarubicin; Menogaril; Mitoguazone; Neoplasms; Nitroimidazoles; Nogalamycin; Organoplatinum Compounds; Paclitaxel; Pentostatin; Polymers; Propylene Glycols; Ribavirin; Sulfonylurea Compounds; Trimetrexate; Vidarabine Phosphate | 1991 |
Palliative chemotherapy in advanced bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Gallium; Gemcitabine; Humans; Ifosfamide; Methotrexate; Paclitaxel; Palliative Care; Urinary Bladder Neoplasms; Vinblastine | 1995 |
New drugs for treating small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan | 1995 |
New drug for therapy of non-small cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1994 |
[Phase II study].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Practice Guidelines as Topic; Taxoids | 1995 |
New chemotherapeutic agents for non-small cell lung cancer.
Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Quinoxalines; Sulfanilamides; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1995 |
[Therapeutic strategy for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 1995 |
Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Gallium; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Staging; Paclitaxel; Pyrimidines; Trimetrexate; Urinary Bladder Neoplasms; Vinblastine | 1995 |
New cytostatic drugs in ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 1993 |
[New promising anticancer drugs for lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Organoplatinum Compounds; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1994 |
Promising new agents in the treatment of non-small cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1996 |
Chemotherapy of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Growth Substances; Humans; Immunologic Factors; Octreotide; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate; Taxoids | 1996 |
Promising new therapies in the treatment of advanced ovarian cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Topotecan | 1995 |
Chemotherapy for advanced bladder carcinoma: new molecules and regimens.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Folic Acid Antagonists; Gallium; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Methotrexate; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 1996 |
New anticancer agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; DNA Topoisomerases, Type I; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Paclitaxel; Prodrugs; Taxoids; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan | 1995 |
Emerging drug treatments for solid tumours.
Topics: Amifostine; Antineoplastic Agents; Aziridines; Deoxycytidine; Gemcitabine; Humans; Indolequinones; Indoles; Neoplasms; Organoplatinum Compounds; Paclitaxel; Protein Kinase C; Topoisomerase I Inhibitors | 1996 |
[Chemotherapy for pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Irinotecan; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Taxoids | 1996 |
Metastatic breast cancer.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Diphosphonates; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Gemcitabine; Humans; Imides; Intercalating Agents; Isoquinolines; Naphthalimides; Neoplasm Metastasis; Neoplasm Proteins; Organophosphonates; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Topoisomerase II Inhibitors; Treatment Outcome | 1996 |
Promising new agents in oncologic treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Mice; Microtubules; Neoplasm Proteins; Neoplasms; Paclitaxel; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan | 1996 |
Overview of current and future chemotherapeutic agents in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Forecasting; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 1997 |
[New wave of chemotherapeutic agents: update in pulmonary oncology].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
New cytostatic agents for the treatment of head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids | 1997 |
Future directions in the chemotherapy of ovarian cancer.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Forecasting; Gemcitabine; Humans; Injections, Intraperitoneal; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Vinblastine; Vinorelbine | 1997 |
[Lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1997 |
[Combination chemotherapy in the treatment of inoperable non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Meta-Analysis as Topic; Mitomycin; Paclitaxel; Survival Rate; Vinblastine; Vindesine; Vinorelbine | 1997 |
["State-of-the-art" chemotherapy for small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine | 1997 |
New chemotherapeutic agents in the treatment of non-small cell lung cancer: the Australian experience.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Australia; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
Experience with new chemotherapeutic agents in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 1998 |
New agents in the treatment of small cell lung cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Menogaril; Paclitaxel; Taxoids; Teniposide; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1998 |
Do newer chemotherapeutic agents improve survival in non-small cell lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1998 |
Gemcitabine and paclitaxel combinations in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 1998 |
New agents in the management of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1998 |
[The role of new drugs in the treatment of locally advanced urothelial tumors of the bladder].
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 1998 |
Chemotherapy for gastric carcinoma: new and old options.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Combinations; Enzyme Inhibitors; Etoposide; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 1998 |
Chemotherapy for non-small cell lung cancer: have we reached a new plateau?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 1999 |
Gemcitabine plus taxane combinations in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds | 1999 |
Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 1999 |
Gemcitabine in the treatment of ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 1999 |
Xeloda in the treatment of metastatic breast cancer.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Paclitaxel; Survival Analysis; Treatment Outcome | 1999 |
Docetaxel (Taxotere) and gemcitabine phase I and early phase II studies: results to date and an overview of ongoing studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) and gemcitabine in combination therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) in non-small cell lung cancer: ongoing studies in Heidelberg and future plans.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Palliative Care; Radiotherapy, Adjuvant; Taxoids | 1999 |
Chemotherapy in head and neck cancer. Overview of newer agents.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Organoplatinum Compounds; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1999 |
The role of radiation, with or without chemotherapy, in the management of NSCLC.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Topotecan; Vinblastine; Vinorelbine | 1999 |
Ifosfamide in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel | 1999 |
Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
Docetaxel and gemcitabine combinations in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Vinblastine; Vinorelbine | 1999 |
[New drugs in gastrointestinal oncology. Current status and future directions].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Taxoids; Tegafur; Thiophenes; Vinblastine; Vinorelbine | 1999 |
[New combination chemotherapy in urological cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Methotrexate; Paclitaxel; Prostatic Neoplasms; Taxoids; Testicular Neoplasms; Urinary Bladder Neoplasms; Vinblastine | 2000 |
New chemotherapy agents for small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2000 |
[Current perspectives of new agents in lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 2000 |
Gemcitabine and paclitaxel combination therapy in transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Urologic Neoplasms | 2000 |
Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Vinblastine; Vinorelbine | 2000 |
Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2000 |
Chemotherapy in metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Mitomycin; Paclitaxel; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2000 |
Extensive small-cell lung cancer: a treatment overview.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 2000 |
State-of-the-art chemotherapy for advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2000 |
[Chemotherapy of stage IV non-small-cell lung cancer: contribution of gemcitabine].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Mitomycin; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2000 |
Gemcitabine: progress in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Matrix Metalloproteinase Inhibitors; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Docetaxel followed by gemcitabine and irinotecan in solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Survival Rate; Taxoids | 2001 |
Chemoradiation in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Forecasting; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Treatment of extensive stage small cell lung cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Genes, Dominant; Growth Substances; Humans; Irinotecan; Lung Neoplasms; Metalloendopeptidases; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasm Staging; Oncogenes; Paclitaxel; Palliative Care; Protease Inhibitors; Randomized Controlled Trials as Topic; Salvage Therapy; Signal Transduction; Taxoids; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids | 2001 |
Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Clinical pharmacokinetics of capecitabine.
Topics: Antacids; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Fluorouracil; Food; Humans; Intestinal Absorption; Leucovorin; Liver Diseases; Paclitaxel; Protein Binding; Taxoids | 2001 |
Recent advances in bladder cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Urinary Bladder Neoplasms | 2001 |
Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Humans; Paclitaxel; Taxoids | 2001 |
New combinations with epirubicin in advanced breast cancer.
Topics: Adult; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Survival Rate; Time Factors | 2001 |
Recent developments in chemotherapy for bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 2001 |
Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non--small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Taxoids | 2001 |
Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; DNA Adducts; Female; Gemcitabine; Humans; Immunologic Factors; Liposomes; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topoisomerase I Inhibitors; Topotecan | 2001 |
Rationale for non-platinum chemotherapy in advanced NSCLC.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2001 |
New cytotoxic agents and schedules for advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Fluorouracil; Gemcitabine; Humans; Liposomes; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Trastuzumab; Vinblastine; Vinorelbine | 2001 |
Indications for chemotherapy in stage IV non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2001 |
Dose scheduling--Herceptin.
Topics: Abdominal Muscles; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Drug Antagonism; Drug Evaluation, Preclinical; Drug Synergism; Feasibility Studies; Female; Fluorouracil; Half-Life; Haplorhini; Humans; Infusions, Intravenous; Injections, Subcutaneous; Methotrexate; Neoplasm Metastasis; Paclitaxel; Safety; Trastuzumab; Treatment Outcome; Vinblastine; Xenograft Model Antitumor Assays | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
Treatment of advanced ovarian cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Liposomes; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Topotecan | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
Radiosensitization with chemotherapeutic agents.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Platinum Compounds; Radiation-Sensitizing Agents; Taxoids; Vinblastine; Vinorelbine | 2001 |
[New developments in chemotherapy for metastasized bladder cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Male; Methotrexate; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms; Vinblastine | 2001 |
Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost of Illness; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Kidney Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2002 |
The role of gemcitabine-based doublets in the management of ovarian carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 2002 |
Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel | 2002 |
Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan | 2002 |
Current and future perspectives in advanced bladder cancer: is there a new standard?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Metastasis; Paclitaxel; Patient Selection; Practice Guidelines as Topic; Research Design; Risk Factors; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Gemcitabine doublets in advanced urothelial cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Renal Insufficiency; Survival Analysis; Trastuzumab; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Novel gemcitabine-containing triplets in the management of urothelial cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Gemcitabine-based combination treatment of pancreatic cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Patient Selection; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2002 |
Taxanes and capecitabine in combination: rationale and clinical results.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Synergism; Fluorouracil; Humans; Paclitaxel; Survival Analysis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2002 |
[Developed new agents for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2002 |
[Does treatment for malignant pleural mesothelioma exist?].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunotherapy; Interferons; Male; Mesothelioma; Middle Aged; Mitomycin; Multivariate Analysis; Paclitaxel; Palliative Care; Pemetrexed; Pleural Neoplasms; Pneumonectomy; Postoperative Care; Radiotherapy Dosage; Time Factors | 2001 |
[New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
Gemcitabine/anthracycline combinations in metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Neoadjuvant gemcitabine therapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2002 |
Epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2002 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Respiratory Distress Syndrome; Taxoids; Treatment Outcome | 2002 |
Management of locally advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Mitomycins; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radioisotope Teletherapy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies; Streptozocin | 2002 |
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; England; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Wales | 2001 |
New treatment approaches for lung cancer and impact on survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Incidence; Lung Neoplasms; Paclitaxel; Survival Rate | 2002 |
Present and future treatment of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids | 2002 |
The present and future of combination chemotherapy in bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Glutamates; Guanine; Humans; Methotrexate; Paclitaxel; Pemetrexed; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2002 |
[Docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2002 |
[Gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2002 |
[Carboplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[Chemotherapy for elderly patients with lung cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vincristine; Vinorelbine | 2002 |
Docetaxel in the management of advanced or metastatic urothelial tract cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Taxoids; Urologic Neoplasms | 2002 |
Gemcitabine and targeted therapy in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2002 |
Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Europe; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome; United Kingdom; Vinblastine; Vinorelbine | 2002 |
Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2002 |
[Gemcitabine-based chemotherapy for non-small cell lung cancer (NSCLC)--a review of 30 randomized trials].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2002 |
Non-platinum gemcitabine combinations in non-small cell lung cancer.
Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Farnesyltransferase inhibitors in breast cancer therapy.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; Fluorouracil; Humans; Mice; Neoplasm Proteins; Paclitaxel; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Design; Drug Synergism; Enzyme Induction; Epirubicin; Female; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Thymidine Phosphorylase; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
[New neoadjuvant approaches using gemcitabine in non-small-cell lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Treatment Outcome | 2002 |
[Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Platinum-free gemcitabine-based combinations: an alternative to conventional chemotherapy of non-small-cell lung cancers?].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Gemcitabine-based combinations in inoperable pancreatic cancers].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Routes; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[Gemcitabine and breast cancer].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Gemicitabine in the treatment of epithelial ovarian cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematologic Diseases; Humans; Multicenter Studies as Topic; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prodrugs; Remission Induction; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Economics, Pharmaceutical; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Combination versus sequential single-agent therapy in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Research Design; Taxoids; Trastuzumab | 2002 |
Challenging the platinum combinations in the chemotherapy of NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2002 |
Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Health Status; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Survival; Taxoids; Vinblastine; Vinorelbine | 2002 |
Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Pancreatic Neoplasms; Signal Transduction; Taxoids; Transcription Factors; Treatment Failure | 2002 |
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Hydroxamic Acids; Irinotecan; Organic Chemicals; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Chemotherapy for elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; SEER Program; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Microtubules; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Palliative Care; Podophyllotoxin; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Role of gemcitabine in the treatment of advanced and metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vindesine; Vinorelbine | 2003 |
Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Carboplatin; Carcinoma, Renal Cell; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kidney Neoplasms; Neoplasm Staging; Nephrectomy; Paclitaxel; Sarcoma; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Gemcitabine combined with docetaxel in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2003 |
Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Trastuzumab | 2003 |
The evolving role of capecitabine in breast cancer.
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Prodrugs; Taxoids; Trastuzumab; Treatment Outcome; United States; Vinblastine; Vinorelbine | 2003 |
Exudative hyponychial dermatitis associated with capecitabine and docetaxel combination chemotherapy for metastatic breast carcinoma: report of three cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Eruptions; Exudates and Transudates; Female; Fluorouracil; Humans; Middle Aged; Nail Diseases; Paclitaxel; Taxoids | 2003 |
Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Enzyme Inhibitors; Gastrointestinal Neoplasms; Gemcitabine; Humans; Paclitaxel; Quinolones; Radiotherapy, Conformal; Treatment Outcome | 2003 |
Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Glutamates; Guanine; Humans; Kidney Neoplasms; Paclitaxel; Pemetrexed; Urogenital Neoplasms; Urothelium | 2003 |
The systemic treatment of advanced and metastatic bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 2003 |
Gemcitabine combination chemotherapy of ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Salvage Therapy | 2003 |
New perspectives in the management of pancreas cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Taxoids | 2003 |
Localized pleural malignant mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Mesothelioma; Neoplasm Recurrence, Local; Paclitaxel; Pleural Neoplasms; Radiography, Thoracic; Tomography, X-Ray Computed | 2003 |
Antiblastic drug combinations with ifosfamide: an update.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Ifosfamide; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
Ifosfamide in non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 2003 |
Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
Bevacizumab in the treatment of breast cancer: rationale and current data.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Paclitaxel; Vascular Endothelial Growth Factor A | 2004 |
[Do combinations without cisplatin represent an alternative to conventional chemotherapy in non-small cell lung cancers?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
Significant responses to platinum-based chemotherapy in renal medullary carcinoma.
Topics: Adolescent; Anemia, Sickle Cell; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Carboplatin; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Medulla; Kidney Neoplasms; Male; Paclitaxel; Treatment Outcome | 2005 |
Anthracycline vs nonanthracycline adjuvant therapy for breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Methotrexate; Paclitaxel | 2004 |
[The second-line chemotherapy for urological cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Male; Methotrexate; Paclitaxel; Survival Rate; Testicular Neoplasms; Treatment Outcome; Urologic Neoplasms; Vinblastine | 2005 |
Gemcitabine and paclitaxel in metastatic breast cancer: a review.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
Adjuvant chemotherapy for early-stage breast cancer: the tAnGo trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Research Design; Survival Analysis | 2004 |
Development of docetaxel in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
Chemoresistance in non-small cell lung cancer.
Topics: Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2005 |
Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Quality Control; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2005 |
Salvage, dose intense and high-dose chemotherapy for the treatment of poor prognosis or recurrent germ cell tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Gemcitabine; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy | 2005 |
Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Male; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Salvage Therapy; Testicular Neoplasms; Vinblastine | 2005 |
[Chemotherapy for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2005 |
Perspectives on salvage therapy for non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Gemcitabine plus paclitaxel in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate | 2005 |
Erlotinib in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2005 |
[Successful removal of T4 lung cancer with left atrial invasion after induction chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cardiac Surgical Procedures; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Heart Atria; Heart Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pneumonectomy | 2005 |
[Molecular targeted therapy--non-small-cell lung cancer and gefitinib].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel; Quinazolines; Survival Rate | 2005 |
What is the best schedule for administration of gemcitabine-taxane?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Remission Induction; Taxoids; Trastuzumab | 2005 |
Role of Gemcitabine in Breast Cancer Management: An Update.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Paclitaxel; Receptor, ErbB-2 | 2006 |
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2006 |
[Progress in therapy for testicular tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lymph Node Excision; Male; Paclitaxel; Taxoids; Testicular Neoplasms | 2006 |
Optimizing adjuvant chemotherapy in early-stage breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2005 |
Identification and treatment of aggressive thyroid cancers. Part 1: subtypes.
Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Paclitaxel; Prognosis; Risk Assessment; Risk Factors; Thyroid Neoplasms | 2006 |
Management of platinum-sensitive recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2006 |
Optimizing gemcitabine regimens in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Decision Trees; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2006 |
The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2006 |
Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Immunohistochemistry; Mastectomy; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2006 |
Overview of gemcitabine activity in advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids | 2006 |
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2006 |
Gemcitabine and taxanes in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2006 |
Non-platinum combination of gemcitabine in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Taxoids; Vinblastine; Vinorelbine | 2006 |
State-of-the-art management of metastatic disease at initial presentation or recurrence.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Taxoids; Urinary Bladder Neoplasms | 2006 |
The role of angiogenesis inhibition in the treatment of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Multicenter Studies as Topic; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 2007 |
[Non-cisplatin based chemotherapy in advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Factors | 2007 |
Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur | 2007 |
Gemcitabine in the management of metastatic breast cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2008 |
[Modern chemotherapy of invasive bladder cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Lymphatic Metastasis; Methotrexate; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2007 |
[Optimal chemotherapy for advanced and recurrent breast cancer patients].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Diphosphonates; Docetaxel; Female; Fluorouracil; Humans; Informed Consent; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Patient Care Team; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Silicates; Taxoids; Titanium; Trastuzumab | 2007 |
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
[Updates on gemcitabine on metastatic breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Trastuzumab; Vinblastine; Vinorelbine | 2007 |
[Gemcitabine and radiotherapy in non-small cell lung cancer: dolce vita at last!].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Remission Induction | 2007 |
[Chemotherapy in lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate | 2007 |
Preclinical investigations with epothilones in breast cancer models.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Epothilones; Female; Fluorouracil; Humans; Mice; Mice, Nude; Microtubules; Paclitaxel; Tubulin Modulators | 2008 |
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Time Factors; Trastuzumab | 2008 |
Analysis of dermatologic events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines; Skin Diseases; Treatment Outcome | 2009 |
Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Urologic Neoplasms; Urothelium | 2008 |
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Fatigue; Feasibility Studies; Female; Fluorouracil; Gastrointestinal Diseases; Germany; Hematologic Diseases; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2008 |
Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overview.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2009 |
Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Consensus Development Conferences as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lapatinib; Paclitaxel; Publication Bias; Publishing; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Technology Assessment, Biomedical; Time; Trastuzumab | 2008 |
[Progress in chemotherapy for advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Fluorouracil; Gefitinib; Humans; Irinotecan; Methotrexate; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Quinazolines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Trastuzumab | 2009 |
[Treatment possibilities in breast cancer progressing after anthracyclines and/or taxanes].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Doxorubicin; Epothilones; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2010 |
Targeting Notch signaling pathway to overcome drug resistance for cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; MicroRNAs; Neoplasms; Paclitaxel; Receptors, Notch; Signal Transduction; Tamoxifen; Taxoids; Trastuzumab | 2010 |
Gemcitabine plus paclitaxel versus carboplatin plus either gemcitabine or paclitaxel in advanced non-small-cell lung cancer: a literature-based meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2010 |
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cetuximab; Cisplatin; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Signal Transduction; Survival Analysis; Translocation, Genetic | 2010 |
[Metastatic non-small cell lung cancer: Systemic treatment of patients aged 70 and over].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Gemcitabine; Humans; Long-Term Care; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Palliative Care; Prognosis; Vinblastine; Vinorelbine | 2011 |
[Combination chemotherapy of paclitaxel, carboplatin and gemcitabine in patients who have received prior cisplatin-based chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Salvage Therapy; Urologic Neoplasms; Urothelium | 2011 |
Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Paclitaxel; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms; Vinblastine | 2011 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines | 2011 |
Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids | 2011 |
[Role of gemcitabine in treatment of metastatic breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Molecular Targeted Therapy; Paclitaxel; Trastuzumab; Treatment Outcome | 2011 |
Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Kidney; Kidney Function Tests; Neoplasm Invasiveness; Paclitaxel; Randomized Controlled Trials as Topic; Urologic Neoplasms; Urothelium | 2012 |
Pharmacokinetic evaluation of gemcitabine hydrochloride for the treatment of cervical cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Topotecan; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2011 |
Systemic management strategies for metastatic soft tissue sarcoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dioxoles; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Lysine; Paclitaxel; Randomized Controlled Trials as Topic; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2011 |
Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Paclitaxel; Randomized Controlled Trials as Topic | 2011 |
Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Middle Aged; Paclitaxel; Taxoids | 2012 |
First-line chemotherapy in epithelial ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Topotecan; Vascular Endothelial Growth Factor A | 2012 |
A rational approach to the management of recurrent or persistent ovarian carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Decision Making; Deoxycytidine; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovary; Paclitaxel; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic | 2012 |
[A case of malignant peritoneal mesothelioma successfully treated with systemic chemothrapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Paclitaxel; Pemetrexed; Peritoneal Neoplasms | 2012 |
Sorafenib in locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sorafenib; Taxoids; Triazoles | 2012 |
Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Odds Ratio; Paclitaxel; Platinum Compounds; Publication Bias; Research Report; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
New insights and emerging therapies for breast cancer brain metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Paclitaxel; Peptides; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Radiotherapy; Receptor, ErbB-2; Trastuzumab | 2012 |
[Thermo-chemotherapy of GP or TP for advanced non-small cell lung cancer: a systematic review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Hyperthermia, Induced; Lung Neoplasms; Paclitaxel; Safety; Taxoids | 2012 |
Trimodality treatment in the conservative management of infiltrating bladder cancer: a critical review of the literature.
Topics: Antineoplastic Agents; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Quality of Life; Radiation-Sensitizing Agents; Urinary Bladder; Urinary Bladder Neoplasms | 2013 |
Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Humans; Mitomycin; Paclitaxel; Taxoids; Thiotepa; Treatment Failure; Urinary Bladder Neoplasms | 2013 |
First-line treatment for advanced pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Signal Transduction; Treatment Outcome; Tumor Microenvironment | 2014 |
Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer.
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Chemoradiotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Survival; Treatment Outcome | 2013 |
Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2013 |
[Contemporary trends of the adjutant chemotherapy in non-small cell lung cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Evidence-Based Medicine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Prognosis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Consistent efficacy and safety of gemcitabine-paclitaxel in patients with metastatic breast cancer: a retrospective comparison of East Asian and global studies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Asia, Western; Breast Neoplasms; China; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic | 2014 |
Liposomal chemotherapeutics.
Topics: Breast Neoplasms; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Female; Gemcitabine; Humans; Liposomes; Multiple Myeloma; Paclitaxel; Pancreatic Neoplasms; Thyroid Neoplasms | 2013 |
[Current status and future directions of chemotherapy for pancreatic cancer].
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Tegafur | 2013 |
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Equilibrative Nucleoside Transporter 1; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2014 |
Treatment of metastatic pancreatic adenocarcinoma: a review.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2014 |
Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Product Surveillance, Postmarketing; Survival Rate; Treatment Outcome | 2014 |
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Deoxycytidine; Docetaxel; Enzyme Induction; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Nicotine; Paclitaxel; Polycyclic Aromatic Hydrocarbons; Quinazolines; Smoking; Taxoids | 2014 |
Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mass Screening; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Topotecan; Uterine Cervical Neoplasms | 2014 |
Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Fluorouracil; Gemcitabine; Humans; Hyaluronic Acid; Mast Cells; Paclitaxel; Pancreatic Neoplasms; Stromal Cells; Treatment Outcome; Tumor Microenvironment | 2014 |
The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Neutropenia; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome | 2015 |
Combined therapy for gastrointestinal carcinomas: exploiting synergies between gene therapy and classical chemo-radiotherapy.
Topics: Antineoplastic Agents; Carcinoma; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Gastrointestinal Neoplasms; Gemcitabine; Genetic Therapy; Humans; Immunotherapy; Paclitaxel | 2015 |
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Gemcitabine; Health Care Costs; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tetrahydroisoquinolines; Topotecan; Trabectedin; Treatment Outcome; United Kingdom | 2015 |
Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Biliary Tract Neoplasms; Bortezomib; Camptothecin; Curcumin; Deoxycytidine; Ditiocarb; Drug Resistance, Neoplasm; Gemcitabine; Guanidines; Humans; Irinotecan; Molecular Targeted Therapy; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Pregnenediones; Treatment Outcome | 2015 |
Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cyclophosphamide; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Killer Cells, Natural; Neoplasms; Paclitaxel; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Escape; Tumor Microenvironment | 2015 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
[Adjuvant treatment for esophagogastric junction cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Digestive System Surgical Procedures; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Europe; Fluorouracil; Humans; Lymph Node Excision; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Taxoids; Tegafur | 2015 |
Maintenance therapy in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2015 |
[Pancreatic adenocarcinoma: 10 years of progress].
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Paclitaxel; Pancreatic Neoplasms; Precancerous Conditions | 2015 |
Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Publication Bias; Randomized Controlled Trials as Topic; Smoking; Treatment Outcome; Young Adult | 2015 |
[CURRENT STATE OF ADJUVANT TREATMENT FOR GASTRIC CANCER AFTER RADICAL SURGERY WITH EXTENDED LYMPH NODE DISSECTION].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Leucovorin; Lymph Node Excision; Multicenter Studies as Topic; Oxaloacetates; Oxonic Acid; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2015 |
Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Factors; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Pyrimidines; Salvage Therapy; Sulfonamides; Urinary Bladder Neoplasms; Vinblastine | 2016 |
[Latest advances in pancreatic tumours].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Contrast Media; Deoxycytidine; Diagnosis, Differential; Disease Progression; Early Detection of Cancer; Elasticity Imaging Techniques; Endosonography; Gemcitabine; Humans; Paclitaxel; Pancreatectomy; Pancreatic Cyst; Pancreatic Neoplasms; Pancreatitis, Alcoholic; Prognosis; Risk | 2015 |
Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Evidence-Based Medicine; Expert Testimony; Gemcitabine; Germany; Humans; Hyperbilirubinemia; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2015 |
The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polypharmacy; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Withholding Treatment; Young Adult | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Fluorouracil; Gemcitabine; Genes, p16; Humans; Irinotecan; Leucovorin; Neoplasms, Cystic, Mucinous, and Serous; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Smad4 Protein; Tumor Suppressor Protein p53 | 2016 |
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Discovery; Gemcitabine; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2016 |
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms | 2017 |
Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nanoparticles; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms | 2016 |
Platinum-refractory germ cell tumors: an update on current treatment options and developments.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Salvage Therapy; Testicular Neoplasms | 2017 |
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2016 |
Surgical treatment of recurrent urachal carcinoma with liver metastasis: a case report and literature review.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Hepatectomy; Humans; Hysterectomy; Liver Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Neoplasms; Salvage Therapy; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2016 |
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2016 |
Combination of metformin with chemotherapeutic drugs via different molecular mechanisms.
Topics: Androgen Antagonists; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Estrogen Receptor Modulators; Fluorouracil; Gemcitabine; Humans; Metformin; Methotrexate; Neoplasms; Paclitaxel; Tubulin Modulators | 2017 |
Surgical strategies and novel therapies for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arteries; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Digestive System Surgical Procedures; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Veins | 2017 |
A case of a patient with granulocyte-colony stimulating factor-producing pancreatic cancer who responded to nab-paclitaxel plus gemcitabine.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatal Outcome; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Paclitaxel; Pancreatic Neoplasms | 2017 |
Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Neoplasm Staging; Osteonectin; Paclitaxel; Pancreas; Pancreatic Neoplasms; Permeability; Treatment Outcome | 2017 |
Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?
Topics: Albumins; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronic Acid; Osteonectin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pyridines; Stromal Cells; Survival Analysis; Treatment Outcome | 2018 |
The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis.
Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Platinum | 2017 |
[A Case of Pathological Complete Response Following Neoadjuvant Chemotherapy with Gemcitabine plus Nab-Paclitaxel in Borderline Resectable Pancreatic Cancer].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms | 2017 |
Chemotherapy and radiotherapy for advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Models, Economic; Nanoparticles; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Technology Assessment, Biomedical | 2018 |
Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hypoxia; Immunotherapy; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2018 |
Scleroderma-like cutaneous lesions during treatment with paclitaxel and gemcitabine in a patient with pancreatic adenocarcinoma. Review of literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Eruptions; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Scleroderma, Localized | 2018 |
Management and supportive treatment of frail patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Frail Elderly; Frailty; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2019 |
Harnessing the Immune System in Pancreatic Cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Irinotecan; Leucovorin; Microsatellite Instability; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2018 |
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Liver Neoplasms; Methotrexate; Nivolumab; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 2019 |
Different Chemotherapy Regimens in the Management of Advanced or Metastatic Urothelial Cancer: a Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Blood Platelet Disorders; Cisplatin; Databases, Factual; Deoxycytidine; Disease-Free Survival; Doxorubicin; Gemcitabine; Humans; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Urologic Neoplasms | 2018 |
Selecting chemotherapy for pancreatic cancer: Far away or so close?
Topics: Albumins; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Margins of Excision; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2019 |
Neoadjuvant Treatment for Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms | 2019 |
[New progress in the treatment of locally advance pancreatic cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Rapid Improvement in Gemcitabine-associated Thrombotic Microangiopathy After a Single Dose of Eculizumab: Case Report and Review of the Literature.
Topics: Adult; Albumins; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Complement Inactivating Agents; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Thrombotic Microangiopathies | 2020 |
Contemporary management of pancreas cancer in older people.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Enhanced Recovery After Surgery; Fluorouracil; Gemcitabine; Geriatric Assessment; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2021 |
Treatment landscape of metastatic pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease Management; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Precision Medicine | 2021 |
Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase II as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
Paraspinal radiation recall myositis after gemcitabine for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Myositis; Paclitaxel; Pancreatic Neoplasms | 2021 |
Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Publication Bias; Treatment Outcome | 2021 |
Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Ethnicity; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Loss of adipose tissue or skeletal muscle during first-line gemcitabine/nab-paclitaxel therapy is associated with worse survival after second-line therapy of advanced pancreatic cancer.
Topics: Adipose Tissue; Albumins; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Cachexia; Deoxycytidine; Gemcitabine; Humans; Muscle, Skeletal; Paclitaxel; Pancreatic Neoplasms | 2022 |
Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Comparative Effectiveness Research; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Pyridines; Survival Rate; Tegafur; Treatment Outcome | 2022 |
Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Procedures; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2022 |
Efficacy and safety of neoadjuvant Folfirinox and Gemcitabine plus Nab-Paclitaxel for borderline resectable and locally advanced pancreatic cancer: a systematic review and meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2022 |
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
Liposomal nanostructures for Gemcitabine and Paclitaxel delivery in pancreatic cancer.
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Liposomes; Nanostructures; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Humans; Oncologists; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2023 |
550 trial(s) available for paclitaxel and deoxycytidine
| Article | Year |
|---|---|
Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Treatment Outcome | 1996 |
Phase I studies of gemcitabine combined with carboplatin or paclitaxel.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel; Ribonucleotide Reductases | 1997 |
Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Salvage Therapy; Survival Analysis | 1997 |
Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1997 |
Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Immunosuppression Therapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 1997 |
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel | 1998 |
Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis | 1998 |
Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Paclitaxel; Survival Analysis; Taxoids | 1999 |
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Survival Analysis | 1999 |
Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids | 1999 |
Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 1999 |
Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Greece; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate | 1999 |
Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Dyspnea; Fatal Outcome; Gemcitabine; Humans; Lung; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Severity of Illness Index; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 1999 |
Is there any impact of new drugs on the outcome of advanced NSCLC? An overview of the Southern Italy Cooperative Oncology Group trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 1999 |
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bilirubin; Capecitabine; Cohort Studies; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia | 1999 |
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Gemcitabine; Humans; In Vitro Techniques; Infusions, Intravenous; Leukocytes, Mononuclear; Linear Models; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel; Statistics, Nonparametric | 1999 |
Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Vomiting | 1999 |
Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Time Factors | 1999 |
Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome | 2000 |
A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Severity of Illness Index; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 1999 |
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
Topics: Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Male; Middle Aged; Nausea; Paclitaxel; Remission Induction; Urologic Neoplasms; Vomiting | 2000 |
A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel | 2000 |
Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Preliminary results. Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2000 |
Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis | 2000 |
The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Tomography, Emission-Computed | 2000 |
Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction | 2000 |
A sensitive docetaxel assay in plasma by solid-phase extraction and high performance liquid chromatography-UV detection: validation and suitability in phase I clinical trial pharmacokinetics.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Calibration; Chromatography, High Pressure Liquid; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Methotrexate; Paclitaxel; Reproducibility of Results; Solvents; Spectrophotometry, Ultraviolet; Taxoids | 1999 |
Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Failure; Vinblastine; Vinorelbine | 2000 |
A phase I trial of docetaxel and gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biotransformation; Capecitabine; Carboxylic Ester Hydrolases; Deamination; Deoxycytidine; Dexamethasone; Docetaxel; Drug Administration Schedule; Female; Fever; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Liver; Male; Maximum Tolerated Dose; Methylprednisolone; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Paronychia; Prodrugs; Remission Induction; Taxoids; Treatment Outcome | 2000 |
Exploring sequenced chemotherapy regimens in the treatment of transitional cell carcinoma of the urothelial tract.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Methotrexate; Paclitaxel; Treatment Outcome; Urologic Neoplasms; Vinblastine | 2000 |
Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Patient Compliance; Survival Rate; Taxoids | 2000 |
Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Deoxycytidine; Diarrhea; Esophageal Neoplasms; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Paresthesia; Urinary Bladder Neoplasms; Vomiting | 2000 |
Gemcitabine, paclitaxel, and carboplatin for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Platelet Count | 2000 |
Interim analysis of a phase III trial. Triple- vs double-agent chemotherapy for advanced non-small-cell lung cancer. Southern Italy Cooperative Oncology Group.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Compliance; Proportional Hazards Models; Research Design; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Interim results of a phase III trial. Paclitaxel/carboplatin vs paclitaxel/gemcitabine in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia | 2000 |
[A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Australia; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Europe; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Failure; United States | 2000 |
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose Fractionation, Radiation; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Survival Analysis; Urologic Neoplasms | 2000 |
Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2000 |
A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia | 2000 |
Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia | 2000 |
Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Allowable Concentration; Middle Aged; Paclitaxel; Pneumonia | 2000 |
Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome; Vomiting | 2000 |
Phase I-II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB-IV non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 2000 |
Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fever; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome | 2000 |
Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recurrence; Topotecan; Treatment Outcome | 2001 |
Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2001 |
Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Taxoids; Treatment Outcome | 2001 |
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Paclitaxel; Survival Analysis; Thiotepa; Treatment Outcome | 2001 |
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Gemcitabine and paclitaxel as salvage therapy in metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Treatment Outcome | 2001 |
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Trastuzumab | 2001 |
The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel | 2001 |
Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Heart; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Thrombocytopenia | 2001 |
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2001 |
Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Patient Compliance; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2001 |
Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2001 |
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2001 |
Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy | 2001 |
Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Survival Rate; Urinary Bladder Neoplasms; Urothelium | 2001 |
A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel | 2001 |
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Treatment Outcome | 2001 |
Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2001 |
Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2001 |
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Tissue Distribution; Treatment Outcome | 2001 |
Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Taxoids | 2001 |
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Selection; Prognosis; Risk Factors; Severity of Illness Index; Survival Analysis; Taxoids | 2001 |
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Failure | 2001 |
Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fever; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Platinum; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2001 |
Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome; Vinblastine | 2001 |
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2002 |
A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids | 2002 |
Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; World Health Organization | 2002 |
A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2002 |
Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Paclitaxel | 2001 |
Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Time Factors | 2002 |
Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 2002 |
Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Survival Rate; Treatment Outcome | 2002 |
Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Monitoring; Female; Follow-Up Studies; Gemcitabine; Heart; Humans; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome | 2000 |
Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Germinoma; Humans; Infusions, Intravenous; Male; Ovarian Neoplasms; Paclitaxel; Seminoma; Testicular Neoplasms; Treatment Outcome; United States | 2002 |
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2002 |
Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Fatigue; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Nausea; Nervous System Diseases; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Thymidine Phosphorylase | 2002 |
Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leiomyosarcoma; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome; Uterine Neoplasms | 2002 |
Long-term follow-up of patients treated with paclitaxel/carboplatin-based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research Network.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Survival Rate | 2002 |
Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Treatment Outcome | 2002 |
A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Chromatography, High Pressure Liquid; Deoxycytidine; Docetaxel; Drug Interactions; Female; Gemcitabine; Half-Life; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2002 |
Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2002 |
Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Docetaxel; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Survival Analysis; Taxoids | 2002 |
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Greece; Health Care Costs; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Retrospective Studies; Survival Rate | 2002 |
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2002 |
Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome | 2002 |
A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pneumonia; Thrombocytopenia; Treatment Outcome | 2002 |
Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost Control; Deoxycytidine; Disease Progression; Docetaxel; Drug Costs; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Survival Analysis; Vinblastine; Vinorelbine | 2002 |
Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Paclitaxel; Quality of Life; Salvage Therapy; Survival Analysis; Taxoids | 2002 |
Phase I trial of gemcitabine, administered as a standard and constant dose-rate infusion, in combination with paclitaxel in patients with advanced solid tumors (LOA-2).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Urologic Neoplasms | 2002 |
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Paclitaxel; Taxoids; Tomography, Spiral Computed; Treatment Outcome | 2002 |
Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Risk Assessment; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Phase I study of gemcitabine (GEM) and docetaxel (TXT) combination chemotherapy for unresectable non-small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids | 2002 |
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2003 |
A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Cytoprotection; Deoxycytidine; Esophagitis; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiation Injuries; Radiation-Protective Agents | 2002 |
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Darbepoetin alfa; Deoxycytidine; Docetaxel; Erythropoietin; Fatigue; Female; Gemcitabine; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 2003 |
Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cell Survival; Cohort Studies; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Urothelium | 2003 |
Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Prospective Studies; Thrombocytopenia; Treatment Outcome | 2003 |
Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Salvage Therapy | 2003 |
Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids | 2003 |
Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC): a dose-optimizing phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2003 |
[Metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Germany; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Patient Selection | 2003 |
Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Staging; Paclitaxel | 2003 |
Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Urologic Neoplasms; Urothelium | 2003 |
Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Budgets; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Neoplasm Metastasis; Ontario; Paclitaxel; Population Surveillance; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine; Women's Health | 2003 |
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclooxygenase 2; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Isoenzymes; Lung Neoplasms; Male; Membrane Proteins; Microtubule Proteins; Middle Aged; Paclitaxel; Phosphoproteins; Predictive Value of Tests; Prostaglandin-Endoperoxide Synthases; Randomized Controlled Trials as Topic; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Stathmin; Survival Rate; Transcription, Genetic; Tubulin; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2003 |
Gemcitabine, Paclitaxel, and piritrexim: a phase I study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Folic Acid Antagonists; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines | 2003 |
Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Mullerian Ducts; Ovarian Neoplasms; Paclitaxel; Taxoids | 2003 |
Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 2003 |
A phase I study of gemcitabine and docetaxel for advanced stage solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Patient Selection; Taxoids | 2003 |
Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Liposomes; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Topotecan | 2003 |
Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel | 2003 |
Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Europe; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2003 |
A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2003 |
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Stomatitis; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Doxorubicin, paclitaxel and gemcitabine: a Phase I study of a new sequential treatment in stage III B - IV breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Maximum Tolerated Dose; Middle Aged; Paclitaxel | 2003 |
Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2003 |
Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Urologic Neoplasms | 2004 |
Taxol plus gemcitabine and vinorelbine given every other week in advanced chemo-naïve non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2004 |
Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies | 2004 |
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA, Neoplasm; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Genes, erbB-2; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Predictive Value of Tests; Prognosis; Treatment Outcome | 2004 |
Gemcitabine/paclitaxel as first-line treatment of advanced breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Confidence Intervals; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Patient Selection; Survival Rate; Treatment Outcome; World Health Organization | 2003 |
Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Patient Selection; Salvage Therapy; Survival Analysis; Trastuzumab; Treatment Outcome; World Health Organization | 2003 |
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Trastuzumab; Treatment Outcome | 2003 |
Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure | 2004 |
Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer.
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Transplantation, Autologous | 2004 |
Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel | 2004 |
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2004 |
Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome | 2004 |
Gemcitabine and vinorelbine as second-line therapy for non-small cell lung cancer after treatment with paclitaxel plus platinum.
Topics: Adult; Aftercare; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Platinum; Survival Rate; Vinblastine; Vinorelbine | 2004 |
A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lung; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2004 |
A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Statistics, Nonparametric; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2004 |
Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy | 2004 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Radiometry; Time Factors; Treatment Outcome | 2004 |
Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase I trial of bi-weekly paclitaxel and gemcitabine as second-line therapy for patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel | 2004 |
Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects | 2004 |
Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Nails; Paclitaxel; Skin; Switzerland; Treatment Outcome | 2004 |
Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Treatment Outcome | 2004 |
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Greece; Humans; Middle Aged; Neutropenia; Paclitaxel; Trastuzumab; Treatment Outcome | 2004 |
Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel | 2005 |
A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Floxuridine; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Radiotherapy Dosage | 2004 |
Alternating weekly administration of paclitaxel and gemcitabine: a phase II study in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 2005 |
Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Germinoma; Humans; Male; Mediastinal Neoplasms; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Survival Analysis; Testicular Neoplasms | 2004 |
Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neutropenia; Paclitaxel; Severity of Illness Index; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2005 |
Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. A single institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Paclitaxel; Time Factors; Urinary Bladder Neoplasms; Urothelium | 2005 |
A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel | 2005 |
A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Survival Analysis; Treatment Outcome | 2005 |
Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia; Urinary Bladder Neoplasms; Urothelium | 2005 |
Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase I
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Taxoids | 2005 |
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Paclitaxel; Radiotherapy Dosage | 2005 |
A nonplatinum combination in metastatic transitional cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Paclitaxel; Survival Analysis; Urinary Bladder Neoplasms | 2005 |
Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Gemcitabine plus cisplatine and paclitaxel (GCP) in second-line treatment of germ cell tumors (GCT): a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Germinoma; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Testicular Neoplasms; Treatment Outcome | 2005 |
Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost Control; Deoxycytidine; Gemcitabine; Health Care Costs; Health Services; Humans; Italy; Lung Neoplasms; Paclitaxel; Retrospective Studies; Vinblastine; Vinorelbine | 2005 |
A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaïve advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2005 |
Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Outpatients; Paclitaxel; Survival Rate | 2005 |
Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis | 2005 |
Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2005 |
Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a Phase II Hoosier Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Gemcitabine and paclitaxel in metastatic or recurrent squamous cell carcinoma of the head and neck: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel | 2005 |
Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel | 2006 |
Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis; Treatment Outcome | 2005 |
First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Remission Induction; Time Factors; Treatment Outcome | 2005 |
Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2005 |
Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2006 |
Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Urologic Neoplasms; Urothelium | 2006 |
Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Paclitaxel; Prognosis; Risk Factors; Survival Rate; Thrombocytopenia; Treatment Outcome | 2006 |
Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cognition; Cognition Disorders; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Longitudinal Studies; Middle Aged; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2006 |
Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Half-Life; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel | 2006 |
Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Treatment Outcome | 2006 |
Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Survival Rate | 2006 |
A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2006 |
[Carboplatin plus gemcitabine therapy versus carboplatin plus weekly paclitaxel therapy for advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia | 2006 |
Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pleural Effusion; Survival Analysis; Treatment Outcome | 2006 |
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Greece; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Patient Compliance; Polyethylene Glycols; Survival Analysis; Treatment Outcome | 2006 |
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2006 |
Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Failure | 2006 |
Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Salvage Therapy; Survival Rate | 2006 |
Stimulation of erythrocyte phosphatidylserine exposure by paclitaxel.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Calcium; Carboplatin; Cell Size; Ceramides; Deoxycytidine; Endometrial Neoplasms; Erythrocytes; Female; Gemcitabine; Hematocrit; Humans; Mice; Mice, Inbred C57BL; Osmotic Pressure; Ovarian Neoplasms; Paclitaxel; Phosphatidylserines; Protein Binding; Sphingomyelin Phosphodiesterase; Time Factors | 2006 |
Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Treatment Outcome | 2006 |
[A randomized comparative trial of three combined regimens containing cisplatin for treatment of advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Paclitaxel; Prospective Studies; Remission Induction; Survival Rate; Vinblastine; Vinorelbine | 2006 |
A phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Multiple Myeloma; Paclitaxel; Recurrence; Time Factors; Treatment Outcome | 2006 |
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2006 |
Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2007 |
Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies | 2007 |
Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative On
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Quality of Life; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2006 |
Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Rate | 2007 |
Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2007 |
Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intravenous; Italy; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Vinblastine; Vinorelbine | 2006 |
A phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Survival Analysis; Treatment Outcome | 2006 |
A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Radiotherapy Dosage | 2007 |
Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Gemcitabine; Humans; Kidney Diseases; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Survival Rate; Urinary Bladder Neoplasms | 2007 |
Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2007 |
Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Indiana; Kaplan-Meier Estimate; Male; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Testicular Neoplasms; Time Factors; Treatment Failure; Treatment Outcome | 2007 |
Intra-patient alternated dose escalation of paclitaxel and gemcitabine versus paclitaxel followed by fixed dose rate infusion of gemcitabine in fit elderly non-small cell lung cancer patients. A Southern Italy Cooperative Oncology Group randomised phase I
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Paclitaxel; Survival Analysis; Survival Rate | 2007 |
A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Survival Rate | 2007 |
Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2006 |
Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Taxoids | 2007 |
A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2007 |
Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Ribonucleotide Reductases; Severity of Illness Index; Survival Rate | 2006 |
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Failure | 2007 |
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Trastuzumab; Urinary Bladder Neoplasms | 2007 |
A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Polyethylene Glycols; Survival Rate | 2007 |
Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2007 |
Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2008 |
Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel | 2008 |
Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Rate | 2008 |
Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 2007 |
Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 2008 |
Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cimetidine; Deoxycytidine; Dexamethasone; Diphenhydramine; Female; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Ondansetron; Paclitaxel; Premedication; Proportional Hazards Models | 2008 |
Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Paclitaxel; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2007 |
Feasibility and efficacy of chemotherapy with gemcitabine mono and with paclitaxel/mitoxantron in gynaecological cancers.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Middle Aged; Mitoxantrone; Paclitaxel; Palliative Care; Survival Analysis | 2007 |
A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2007 |
Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Feasibility Studies; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Testicular Neoplasms; Thrombocytopenia; Treatment Outcome | 2008 |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel | 2008 |
A phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weekly paclitaxel in elderly patients with advanced non-small cell lung cancer (NSCLC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel | 2008 |
Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome | 2008 |
Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Comorbidity; Deoxycytidine; Female; Gemcitabine; HIV Infections; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Organ Transplantation; Paclitaxel | 2008 |
A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2008 |
Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nanoparticles; Paclitaxel; Survival Rate; Treatment Outcome | 2008 |
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab | 2009 |
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Placebos; Prognosis; Radiography; Radiotherapy Dosage; Radiotherapy, Conformal; Remission Induction; Survival Rate; Thoracic Neoplasms | 2008 |
Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Cross-Over Studies; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Taxoids | 2009 |
Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polyglutamic Acid; Survival Rate | 2008 |
[Randomized phase II study of carboplatin/paclitaxel followed by gemcitabine versus carboplatin/gemcitabine followed by docetaxel in patients with advanced nonsmall cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2008 |
Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Patient Compliance | 2008 |
tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Heart; Heart Function Tests; Humans; Liver; Liver Function Tests; Lung; Paclitaxel; Prospective Studies; Respiratory Function Tests; Survival Rate | 2008 |
Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel | 2008 |
Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2009 |
Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Skin Diseases | 2008 |
Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Greece; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quality-Adjusted Life Years; Survival Rate; Taxoids | 2009 |
Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Urinary Bladder Neoplasms | 2008 |
A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia; Treatment Outcome | 2009 |
[A phase I study of combination therapy with capecitabine and paclitaxel for patients with inoperable breast cancer or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2008 |
Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Smoking; Taxoids; Vinblastine; Vinorelbine | 2008 |
Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Proportional Hazards Models; Prospective Studies; Vinblastine; Vinorelbine | 2009 |
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2009 |
RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 2009 |
Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Survival Rate; Treatment Failure; Treatment Outcome | 2009 |
A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisplatin
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quality of Life; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2009 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2009 |
Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Preoperative Care; Probability; Respiratory Function Tests; Risk Assessment; Survival Analysis | 2009 |
Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Eruptions; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Survival Rate; Thrombocytopenia; Urinary Bladder Neoplasms | 2009 |
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Topotecan | 2009 |
Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Paclitaxel | 2010 |
A landmark point analysis with cytotoxic agents for advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Prognosis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2009 |
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Urinary Bladder Neoplasms | 2009 |
Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Urinary Bladder Neoplasms | 2009 |
A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Fever; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2009 |
Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pemetrexed; Peripheral Nervous System Diseases; Survival Analysis | 2010 |
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2009 |
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Quality of Life; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine; Young Adult | 2009 |
Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2009 |
Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Carcinoma, Medullary; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Thyroid Neoplasms | 2010 |
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Catheter Ablation; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Paclitaxel; Radiosurgery; Radiotherapy, Adjuvant; Salvage Therapy; Time Factors; Treatment Outcome; Young Adult | 2009 |
Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2010 |
Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2010 |
Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Risk Factors; Taxoids; Treatment Outcome; Young Adult | 2009 |
The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2010 |
A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis | 2010 |
First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2010 |
ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Young Adult | 2010 |
Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Risk Factors; Treatment Outcome | 2010 |
High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Ribonucleoside Diphosphate Reductase; Survival; Time Factors; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2011 |
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Breast Neoplasms, Male; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Florida; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2010 |
A Comparison of white and African American outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; White People | 2010 |
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Paclitaxel; Phenotype; Receptor, ErbB-2 | 2011 |
Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ascites; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Quality of Life; Retrospective Studies; Treatment Failure; Treatment Outcome | 2010 |
A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Polyethylene Glycols; Recombinant Proteins | 2010 |
Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dyspnea; Emotions; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Quality of Life; Regression Analysis; Sleep Initiation and Maintenance Disorders; Social Behavior; Surveys and Questionnaires; Sweden; Time Factors; Treatment Outcome; Young Adult | 2010 |
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Middle Aged; Paclitaxel; Prognosis; Urinary Bladder Neoplasms | 2011 |
Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Risk Factors; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2010 |
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Prospective Studies; Quality of Life; Time Factors; Treatment Outcome; Young Adult | 2010 |
Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2010 |
Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Greece; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Vinblastine; Vinorelbine | 2011 |
A phase II study of gemcitabine plus paclitaxel in patients with metastatic breast cancer and prior anthracycline treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome | 2010 |
A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Endostatins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Recombinant Proteins; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Paclitaxel; Polymorphism, Genetic; Risk Factors; Survival Rate; Treatment Outcome | 2011 |
A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Survival Rate; Treatment Outcome | 2011 |
[Clinical efficacy and adverse effects of taxol plus carboplatin or gemcitabine plus carboplatin in patients with advanced non-small-cell lung carcinoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2010 |
Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Survival Rate; Treatment Outcome | 2011 |
Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: a phase III study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Young Adult | 2012 |
Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gamma Rays; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Radiography, Thoracic; Radiotherapy Dosage; Standard of Care; Survival Rate; Treatment Outcome | 2011 |
Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infections; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Health Status; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Young Adult | 2012 |
First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Hypertension; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2012 |
Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2011 |
Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Grou
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung; Lung Neoplasms; Male; Middle Aged; Organs at Risk; Paclitaxel; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal | 2011 |
Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome; Young Adult | 2011 |
Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome | 2011 |
A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Rate; Treatment Outcome | 2011 |
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Leukopenia; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Neutropenia; Paclitaxel; Receptors, Estrogen; Treatment Outcome | 2012 |
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 2011 |
Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Decision Support Techniques; Deoxycytidine; Female; Gemcitabine; Germany; Hemoglobins; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Patient Selection; Regression Analysis; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium; Vinblastine | 2011 |
Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Self-Assessment; Surveys and Questionnaires; Taxoids; Vinblastine; Vinorelbine | 2011 |
Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 2011 |
Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cations; Deoxycytidine; Disease Progression; Dosage Forms; Female; Gemcitabine; Humans; Liposomes; Male; Middle Aged; Models, Biological; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2012 |
Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Paclitaxel; Survival Analysis; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2011 |
Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monothe
Topics: Adaptation, Psychological; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Data Collection; Deoxycytidine; Female; Gemcitabine; Health Status Indicators; Humans; Internationality; Middle Aged; Paclitaxel; Pain Measurement; Psychometrics; Quality of Life; Stress, Psychological; Treatment Outcome | 2012 |
A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2012 |
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mice; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Retreatment; Treatment Outcome | 2011 |
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Induction Chemotherapy; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult | 2011 |
A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2 | 2012 |
Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemistry, Pharmaceutical; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Micelles; Middle Aged; Organoplatinum Compounds; Paclitaxel; Polyethylene Glycols; Polymers; Prognosis; Urologic Neoplasms | 2012 |
Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Logistic Models; Mastectomy; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Receptor, ErbB-2; Republic of Korea; Risk Assessment; Risk Factors; Time Factors; Trastuzumab; Treatment Outcome | 2012 |
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Recurrence; Treatment Outcome | 2012 |
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Polymorphism, Genetic; Topotecan; Young Adult | 2012 |
Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Young Adult | 2012 |
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2012 |
[A randomized controlled trial of the efficacy of combination of gemcitabine and carboplatin or paclitaxel and combination of paclitaxel and carboplatin in the treatment for advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Rate; Thrombocytopenia | 2011 |
Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Thailand; Treatment Outcome | 2012 |
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Hemorrhage; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Urologic Neoplasms; Urothelium | 2012 |
An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Calcium-Calmodulin-Dependent Protein Kinases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytoskeleton; Death-Associated Protein Kinases; Deoxycytidine; Disease-Free Survival; DNA Methylation; ErbB Receptors; Female; Gemcitabine; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2012 |
Gemcitabine and paclitaxel combination as second-line chemotherapy in patients with small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Neutropenia; Paclitaxel; Small Cell Lung Carcinoma | 2013 |
Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Extracellular Signal-Regulated MAP Kinases; Female; Gemcitabine; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Polymorphism, Single Nucleotide; Receptors, Estrogen; Survivin | 2012 |
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Receptor, ErbB-2 | 2012 |
Intermittent chemotherapy is a treatment choice for advanced urothelial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Prospective Studies; Quality of Life; Serum Albumin; Survival Rate; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium | 2012 |
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Urinary Bladder Neoplasms | 2013 |
Cisplatin-based therapy for the treatment of elderly patients with non-small-cell lung cancer: a retrospective analysis of a single institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2012 |
A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytokines; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Survival Rate; Treatment Outcome | 2012 |
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Taxoids; Treatment Outcome | 2012 |
Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2013 |
Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Radiation-Sensitizing Agents; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins; Vinblastine; Vinorelbine; Young Adult | 2013 |
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2012 |
Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neutropenia; Paclitaxel; Polyglutamic Acid; Proportional Hazards Models; Treatment Outcome | 2014 |
Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung can
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2013 |
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2 | 2013 |
The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Treatment Outcome | 2013 |
Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Sample Size; Survival Analysis | 2013 |
A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel | 2013 |
Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemistry, Pharmaceutical; China; Cisplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Kaplan-Meier Estimate; Liposomes; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Paclitaxel; Prospective Studies; Research Design; Time Factors; Treatment Outcome | 2013 |
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2013 |
Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2013 |
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Medical Futility; Middle Aged; Neoplasm Metastasis; Paclitaxel; Patient Compliance; Taxoids; Treatment Outcome | 2013 |
Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Republic of Korea; Treatment Outcome; Watchful Waiting | 2013 |
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate | 2013 |
Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Squamous Cell; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Paclitaxel; Thrombocytopenia; Urinary Bladder Neoplasms | 2013 |
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate | 2013 |
A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Paclitaxel; Perioperative Care; Preoperative Care; Quality of Life; Treatment Outcome; Vomiting | 2013 |
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Paclitaxel; Quality of Life; Treatment Outcome | 2013 |
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Diphosphonates; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Germany; Humans; Ibandronic Acid; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Young Adult | 2013 |
Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Survival Rate; Trastuzumab | 2014 |
A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation Injuries; Radiotherapy, Conformal; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Pancreatic Neoplasms | 2013 |
Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes.
Topics: Adult; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Retrospective Studies; Salvage Therapy; Survival; Treatment Outcome | 2014 |
Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2014 |
Bi-weekly paclitaxel and capecitabine as a second- or third-line treatment for advanced breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Salvage Therapy; Survival Rate | 2013 |
Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy; Thorax | 2014 |
Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Demography; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome; Urologic Neoplasms; Urothelium | 2014 |
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden; United Kingdom | 2014 |
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Membrane Transport Proteins; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polymorphism, Genetic; Prognosis; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
[ATP-tumor chemosensitivity assay directed chemotherapy in patients with cervical cancer].
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Uterine Cervical Neoplasms; Vincristine | 2013 |
The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Paclitaxel; Prospective Studies; Stomach Neoplasms; Survival Analysis | 2014 |
A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Platinum; Pyrimidines; Stomach Neoplasms | 2013 |
[Efficacy of albumin-bound paclitaxel in advanced gastric cancer patients].
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Middle Aged; Paclitaxel; Remission Induction; Stomach Neoplasms; Trastuzumab | 2014 |
Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2014 |
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Catheter-Related Infections; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Fatigue; Feasibility Studies; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2014 |
A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; E-Selectin; Female; Fibroblast Growth Factor 2; Gemcitabine; Humans; Intercellular Adhesion Molecule-1; Lung Neoplasms; Male; Neuropilins; Paclitaxel; Placenta Growth Factor; Platelet Endothelial Cell Adhesion Molecule-1; Pregnancy Proteins; Prospective Studies; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triple Negative Breast Neoplasms; Young Adult | 2014 |
A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liposomes; Lung Neoplasms; Male; Middle Aged; Nanoparticles; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Survival Rate; Young Adult | 2014 |
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Broadly Neutralizing Antibodies; Carboplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Polyethylene Glycols; Taxoids | 2015 |
Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2014 |
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult | 2014 |
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Paclitaxel; Prognosis; Receptor, Angiotensin, Type 1; Receptor, ErbB-2; Survival Rate; Translational Research, Biomedical | 2015 |
A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Prospective Studies; Treatment Outcome; Young Adult | 2014 |
Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intralesional; Kaplan-Meier Estimate; Liposomes; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel | 2015 |
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis | 2015 |
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; International Cooperation; Kaplan-Meier Estimate; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Paclitaxel; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2015 |
Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Damage; Gemcitabine; Humans; Mice; Nitroimidazoles; Paclitaxel; Phosphoramide Mustards; Xenograft Model Antitumor Assays | 2015 |
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Patient Compliance; Quality of Life; Radiation-Sensitizing Agents | 2015 |
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Neoplasm Metastasis; Paclitaxel; Quality of Life; Treatment Outcome | 2015 |
SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Mice, Knockout; Neoplasm Metastasis; Osteonectin; Paclitaxel; Pancreatic Neoplasms; Stromal Cells; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Paclitaxel; Pain Measurement; Phenylurea Compounds; Quality of Life; Sorafenib; Urinary Bladder Neoplasms | 2015 |
A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Clinical Protocols; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Translational Research, Biomedical | 2015 |
Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT).
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2016 |
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Research Design; Survival Analysis; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Consolidation Chemotherapy; Cystectomy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Sparing Treatments; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Remission Induction; Salvage Therapy; Urinary Bladder Neoplasms | 2016 |
Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kidney; Male; Middle Aged; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Renal Insufficiency; Urologic Neoplasms | 2016 |
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Topics: Aged; Anemia; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cancer Vaccines; Carboplatin; Carcinoma, Non-Small-Cell Lung; CD56 Antigen; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Fatigue; Female; Gemcitabine; Humans; Immunotherapy; Lectins, C-Type; Lung Neoplasms; Lymphocyte Activation; Lymphocytes; Male; Membrane Glycoproteins; Middle Aged; Mucin-1; Neutropenia; Paclitaxel; Pemetrexed; Predictive Value of Tests; Receptors, IgG | 2016 |
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Treatment Outcome | 2016 |
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Biomarkers, Pharmacological; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2016 |
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quality of Life; Survival Rate; Taxoids | 2016 |
A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2016 |
A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomiz
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Drugs, Chinese Herbal; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Proportional Hazards Models; Quality of Life; Research Design; Taxoids; Time Factors; Treatment Outcome | 2016 |
Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pain; Pain Measurement; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Quality of Life; Treatment Outcome | 2016 |
nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Canada; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan | 2016 |
A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2016 |
Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Decision Making; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Surveys and Questionnaires; Time Factors; Vinblastine; Vinorelbine | 2016 |
Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Parenteral; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2016 |
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2016 |
Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2016 |
Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Paclitaxel; Pemetrexed; Taxoids | 2016 |
Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT).
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retreatment; Survival Analysis; Treatment Outcome | 2016 |
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Austria; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality of Life; Topotecan | 2016 |
Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Retrospective Studies | 2017 |
Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer.
Topics: Aged; Albumins; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2017 |
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Albumins; Anorexia; Antineoplastic Agents; Body Image; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cancer Pain; Deoxycytidine; Docetaxel; Dyspnea; Epothilones; Fatigue; Female; Furans; Gemcitabine; Health Status; Heterocyclic Compounds, 4 or More Rings; Humans; Ketones; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Paclitaxel; Polyethylene Glycols; Quality of Life; Reproductive Health; Sleep Initiation and Maintenance Disorders; Taxoids; Vinblastine; Vinorelbine; Vomiting | 2017 |
Thyroid V40 Predicts Primary Hypothyroidism After Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Hypothyroidism; Incidence; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Pituitary Gland; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Regression Analysis; Thyroid Gland; Time Factors | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multicenter Phase II Trial (NAC-GA Trial).
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Young Adult | 2017 |
Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Lipids; Nanoparticles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 2017 |
The Safety and Efficacy of an Alcohol-Free Pancreatic Cyst Ablation Protocol.
Topics: Ablation Techniques; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Ethanol; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Pancreatic Cyst; Pancreatic Neoplasms; Pennsylvania; Postoperative Complications; Prospective Studies; Risk Factors; Therapeutic Irrigation; Time Factors; Treatment Outcome | 2017 |
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Tetrahydroisoquinolines; Time Factors; Topotecan; Trabectedin; Treatment Outcome | 2017 |
A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; HSP27 Heat-Shock Proteins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oligonucleotides, Antisense; Paclitaxel; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2017 |
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Furans; Gemcitabine; Humans; Kaplan-Meier Estimate; Ketones; Middle Aged; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Prospective Studies; Receptor, ErbB-2; Republic of Korea; Time Factors; Treatment Outcome; Young Adult | 2017 |
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2018 |
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Enoxaparin; Female; Fibrinolytic Agents; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Thromboembolism; Time Factors | 2018 |
HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Recombinant Proteins; Tumor Microenvironment | 2018 |
PEGPH20 for metastatic pancreatic ductal adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Hyaluronoglucosaminidase; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; San Francisco; Survival Rate; Treatment Outcome | 2018 |
Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cachexia; Camptothecin; Combined Modality Therapy; Deoxycytidine; Dietary Supplements; Drug Combinations; Fatty Acids, Omega-3; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nutritional Support; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur | 2018 |
Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Prospective Studies; Survival Rate; Time-to-Treatment; Treatment Failure | 2018 |
FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2018 |
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Paclitaxel; Progression-Free Survival; Triple Negative Breast Neoplasms | 2018 |
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphocyte Count; Lymphocytes; Middle Aged; Neoplasm Metastasis; Neutrophils; Paclitaxel; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms | 2018 |
Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Germ-Line Mutation; Humans; Kaplan-Meier Estimate; Models, Biological; Paclitaxel; Patient Selection; Progression-Free Survival; Prospective Studies; Risk Assessment; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Australia; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2018 |
A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients (GrantPax).
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Geriatric Assessment; Humans; Paclitaxel; Pancreatic Neoplasms | 2018 |
Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407).
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2018 |
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Janus Kinase 1; Janus Kinase 2; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Pyrimidines; Tissue Distribution | 2019 |
Phase I Trial Evaluating the Safety of Preoperative Gemcitabine/nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Febrile Neutropenia; Female; Gemcitabine; Humans; Infections; Male; Middle Aged; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Preoperative Period | 2018 |
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Time Factors; Young Adult | 2018 |
Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2018 |
Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nitriles; Paclitaxel; Pancreatic Neoplasms; Phenylthiohydantoin; Prognosis; Survival Rate; Tissue Distribution | 2019 |
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Fluorouracil; Gemcitabine; Germany; Humans; Irinotecan; Leucovorin; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Young Adult | 2018 |
The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2019 |
A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Quality of Life; Survival Rate | 2019 |
CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine.
Topics: Administration, Oral; Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Multicenter Studies as Topic; Naphthoquinones; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Randomized Controlled Trials as Topic; Young Adult | 2019 |
Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiosurgery; Survival Rate; Tegafur; Young Adult | 2019 |
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2019 |
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Hydroxychloroquine; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2019 |
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Can
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Ketones; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Receptor, ErbB-2; Republic of Korea; Surveys and Questionnaires | 2019 |
A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method.
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Repositioning; Gemcitabine; Humans; Maximum Tolerated Dose; Paclitaxel; Pancreas; Pancreatic Neoplasms; Patient Selection; Research Design; Response Evaluation Criteria in Solid Tumors; Tretinoin | 2019 |
Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Pancreatic Cancer.
Topics: Acute Disease; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Pancreatitis; Tomography, X-Ray Computed | 2019 |
A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prospective Studies; Treatment Outcome | 2019 |
Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomiz
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Quality of Life; Treatment Outcome | 2019 |
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Wnt Signaling Pathway | 2020 |
A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Deoxycytidine; Disease Management; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Pancreatic Neoplasms; Prognosis; Receptor, Notch2; Receptor, Notch3; Treatment Outcome | 2019 |
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Double-Blind Method; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Reported Outcome Measures; Progression-Free Survival; Receptor, ErbB-3; RNA, Messenger; Topotecan | 2019 |
Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Laparotomy; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Survival Rate | 2019 |
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Safety; Polyethylene Glycols; Survival Rate; Topotecan; Treatment Outcome | 2020 |
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma.
Topics: Aged; Albumins; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Pyridines; Treatment Outcome | 2020 |
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2020 |
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Progression-Free Survival; Prospective Studies; Radiofrequency Ablation; Treatment Outcome; Vinorelbine | 2020 |
Phase II Study of Second-line Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin for Advanced Urothelial Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Urologic Neoplasms | 2020 |
A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Deoxycytidine; Female; Gemcitabine; Humans; Hydroxychloroquine; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Preoperative Care; Recurrence; Survival Analysis; Treatment Outcome | 2020 |
Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 2020 |
Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial.
Topics: Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Frail Elderly; Gemcitabine; Germany; Humans; Immunotherapy; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Prospective Studies; Randomized Controlled Trials as Topic; Vinorelbine | 2020 |
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival | 2020 |
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Heparitin Sulfate; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Survival Rate | 2020 |
Relapse and Prognosis of Non-Muscle Invasive Bladder Cancer After Combined HOLRBT with Sunitinib and TGC Perfusion Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Lasers, Solid-State; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Sunitinib; Survival Rate; Urinary Bladder; Urinary Bladder Neoplasms | 2020 |
Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2020 |
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Drug Substitution; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Treatment Outcome | 2020 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunoglobulin Fc Fragments; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Receptors, G-Protein-Coupled; Recombinant Fusion Proteins; Wnt Proteins | 2020 |
Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Perioperative Care; Prospective Studies; Treatment Outcome | 2020 |
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.
Topics: Adenocarcinoma; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome; Tumor Microenvironment | 2020 |
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer.
Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreas; Pancreatic Neoplasms; Tomography, X-Ray Computed; Young Adult | 2020 |
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Confidence Intervals; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Genes, erbB-1; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Programmed Cell Death 1 Receptor; Progression-Free Survival; Treatment Outcome | 2020 |
Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study.
Topics: Adenocarcinoma; Aged; Albumins; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Progression-Free Survival; Radiation-Sensitizing Agents; Thrombocytopenia; Treatment Outcome | 2020 |
A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Tegafur | 2020 |
Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony-Stimulating Factor Response Using Model-Based In Vitro to Clinical Translation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Cells, Cultured; Deoxycytidine; Doxorubicin; Filgrastim; Gemcitabine; Humans; Incidence; Models, Biological; Myelopoiesis; Neoplasms; Neutropenia; Paclitaxel; Polyethylene Glycols; Primary Cell Culture; Risk Assessment; Treatment Outcome | 2020 |
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2020 |
Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Tegafur | 2021 |
Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Time Factors | 2021 |
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Progression-Free Survival; Survival Rate | 2021 |
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Standard of Care; Survival Analysis | 2022 |
A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Prospective Studies; Survival Rate; Treatment Outcome | 2021 |
Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Rate | 2021 |
Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome | 2021 |
Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Furans; Gemcitabine; Humans; Ketones; Nuclear Proteins; Paclitaxel; Pharmacogenomic Testing; Polymorphism, Genetic; Prospective Studies; Repressor Proteins | 2021 |
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-G
Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; GTP-Binding Proteins; Humans; Membrane Proteins; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Prospective Studies | 2021 |
Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Markov Chains; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; United States | 2021 |
Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical stu
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liposomes; Lung; Lung Neoplasms; Middle Aged; Paclitaxel; Young Adult | 2022 |
Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Contact or Invasion to Major Arteries.
Topics: Aged; Aged, 80 and over; Albumins; Arteries; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Vascular Neoplasms | 2021 |
Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan.
Topics: Adenocarcinoma; Albumins; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Japan; Markov Chains; Paclitaxel; Pancreatic Neoplasms | 2022 |
Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2021 |
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Methotrexate; Neoadjuvant Therapy; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 2021 |
Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study).
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms | 2022 |
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects.
Topics: Adenoviridae; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mesocricetus; Mice; Mice, Inbred C57BL; Oncolytic Virotherapy; Paclitaxel; Pancreatic Neoplasms; Prognosis; Stromal Cells | 2021 |
Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Biomarkers, Tumor; Cancer-Associated Fibroblasts; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Repositioning; Female; Gemcitabine; Humans; Immunoglobulins; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Stromal Cells; Tetrahydronaphthalenes; Treatment Outcome; Tumor Microenvironment; Young Adult | 2022 |
Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies | 2022 |
A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Carcinoma, Pancreatic Ductal; Deoxycytidine; Humans; Induction Chemotherapy; Paclitaxel; Pancreatic Neoplasms | 2022 |
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras) | 2022 |
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Mice; Paclitaxel; Pancreatic Neoplasms | 2022 |
Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2023 |
A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Pilot Projects; Prospective Studies; Treatment Outcome | 2023 |
A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms | 2023 |
A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic | 2023 |
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial).
Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Clinical Trials, Phase II as Topic; Deoxycytidine; Humans; Middle Aged; Paclitaxel; Prospective Studies; Young Adult | 2023 |
844 other study(ies) available for paclitaxel and deoxycytidine
| Article | Year |
|---|---|
Ovarian cancer--new insights into systemic therapy.
Topics: Antimetabolites, Antineoplastic; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel | 1995 |
Docetaxel and gemcitabine released for cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Approval; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids; United States; United States Food and Drug Administration | 1996 |
In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Glutathione; Humans; Lung Neoplasms; Neoplasm Proteins; Paclitaxel; Taxoids; Topotecan; Tumor Cells, Cultured | 1997 |
Recent advances in managing non-small-cell lung cancer: 4. Chemotherapy of metastatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Taxoids; Topoisomerase I Inhibitors | 1997 |
New drugs for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vincristine | 1997 |
Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Tumor Cells, Cultured | 1998 |
Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Docetaxel; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Induction; Female; Fluorouracil; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Taxoids; Thymidine Phosphorylase; Transplantation, Heterologous; Tumor Necrosis Factor-alpha; Up-Regulation | 1998 |
[New cytostatics in the therapy of non-small cell bronchial carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1998 |
Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Deoxycytidine; Drug Resistance; Gemcitabine; Humans; Multiple Myeloma; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Gemcitabine; Humans; Male; Paclitaxel; Prostatic Neoplasms; Sarcoma; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 1998 |
Cancer treatment in Sweden--costs of drugs, inpatient and outpatient care from 1985 to 1996 and cost effectiveness of new drugs.
Topics: Ambulatory Care; Androgen Antagonists; Antineoplastic Agents; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Filgrastim; Gemcitabine; Gonadotropin-Releasing Hormone; Granulocyte Colony-Stimulating Factor; Humans; Neoplasms; Paclitaxel; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Recombinant Proteins; Sweden | 1998 |
Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Interactions; Female; Flow Cytometry; Gemcitabine; Humans; Paclitaxel; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Choroid Neoplasms; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Melanoma; Paclitaxel; Tumor Stem Cell Assay | 1999 |
The Gynecologic Oncology Group experience in ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Decision Making; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 1999 |
Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin.
Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; DNA Repair; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Paclitaxel; Topotecan; Tumor Cells, Cultured | 1999 |
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |
Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.
Topics: 3T3 Cells; Adenocarcinoma; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Division; Cisplatin; Deoxycytidine; Enzyme Inhibitors; Farnesyltranstransferase; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Structure; Oligopeptides; Paclitaxel; rap1 GTP-Binding Proteins; ras Proteins; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Docetaxel; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1999 |
A brief historical review of the development of chemotherapy for the treatment of advanced non-small cell lung cancer: why we should look beyond platinum.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy; Gemcitabine; History, 20th Century; Humans; Irinotecan; Lung Neoplasms; Medical Oncology; Paclitaxel; Vinblastine; Vinorelbine | 1999 |
Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Caspase 8; Caspase 9; Caspases; Cisplatin; Deoxycytidine; Fas Ligand Protein; fas Receptor; Flow Cytometry; Gemcitabine; Genes, p53; Humans; Lung Neoplasms; Membrane Glycoproteins; Paclitaxel; Recombinant Proteins; Signal Transduction; Topotecan; Transfection; Tumor Cells, Cultured | 2000 |
Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Doxorubicin; Ellipticines; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Pleural Neoplasms; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2000 |
Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hospitalization; Humans; Incidence; Liver; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy Dosage; Retrospective Studies; Stents | 2000 |
In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Transformed; Cell Survival; Comet Assay; Deoxycytidine; DNA Damage; Docetaxel; Epithelial Cells; Gemcitabine; Humans; Irinotecan; Mesothelioma; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2000 |
In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Etoposide; Fluorouracil; Gemcitabine; Humans; Mitomycin; Models, Chemical; Paclitaxel; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2000 |
Schedule dependent toxicity and efficacy of combined gemcitabine/paclitaxel treatment in mouse adenocarcinoma.
Topics: Adenocarcinoma; Analysis of Variance; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Mammary Neoplasms, Experimental; Mice; Mice, Inbred Strains; Paclitaxel; Statistics, Nonparametric | 2000 |
Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Biotransformation; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cell Survival; Deoxycytidine; DNA, Neoplasm; Gemcitabine; Humans; Kinetics; Lung Neoplasms; Mice; Paclitaxel; RNA, Neoplasm; Tumor Cells, Cultured | 2000 |
[A case of docetaxel-resistant lung cancer effectively treated with chemotherapy of gemcitabine and vinorelbine].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support.
Topics: Adrenal Cortex Hormones; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Liver Neoplasms; Lymphatic Metastasis; Paclitaxel; Pulmonary Edema; Radiography; Taxoids | 2000 |
The role of laparoscopy in second-look evaluations for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intraperitoneal; Injections, Intravenous; Laparoscopy; Middle Aged; Mitoxantrone; Ovarian Neoplasms; Paclitaxel; Reoperation; Retrospective Studies | 2001 |
Derivation and initial characterization of a mouse mammary tumor cell line carrying the polyomavirus middle T antigen: utility in the development of novel cancer therapeutics.
Topics: Adenoviridae; Alkyl and Aryl Transferases; Animals; Antigens, Polyomavirus Transforming; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blotting, Western; Bridged-Ring Compounds; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Farnesyltranstransferase; Female; Gemcitabine; Gene Transfer Techniques; Genes, p53; Mammary Neoplasms, Animal; Mice; Mice, Transgenic; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Phosphoric Monoester Hydrolases; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sequence Analysis, DNA; Taxoids; Time Factors; Transduction, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2000 |
[Refractory non-small-cell lung cancer responding to combination chemotherapy with docetaxel, gemcitabine and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2001 |
Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Models, Animal; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Floxuridine; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Paclitaxel; Taxoids; Thymidine Phosphorylase; Tumor Cells, Cultured; Up-Regulation; Xenograft Model Antitumor Assays | 2001 |
Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Survival Rate; Urinary Bladder Neoplasms | 2001 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
Intestinal permeability in patients with chemotherapy-induced stomatitis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Digestive System Neoplasms; Doxorubicin; Drug Evaluation; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Intestinal Absorption; Intestinal Mucosa; Lactulose; Leucovorin; Male; Mannitol; Middle Aged; Paclitaxel; Permeability; Stomatitis; Tegafur; Treatment Outcome; Xylose | 2001 |
Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Survival Rate; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2001 |
Evaluating new treatments for advanced cancer.
Topics: Antineoplastic Agents; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Neoadjuvant chemotherapy with docetaxel in non--small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Taxoids | 2001 |
Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Death; Cell Line; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Immunohistochemistry; Mutation; Paclitaxel; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms | 2001 |
Bladder tumor markers, intravesical therapy and systemic chemotherapy.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Biomarkers, Tumor; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2001 |
Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Base Pair Mismatch; Breast Neoplasms; Carrier Proteins; Colorectal Neoplasms; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Enzyme Inhibitors; Epirubicin; Female; Gemcitabine; Humans; Intercalating Agents; Mitoxantrone; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Endodermal Sinus Tumor; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Thalidomide | 2001 |
[Concomitant radiochemotherapy for non-small-cell lung cancer: towards an ideal strategy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Immunologic Factors; Lung Neoplasms; Mitomycin; Neoplasm Metastasis; Paclitaxel; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2001 |
Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Drug Screening Assays, Antitumor; Epirubicin; Female; Gemcitabine; Humans; Paclitaxel; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2001 |
Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Genes, p53; Genes, Retinoblastoma; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2001 |
Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2001 |
Chemotherapy for non-small-cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Taxoids | 2001 |
From the Food and Drug Administration.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Diethylhexyl Phthalate; Docetaxel; Female; Financing, Government; Fluorouracil; Heart Failure; Humans; Male; Orphan Drug Production; Pacemaker, Artificial; Paclitaxel; Spermatogenesis; Taxoids; Testis; United States; United States Food and Drug Administration | 2001 |
Combination chemotherapy of the taxanes and antimetabolites: its use and limitations.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Methotrexate; Paclitaxel | 2001 |
Biological basis for chemo-radiotherapy interactions.
Topics: Antineoplastic Agents; Apoptosis; Cell Transformation, Neoplastic; Cisplatin; Combined Modality Therapy; Deoxycytidine; DNA Adducts; DNA Repair; Docetaxel; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Paclitaxel; Radiotherapy; Taxoids | 2002 |
Clinical experience of capecitabine in metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Failure | 2002 |
Future treatment options with capecitabine in solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Forecasting; Humans; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Taxoids | 2002 |
Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cisplatin; Deoxycytidine; Diffusion; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Mammary Neoplasms, Experimental; Membranes, Artificial; Mice; Neoplasm Staging; Paclitaxel; Polytetrafluoroethylene; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Monitoring; Epirubicin; Female; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Humans; Liver Neoplasms; Lung Neoplasms; Paclitaxel; Predictive Value of Tests; Radiopharmaceuticals; Remission Induction; Soft Tissue Neoplasms; Survival Analysis; Time Factors; Tomography, Emission-Computed; Treatment Outcome | 2000 |
[Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
[An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Osteosarcoma; Paclitaxel; Spinal Cord Neoplasms; Survivors; Taxoids; Vincristine; Vindesine | 2002 |
Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Docetaxel; Gels; Gemcitabine; Half-Life; Humans; Liposomes; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Phospholipids; Sarcoma; Taxoids; Tissue Distribution; Transplantation, Heterologous; Urinary Bladder Neoplasms; Vindesine | 2002 |
Durable control of small cell carcinoma of the urinary bladder by gemcitabine and paclitaxel.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Urinary Bladder Neoplasms | 2002 |
Evaluation of a gemcitabine-doxorubicin-paclitaxel combination schedule through flow cytometry assessment of apoptosis extent induced in human breast cancer cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Division; Cell Survival; Clinical Trials as Topic; Dactinomycin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Flow Cytometry; Gemcitabine; Humans; Paclitaxel; Time Factors; Tumor Cells, Cultured | 2002 |
Salvage chemotherapy with the gemcitabine/docetaxel combination in non-small cell lung cancer: an overview of recent phase II studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids | 2002 |
Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Outcome Assessment, Health Care; Paclitaxel; Practice Guidelines as Topic; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vinorelbine; World Health Organization | 2002 |
Fixed erythrodysaesthesia plaque due to gemcitabine and epirubicin treatment.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Eruptions; Epirubicin; Erythema; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Paresthesia; Skin; Taxoids | 2002 |
Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Flow Cytometry; Gemcitabine; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2002 |
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma. Carboplatin and gemcitabine followed by paclitaxel.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2002 |
[Ureteroplasty using the appendix: apropos of a case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendix; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Laparotomy; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrostomy, Percutaneous; Paclitaxel; Prostatectomy; Retroperitoneal Space; Transplantation, Autologous; Transplantation, Heterotopic; Ureter; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2002 |
Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiation Tolerance; Tumor Cells, Cultured | 2002 |
Treatment of advanced non-small-cell lung cancer with two-drug combinations.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Patient Selection | 2002 |
Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Endothelium, Vascular; ErbB Receptors; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Pyrimidines; Pyrroles; Signal Transduction; Tumor Cells, Cultured | 2002 |
An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy.
Topics: 3T3 Cells; Animals; Carboplatin; Cytokines; Deoxycytidine; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Fibroblast Growth Factor 2; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Neoplasms; Paclitaxel; Transforming Growth Factor beta; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Improved survival in advanced breast cancer with docetaxel and capecitabine in combination: biological synergy or an artefact of trial design?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Cytotoxicity of combinations of IFN-beta and chemotherapeutic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Division; Cisplatin; Deoxycytidine; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Interferon-beta; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
Chemoradiation protocols offer only incremental gains for pancreatic cancer patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Feasibility Studies; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2002 |
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Mitomycins; Multicenter Studies as Topic; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Radiotherapy; Remission Induction; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2002 |
Early detection and successful treatment of drug-induced pneumonitis with corticosteroids.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Glucocorticoids; Humans; Lung Neoplasms; Male; Paclitaxel; Pneumonia; Prednisone; Radiography, Thoracic; Tomography, X-Ray Computed; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Combined platinum containing treatment in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Prognosis | 2002 |
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.
Topics: Antineoplastic Agents; Bone Marrow; Camptothecin; Deoxycytidine; Docetaxel; Etoposide; Humans; Irinotecan; Leukocytes; Models, Biological; Neutrophils; Paclitaxel; Taxoids; Vinblastine | 2002 |
Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma, B-Cell; Paclitaxel; Rituximab; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2002 |
[New data presented at ASCO 2002 concerning non-small cell bronchial cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Therapeutic strategies in advanced non-small cell bronchial cancers: platin-based combinations].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Patient Selection; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Two cases of complete response to combination chemotherapy of gemcitabine and docetaxel for recurrent ovarian cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pelvic Neoplasms; Taxoids | 2003 |
In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Survival; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Stomach Neoplasms; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2003 |
Timing is everything, or could be.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2003 |
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Daunorubicin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Idarubicin; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids; Thiotepa; Time Factors; Transplantation Conditioning; Treatment Outcome | 2003 |
[Preclinical studies of concomitant chemoradiation].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Child; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Radiation Tolerance; Time Factors; Topotecan; Transplantation, Heterologous | 2003 |
Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; DNA, Neoplasm; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; HeLa Cells; Humans; In Vitro Techniques; Mice; Mice, Nude; Middle Aged; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Nucleosomes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Papillomaviridae; Papillomavirus Infections; Prognosis; Rats; Rats, Wistar; Tumor Virus Infections; Uterine Cervical Neoplasms | 2003 |
Effect of metal-based anticancer drugs on wild type and metallothionein null cell lines.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cadmium Chloride; Carboplatin; Cell Division; Cell Line; Chlorides; Cisplatin; Copper Sulfate; Deoxycytidine; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Ferrous Compounds; Fibroblasts; Gemcitabine; Inhibitory Concentration 50; Metallothionein; Metals, Heavy; Mice; Mice, Knockout; Paclitaxel; Spectrophotometry, Atomic; Survival Analysis; Survival Rate; Vinblastine; Zinc Compounds | 2003 |
Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia.
Topics: Animals; Antineoplastic Agents; Camptothecin; Deoxycytidine; Drug Screening Assays, Antitumor; Fibrosarcoma; Gemcitabine; Hyperthermia, Induced; Irinotecan; Melphalan; Mice; Mice, Inbred C3H; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2003 |
NICE recommends new treatment for breast and bowel cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Practice Guidelines as Topic; Taxoids; Tegafur; Uracil | 2003 |
Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neurologic Examination; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 2003 |
A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Rate; Thrombocytopenia; Topotecan; Treatment Failure | 2003 |
Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines.
Topics: Antigens, Neoplasm; Blotting, Northern; Calcium-Binding Proteins; Cell Cycle Proteins; Cell Line, Tumor; Chromosomes, Human, X; Cluster Analysis; Deoxycytidine; DNA Primers; DNA, Complementary; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunotherapy; Male; Multigene Family; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Oligonucleotides; Paclitaxel; Phenotype; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Testis; Time Factors; Transfection | 2003 |
Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Division; Cell Line; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Drug Screening Assays, Antitumor; Fenretinide; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Mesothelioma; Paclitaxel; Taxoids; Topotecan | 2003 |
Large cell neuroendocrine carcinoma of the urinary bladder with lymphoepithelioma-like features.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2003 |
Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven Stage IIIA(N2) nonsmall cell lung carcinoma: a Phase II multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2003 |
Combination chemotherapy with topotecan for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2003 |
Effects of intraperitoneal administration of gemcitabine and paclitaxel on hepatic regeneration in rats.
Topics: Animals; Biopsy, Needle; Deoxycytidine; Disease Models, Animal; Gemcitabine; Hepatectomy; Immunohistochemistry; Injections, Intraperitoneal; Liver; Liver Function Tests; Liver Regeneration; Male; Paclitaxel; Rats; Rats, Inbred Strains; Sensitivity and Specificity | 2003 |
[Chemotherapy of bladder cancer. Systemic therapy with reduced toxicity].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Clinical Trials as Topic; Deoxycytidine; Feasibility Studies; Gemcitabine; Humans; Neoplasm Staging; Paclitaxel; Palliative Care; Urinary Bladder Neoplasms | 2003 |
[Non-platinum induction chemotherapy for stage III non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2003 |
Highlights from the 10th World Conference on Lung Cancer. Vancouver, British Columbia, Canada, August 10-14, 2003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Taxoids | 2003 |
[New: gemzar plus taxan in metastatic breast carcinoma. Optimal combination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2003 |
Recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure | 2004 |
Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Northern; Cell Line, Tumor; Clusterin; Coloring Agents; Deoxycytidine; DNA; DNA Fragmentation; Dose-Response Relationship, Drug; Gemcitabine; Glycoproteins; Humans; Immunohistochemistry; In Vitro Techniques; Lung Neoplasms; Mice; Molecular Chaperones; Nucleotides; Oligonucleotide Array Sequence Analysis; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Double-Stranded; RNA, Small Interfering; Tetrazolium Salts; Thiazoles; Time Factors | 2004 |
Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer.
Topics: Adolescent; Adult; Aged; Deoxycytidine; Drug Costs; Drug Resistance, Neoplasm; Female; Gemcitabine; Health Care Costs; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Topotecan | 2004 |
Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Genes, bcl-2; Humans; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Phospholipid Ethers; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction | 2004 |
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; DNA, Neoplasm; Docetaxel; Doxorubicin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Floxuridine; Gemcitabine; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins; Receptor, ErbB-2; Taxoids; Transplantation, Heterologous; Trastuzumab; Tumor Stem Cell Assay; Up-Regulation; Vinblastine; Vinorelbine | 2004 |
[Bronchiolitis obliterans organizing pneumonia induced by chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bronchoalveolar Lavage; Cryptogenic Organizing Pneumonia; Deoxycytidine; Female; Gemcitabine; Glucocorticoids; Humans; Lung Neoplasms; Paclitaxel; Treatment Outcome | 2004 |
Non-allergic nature of docetaxel-induced acute hypersensitivity reactions.
Topics: Administration, Oral; Adult; Blood Pressure; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Hypersensitivity; Female; Gemcitabine; Histamine; Histamine Antagonists; Humans; Hypersensitivity, Immediate; Infusions, Intravenous; Male; Methylprednisolone; Middle Aged; Paclitaxel; Premedication; Serine Endopeptidases; Tachycardia; Taxoids; Time Factors; Tryptases | 2004 |
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Paclitaxel; Prognosis; Receptor, ErbB-2; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Treatment Outcome | 2004 |
[Synergistic effects of paclitaxel and gemcitabine on androgen-independent prostate cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms | 2004 |
[The synergistic effects of paclitaxel and gemcitabine on prostate cancer cell line PC-3].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Male; Paclitaxel; Prostatic Neoplasms | 2004 |
Treatment of advanced non-small-cell lung cancer in special populations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Humans; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Staging; Neutropenia; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Cell Line, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Topotecan; Xenograft Model Antitumor Assays | 2005 |
[A new therapy standard in metastatic breast cancer--gemzar/paclitaxel. Longer survival by optimized combination therapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate | 2004 |
Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Marrow Cells; Caspase 3; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Cisplatin; Clinical Trials as Topic; Cytochromes c; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Enzyme Activation; Farnesyltranstransferase; Flow Cytometry; Fluorouracil; G2 Phase; Gemcitabine; Homozygote; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Mice; Mice, SCID; Mitosis; Multiple Myeloma; Paclitaxel; Quinolones; Taxoids; Tetrazolium Salts; Thiazoles | 2005 |
Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Approval; Drug Combinations; France; Humans; Infusions, Intravenous; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vindesine | 2005 |
Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspase 7; Caspases; Cell Cycle; Chlorambucil; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Activation; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Leukemia, Myeloid; Mitoxantrone; Paclitaxel; U937 Cells; Vidarabine | 2005 |
["Second line" polychemotherapy in metastatic urothelial cancer of the renal pelvis. Persisting partial remission by 18 treatment cycles of gemcitabine/paclitaxel after 24 treatment cycles gemcitabine/cisplatin "stable disease"].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Retroperitoneal Neoplasms; Tomography, X-Ray Computed | 2005 |
Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs.
Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Cell Line, Tumor; Cell Survival; Cisplatin; Codon; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gemcitabine; Genes, Tumor Suppressor; Humans; Mutation, Missense; Nuclear Proteins; Paclitaxel; Plasmids; Polymorphism, Genetic; Transfection; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vinblastine | 2005 |
The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Thymidylate Synthase | 2005 |
Chemotherapy for non-small cell lung cancer in elderly patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Deoxycytidine; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Thyroid Neoplasms; Topotecan; Vinblastine; Vinorelbine | 2005 |
[Cut-off level of docetaxel, paclitaxel and gemcitabine in histoculture drug response assay for non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2005 |
[Application of adenosine triphosphate tumor chemosensitive assay system to individual chemotherapy for hepatocellular carcinoma].
Topics: Adenosine Triphosphate; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Postoperative Period; Remission Induction; Sensitivity and Specificity; Survival Rate | 2005 |
Albumin-bound nanoparticle paclitaxel.
Topics: Albumin-Bound Paclitaxel; Albumins; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Nanostructures; Nanotechnology; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Polyethylene Glycols; Prodrugs | 2005 |
Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Complementary Therapies; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Genistein; Glucuronides; Humans; Isoflavones; Middle Aged; Ovarian Neoplasms; Paclitaxel; Soy Milk; Topotecan | 2006 |
Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells.
Topics: Animals; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Paclitaxel; Taxoids; Xenograft Model Antitumor Assays | 2005 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Irinotecan; Male; Mandibular Diseases; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Osteoradionecrosis; Paclitaxel; Prognosis; Radiotherapy Dosage; Treatment Failure; Treatment Outcome | 2006 |
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; BRCA2 Protein; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Chlorambucil; Cisplatin; Cross-Linking Reagents; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Fanconi Anemia Complementation Group C Protein; Fanconi Anemia Complementation Group G Protein; Fanconi Anemia Complementation Group Proteins; Female; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Melphalan; Mice; Mice, Nude; Mitomycin; Mutation; Paclitaxel; Pancreatic Neoplasms; Time Factors; Vinblastine; Xenograft Model Antitumor Assays | 2005 |
Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Prognosis; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Survival Analysis; Survival Rate | 2005 |
Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost of Illness; Deoxycytidine; Gemcitabine; Hospitalization; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Prospective Studies | 2005 |
North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caveolin 1; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel | 2005 |
Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Treatment Outcome | 2006 |
Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; DNA Mutational Analysis; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Survival Analysis; Survival Rate; Treatment Outcome | 2005 |
[A paclitaxel-resistant case of recurrent breast cancer responded to combination therapy of capecitabine and trastuzumab].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lung; Lymphatic Metastasis; Lymphatic System; Neoplasm Recurrence, Local; Paclitaxel; Trastuzumab | 2005 |
Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carboplatin; Carcinoma; Caspase 2; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Interactions; Enzyme Activation; Female; Gemcitabine; Humans; Isoflavones; Mice; Ovarian Neoplasms; Paclitaxel; Proteasome Endopeptidase Complex; Transplantation, Heterologous | 2006 |
Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Drug Synergism; Female; Fibrosarcoma; Gemcitabine; Lymphoma; Mice; Neoplasm Transplantation; Neoplasms; Paclitaxel; Tumor Necrosis Factor-alpha | 2006 |
Response to paclitaxel, gemcitabine, and cisplatin in renal medullary carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Medullary; Cisplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Kidney Medulla; Kidney Neoplasms; Male; Paclitaxel | 2006 |
Aggressive multimodality treatment in transitional cell carcinoma of the parafallopian tube: report of 2 cases and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel | 2006 |
Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; HCT116 Cells; Hedgehog Proteins; Humans; Paclitaxel; Pancreatic Neoplasms; Radiation, Ionizing; Time Factors; Veratrum Alkaloids | 2006 |
Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatin Immunoprecipitation; Cisplatin; Deoxycytidine; Dihydro-beta-Erythroidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Nicotine; Paclitaxel; Promoter Regions, Genetic; Receptors, Nicotinic; Retinoblastoma Protein; Survivin; Up-Regulation; X-Linked Inhibitor of Apoptosis Protein | 2006 |
Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; National Health Programs; Paclitaxel; Portugal; Taxoids | 2006 |
[Maintenance chemotherapy in advanced NSCLC].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Karnofsky Performance Status; Lung; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Time Factors; Vinblastine; Vinorelbine | 2006 |
High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Treatment Outcome | 2006 |
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2006 |
Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Antineoplastic Agents; Breast Neoplasms; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gemcitabine; Humans; Mammary Glands, Animal; Mice; Paclitaxel; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Cells, Cultured | 2006 |
Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gemcitabine; Genes, erbB-1; Genes, ras; Humans; Immunohistochemistry; Lung Neoplasms; Mutation; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Retrospective Studies | 2006 |
Growth inhibition and apoptosis induction in ovarian cancer cells.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Genes, p53; Humans; Ovarian Neoplasms; Paclitaxel; Tetrazolium Salts; Thiazoles; Tumor Suppressor Protein p53 | 2006 |
Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; I-kappa B Kinase; Mitosis; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2006 |
Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Tumor Cells, Cultured | 2006 |
Advanced non-small-cell lung cancer: 'triplets' better than 'doublets'?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2006 |
[Analysis of antineoplastic drugs used in Cancer Center, Sun Yat-sen University, during the period of 1996-2005].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Drug Utilization Review; Gemcitabine; Humans; Neoplasms; Paclitaxel; Rituximab; Vinblastine; Vinorelbine | 2006 |
Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cerebral Ventricle Neoplasms; Combined Modality Therapy; Consciousness Disorders; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Etoposide; Female; Gemcitabine; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Hypophysectomy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pituitary Neoplasms; Temozolomide; Thiotepa; Topotecan | 2008 |
Diverse resveratrol sensitization to apoptosis induced by anticancer drugs in sensitive and resistant leukemia cells.
Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Busulfan; Cell Cycle; Cell Line, Tumor; Cycloheximide; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Leukemia; Paclitaxel; Resveratrol; Stilbenes | 2006 |
A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Failure; Treatment Outcome | 2006 |
[A case of leiomyosarcoma of the scrotum: chemotherapy with anti-cancer agents was effective for the lung metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Genital Neoplasms, Male; Humans; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Scrotum | 2006 |
[Onycholysis with hyponychium exudate secondary to chemotherapy with paclitaxel and capecitabine].
Topics: Adult; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Astringents; Breast Neoplasms; Capecitabine; Deoxycytidine; Exudates and Transudates; Female; Fluorouracil; Hallux; Humans; Keratosis; Mupirocin; Nail Diseases; Ointments; Paclitaxel; Time Factors; Treatment Outcome; Zinc Sulfate | 2006 |
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Caveolin 1; Cisplatin; Databases as Topic; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Time Factors; Treatment Outcome; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2007 |
Data acquisition for the histoculture drug response assay in lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Probability; Retrospective Studies; Sensitivity and Specificity; Tumor Cells, Cultured | 2007 |
Prediction of drug combination chemosensitivity in human bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Paclitaxel; Predictive Value of Tests; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2007 |
Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cell
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Curcumin; Cyclooxygenase 2; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Interferon-alpha; Membrane Proteins; NF-kappa B; Paclitaxel; Poly(ADP-ribose) Polymerases; Smoking; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2006 |
Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Salvage Therapy; Statistics, Nonparametric; Survival Analysis; Taiwan; Taxoids; Treatment Outcome | 2006 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; ErbB Receptors; Female; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel.
Topics: Apoptosis; Blotting, Western; Carcinoma, Renal Cell; Caspases; Deoxycytidine; Drug Synergism; Flow Cytometry; Fluorouracil; History, Ancient; Humans; Kidney Neoplasms; Paclitaxel; Sensitivity and Specificity; Tumor Cells, Cultured; Vinblastine | 2007 |
Moving forward in advanced bladder cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; ErbB Receptors; Gemcitabine; Humans; Methotrexate; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Urinary Bladder Neoplasms; Vinblastine | 2007 |
Developmental chemotherapy and management of recurrent ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2003 |
[A case of severe hand-foot syndrome caused by capecitabine].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Paclitaxel; Paresthesia; Postoperative Period; Syndrome | 2007 |
Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Deoxycytidine; Gemcitabine; Genotype; Humans; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel; Polymorphism, Genetic; Prostate-Specific Antigen; Urogenital Neoplasms | 2007 |
[Lung cancer treatment in elderly patients].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2007 |
Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Costs; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2007 |
Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies | 2007 |
The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma; Cell Cycle; Cell Line, Tumor; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Dyes; Fluorouracil; Gemcitabine; Humans; Laryngeal Neoplasms; Multidrug Resistance-Associated Proteins; Paclitaxel; Rhodamine 123 | 2007 |
Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Electrocoagulation; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Nephrectomy; Paclitaxel; Taxoids; Ureteroscopy | 2007 |
Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute.
Topics: Albumin-Bound Paclitaxel; Albumins; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Genes, erbB-2; Humans; Paclitaxel; Retrospective Studies | 2007 |
[Non-small-cell bronchial carcinoma--induction--combined with radiochemotherapy--a more certain alternative].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2007 |
Gemcitabine plus paclitaxel may be a promising chemotherapy regimen for metastatic granular cell tumour.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Granular Cell Tumor; Humans; Male; Middle Aged; Paclitaxel; Positron-Emission Tomography | 2008 |
Comparative cytotoxicity of C-1311 in colon cancer in vitro and in vivo using the hollow fiber assay.
Topics: Aminoacridines; Animals; Antineoplastic Agents; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Fluorouracil; HT29 Cells; Humans; In Vitro Techniques; Irinotecan; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2007 |
Carbon beam therapy in recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hysterectomy; Irinotecan; Lymph Node Excision; Neoplasm Recurrence, Local; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Radiotherapy, High-Energy; Remission Induction; Salvage Therapy | 2008 |
Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Gemcitabine; Humans; Paclitaxel; Poly(ADP-ribose) Polymerases | 2008 |
Combined systemic therapy and radiotherapy for bladder cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Methotrexate; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Salvage Therapy; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2007 |
Inoperable pancreatic cancer: standard of care.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Platinum Compounds; Tomography, X-Ray Computed | 2007 |
Bevacizumab: optimal dose, schedule, and duration of therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2007 |
[Non-small cell lung neoplasms--weekly taxane combinations are possible].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Failure; Treatment Outcome | 2007 |
Predictive value of individualized tumor response testing by ATP-based chemotherapy response assay in ovarian cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Sensitivity and Specificity; Single-Blind Method; Treatment Outcome; Tumor Cells, Cultured | 2008 |
A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols | 2008 |
Highly elevated serum CA 125 in a lady with ascites and retroperitoneal mass--a diagnostic dilemma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; CA-125 Antigen; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Paclitaxel; Prednisone; Radiography, Abdominal; Retroperitoneal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2008 |
[A case of occult breast cancer successfully treated by capecitabine in combination with weekly paclitaxel followed by FEC (75)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Paclitaxel; Positron-Emission Tomography; Treatment Outcome | 2008 |
Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Taxoids | 2008 |
Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Carcinoma, Squamous Cell; Cell Survival; Cetuximab; Cisplatin; Combined Modality Therapy; Deoxycytidine; Down-Regulation; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Myeloid Cell Leukemia Sequence 1 Protein; Oligonucleotides, Antisense; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2008 |
Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Prognosis; Quality of Life; Survival Rate | 2008 |
Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids; Topotecan | 2008 |
Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cations; Cisplatin; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interferon-beta; Irinotecan; Kidney Neoplasms; Liposomes; Mice; Mice, SCID; Paclitaxel; Thymidine Phosphorylase; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2008 |
Docetaxel as second line therapy in advanced non-small cell lung cancer-the dose and combination may matter!
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Salvage Therapy; Taxoids; Treatment Outcome | 2008 |
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Proliferation; Chemokine CXCL12; Deoxycytidine; Drug Therapy, Combination; Endothelial Cells; Female; Gemcitabine; Humans; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Paclitaxel; Stem Cells; Tumor Burden; Vascular Endothelial Growth Factor A | 2008 |
Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Mastectomy; Neoplasms, Second Primary; Paclitaxel; Receptor, ErbB-2; Remission Induction; Skin Neoplasms; Survival Rate; Trastuzumab | 2008 |
Craniocervical paraganglioma with numerous pulmonary metastases--case report.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cervical Vertebrae; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Glomus Jugulare Tumor; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Paclitaxel; Paraganglioma; Treatment Outcome | 2008 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Outcome and Process Assessment, Health Care; Paclitaxel; Radiography; Retrospective Studies; Vascular Endothelial Growth Factor A | 2009 |
Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Hospitalization; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Retrospective Studies; Taxoids; Treatment Outcome | 2009 |
Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Failure | 2009 |
MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.
Topics: Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Linear Models; MicroRNAs; Ovarian Neoplasms; Paclitaxel; RNA, Messenger; Taxoids; Topotecan | 2009 |
Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Epidemiologic Methods; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Remission Induction; Salvage Therapy; Survivors; Testicular Neoplasms; Treatment Outcome | 2009 |
Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Records; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Interphase; Ligands; Mice; Mice, Inbred C57BL; Paclitaxel; Pancreatic Neoplasms; Receptors, sigma; Survival Analysis | 2009 |
Experimental study of combination therapy with S-1 against pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Doxorubicin; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Inbred BALB C; Mitomycin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur; Xenograft Model Antitumor Assays | 2009 |
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Fluorouracil; Hand; Humans; Lapatinib; Middle Aged; Onycholysis; Paclitaxel; Paresis; Peripheral Nervous System Diseases; Quinazolines; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies | 2009 |
Final overall results of a study with a novel triplet induction chemotherapy regimen (PACCAGE) followed by consolidation radiotherapy in locally advanced inoperable non-small cell lung cancer (NSCLC).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Patient Selection; Retrospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2009 |
XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Gemcitabine; Gene Frequency; Genotype; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Transcription Factors; Treatment Outcome; Vinblastine; Vinorelbine; Xeroderma Pigmentosum Group A Protein | 2009 |
Acute rhabdomyolysis as a complication of paclitaxel-gemcitabine chemotherapy for ovarian cancer.
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Rhabdomyolysis | 2009 |
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Vinblastine; Vinorelbine | 2009 |
Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Gene Expression Regulation, Enzymologic; Humans; Lung Neoplasms; Paclitaxel; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2009 |
Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Dacarbazine; Deoxycytidine; Deoxyguanosine; DNA Adducts; DNA Methylation; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Mice; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Piperidines; Pyridines; Temozolomide | 2009 |
Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Enzyme Activation; Gemcitabine; Humans; Lung Neoplasms; Mammalian orthoreovirus 3; Oncolytic Virotherapy; Paclitaxel; Poly(ADP-ribose) Polymerases; ras Proteins; Vinblastine; Virion | 2009 |
Cisplatin-Ifosfamide-gemcitabine as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and Paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Salvage Therapy | 2009 |
[Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Vomiting; Young Adult | 2009 |
[A resected case of effective treatment with S-1/gemcitabine and Paclitaxel combination chemotherapy for advanced pancreatic cancer with peritoneal and liver metastases].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Tegafur | 2009 |
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cisplatin; Cricetinae; Deoxycytidine; Drug Administration Schedule; Drug Delivery Systems; Gemcitabine; Humans; Immunohistochemistry; Lipopeptides; Liposomes; Lung Neoplasms; Male; Mice; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms | 2010 |
Effects of taxane-based chemotherapy on inhibin B and gonadotropins as biomarkers of spermatogenesis.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Deoxycytidine; Docetaxel; Fertility; Follicle Stimulating Hormone; Gemcitabine; Humans; Infertility, Male; Inhibins; Luteinizing Hormone; Male; Middle Aged; Neoplasms; Paclitaxel; Spermatogenesis; Taxoids; Testis; Ultrasonography; Young Adult | 2010 |
Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Paclitaxel; Retrospective Studies; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2009 |
A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Postoperative Care; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carboplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Modified Radical; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiodermatitis; Radiotherapy, Adjuvant; Retrospective Studies | 2010 |
Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gemcitabine; Humans; Incidence; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; SEER Program; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Ultrasonic nanotherapy of pancreatic cancer: lessons from ultrasound imaging.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Gemcitabine; Humans; Luminescent Proteins; Mice; Mice, Nude; Micelles; Microbubbles; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Recombinant Proteins; Red Fluorescent Protein; Transfection; Ultrasonography; Xenograft Model Antitumor Assays | 2010 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine | 2010 |
ABC transporter gene expression in benign and malignant ovarian tissue.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Carboplatin; Cyclophosphamide; Cystadenoma; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Multidrug Resistance-Associated Protein 2; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; ROC Curve; Up-Regulation | 2010 |
Successful use of biweekly gemcitabine plus nab-paclitaxel in two male patients with stage iv breast cancer: case reports and review of the literature.
Topics: Angiography; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mastectomy; Middle Aged; Obesity; Paclitaxel; Skin Ulcer | 2011 |
Second and third line treatment in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Paclitaxel; Pemetrexed; Taxoids | 2009 |
[Combination chemotherapy with gemcitabine and paclitaxel in a hemodialysis patient with metastatic urothelial carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Renal Dialysis; Urinary Bladder Neoplasms | 2010 |
[Current status of adjuvant chemotherapy for resected lung cancer at our institute--focus on clinical trial enrollment].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Selection; Small Cell Lung Carcinoma; Tegafur; Uracil; Vinblastine; Vinorelbine | 2010 |
Stromal depletion goes on trial in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Hedgehog Proteins; Humans; Off-Label Use; Osteonectin; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Survival Analysis; United States | 2010 |
Tubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cells.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, SCID; Microbial Sensitivity Tests; Microtubules; Molecular Chaperones; Paclitaxel; Transfection; Tubulin; Tubulin Modulators; Vinblastine; Vinorelbine | 2010 |
Establishment and characterization of multidrug-resistant gastric cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B; Calcium-Calmodulin-Dependent Protein Kinases; Camptothecin; Cell Cycle; Cell Line, Tumor; Death-Associated Protein Kinases; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms | 2010 |
A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Immunoglobulin E-mediated severe anaphylaxis to paclitaxel.
Topics: Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Asthma; Cisplatin; Deoxycytidine; Drug Hypersensitivity; Dyspnea; Epitopes; Female; Gemcitabine; Humans; Hypersensitivity, Immediate; Hypotension; Immunoglobulin E; Middle Aged; Neoplasms; Paclitaxel; Pulmonary Atelectasis; Remission Induction; Skin Tests | 2010 |
Combinatorial drug conjugation enables nanoparticle dual-drug delivery.
Topics: Cell Death; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Hydrolysis; Lipids; Magnetic Resonance Spectroscopy; Nanoparticles; Paclitaxel | 2010 |
Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Everolimus; Gemcitabine; Humans; Immunosuppressive Agents; Jurkat Cells; Lymphoma, Non-Hodgkin; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2010 |
[Primary urothelial carcinoma with sarcomatous transformation of the prostate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Sarcoma; Treatment Outcome; Urethral Neoplasms | 2010 |
Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer.
Topics: Amphiregulin; Antibodies; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; EGF Family of Proteins; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Glycoproteins; Humans; Immunoblotting; Intercellular Signaling Peptides and Proteins; Paclitaxel; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2010 |
Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC).
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost of Illness; Deoxycytidine; European Union; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel | 2010 |
Phenotyping breast cancer cell lines EM-G3, HCC1937, MCF7 and MDA-MB-231 using 2-D electrophoresis and affinity chromatography for glutathione-binding proteins.
Topics: Adult; Aged; Alcohol Oxidoreductases; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Capecitabine; Carboplatin; Case-Control Studies; Chromatography, Affinity; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Female; Fluorouracil; Glutathione S-Transferase pi; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neurophysiology; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Phenotype; Survival Rate; Treatment Outcome | 2010 |
Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Motor Neuron Disease; Neoplasm Staging; Neurophysiology; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Chemoresistance testing of human ovarian cancer cells and its in vitro model.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Gemcitabine; Humans; Models, Biological; Ovarian Neoplasms; Paclitaxel; Topotecan | 2010 |
[Digital necrosis related to gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Fingers; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Necrosis; Paclitaxel; Palliative Care | 2010 |
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Blood Platelets; Carboplatin; Cell Proliferation; Deoxycytidine; Etoposide; Female; France; Gemcitabine; Humans; Leukocyte Count; Male; Middle Aged; Models, Biological; Neutropenia; Neutrophils; Paclitaxel; Platelet Count; Prospective Studies; Risk Assessment; Risk Factors; Thrombocytopenia; Young Adult | 2010 |
Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Contrast Media; Deoxycytidine; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Medical Records; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Platinum Compounds; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Treatment Outcome | 2010 |
Sister Mary Joseph's nodule as a metastasis of ovarian adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Carboplatin; Colonoscopy; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Neprilysin; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Sister Mary Joseph's Nodule; Skin Neoplasms; Treatment Outcome; Umbilicus; Vimentin; WT1 Proteins | 2010 |
Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Epothilones; Everolimus; Female; Fluorouracil; Gemcitabine; HCT116 Cells; Humans; Mice; Mice, Nude; Paclitaxel; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2011 |
Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Renal Cell; Child; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Male; Paclitaxel; Sickle Cell Trait; Treatment Outcome | 2010 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
E phage gene transfection enhances sensitivity of lung and colon cancer cells to chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Carcinoma; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genetic Therapy; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Paclitaxel; Transfection; Viral Proteins | 2010 |
Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; China; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Paclitaxel; Pharmacogenetics; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-akt; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Introns; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Minisatellite Repeats; Neoplasm Staging; Nitric Oxide Synthase Type III; Paclitaxel; Polymorphism, Single Nucleotide; Survival Rate; Treatment Outcome | 2010 |
Additive growth inhibition after combined treatment of 2-methoxyestradiol and conventional chemotherapeutic agents in human pancreatic cancer cells.
Topics: 2-Methoxyestradiol; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cetuximab; Cisplatin; Deoxycytidine; Drug Synergism; Estradiol; Female; Flow Cytometry; Fluorescent Antibody Technique; Fluorouracil; Gemcitabine; Humans; Mice; Mice, Nude; Paclitaxel; Pancreatic Neoplasms; Tubulin Modulators | 2010 |
Cytotoxic effects of new trans-2,4-diaryl-r-3-methyl-1,2,3,4-tetrahydroquinolines and their interaction with antitumoral drugs gemcitabine and paclitaxel on cellular lines of human breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gemcitabine; Humans; Paclitaxel; Quinolines | 2011 |
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Health Care Surveys; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Vinblastine; Vinorelbine | 2011 |
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Weekly paclitaxel combining with gemcitabine is an effective and safe treatment for advanced breast cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
[Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Luminescent Measurements; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Topotecan | 2010 |
Peritoneal fibrosis leading to small bowel obstruction two years after first-line intraperitoneal chemotherapy for optimally debulked ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisplatin; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Intestinal Obstruction; Intestine, Small; Liver Neoplasms; Membrane Proteins; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Fibrosis; Treatment Outcome | 2011 |
Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice; Mice, Nude; Paclitaxel; Pancreatic Neoplasms | 2011 |
Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Biomarkers, Pharmacological; CA-19-9 Antigen; Carcinoembryonic Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Salvage Therapy | 2011 |
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Topotecan; Treatment Outcome | 2011 |
A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Endonucleases; Etoposide; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinolines; Receptor, Fibroblast Growth Factor, Type 2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Bevacizumab in the treatment of metastatic breast cancer: three case reports.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma in Situ; Carcinoma, Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Doxorubicin; Endonucleases; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Topotecan | 2011 |
Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2011 |
AACR highlights: promise for treating pancreatic cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Anilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Clinical Trials as Topic; Delayed Diagnosis; Deoxycytidine; Disease Progression; Gemcitabine; Genes, ras; Humans; Mice; Molecular Targeted Therapy; Mutation; Off-Label Use; Paclitaxel; Pancreatic Neoplasms; Pyridines; Signal Transduction; Transcription Factors; United States | 2011 |
[Relationship between the protein expression of ERCC1, BRCA, β-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; ras Proteins; Remission Induction; Survival Rate; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2011 |
Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; China; Deoxycytidine; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Thymidine Phosphorylase; Treatment Outcome; Tubulin | 2011 |
Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Labeling; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Heart Failure; Humans; Lymphoma, Large B-Cell, Diffuse; Meta-Analysis as Topic; Paclitaxel; Prednisone; Razoxane; Remission, Spontaneous; Rituximab; Trastuzumab; Vincristine | 2011 |
Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Codon; Deoxycytidine; DNA-Binding Proteins; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Survival Rate; Taxoids; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2011 |
Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Retrospective Studies; Salvage Therapy; Testicular Neoplasms; Treatment Outcome; Young Adult | 2011 |
Successful management of metastatic urothelial carcinoma with gemcitabine and Paclitaxel chemotherapy in a hemodialysis patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Renal Dialysis; Time Factors; Tomography, X-Ray Computed; Urinary Bladder Neoplasms; Urothelium | 2011 |
Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Basigin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Combination chemotherapy for older adults with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Vinblastine; Vinorelbine | 2011 |
Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Ethnicity; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Review Literature as Topic | 2011 |
A novel effective therapy for refractory angiosarcoma of the face and scalp.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Face; Female; Gemcitabine; Hemangiosarcoma; Humans; Methotrexate; Paclitaxel; Radiotherapy; Salvage Therapy; Scalp; Skin Neoplasms | 2011 |
Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Time Factors; Tomography, X-Ray Computed | 2011 |
SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 9; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondrial Proteins; Molecular Mimicry; Paclitaxel; RNA Interference; Tumor Burden; Tumor Necrosis Factor-alpha; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2011 |
Bevacizumab-induced laryngeal necrosis.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Laryngeal Diseases; Lung Neoplasms; Middle Aged; Necrosis; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Tubulin Modulators | 2012 |
Silencing of X-linked inhibitor of apoptosis decreases resistance to cisplatin and paclitaxel but not gemcitabine in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Lung Neoplasms; Paclitaxel; RNA Interference; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-κB and NF-κB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Capecitabine; Cell Differentiation; Cell Proliferation; Curcuma; Cyclin D1; Deoxycytidine; Down-Regulation; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Mice; NF-kappa B; Osteoclasts; Paclitaxel; Plant Extracts; RANK Ligand; Reactive Oxygen Species; Receptors, CXCR4; Receptors, Death Domain; STAT3 Transcription Factor; X-Linked Inhibitor of Apoptosis Protein | 2012 |
Targeting quiescent tumor cells via oxygen and IGF-I supplementation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Culture Techniques; Cell Hypoxia; Cell Proliferation; Cell Survival; Colonic Neoplasms; Deoxycytidine; Drug Synergism; Gemcitabine; HCT116 Cells; HT29 Cells; Humans; Insulin; Insulin-Like Growth Factor I; Mice; Mice, Inbred NOD; Mice, SCID; Oxygen; Paclitaxel; Receptor, IGF Type 1; Xenograft Model Antitumor Assays | 2012 |
Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Regression Analysis; Taxoids; Trastuzumab | 2012 |
Video-assisted thoracoscopic surgery is more favorable than thoracotomy for administration of adjuvant chemotherapy after lobectomy for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Compliance; Pneumonectomy; Postoperative Complications; Psychosurgery; Retrospective Studies; Thoracic Surgery, Video-Assisted; Thoracotomy; Treatment Outcome | 2011 |
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Down-Regulation; Doxorubicin; Etoposide; Floxuridine; Fluorescent Antibody Technique; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomic Instability; Humans; Irinotecan; Metaphase; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; Protein Array Analysis; Reproducibility of Results; Tegafur; Tissue Array Analysis; Tumor Cells, Cultured; Up-Regulation; Uracil | 2012 |
[Results of chemotherapy for gynecologic cancer patients in ambulatory care].
Topics: Ambulatory Care; Ambulatory Care Facilities; Anemia, Hypochromic; Antineoplastic Agents; Carboplatin; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Endometrial Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Hospitalization; Humans; Middle Aged; Neutropenia; Outpatients; Ovarian Neoplasms; Paclitaxel; Quality of Life; Russia; Thrombocytopenia; Treatment Outcome; Uterine Cervical Neoplasms | 2011 |
Effect of maintenance chemotherapy with gemcitabine and paclitaxel on recurrent squamous cell carcinoma of the bladder: a case report.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cystectomy; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Japan; Male; Methotrexate; Middle Aged; Paclitaxel; Prognosis; Recurrence; Remission Induction; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2011 |
Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytostatic Agents; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Mice; Mice, SCID; Neural Cell Adhesion Molecule L1; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms | 2012 |
The role of chemoradiotherapy in patients with unresectable T4 breast tumors.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoradiotherapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Remission Induction; Survival Rate; Taxoids | 2013 |
In vitro evaluation of photon and carbon ion radiotherapy in combination with chemotherapy in glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon; Cell Line, Tumor; Chemoradiotherapy; Cisplatin; Deoxycytidine; Dose-Response Relationship, Radiation; Gemcitabine; Glioblastoma; Humans; In Vitro Techniques; Paclitaxel; Photons; Tumor Stem Cell Assay | 2012 |
Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cell Line, Tumor; Chromones; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Morpholines; Ovarian Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Topotecan | 2012 |
Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Immunohistochemistry; Ovarian Neoplasms; Paclitaxel; Sulfonamides | 2012 |
[A case of breast cancer with brain metastases responding to paclitaxel and capecitabine therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Paclitaxel; Tomography, X-Ray Computed | 2012 |
MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Genes, p53; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-mdm2; Treatment Outcome; Young Adult | 2012 |
The effect of gemcitabine/paclitaxel chemotherapy on the survival of patients with metastatic urothelial cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2013 |
[A case of pancreatic cancer with liver metastasis controlled effectively by chemotherapy based on chemosensitivity test and stereotactic body radiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Radiosurgery; Tomography, X-Ray Computed | 2012 |
Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Taxoids; Treatment Outcome; Young Adult | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cross-Sectional Studies; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2012 |
ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Neoplasms; Deoxycytidine; Depsipeptides; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mitogen-Activated Protein Kinases; Paclitaxel; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4 | 2012 |
A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carboplatin; Confidence Intervals; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Fluorouracil; Gemcitabine; Health Services Accessibility; Humans; Logistic Models; Lymphatic Metastasis; Medication Adherence; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Paclitaxel; Receptors, Estrogen; Switzerland; Taxoids; Vinblastine; Vinorelbine | 2012 |
Drug interactions: the importance of looking inside cancer cells.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Paclitaxel; Pancreatic Neoplasms | 2012 |
nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; Drug Synergism; Gemcitabine; Mice; Paclitaxel; Pancreatic Neoplasms | 2012 |
Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Retrospective Studies | 2012 |
[Basic investigation for classification of anticancer drugs by pharmacological effects].
Topics: Antineoplastic Agents; Carboplatin; Cell Survival; Cisplatin; Deoxycytidine; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; MCF-7 Cells; Paclitaxel; Time Factors; Tumor Cells, Cultured | 2012 |
UbcH10 expression provides a useful tool for the prognosis and treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Ubiquitin-Conjugating Enzymes | 2012 |
Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asian People; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Prognosis; ROC Curve; Sensitivity and Specificity; Stomach Neoplasms; Tubulin; Young Adult | 2012 |
Targeting angiogenesis in metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis.
Topics: Aged; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pain; Pain Measurement; Retrospective Studies; Salvage Therapy; Treatment Outcome; Urologic Neoplasms; Urothelium | 2012 |
Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2012 |
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Stomach Neoplasms; Survival Rate; Taxoids; TOR Serine-Threonine Kinases; Vinblastine; Vinorelbine | 2012 |
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascites; Blotting, Western; Carboplatin; Cell Line, Tumor; Cisplatin; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, SCID; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan; Xenograft Model Antitumor Assays | 2012 |
Role of taxanes in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Radiotherapy; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Platinum; Premedication; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult | 2012 |
Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Protein Structure, Tertiary; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Decision Making, Computer-Assisted; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Furans; Humans; Ketones; Markov Chains; Neoplasm Metastasis; Paclitaxel; Quality of Life; Treatment Outcome | 2013 |
Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Taxoids | 2013 |
Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Genotype; Glutathione S-Transferase pi; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Prospective Studies; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2012 |
Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Humans; Neoplasm Staging; Paclitaxel; Platinum; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Topics: 3' Untranslated Regions; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Paclitaxel; Polymorphism, Genetic; Stomach Neoplasms; Survival Analysis; Thymidylate Synthase | 2013 |
Breast cancer: assessing response to neoadjuvant chemotherapy by using US-guided near-infrared tomography.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Breast Neoplasms; Capecitabine; Carboplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neovascularization, Pathologic; Paclitaxel; ROC Curve; Spectroscopy, Near-Infrared; Trastuzumab; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Self-assembly of thermally responsive nanoparticles of a genetically encoded peptide polymer by drug conjugation.
Topics: Amino Acid Sequence; Deoxycytidine; Drug Carriers; Gemcitabine; Hydrophobic and Hydrophilic Interactions; Nanoparticles; Oxycodone; Paclitaxel; Peptides; Pharmaceutical Preparations; Polymers; Temperature | 2013 |
Suppressive oligodeoxynucleotides synergistically enhance antiproliferative effects of anticancer drugs in A549 human lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Oligodeoxyribonucleotides; Paclitaxel; Proto-Oncogene Proteins c-akt; Repetitive Sequences, Nucleic Acid | 2013 |
Bevacizumab in breast cancer: fundamental questions remain.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Paclitaxel | 2013 |
The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
Topics: Aneuploidy; Animals; Apoptosis; Aurora Kinase A; Aurora Kinases; Azepines; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cluster Analysis; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression; Gene Expression Profiling; Humans; M Phase Cell Cycle Checkpoints; Mice; Neoplasm Invasiveness; Paclitaxel; Phenotype; Protein Serine-Threonine Kinases; Pyrimidines; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Ifosfamide; Kidney Neoplasms; Male; Middle Aged; Nomograms; Paclitaxel; Predictive Value of Tests; Prognosis; Survival Analysis; Treatment Outcome; Urothelium | 2013 |
Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Mitochondria; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; STAT3 Transcription Factor | 2012 |
Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Remission Induction; Treatment Outcome | 2013 |
A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2013 |
A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Receptors, Calcitriol; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Confidence Intervals; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2013 |
Juxtaglomerular cell tumor: multicentric synchronous disease associated with paraneoplastic syndrome.
Topics: Antidiuretic Hormone Receptor Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Dacarbazine; Deoxycytidine; Diagnosis, Differential; Disease Progression; Doxorubicin; Gemcitabine; Humans; Hyponatremia; Ifosfamide; Immunohistochemistry; Immunophenotyping; Inappropriate ADH Syndrome; Juxtaglomerular Apparatus; Kidney Neoplasms; Luminescent Measurements; Male; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Paraneoplastic Syndromes; Renin; Tolvaptan; Vinblastine; Vinorelbine | 2013 |
Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; SEER Program; Survival Analysis; Taxoids; Treatment Outcome; United States | 2013 |
Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Comorbidity; Deoxycytidine; Docetaxel; Esophageal Diseases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Taxoids | 2013 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
Sleeve lobectomy compared with pneumonectomy after induction therapy for non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Proportional Hazards Models; Survival Rate; Vinblastine; Vinorelbine | 2013 |
Drug combination extends late-stage pancreatic cancer survival in Phase III clinical trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2013 |
Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Xeroderma Pigmentosum Group A Protein; Xeroderma Pigmentosum Group D Protein | 2013 |
Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Predictive Value of Tests; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Genital Neoplasms, Female; Humans; Irinotecan; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Exenteration; Prognosis; Retrospective Studies; Survival Rate; Topotecan | 2013 |
Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Establishing the optimal nebulization system for paclitaxel, docetaxel, cisplatin, carboplatin and gemcitabine: back to drawing the residual cup.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Equipment Design; Gemcitabine; Nebulizers and Vaporizers; Paclitaxel; Taxoids | 2013 |
Gemcitabine with paclitaxel therapy against mesocolic leiomyosarcoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Leiomyosarcoma; Male; Mesocolon; Neoplasm Recurrence, Local; Paclitaxel; Prognosis | 2013 |
Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Docetaxel; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Neoplasms, Experimental; Paclitaxel; Pancreatic Neoplasms; Stathmin; Stromal Cells; Taxoids; Tubulin; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cathepsin B; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Deoxycytidine; Drug Carriers; Drug Stability; Drug Synergism; Female; Gemcitabine; Humans; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Male; Molecular Weight; Ovarian Neoplasms; Paclitaxel; Polymerization; Polymethacrylic Acids; Solubility; Technology, Pharmaceutical | 2013 |
First line therapy for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fatigue; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2013 |
Preclinical research in treatment of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Deoxycytidine; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Imidazoles; Mice; Paclitaxel; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
[A case of triple-negative breast cancer achieved pCR by epirubicin and cyclophosphamide(EC)therapy followed by gemcitabine plus paclitaxel combination preoperative therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Remission Induction | 2013 |
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Collagen; Deoxycytidine; Disease Models, Animal; Elasticity Imaging Techniques; Endosonography; Female; Fibroblasts; Gemcitabine; Humans; Male; Mice; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography | 2013 |
Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Movement; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Indoles; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Topotecan | 2013 |
Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India.
Topics: Camptothecin; Cost Savings; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Drugs, Generic; Gemcitabine; Humans; India; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Poverty; Taxoids | 2013 |
Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; SOXB1 Transcription Factors; Survival Analysis; Taxoids; Treatment Outcome; Tumor Suppressor Protein p53 | 2013 |
PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Liposomes; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nanoparticles; Paclitaxel; Polyethylene Glycols; Time Factors; Treatment Outcome; Tumor Burden | 2013 |
Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Capecitabine; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Deoxycytidine; Female; Fluorouracil; Genotype; Humans; Interleukin-10; Mexico; Middle Aged; Paclitaxel; Polymorphism, Genetic; Spain; Tamoxifen | 2013 |
Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Proteome; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2013 |
High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients.
Topics: Adult; Aged; Alpha-Globulins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms | 2013 |
Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2014 |
Pancreatic cancer: standing on the shoulders of mice, making an iMPACT on pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Humans; Male; Paclitaxel; Pancreatic Neoplasms | 2013 |
Comparison of the effects of photon versus carbon ion irradiation when combined with chemotherapy in vitro.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carbon; Cell Cycle; Cell Line, Tumor; Cell Separation; Chemoradiotherapy; Cisplatin; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; Flow Cytometry; Gemcitabine; Glioblastoma; Humans; Ions; Lung Neoplasms; Paclitaxel; Pancreatic Neoplasms; Photons; Propidium; Radiotherapy; Relative Biological Effectiveness; Time Factors | 2013 |
Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, University; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Paclitaxel; Palliative Care; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Hypertension, Pulmonary; Paclitaxel; Pancreatic Neoplasms; Time Factors; Tomography, X-Ray Computed; Ultrasonography, Doppler | 2013 |
U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Approval; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
[nab-Paclitaxel as new therapeutic option for pancreatic cancer].
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cytidine Deaminase; Deoxycytidine; Paclitaxel; Pancreatic Neoplasms | 2013 |
Clinical outcome of paclitaxel and carboplatin as second-line chemotherapy for advanced urothelial carcinoma resistant to first-line therapy with gemcitabine and cisplatin.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2014 |
Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Endosonography; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Gemcitabine; Humans; Injections, Intralesional; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Phytotherapy; Plant Extracts; Retrospective Studies; Survival Rate; Ultrasonography, Interventional; Viscum album | 2014 |
Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Giant Cell Tumors; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Sarcoma; Survival Rate; Young Adult | 2013 |
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Humans; Male; Paclitaxel; Pancreatic Neoplasms | 2014 |
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Humans; Male; Paclitaxel; Pancreatic Neoplasms | 2014 |
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Humans; Male; Paclitaxel; Pancreatic Neoplasms | 2014 |
Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Genotype; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Nucleoside Transport Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Treatment Failure | 2014 |
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycytidine; Disease Progression; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2013 |
Updates on first-line therapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Is there a role for second line therapy in advanced pancreatic cancer?
Topics: Albumins; Antineoplastic Agents; Deoxycytidine; Disease Progression; Drug Therapy; Drug Therapy, Combination; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Association between CHFR methylation and chemosensitivity of paclitaxel in advanced gastric cancer.
Topics: Antineoplastic Agents; Biopsy; Capecitabine; Cell Cycle Proteins; China; Cisplatin; Deoxycytidine; DNA Methylation; Fluorouracil; Humans; Middle Aged; Neoplasm Proteins; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Retrospective Studies; Stomach Neoplasms; Ubiquitin-Protein Ligases | 2014 |
Examining and predicting drug preferences of patients with metastatic breast cancer: using conjoint analysis to examine attributes of paclitaxel and capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Data Collection; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Patient Preference | 2014 |
Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis.
Topics: Adenocarcinoma; Age Factors; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Multicenter Studies as Topic; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic | 2014 |
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Hospitalization; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Registries; Retrospective Studies; Survival Rate; Taxoids; United States; United States Department of Veterans Affairs; Vinblastine; Vinorelbine | 2014 |
Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; DNA Glycosylases; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate; Taxoids; X-ray Repair Cross Complementing Protein 1 | 2014 |
Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deglutition Disorders; Deoxycytidine; Gemcitabine; Humans; Interpersonal Relations; Lung Neoplasms; Multicenter Studies as Topic; Nausea; Paclitaxel; Pain; Palliative Care; Prognosis; Proportional Hazards Models; Quality of Life; Randomized Controlled Trials as Topic; Risk; Severity of Illness Index; Surveys and Questionnaires; Survival Analysis | 2014 |
[Outcomes of treatment of 32 cases of advanced or relapsed post-surgery pulmonary sarcomatoid carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Postoperative Period; Survival Rate | 2014 |
[Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Thrombocytopenia; Urinary Bladder Neoplasms; Urothelium | 2014 |
In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Ki-67 Antigen; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2014 |
E2F inhibition synergizes with paclitaxel in lung cancer cell lines.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Drug Synergism; E2F3 Transcription Factor; Gemcitabine; Humans; Hydroxyquinolines; Inhibitory Concentration 50; Lung Neoplasms; Paclitaxel; RNA, Small Interfering; Small Cell Lung Carcinoma | 2014 |
Human ovarian cancer multicellular spheroids: a model for testing antiproliferation activity of Devil's club (Oplopanax horridus) and anticancer agents.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Proliferation; Chromatography, High Pressure Liquid; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Oplopanax; Ovarian Neoplasms; Paclitaxel; Plant Bark; Plant Extracts; Plants, Medicinal; Proteome; Spheroids, Cellular; Tumor Cells, Cultured | 2014 |
Paclitaxel and gemcitabine combinational drug-loaded mucoadhesive delivery system in the treatment of colon cancers.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cell Survival; Chitosan; Colonic Neoplasms; Deoxycytidine; Drug Carriers; Drug Liberation; Drug Therapy, Combination; Gemcitabine; Humans; Mice; Nanoparticles; Paclitaxel; Succinic Anhydrides; Survival Rate; Xenograft Model Antitumor Assays | 2015 |
New option for the initial management of metastatic pancreatic cancer?
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Humans; Male; Paclitaxel; Pancreatic Neoplasms | 2014 |
Fat composition changes in bone marrow during chemotherapy and radiation therapy.
Topics: Adipose Tissue; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Blood Cell Count; Bone Marrow; Bone Marrow Cells; Capecitabine; Cervical Vertebrae; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Endometrial Neoplasms; Female; Fluorouracil; Humans; Lumbar Vertebrae; Magnetic Resonance Imaging; Male; Middle Aged; Mitomycin; Paclitaxel; Prospective Studies; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Spine; Thoracic Vertebrae; Uterine Cervical Neoplasms | 2014 |
Combination of microtubule associated protein-tau and β-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cell Line, Tumor; Cell Survival; Cisplatin; Clinical Trials, Phase II as Topic; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubule-Associated Proteins; Middle Aged; Paclitaxel; Stomach Neoplasms; tau Proteins; Transfection; Treatment Outcome; Tubulin; Xenograft Model Antitumor Assays; Young Adult | 2014 |
Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Capecitabine; Cell Cycle Checkpoints; Cell Line, Tumor; Citric Acid Cycle; Cytotoxins; Deoxycytidine; Fluorouracil; Glutamine; Humans; Mutation; Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2015 |
Second-line treatment for pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Metformin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Adjuvant treatment for pancreatic cancer.
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Role of neoadjuvant therapy in management of pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2014 |
Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates.
Topics: Acrylamides; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2014 |
Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Heterozygote; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Polymorphism, Genetic; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclooxygenase 2; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel | 2014 |
Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Prognosis; Salvage Therapy; Survival Analysis; Treatment Failure; Treatment Outcome; Urologic Neoplasms | 2015 |
Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.
Topics: Analysis of Variance; Cell Line, Tumor; Deoxycytidine; DNA Primers; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1; Image Processing, Computer-Assisted; Immunoblotting; Interleukin-6; Interleukin-8; Kaplan-Meier Estimate; Luciferases; Microscopy; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Triple Negative Breast Neoplasms | 2014 |
Trastuzumab in advanced breast cancer--a decade of experience in Germany.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Germany; Hormones; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Survival Rate; Trastuzumab; Vinblastine; Vinorelbine; Young Adult | 2014 |
Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diuretics; Female; Gemcitabine; Heart Failure; Humans; Paclitaxel; Pancreatic Neoplasms | 2014 |
Quality of life in advanced non-small cell lung cancer receiving chemotherapy of platinum combination in old versus new standard chemotherapy regimen.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Prospective Studies; Quality of Life | 2014 |
Successful treatment of metastatic urothelial carcinoma arising in a transplanted renal allograft with paclitaxel, cisplatin, and gemcitabine combination therapy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Hematuria; Humans; Kidney Transplantation; Lung Neoplasms; Male; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2015 |
[Association between ABCB1 G2677T/A polymorphisms and chemosensitivity of paclitaxel in advanced gastric cancer].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Fluorouracil; Genotype; Humans; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Retrospective Studies; Stomach Neoplasms; Survival Analysis | 2015 |
Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lipocalin-2; Lipocalins; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Taxoids | 2015 |
Outcome of recurrent uterine papillary serous carcinoma treated with platinum-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome; Uterine Neoplasms | 2015 |
Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2015 |
Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Topics: Albumins; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Cytidine Deaminase; Deoxycytidine; Drug Carriers; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lipid Bilayers; Mice; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Porosity; Silicon Dioxide | 2015 |
Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Survival Analysis; Treatment Outcome | 2015 |
Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer.
Topics: Adult; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Analysis; United Kingdom | 2015 |
Old drugs, new tricks for triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2015 |
A retrospective clinical study of bevacizumab combined with gemcibabine or paclitaxel in the treatment of recurrent ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Transitional Cell; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Blood Platelets; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Genome-Wide Association Study; Hemoglobins; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Vinblastine; Vinorelbine | 2016 |
[Therapy in pancreatic cancer - and still it moves along!].
Topics: Albumins; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Palliative Care; Pancreatic Neoplasms | 2015 |
Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Deoxycytidine; Eligibility Determination; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Pancreatic Neoplasms | 2017 |
[FOLFIRINOX, nab-paclitaxel + gemcitabine].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms | 2015 |
[Nab-paclitaxel use in pancreatic cancer: practical aspects and consequences in a French oncology day-care unit].
Topics: Adenocarcinoma; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2015 |
Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2015 |
Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Nanoparticles; Paclitaxel; Pancreatic Neoplasms | 2015 |
Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Hyaluronan Receptors; Nanoparticles; Paclitaxel | 2015 |
Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; MCF-7 Cells; MicroRNAs; Mutation; Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Ribonucleoside Diphosphate Reductase; Signal Transduction; Transfection; Tubulin | 2015 |
Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Binding Sites; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Mice; Molecular Docking Simulation; Molecular Sequence Data; Paclitaxel; Sequence Alignment; Structural Homology, Protein; Taxoids; Thermodynamics | 2015 |
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Middle Aged; Mitomycin; Neoadjuvant Therapy; Paclitaxel; Perioperative Care; Retrospective Studies; Urethra; Urethral Neoplasms; Urinary Diversion | 2015 |
Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Maytansine; MCF-7 Cells; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Up-Regulation | 2015 |
Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2015 |
Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Spain | 2015 |
Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care.
Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Florida; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Audit; Middle Aged; Paclitaxel; Pneumonectomy; Practice Patterns, Physicians'; Quality of Health Care; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2015 |
Multidisciplinary management of pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2015 |
Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness.
Topics: Bile Duct Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cholangiocarcinoma; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Paclitaxel | 2015 |
Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Paclitaxel; Prognosis; Survival Analysis; Treatment Outcome | 2015 |
[Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use].
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2015 |
Association of TERT Polymorphisms with Clinical Outcome of Non-Small Cell Lung Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression; Heterozygote; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Survival Analysis; Telomerase; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Analysis on clinical characteristics and influencing factors of patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Risk Factors | 2015 |
Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adenosine Triphosphatases; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cation Transport Proteins; Cisplatin; Copper-Transporting ATPases; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutathione S-Transferase pi; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2015 |
Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy.
Topics: Adoptive Transfer; Animals; Cisplatin; Cyclophosphamide; Cytotoxins; Deoxycytidine; Drug Resistance; Etoposide; Female; Fibrosarcoma; Gemcitabine; Lymph Nodes; Lymphocyte Depletion; Lymphopenia; Methylcholanthrene; Mice; Mice, Inbred C57BL; Mice, Knockout; Paclitaxel; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Cells, Cultured; Vidarabine; Whole-Body Irradiation | 2015 |
Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Endothelial Cells; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Pancreatic Adenocarcinoma Treated With Irreversible Electroporation Case Report: First Experience and Outcome.
Topics: Adenocarcinoma; Aged; Albumins; Antimetabolites, Antineoplastic; Deoxycytidine; Electrochemotherapy; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms | 2015 |
EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Movement; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pneumonectomy; Prognosis; RNA Interference; RNA, Small Interfering; Transcription Factors; Vinblastine; Vinorelbine | 2015 |
Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chorionic Gonadotropin; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Longitudinal Studies; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Remission Induction; Retroperitoneal Neoplasms; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Testicular Neoplasms; Treatment Outcome | 2015 |
Inhibition of Human Pancreatic Cancer Cell Proliferation by Devil's Club Oplopanax horridus and Its Polyacetylene Bioactive Compound.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Inhibitory Concentration 50; Oplopanax; Paclitaxel; Pancreatic Neoplasms; Plant Extracts; Plant Roots; Polyynes; Signal Transduction | 2015 |
[A Case of Gastrointestinal Metastases of Breast Cancer Effectively Treated with Gemcitabine and Paclitaxel Combination Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Intestinal Obstruction; Middle Aged; Paclitaxel; Stomach Neoplasms | 2015 |
New mouse xenograft model modulated by tumor-associated fibroblasts for human multi-drug resistance in cancer.
Topics: Actins; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fibroblasts; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; NIH 3T3 Cells; Paclitaxel; Xenograft Model Antitumor Assays | 2015 |
Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Machine Learning; Paclitaxel; Support Vector Machine | 2016 |
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan | 2015 |
Gemcitabine-releasing mesenchymal stromal cells inhibit in vitro proliferation of human pancreatic carcinoma cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Mesenchymal Stem Cells; Paclitaxel; Pancreatic Neoplasms | 2015 |
Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate | 2016 |
[The Combination Therapy of Gemcitabine Plus Paclitaxel Induced Complete Response in a Tongue Skin Brain Metastasis of Bladder Carcinoma: A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Skin Neoplasms; Tongue Neoplasms; Urinary Bladder Neoplasms | 2015 |
Metastatic cardiac tumor from urothelial carcinoma detected by transthoracic echocardiography: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Echocardiography; Fatal Outcome; Gemcitabine; Heart Neoplasms; Humans; Male; Multiple Organ Failure; Paclitaxel; Tomography, X-Ray Computed; Treatment Outcome; Urothelium | 2015 |
[Intraperitoneal chemotherapy--a method of improving treatment effectiveness in ovarian cancer].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Infusions, Intravenous; Infusions, Parenteral; Maximum Tolerated Dose; Melphalan; Mitomycin; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Rats; Rats, Wistar; Triazines | 2015 |
Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Conformal; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Synergism; Gemcitabine; Humans; Niacinamide; Organoplatinum Compounds; Paclitaxel; Phenylurea Compounds; Pyridines; Radiation Tolerance; Radiopharmaceuticals; Sorafenib; Yttrium Radioisotopes | 2015 |
Changes of Lymphocyte Subgroups in Non-Small Cell Lung Cancer Patients Before and During Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; CD28 Antigens; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cisplatin; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Paclitaxel; Time Factors | 2015 |
SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway.
Topics: Anilides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Female; Gemcitabine; Heterocyclic Compounds, 4 or More Rings; Humans; Lysosomes; Mice; Mice, Nude; Paclitaxel; Pancreatic Neoplasms; Sirtuin 1; Thiazoles | 2016 |
Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Registries; Retrospective Studies; Survival Analysis; Testicular Neoplasms | 2016 |
Evolution of a Lung-Sparing Strategy with Sleeve Lobectomy and Induction Therapy for Non-small Cell Lung Cancer: 20-Year Experience at a Single Institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Oxonic Acid; Paclitaxel; Platinum Compounds; Pneumonectomy; Remission Induction; Retrospective Studies; Survival Rate; Tegafur; Tumor Burden | 2016 |
Cost-Utility of "Doxorubicin and Cyclophosphamide" versus "Gemcitabine and Paclitaxel" for Treatment of Patients with Breast Cancer in Iran.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Cross-Sectional Studies; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Iran; Neoplasm Staging; Paclitaxel; Prognosis; Quality of Life | 2015 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Silicates; Singapore; Titanium | 2015 |
Singapore Cancer Network (SCAN) Guidelines for Front-Line Systemic Therapy of Newly Diagnosed Advanced Epithelial Ovarian Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Parenteral; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Polyethylene Glycols; Singapore | 2015 |
[Nab-Paclitaxel plus Gemcitabine for Metastatic Pancreatic Cancer].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2015 |
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Treatment Outcome; Young Adult | 2016 |
The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cystadenocarcinoma, Serous; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Deoxycytidine; Disease Models, Animal; Drug Synergism; Female; Gemcitabine; Humans; Mice; Microcirculation; Osteonectin; Paclitaxel; Pancreatic Neoplasms; Stromal Cells; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Prospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2016 |
Penile cancer metastasizing to the breast: a case report.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms, Male; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Penile Neoplasms | 2016 |
Gemcitabine and Paclitaxel for Primary Bladder Carcinoma in Renal Transplant Recipients: A Case Report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Kidney Transplantation; Male; Paclitaxel; Urinary Bladder; Urinary Bladder Neoplasms; Young Adult | 2016 |
Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Clinical Trials as Topic; Cost-Benefit Analysis; Decision Support Techniques; Deoxycytidine; Drug Costs; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Analysis | 2016 |
Adenocarcinoma of the ampulla of Vater metastasising into the right ventricle.
Topics: Adenocarcinoma; Adult; Albumins; Ampulla of Vater; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Gemcitabine; Heart Neoplasms; Heart Ventricles; Humans; Neoplasm Recurrence, Local; Paclitaxel | 2016 |
Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Costs and Cost Analysis; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2016 |
Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prospective Studies | 2016 |
Reply to the comment on 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prospective Studies | 2016 |
CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.
Topics: Albumins; Animals; Antibodies; Antigen-Presenting Cells; Carcinoma, Pancreatic Ductal; CD40 Antigens; CD8-Positive T-Lymphocytes; Clone Cells; Deoxycytidine; Gemcitabine; Immunity, Innate; Interferon-gamma; Lymphocyte Subsets; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Paclitaxel; Pancreatic Neoplasms; T-Lymphocytes; Treatment Outcome; Tumor Microenvironment | 2016 |
Neutrophil-lymphocyte ratio as a prognostic marker for chemotherapy in advanced lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Analysis | 2016 |
Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Splenic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Substitution; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Ontario; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Sepsis; Treatment Outcome | 2016 |
Recapitulating epithelial tumor microenvironment in vitro using three dimensional tri-culture of human epithelial, endothelial, and mesenchymal cells.
Topics: Cell Line, Tumor; Coculture Techniques; Deoxycytidine; Drug Resistance, Neoplasm; Endothelial Cells; Epithelial Cells; Gemcitabine; HEK293 Cells; Humans; Keratin-18; Mesenchymal Stem Cells; Paclitaxel; Reactive Oxygen Species; Spheroids, Cellular; Tumor Microenvironment; Vimentin | 2016 |
Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Tumor Burden | 2016 |
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Compassionate Use Trials; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
A Case of Mixed Germ Cell Tumor in the Intramedullary Spinal-cord.
Topics: Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Bleomycin; Chorionic Gonadotropin; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Guillain-Barre Syndrome; Humans; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Paclitaxel; Paraplegia; Spinal Cord Neoplasms; Tomography, X-Ray Computed | 2016 |
Prolonged Remission of Upper Urinary Tract Urothelial Carcinoma With Prominent Choriocarcinomatous Differentiation: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Transitional Cell; Choriocarcinoma; Cisplatin; Cyclophosphamide; Dactinomycin; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pelvic Neoplasms; Remission Induction; Ureteral Neoplasms | 2017 |
Nab-paclitaxel+gemcitabine therapy for adenosquamous carcinoma of the pancreas: an autopsy case.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Carcinoma, Adenosquamous; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2016 |
Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Topics: Animals; Anti-Inflammatory Agents; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Complement Activation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Etanercept; Female; Gemcitabine; Humans; Infliximab; Kaplan-Meier Estimate; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Pancreatic Stellate Cells; Proportional Hazards Models; Stromal Cells; Time Factors; Tumor Microenvironment; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2016 |
Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy; Retrospective Studies; Survival Rate | 2017 |
New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamidines; Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Guanidines; Humans; Injections, Intraperitoneal; Injections, Intravenous; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Markov Chains; Models, Econometric; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; United States | 2017 |
Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Infusions, Parenteral; Male; Middle Aged; Oxaloacetates; Paclitaxel; Peritoneal Neoplasms; Peritoneum; Stomach Neoplasms; Survival Rate | 2017 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Prognosis; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2017 |
Designing geriatric-specific trials in advanced lung cancer: What, who and how to study?
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Paclitaxel; Vinorelbine | 2017 |
MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Glycosylases; Dose-Response Relationship, Drug; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; Mice, Nude; Oxidative Stress; Paclitaxel; Pancreatic Neoplasms; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Tumor Hypoxia; Tumor Microenvironment; Vincristine; Xenograft Model Antitumor Assays | 2017 |
Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis; Young Adult | 2016 |
Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Erlotinib Hydrochloride; Europe; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Surveys and Questionnaires | 2016 |
Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Computer Simulation; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; Vinblastine; Vinorelbine | 2017 |
Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases.
Topics: Adolescent; Anemia, Sickle Cell; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carcinoma, Medullary; Child; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Paclitaxel | 2017 |
Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2017 |
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Hypersensitivity; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Retrospective Studies | 2017 |
Backbone Degradable N-(2-Hydroxypropyl)methacrylamide Copolymer Conjugates with Gemcitabine and Paclitaxel: Impact of Molecular Weight on Activity toward Human Ovarian Carcinoma Xenografts.
Topics: Acrylamides; Animals; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Polymers; Xenograft Model Antitumor Assays | 2017 |
Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy?
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Tertiary Care Centers | 2017 |
The Value of Survival Gains in Pancreatic Cancer from Novel Treatment Regimens.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2017 |
[Experience with Gemcitabine plus Nab-Paclitaxel Therapy for Advanced Metastatic Pancreatic Cancer in Our Hospital].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Multimodal Imaging; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
[Nab-Paclitaxel plus Gemcitabine Hydrochloride in Patients with Metastatic or Recurrent Pancreatic Cancer - A Single Institution Experience].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Recurrence; Treatment Outcome | 2016 |
[A Study of Gemctabine plus Nab-Paclitaxel Therapy for Advanced Local Progressive Pancreatic Cancer].
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2016 |
[A Case of Borderline Resectable Pancreatic Cancer Responding to Preoperative GEM plus Nab-PTX Combination Chemotherapy].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2016 |
[A Case of Curatively Resected Locally Advanced Cancer of the Pancreatic Body Treated by Distal Pancreatectomy with En Bloc Celiac Axis Resection after Preoperative Intensive Treatment].
Topics: Aged; Albumins; Celiac Artery; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms | 2016 |
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Carboplatin; Cyclophosphamide; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Niacinamide; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult | 2017 |
Thrombotic Microangiopathy in a Patient Treated With Gemcitabine.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Thrombotic Microangiopathies | 2017 |
A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel.
Topics: Adenoviridae; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplastic Stem Cells; Oncolytic Virotherapy; Paclitaxel; Pancreatic Neoplasms; Receptors, Notch; Receptors, Urokinase Plasminogen Activator; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Treatment Failure; Treatment Outcome | 2017 |
[Conversion Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer Following Gemcitabine plus Nab-Paclitaxel - A Case Report].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Metabolic profiling of gemcitabine- and paclitaxel-treated immortalized human pancreatic cell lines with K-RAS
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, ras; Glycolysis; Humans; Metabolome; Mutation; Paclitaxel; Pancreatic Neoplasms | 2017 |
Modulation of chemotherapy-induced cytotoxicity in SH-SY5Y neuroblastoma cells by caffeine and chlorogenic acid.
Topics: Antineoplastic Agents; Apoptosis; Caffeine; Cell Line, Tumor; Cell Survival; Chlorogenic Acid; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Gemcitabine; Humans; Paclitaxel; Reactive Oxygen Species | 2017 |
Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biocompatible Materials; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Stability; Endocytosis; Galactose; Gemcitabine; Humans; Inhibitory Concentration 50; Lipids; Lung Neoplasms; Mice; Nanostructures; Paclitaxel; Polymers | 2017 |
Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Delivery of Health Care; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Length of Stay; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Time Factors | 2017 |
Concurrent Chemotherapy Improves the Overall Survival of Patients Irradiated for Locally Recurrent Bladder Cancer.
Topics: Aged; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Deoxycytidine; Gemcitabine; Humans; NAD(P)H Dehydrogenase (Quinone); Naphthoquinones; Paclitaxel; Pancreatic Neoplasms | 2017 |
Hypoxia Induces Multidrug Resistance via Enhancement of Epidermal Growth Factor-Like Domain 7 Expression in Non-Small Lung Cancer Cells.
Topics: A549 Cells; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium-Binding Proteins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; EGF Family of Proteins; Endothelial Growth Factors; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; RNA Interference; RNA, Small Interfering | 2017 |
Fluorescent Immortalized Human Adipose Derived Stromal Cells (hASCs-TS/GFP+) for Studying Cell Drug Delivery Mediated by Microvesicles.
Topics: Adipose Tissue; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Screening Assays, Antitumor; Fluorescence; Gemcitabine; Green Fluorescent Proteins; Humans; Mesenchymal Stem Cells; Molecular Structure; Paclitaxel; Simian virus 40; Structure-Activity Relationship; Telomerase | 2017 |
Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Survival Rate | 2017 |
Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2017 |
Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Decision Making; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; United States | 2017 |
Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions.
Topics: Adult; Aged; Albumins; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Drug Hypersensitivity; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Retreatment; Retrospective Studies; Taxoids; Thrombocytopenia | 2017 |
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Netherlands; Paclitaxel; Pemetrexed; Registries; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2017 |
Pancreatic cancer heterogeneity and response to Mek inhibition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Methylation; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Gemcitabine; Genetic Heterogeneity; Humans; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mutation; Paclitaxel; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Xenograft Model Antitumor Assays | 2017 |
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Topotecan | 2017 |
Does "OPTINAB" strategy ("stop-and-go") work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel-gemcitabine?
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Retrospective Studies; Survival Rate | 2017 |
Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hospitals, High-Volume; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate | 2017 |
Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX.
Topics: Aged; Albumins; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Cost of Illness; Deoxycytidine; Drug Costs; Female; Filgrastim; Fluorouracil; Gemcitabine; Granulocyte Colony-Stimulating Factor; Health Care Costs; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Time Factors | 2017 |
Mixed Liposome Approach for Ratiometric and Sequential Delivery of Paclitaxel and Gemcitabine.
Topics: Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Liberation; Gemcitabine; Humans; Liposomes; Paclitaxel | 2018 |
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Costs; European Union; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Survival Rate; Tetrahydroisoquinolines; Trabectedin | 2017 |
A successful case of locally advanced pancreatic cancer undergoing curative distal pancreatectomy with en bloc celiac axis resection after combination chemotherapy of nab-paclitaxel with gemcitabine.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Gemcitabine; Hepatic Artery; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Splenic Artery | 2017 |
A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2017 |
A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2019 |
[Clinical analysis of 36 cases of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4].
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Hypoxia; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Remission Induction; Response Evaluation Criteria in Solid Tumors; Severity of Illness Index; Taxoids | 2017 |
PEGPH20 May Improve Standard-of-Care Therapy in Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Paclitaxel; Pancreatic Neoplasms | 2018 |
Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-paclitaxel Reduces the Number of Cancer-associated Fibroblasts Through Depletion of Pancreatic Stroma.
Topics: Actins; Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; CA-19-9 Antigen; Cancer-Associated Fibroblasts; Collagen; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Retrospective Studies; Stromal Cells | 2018 |
Re-irradiation with 36 Gy (1.5 Gy Twice Daily) Plus Paclitaxel for Advanced Recurrent and Previously Irradiated SCCHN is Feasible.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Re-Irradiation; Squamous Cell Carcinoma of Head and Neck | 2018 |
The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma.
Topics: Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Treatment Outcome; Tubulin | 2018 |
Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Infusions, Intravenous; Isoflurophate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2018 |
Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines.
Topics: Aminoquinolines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Lung Neoplasms; Mice; Paclitaxel; Thiosemicarbazones; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2018 |
Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Recurrence, Local; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Xenograft Model Antitumor Assays | 2018 |
[Multidisciplinary Therapy with Gemcitabine and Nab-Paclitaxel for Unresectable Pancreatic Cancer].
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2017 |
[A Case of Gemcitabine and Nab-Paclitaxel Therapy for Multiple Metastatic Pancreatic Cancer].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2017 |
[A Case of Unresectable Locally Advanced Pancreatic Cancer Resulted in R0 Surgery after Chemotherapy].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2017 |
[A Case of Successful Adjuvant Surgery for the Pancreas Head Cancer with Peritoneal Metastasis].
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Peritoneal Neoplasms | 2017 |
[Long-Term Survival after Multidisciplinary Treatment for Resected Pancreatic Adenocarcinoma with Recurrence of Pulmonary Metastases - A Case Report].
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Paclitaxel; Pancreaticoduodenectomy; Pneumonectomy; Recurrence; Tegafur; Time Factors | 2017 |
Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Combinations; Drug Incompatibility; Drug Stability; Female; Gemcitabine; Granisetron; Humans; Infusions, Intravenous; Male; Paclitaxel; Risk Factors | 2017 |
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2018 |
Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies | 2018 |
[A Case of Successful Treatment with Gemcitabine plus Nab-Paclitaxel Therapy for Nonresected Pancreatic Body Cancer(Stage IVb)].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2018 |
The Combination of Gemcitabine, Cisplatin, and Paclitaxel as Salvage Chemotherapy for Advanced Urothelial Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Salvage Therapy; Treatment Outcome; Urologic Neoplasms | 2018 |
Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biopsy; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Programmed Cell Death 1 Receptor | 2018 |
[Novel Palliative Chemotherapy in Patients with Metastatic Pancreatic Cancer: PEGPH20].
Topics: Albumins; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2018 |
Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Patient Compliance; Proportional Hazards Models; Retrospective Studies; Tegafur; Treatment Outcome | 2018 |
Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic efficacy in pancreatic cancer.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Deoxycytidine; Drug Liberation; Gemcitabine; Humans; Immunoglobulin Fragments; Liposomes; Microscopy, Confocal; Microscopy, Electron, Transmission; Paclitaxel; Pancreatic Neoplasms; Particle Size; Proto-Oncogene Proteins c-bcl-2 | 2018 |
Gemcitabine/nab-paclitaxel for pediatric relapsed/refractory sarcomas.
Topics: Adolescent; Albumins; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Infections; Kaplan-Meier Estimate; Male; Paclitaxel; Recurrence; Salvage Therapy; Sarcoma; Young Adult | 2018 |
Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Urologic Neoplasms | 2018 |
Total pancreatoduodenectomy en bloc with superior mesenteric artery and vein resection after gemcitabine and nab-paclitaxel neoadjuvancy.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Mesenteric Artery, Superior; Mesenteric Veins; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis | 2017 |
Co-delivery of paclitaxel and gemcitabine by methoxy poly(ethylene glycol)-poly(lactide-coglycolide)-polypeptide nanoparticles for effective breast cancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Female; Gemcitabine; Humans; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Transplantation; Paclitaxel; Particle Size; Peptides; Polyesters; Polyethylene Glycols; Surface Properties | 2018 |
Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2018 |
Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622).
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prospective Studies | 2018 |
A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2018 |
Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Platinum; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinorelbine | 2018 |
Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neurotoxicity Syndromes; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Progression-Free Survival; Republic of Korea; Survival Rate; Treatment Outcome | 2017 |
Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Gemcitabine; Humans; Inhibitory Concentration 50; Models, Biological; Neoplastic Stem Cells; Paclitaxel; Pancreatic Neoplasms; Trifluoperazine | 2018 |
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Retreatment; Retrospective Studies; Survival Rate; Topotecan | 2017 |
Nab-paclitaxel in combination with gemcitabine for the treatment of metastatic pancreas cancer: the South Wales experience.
Topics: Adult; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome; United Kingdom; Venous Thromboembolism | 2018 |
Neoadjuvant
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
A population-based analysis of urban-rural disparities in advanced pancreatic cancer management and outcomes.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Healthcare Disparities; Humans; Irinotecan; Leucovorin; Male; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Rural Health; Rural Population; Urban Health; Urban Population | 2018 |
Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals.
Topics: Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Glycogen Synthase Kinase 3; Humans; Irinotecan; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Signal Transduction | 2018 |
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Topics: Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Quality-Adjusted Life Years; United Kingdom | 2018 |
Selecting patients with triple negative breast cancer for platinum-based therapy: we still haven't found what we're looking for.
Topics: Biomarkers; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Platinum | 2018 |
Five Cases of Interstitial Pneumonitis Due to Gemcitabine and Nab-Paclitaxel Combination Treatment in Pancreatic Cancer Patients.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms | 2018 |
GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells.
Topics: Alkaline Phosphatase; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Deoxycytidine; Female; GATA3 Transcription Factor; Gemcitabine; Histone Demethylases; Humans; Neoplastic Stem Cells; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; Prognosis; Protein Binding; Spheroids, Cellular | 2018 |
Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Databases, Factual; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Hyperbilirubinemia; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2018 |
Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Oxaliplatin; Paclitaxel; Xenograft Model Antitumor Assays | 2018 |
[Retrospective Analysis of Weekly Paclitaxel Chemotherapy for Gemcitabine- and S-1-Resistant Pancreatic Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Tegafur | 2018 |
[Maintenance strategies for advanced pancreatic cancer: Rationale and issues].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Maintenance Chemotherapy; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome; United States | 2018 |
Chemotherapy for pancreatic cancer: the rise of multidrug regimens.
Topics: Adenocarcinoma; Albumins; Capecitabine; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2018 |
Tumor-stromal cross-talk modulating the therapeutic response in pancreatic cancer.
Topics: Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Survival; Coculture Techniques; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Risk Factors; Sensitivity and Specificity; Stromal Cells; Tumor Cells, Cultured | 2018 |
Evaluation of the use of nab-paclitaxel and gemcitabine in clinical practice.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2018 |
ASO Author Reflections: Neoadjuvant Treatment of Resectable and Borderline-Resectable Pancreatic Head Adenocarcinoma: Is FOLFIRINOX Better than Gem/Nab-Paclitaxel?
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms | 2018 |
Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Platelets; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Inflammation; Liver Neoplasms; Lymphatic Metastasis; Lymphocytes; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neutrophils; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2019 |
First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Mice, Transgenic; MicroRNAs; Paclitaxel; Pancreatic Neoplasms; Prodrugs; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Linear Models; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2018 |
Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Delivery Systems; Gemcitabine; Lipids; Mice; Nanoparticles; Oligopeptides; Paclitaxel; Tissue Distribution | 2018 |
Tumor Volume Reduction After Gemcitabine Plus Cisplatin Induction Chemotherapy in Locally Advanced Nasopharyngeal Cancer: Comparison with Paclitaxel and Cisplatin Regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; China; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis; Tumor Burden | 2018 |
Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives.
Topics: Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2018 |
Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Monitoring; Female; Gemcitabine; Humans; India; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2018 |
Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate | 2019 |
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non-predominant lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pemetrexed; Retrospective Studies; Survival Rate; Vinorelbine | 2019 |
Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2019 |
The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Mice; Mice, Nude; Middle Aged; Paclitaxel; Sarcoma; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pancreas; Sweden; Treatment Outcome | 2019 |
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Treatment Outcome | 2019 |
Attempts to strengthen and simplify the tumor vascular normalization strategy using tumor vessel normalization promoting nanomedicines.
Topics: Angiogenesis Inhibitors; Animals; Cell Survival; Deoxycytidine; Gemcitabine; Hep G2 Cells; Heparin, Low-Molecular-Weight; Human Umbilical Vein Endothelial Cells; Humans; Lipids; Liver Neoplasms; Mice; Microscopy, Fluorescence; Nanomedicine; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Transplantation, Heterologous | 2019 |
[A Case of Pathological Complete Response Induced by Preoperative Chemotherapy with Gemcitabine plus Nab-Paclitaxel in a Patient with Pancreatic Cancer on Hemodialysis].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Renal Dialysis | 2018 |
[A Case of Unresectable Pancreas Cancer with 32 Months Survival after Chemotherapy].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2018 |
Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Combinations; Drug Liberation; Gemcitabine; Glioblastoma; Hydrogels; Injections; Lipids; Mice; Nanocapsules; Nanomedicine; Paclitaxel; Rats | 2019 |
Glucose-Regulated Protein 94 Modulates the Response of Osteosarcoma to Chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Membrane Glycoproteins; Osteosarcoma; Paclitaxel | 2019 |
MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.
Topics: 3' Untranslated Regions; Albumins; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Kaplan-Meier Estimate; Male; MicroRNAs; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Sequence Homology, Nucleic Acid | 2019 |
A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2018 |
Emerging new predictive biomarkers in metastatic breast cancer: Caveolin-1 and weekly nab-paclitaxel plus gemcitabine, are we on for tomorrow?
Topics: Albumins; Biomarkers; Breast Neoplasms; Caveolin 1; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Paclitaxel | 2019 |
Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dasatinib; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Signal Transduction; STAT3 Transcription Factor | 2019 |
Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Expression profile and prognostic value of SFN in human ovarian cancer.
Topics: 14-3-3 Proteins; Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Exoribonucleases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; RNA, Messenger | 2019 |
Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Longitudinal Studies; Models, Statistical; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate | 2019 |
Ocoxin Oral Solution Exerts an Antitumoral Effect in Pancreatic Cancer and Reduces the Stromal-Mediated Chemoresistance.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Ascorbic Acid; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Folic Acid; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred C57BL; Neoplasms, Experimental; Paclitaxel; Pancreatic Neoplasms; Pantothenic Acid; Plant Extracts; Solutions; Vitamin B 12; Vitamin B 6; Zinc Sulfate | 2019 |
Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Glucocorticoids; Hemolytic-Uremic Syndrome; Humans; Methylprednisolone; Paclitaxel; Pancreatic Neoplasms | 2019 |
Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Kidney Failure, Chronic; Liver Neoplasms; Male; Paclitaxel; Pancreatic Neoplasms; Peritoneal Dialysis; Tomography, X-Ray Computed | 2019 |
Gemcitabine, Cisplatin, and nab-Paclitaxel for Patients With Advanced Biliary Tract Cancer: Closing the GAP.
Topics: Albumins; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel | 2019 |
Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Clinical Decision-Making; Computer Simulation; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Models, Biological; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Remission Induction; Tumor Burden | 2019 |
Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome; Urologic Neoplasms; Urothelium | 2019 |
Codelivery Nanosystem Targeting the Deep Microenvironment of Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Mice; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2019 |
Durable response for ampullary and duodenal adenocarcinoma with a nab-paclitaxel plus gemcitabine ± cisplatin combination.
Topics: Adenocarcinoma; Albumins; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Deoxycytidine; Duodenal Neoplasms; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Heterocyclic Compounds, 3-Ring; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Paclitaxel; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyridones; Pyrimidinones; Xenograft Model Antitumor Assays | 2019 |
[A Case of Boderline Resectable Pancreatic Cancer Curatively Resected after Chemotherapy with Gemcitabine and Nab-Paclitaxel].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms | 2019 |
Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma.
Topics: Albumins; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Immunohistochemistry; Mice; Microtubules; Paclitaxel; Pancreatic Neoplasms; Protein Multimerization; Tubulin Modulators; Xenograft Model Antitumor Assays | 2019 |
Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study.
Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Community Health Planning; Deoxycytidine; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Saskatchewan | 2019 |
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Failure | 2019 |
The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Patient Safety; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2019 |
Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Topotecan; Treatment Outcome; Young Adult | 2019 |
Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Topics: Academic Medical Centers; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cause of Death; Combined Modality Therapy; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome | 2019 |
Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer.
Topics: Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2019 |
Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retreatment; Retrospective Studies | 2020 |
Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies | 2020 |
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Survival Analysis | 2019 |
KRAS pathway expression changes in pancreatic cancer models by conventional and experimental taxanes.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Paclitaxel; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Taxoids; Transcriptome | 2019 |
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Kaplan-Meier Estimate; Ketones; Middle Aged; Multicenter Studies as Topic; Mutation; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Risk Factors; Treatment Outcome; Young Adult | 2019 |
Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2019 |
Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Cadherins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Radiation Tolerance; Snail Family Transcription Factors; Survivin; Vascular Endothelial Growth Factor A; X-Linked Inhibitor of Apoptosis Protein; Zinc Finger E-box-Binding Homeobox 1 | 2020 |
Development and validation of a liquid chromatography tandem mass spectrometry quantification method for 14 cytotoxic drugs in environmental samples.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Environmental Pollutants; Gemcitabine; Occupational Exposure; Paclitaxel; Sensitivity and Specificity; Tandem Mass Spectrometry | 2020 |
[A Case of an Elderly Patient with Multiple Lung Metastases of Postoperative Pancreatic Cancer in Whom Lung Metastases Were Controlled by Biweekly Dose-Down Administration of Gemcitabine].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms | 2019 |
ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes.
Topics: Albumins; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2019 |
Impact of Extravasated Platelet Activation and Podoplanin-positive Cancer-associated Fibroblasts in Pancreatic Cancer Stroma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cancer-Associated Fibroblasts; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Membrane Glycoproteins; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Platelet Activation; Platelet Glycoprotein GPIb-IX Complex; Tegafur | 2019 |
Optimal first-line treatment for advanced thymic carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Survival Analysis; Thymoma; Thymus Neoplasms; Treatment Outcome; Young Adult | 2019 |
Expanding the Arsenal of Pt
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbonates; Carcinoma, Lewis Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Estramustine; Female; Gemcitabine; Humans; Ligands; Male; Mice, Inbred C57BL; Organoplatinum Compounds; Paclitaxel; Prodrugs; Prohibitins; Structure-Activity Relationship | 2019 |
Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines | 2019 |
Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2019 |
Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Treatment Failure | 2020 |
Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2020 |
Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retreatment; Retrospective Studies; Risk Assessment; Survival Analysis; Tertiary Care Centers; Treatment Failure; Treatment Outcome | 2019 |
Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Deoxycytidine; Emergency Service, Hospital; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hospitalization; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Ontario; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Propensity Score; Treatment Outcome | 2020 |
Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Prognosis; Salvage Therapy; Testicular Neoplasms | 2020 |
Conversion surgery for positive peritoneal washing cytology in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Cytodiagnosis; Deoxycytidine; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Peritoneum; Treatment Outcome | 2019 |
GEM + nab-PTX Therapy for Pancreatic Body Cancer cStage IVb for Conversion Surgery: A Case Report.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Treatment Outcome | 2019 |
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cisplatin; Deoxycytidine; Fanconi Anemia Complementation Group N Protein; Female; Fluorouracil; Gemcitabine; Germ-Line Mutation; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Retrospective Studies | 2020 |
Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate | 2020 |
ATM-Mutated Pancreatic Cancer: Clinical and Molecular Response to Gemcitabine/Nab-Paclitaxel After Genome-Based Therapy Resistance.
Topics: Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Germ-Line Mutation; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer.
Topics: Albumins; Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Knockout Techniques; Humans; Interferon-gamma; Killer Cells, Natural; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred C57BL; Myeloid-Derived Suppressor Cells; Paclitaxel; Pancreatic Neoplasms; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured; Tumor Microenvironment; Ubiquitin Thiolesterase | 2020 |
Charging forward in locally advanced pancreatic cancer.
Topics: Albumins; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2020 |
Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Liberation; Enzyme Inhibitors; Female; Gemcitabine; Imidazoles; Immunity; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Isoindoles; Mice, Inbred BALB C; Micelles; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Prodrugs | 2020 |
A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Exanthema; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2020 |
Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Medical Staff, Hospital; Middle Aged; Netherlands; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Regression Analysis; Young Adult | 2020 |
Chemotherapy-induced pneumonitis associated with transient CA 15-3 elevation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Paclitaxel; Pneumonia; Tomography, X-Ray Computed | 2020 |
A NAG-Guided Nano-Delivery System for Redox- and pH-Triggered Intracellularly Sequential Drug Release in Cancer Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Liberation; Gemcitabine; Humans; Hydrogen-Ion Concentration; Lung Neoplasms; Male; Mice, Inbred BALB C; Nanostructures; Oxidation-Reduction; Paclitaxel; Polymers; Xenograft Model Antitumor Assays | 2020 |
Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Deoxycytidine; Dose-Response Relationship, Drug; Drug Compounding; Drug Synergism; Female; Gemcitabine; Lung Neoplasms; Mice; Mice, Inbred C57BL; Nanoparticles; Paclitaxel; Treatment Outcome | 2020 |
Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Oncogene Proteins, Fusion; Paclitaxel; Pemetrexed; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Retrospective Studies; Survival Rate | 2020 |
Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Drug Resistance, Neoplasm; Evidence-Based Medicine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2020 |
A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; Female; Fluorouracil; Gemcitabine; Heterografts; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Jejunal Neoplasms; Leucovorin; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Treatment Failure; Trifluridine; Xenograft Model Antitumor Assays | 2020 |
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; Deoxycytidine; Docetaxel; Female; Gemcitabine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oncogene Fusion; Paclitaxel; Pemetrexed; Platinum Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Retrospective Studies; Treatment Outcome | 2020 |
Type 2 diabetes induced microbiome dysbiosis is associated with therapy resistance in pancreatic adenocarcinoma.
Topics: Animals; Deoxycytidine; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Dysbiosis; Gastrointestinal Microbiome; Gemcitabine; Hyperglycemia; Male; Mice; Mice, Inbred C57BL; Paclitaxel; Pancreatic Neoplasms | 2020 |
Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis.
Topics: Aged; Aged, 80 and over; Albumins; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Duration of Therapy; Emergency Service, Hospital; Female; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Insurance, Health; Irinotecan; Leucovorin; Male; Medicare Part C; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; United States | 2020 |
FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Substitution; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Salvage Therapy | 2020 |
Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Pyridines; Radiotherapy; Retrospective Studies; Tegafur; Time Factors | 2020 |
Cardiac Masses in a Patient With Pancreatic Adenocarcinoma and a History of Breast Carcinoma.
Topics: Adenocarcinoma; Albumins; Anticoagulants; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Heart Ventricles; Humans; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Thrombosis; Warfarin | 2020 |
The yield of chest computed tomography in patients with locally advanced pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Multiple Pulmonary Nodules; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Radiosurgery; Retrospective Studies; Tomography, X-Ray Computed | 2020 |
Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Linear Models; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Adjuvant; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tumor Burden | 2020 |
Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
Topics: A549 Cells; Adenocarcinoma of Lung; Adenosine Triphosphate; Alarmins; Antineoplastic Agents; Apoptosis; Autophagy; Calreticulin; Carboplatin; Caspase 3; Cell Survival; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; HMGB1 Protein; Humans; Immunogenic Cell Death; Lung Neoplasms; Paclitaxel; Prognosis | 2020 |
Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2020 |
An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; High-Throughput Screening Assays; Humans; Keratin-17; Mice, Inbred C57BL; Microtubules; Paclitaxel; Pancreatic Neoplasms; Podophyllotoxin; Tumor Burden | 2020 |
Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Multivariate Analysis; Nomograms; Outcome Assessment, Health Care; Paclitaxel; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Reproducibility of Results | 2020 |
Gemcitabine plus nab-paclitaxel with initial dose reduction for older patients with advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Tapering; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Cisplatin, Gemcitabine, and Paclitaxel as a Salvage Second-Line Therapy for Metastatic Germ-Cell Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Ifosfamide; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Salvage Therapy; Treatment Outcome | 2021 |
Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Immunohistochemistry; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Markov Chains; Middle Aged; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Confidence Intervals; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Retrospective Studies | 2021 |
The Complexity of Neoadjuvant Therapy for Operable Pancreatic Cancer: Lessons Learned From SWOG S1505.
Topics: Adenocarcinoma; Albumins; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Diagnostic Imaging; Dose Fractionation, Radiation; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Neoadjuvant Therapy; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreas; Pancreatic Neoplasms; Radiosurgery | 2020 |
Should All Patients With Pancreatic Cancer Receive Chemotherapy Before Surgery?
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2020 |
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Radiography; Survival Rate; Treatment Outcome | 2020 |
Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Tegafur | 2020 |
Multiple Liver Metastases Rather Than the Presence of Liver Metastasis Is a Significantly Poor Prognostic Factor for Patients With Advanced Pancreatic Cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Pancreatic Neoplasms; Prognosis; Tomography Scanners, X-Ray Computed | 2020 |
Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma.
Topics: Adult; Albumin-Bound Paclitaxel; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Retrospective Studies; Sarcoma; Treatment Outcome | 2020 |
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?
Topics: Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2020 |
Clear cell adenocarcinoma presenting as acute pancreatitis: A rare form of primary pancreatic malignancy.
Topics: Adenocarcinoma, Clear Cell; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pancreas; Pancreatic Neoplasms; Pancreatitis; Tomography, X-Ray Computed | 2020 |
[A Case of a Huge, Mixed-Type IPMC with Suspected Rupture of the Omental Bursa That Was Effectively Treated with Gemcitabine plus Nab-Paclitaxel].
Topics: Adenocarcinoma, Mucinous; Albumins; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peritoneal Cavity; Positron Emission Tomography Computed Tomography | 2020 |
Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2021 |
Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cross-Over Studies; Deoxycytidine; Febrile Neutropenia; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Progression-Free Survival; Registries; Republic of Korea; Survival Rate; Treatment Outcome | 2020 |
Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker.
Topics: Administration, Intravenous; Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow; Carboplatin; Contrast Media; Creatinine; Cytochrome P-450 Enzyme System; Deoxycytidine; Drug Dosage Calculations; Drug Interactions; Female; Gemcitabine; Glomerular Filtration Rate; Glucuronosyltransferase; Humans; Iohexol; Kidney; Metabolic Clearance Rate; Mice; Microsomes, Liver; Models, Animal; Paclitaxel; Specific Pathogen-Free Organisms; Tandem Mass Spectrometry; Tissue Distribution | 2020 |
Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Italy; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2020 |
Secondary Minimal Change Disease Due to Pancreatic Cancer Improved by Chemotherapy.
Topics: Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Humans; Male; Nephrosis, Lipoid; Paclitaxel; Pancreatic Neoplasms | 2021 |
Novel Long-Acting Drug Combination Nanoparticles Composed of Gemcitabine and Paclitaxel Enhance Localization of Both Drugs in Metastatic Breast Cancer Nodules.
Topics: Animals; Breast Neoplasms; Deoxycytidine; Drug Combinations; Drug Delivery Systems; Female; Gemcitabine; Kidney; Liver; Lung; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Spleen; Tissue Distribution | 2020 |
Predictive implications of decreased CA19-9 at 8 weeks during nab-paclitaxel plus gemcitabine for the induction of second-line chemotherapy for patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2020 |
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Rate | 2021 |
Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2020 |
Dual Delivery of Gemcitabine and Paclitaxel by Wet-Spun Coaxial Fibers Induces Pancreatic Ductal Adenocarcinoma Cell Death, Reduces Tumor Volume, and Sensitizes Cells to Radiation.
Topics: Adenocarcinoma; Animals; Cell Death; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Paclitaxel; Pancreatic Neoplasms; Tumor Burden | 2020 |
Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response to Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Circulating Tumor DNA; Deoxycytidine; Disease Progression; Female; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Mutation; Paclitaxel; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins p21(ras); Survival Analysis | 2020 |
Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Tegafur; Treatment Outcome | 2020 |
Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2020 |
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Transla
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Registries; Treatment Outcome | 2021 |
Toxic erythema of chemotherapy secondary to gemcitabine and paclitaxel.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Deoxycytidine; Erythema; Female; Gemcitabine; Humans; Intertrigo; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms | 2020 |
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan | 2020 |
Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Intention to Treat Analysis; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Caveolin 1; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred NOD; Mice, Knockout; Mice, Nude; Mice, SCID; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors | 2021 |
Assessment of efficacy of postinfusion tubing flushing in reducing risk of cytotoxic contamination.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Cytarabine; Decontamination; Deoxycytidine; Gemcitabine; Health Personnel; Humans; Infusions, Parenteral; Occupational Exposure; Paclitaxel | 2020 |
Treatment patterns in pancreatic cancer patients based on a hospital claims database in Japan.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Databases as Topic; Deoxycytidine; Female; Gemcitabine; Hospitals; Humans; Insurance; Japan; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Lung Diseases, Interstitial; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Risk Factors | 2021 |
Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2021 |
Thermosensitive and biodegradable hydrogel encapsulating targeted nanoparticles for the sustained co-delivery of gemcitabine and paclitaxel to pancreatic cancer cells.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Hydrogels; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols | 2021 |
Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort.
Topics: Adenocarcinoma; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2021 |
Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms | 2021 |
Efficacy of chemotherapy combined with toripalimab in PD-L1-positive and high tumor mutation burden pancreatic acinar cell carcinoma: case report.
Topics: Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Acinar Cell; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Male; Mutation; Paclitaxel; Pancreatic Neoplasms | 2021 |
Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell-Free Nucleic Acids; Circulating Tumor DNA; Cisplatin; Deoxycytidine; DNA Copy Number Variations; Female; Gemcitabine; Humans; Lung Neoplasms; Machine Learning; Male; Middle Aged; Paclitaxel; Prognosis; Progression-Free Survival; Survival Rate; Treatment Outcome | 2021 |
FDA Approves Pembrolizumab + Chemotherapy Combination for Locally Recurrent Unresectable or Metastatic TNBC.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Double-Blind Method; Drug Approval; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms; United States; United States Food and Drug Administration | 2020 |
Metastatic Pancreatic Cancer Second-Line Treatment Options: Is the Difference Only in Cost?
Topics: Adolescent; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2022 |
[A case of advanced pancreatic cancer with oculomotor nerve palsy caused by herpes zoster after introduction of gemcitabine plus nab-paclitaxel].
Topics: Acyclovir; Aged; Albumins; Antiviral Agents; Deoxycytidine; Female; Gemcitabine; Humans; Oculomotor Nerve Diseases; Paclitaxel; Pancreatic Neoplasms | 2021 |
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel.
Topics: Adult; Aged; Albumins; Alleles; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cytidine Deaminase; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Genotype; Glucuronosyltransferase; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Pharmacogenomic Testing; Polymorphism, Genetic | 2021 |
[Nab-Paclitaxel plus Gemcitabine for Patients with Recurrence after Resection for Adenocarcinoma of the Pancreas].
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2021 |
Targeting B cells in pancreatic adenocarcinoma: does RESOLVE resolve the question?
Topics: Adenine; Adenocarcinoma; Albumins; B-Lymphocytes; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Piperidines | 2021 |
Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution.
Topics: Albumins; China; Deoxycytidine; Gemcitabine; Humans; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2020 |
Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Veterans | 2021 |
Improved prognosis of pancreatic cancer patients with peritoneal metastasis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Peritoneum; Prognosis; Retrospective Studies | 2021 |
Impact of paclitaxel, cisplatin, and gemcitabine as first-line chemotherapy in cisplatin-fit and -unfit patients with advanced/metastatic urothelial carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Retrospective Studies; Survival Analysis; Urinary Bladder Neoplasms | 2021 |
Abdominal Wall Metastasis of Pancreatic Cancer: The Tip of the Iceberg-Case Report.
Topics: Abdominal Wall; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2021 |
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Deoxycytidine; Female; Fluorouracil; Forkhead Transcription Factors; Gemcitabine; Hepatitis A Virus Cellular Receptor 2; Humans; Immune Checkpoint Proteins; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pilot Projects; Programmed Cell Death 1 Receptor; Progression-Free Survival; Prospective Studies; T-Lymphocytes, Regulatory | 2021 |
Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Propensity Score; Retrospective Studies; Treatment Outcome | 2021 |
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Austria; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Progression-Free Survival; Propensity Score; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors | 2021 |
Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Propensity Score | 2021 |
Chemotherapy-induced early transient increase and surge of CA 19-9 level in patients with pancreatic Adenocarcinoma
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Female; Gemcitabine; Humans; Male; Mice; Microbubbles; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Phospholipids; Ultrasonic Waves; Xenograft Model Antitumor Assays | 2021 |
A sulfobetaine zwitterionic polymer-drug conjugate for multivalent paclitaxel and gemcitabine co-delivery.
Topics: Animals; Betaine; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Mice; Paclitaxel; Pharmaceutical Preparations; Polymers | 2021 |
Safety and Efficacy of Gemcitabine Plus Nab-Paclitaxel for Metastatic Pancreatic Cancer Patients Undergoing Biliary Stent Placement.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Stents; Treatment Outcome | 2022 |
Treatment Outcome of Nab-paclitaxel Plus Gemcitabine for Leptomeningeal Carcinomatosis from Pancreatic Ductal Adenocarcinoma: An Autopsy Case Report.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Deoxycytidine; Female; Gemcitabine; Humans; Meningeal Carcinomatosis; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Combinatorial Treatment of Tinzaparin and Chemotherapy Can Induce a Significant Antitumor Effect in Pancreatic Cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Paclitaxel; Pancreatic Neoplasms; Tinzaparin; Xenograft Model Antitumor Assays | 2021 |
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study).
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nanoparticles; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Comparison of Chemotherapy-induced Nausea and Vomiting Between Gemcitabine Plus Nab-paclitaxel Combination Chemotherapy and Gemcitabine Monotherapy in Patients With Advanced Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Vomiting | 2021 |
Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Platinum; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Editorial Comment to Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
Topics: Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Platinum | 2021 |
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Venous Thromboembolism | 2022 |
Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.
Topics: Adult; Aged; Albumins; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Risk Factors | 2021 |
Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Survival Rate; Treatment Outcome | 2021 |
Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies | 2021 |
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Topics: Adult; Aged; Albumins; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body Mass Index; Body Surface Area; Canada; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lumbar Vertebrae; Male; Maximum Tolerated Dose; Middle Aged; Muscle, Skeletal; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Predictive Value of Tests; Reference Values; Retrospective Studies; Tomography, X-Ray Computed | 2021 |
Establishment of Pancreatobiliary Cancer Zebrafish Avatars for Chemotherapy Screening.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zebrafish | 2021 |
Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Bevacizumab; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Databases as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Paclitaxel; Pancreatic Neoplasms; Racial Groups; Retrospective Studies; Sex Factors; Treatment Outcome | 2021 |
Use of
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Colony-Stimulating Factors; Deoxycytidine; Gemcitabine; Granulocytes; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Gemcitabine and nab-paclitaxel induced interstitial pneumonia.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Lung Diseases, Interstitial; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Supramolecular Organization of Polymer Prodrug Nanoparticles Revealed by Coarse-Grained Simulations.
Topics: Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Hydrophobic and Hydrophilic Interactions; Molecular Dynamics Simulation; Nanoparticles; Paclitaxel; Polymers; Prodrugs | 2021 |
Role of biliary stent and neoadjuvant chemotherapy in the pancreatic tumor microbiome.
Topics: Aged; Carcinoma, Pancreatic Ductal; Deoxycytidine; Enterobacteriaceae; Female; Gemcitabine; Humans; Male; Microbiota; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Stents; Tumor Microenvironment | 2021 |
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Nanoconjugates; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies | 2021 |
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2021 |
Advanced Nanoengineering Approach for Target-Specific, Spatiotemporal, and Ratiometric Delivery of Gemcitabine-Cisplatin Combination for Improved Therapeutic Outcome in Pancreatic Cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Mice; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2022 |
Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer.
Topics: Albumins; Antineoplastic Agents; CA-19-9 Antigen; Carcinoembryonic Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Nomograms; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Probability; Proportional Hazards Models; ROC Curve; Sex Factors; Survival Rate; Tegafur | 2021 |
Inclusion of cancer-associated fibroblasts in drug screening assays to evaluate pancreatic cancer resistance to therapeutic drugs.
Topics: Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; Early Detection of Cancer; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2022 |
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Nomograms; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Treatment Outcome | 2022 |
Ad-VT enhances the sensitivity of chemotherapy-resistant lung adenocarcinoma cells to gemcitabine and paclitaxel in vitro and in vivo.
Topics: Adenocarcinoma of Lung; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Xenograft Model Antitumor Assays | 2022 |
[A Case of Advanced Bladder Carcinoma Treated by Third-Line Gemcitabine and Paclitaxel Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Paclitaxel; Urinary Bladder; Urinary Bladder Neoplasms | 2021 |
Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Propensity Score | 2022 |
Impact of sarcopenia on prediction of progression-free survival and overall survival of patients with pancreatic ductal adenocarcinoma receiving first-line gemcitabine and nab-paclitaxel chemotherapy.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Sarcopenia | 2022 |
Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Nausea; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2022 |
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Progressive digital necrosis during gemcitabine/nab-paclitaxel chemotherapy in a patient with pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Necrosis; Paclitaxel; Pancreatic Neoplasms | 2022 |
Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Feasibility Studies; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Mice; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Optimal Relative Dose Intensity in the First 4 Weeks During Nab-Paclitaxel Plus Gemcitabine for Older Patients With Advanced Pancreatic Cancer in Japan.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Male; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2022 |
Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Early Detection of Cancer; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Venous Thromboembolism | 2022 |
Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Sarcopenia: Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Sarcopenia | 2022 |
Contrast-enhanced harmonic endoscopic ultrasonography for predicting the efficacy of first-line gemcitabine and nab-paclitaxel chemotherapy in pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Endosonography; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2022 |
5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Resu
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Microangiopathy associated with gemcitabine: a drug interaction with nab-paclitaxel? A case series and literature review.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Interactions; Gemcitabine; Humans; Mice; Paclitaxel; Pancreatic Neoplasms; Thrombotic Microangiopathies | 2022 |
Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer.
Topics: Albumins; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Quality of Life; Risk Factors | 2022 |
The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2022 |
Baseline Factors Predictive of the Receipt of Second-Line Chemotherapy After Nab-Paclitaxel Plus Gemcitabine for Patients With Advanced Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Hypoalbuminemia; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Sarcopenia | 2022 |
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Flavonoids; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Tubulin | 2022 |
Application of Nab-paclitaxel combined with gemcitabine in neoadjuvant chemotherapy laparoscopic followed by pancreatoduodenectomy to a patient with pancreas head cancer invading to protal vein.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Laparoscopy; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2022 |
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Ontario; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Efficacy of Gemcitabine, Paclitaxel, and Oxaliplatin Protocol in the Treatment of Relapsed or Refractory Germ Cell Tumours.
Topics: Adult; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Neoplasms, Germ Cell and Embryonal; Observational Studies as Topic; Oxaliplatin; Paclitaxel | 2022 |
Mild forms of thrombotic microangiopathy in patients with advanced pancreatic cancer receiving gemcitabine and nab-paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Purpura, Thrombotic Thrombocytopenic; Thrombotic Microangiopathies | 2023 |
Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2022 |
Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Registries | 2022 |
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Quality of Life | 2023 |
Is Weight Loss During Chemotherapy for Pancreatic Cancer Prognostic?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Weight Loss | 2023 |
The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; COVID-19; Deoxycytidine; Fluorouracil; Humans; Paclitaxel; Pancreatic Neoplasms; Pandemics; Retrospective Studies; Terminal Care | 2022 |
Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Feasibility Studies; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2023 |
Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |
The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy Protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
[A Case of Multiple Lung Metastases of Pancreatic Cancer with 50 Months Survival by Sequential Chemotherapy].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms | 2022 |
Partial response in non-resectable adenosquamous carcinoma of the pancreas with high tumour mutation burden treated with gemcitabine, nab-paclitaxel and pembrolizumab.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Gemcitabine; Humans; Male; Mutation; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2023 |
CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms | 2023 |
Implication of Skeletal Muscle Loss in the Prognosis of Patients with Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Muscle, Skeletal; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Sarcopenia | 2023 |
Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Fluorouracil; Genomics; Humans; Induction Chemotherapy; Paclitaxel; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras) | 2023 |
Efficacy of gemcitabine in combination with nanoparticle albumin-bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome | 2023 |
Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Ontario; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients: A Multicenter Real-Life Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival | 2022 |
Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Nutritional Support; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Retrospective Studies; Weight Loss | 2023 |
Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2023 |
Treatment patterns and cost estimations of systemic chemotherapy for pancreatic cancer in Japan: A retrospective database study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Japan; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Serum Albumin | 2023 |
Bromo- and Extra-Terminal Domain Inhibitors Induce Mitochondrial Stress in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Mice; Mitochondria; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Trends in treatment patterns and survival outcomes in pancreatic cancer: A nationwide population-based study in Korea.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infant; Leucovorin; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Republic of Korea; Retrospective Studies | 2023 |
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Cicatrix; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Deoxycytidine; Humans; Paclitaxel; Pancreatic Neoplasms | 2023 |
[Advanced Bladder Cancer with Multiple Pulmonary Metastases Treated with Paclitaxel/Ifosfamide/Nedaplatin Therapy : Two Case Reports].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Paclitaxel; Urinary Bladder Neoplasms | 2023 |
Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Deoxycytidine; Fasting; Female; Humans; Paclitaxel; Prognosis; Triple Negative Breast Neoplasms | 2024 |
Efficacy and safety of gemcitabine plus S-1
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2023 |
Predictive and Prognostic Value of TUBB3, RRM1, APE1, and Survivin Expression in Chemotherapy-Receiving Patients with Advanced Non‑Small Cell Lung Cancer.
Topics: Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Ribonucleoside Diphosphate Reductase; Survivin; Tubulin; Tumor Suppressor Proteins | 2023 |
[Resection of locally advanced pancreatic cancer: careful selection and shared decision making].
Topics: Antineoplastic Combined Chemotherapy Protocols; Decision Making, Shared; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2023 |